introduct
effect
anti
ige
describ
function
complex
free
ige
reduc
mast
cell
implant
consequ
reduct
mast
cell
degranul
upon
exposur
antigen
theoret
total
free
ige
drop
ngml
improv
occur
free
cell
bound
ige
equilibr
allerg
reaction
subsid
initi
observ
togia
et
al
j
allergi
clin
immunol
suggest
prick
skin
test
consist
reach
low
point
day
signific
reduct
size
laynadi
leynadi
f
doudou
gaouar
h
le
gro
v
bourdeix
guyomarchcocco
l
trunet
p
effect
omalizumab
health
care
worker
occup
latex
allergyj
allergi
clin
immunol
note
reduct
skin
test
sixti
percent
patient
treat
six
month
period
monoclon
antiig
clinician
sinc
approv
drug
note
even
presenc
good
clinic
respons
asthma
skin
test
reactiv
still
obviou
mani
case
unchang
method
follow
suggest
standard
clinic
follow
lanier
marshal
annal
may
routin
skin
prick
skin
test
complet
inform
consent
patient
onset
antiig
therapi
repeat
month
instanc
skin
test
done
photograph
standard
manner
case
skin
test
repeat
patient
receiv
anti
ige
long
five
year
result
photograph
evid
present
patient
current
therapi
prick
skin
test
remain
almost
ident
photograph
level
baselin
analysi
correl
patient
lowest
serum
ige
likelihood
appar
reduct
correl
reduct
skin
test
clinic
respons
anti
ige
sinc
patient
experi
signific
qualiti
life
improv
conclus
anti
ige
variabl
effect
reduc
prick
skin
test
greater
like
hood
associ
low
extrem
low
initi
total
ige
level
skin
test
sensit
detect
allergenspecif
ige
immunoassay
allergenspecif
ige
assay
method
qualit
cutoff
kul
inappropri
high
studi
conduct
order
determin
whether
particular
assay
system
use
measur
lower
level
allergenspecif
ige
pharmacia
unicap
system
studi
reagent
purchas
manufactur
studi
approv
local
human
assur
committe
determin
background
calibr
curv
fluoresc
unit
fu
respons
replic
assay
diluent
measur
antiig
solid
phase
determin
background
respons
arbitrarili
select
allergen
solid
phase
oak
timothi
short
ragwe
pollen
cat
peanut
yellow
jacket
venom
penicillin
g
also
measur
lower
detect
limit
lld
calcul
use
mean
background
measur
standard
deviat
sd
examin
linear
lowrang
calibr
curv
dilut
extinct
made
start
kul
calibr
mean
background
antiig
solid
phase
fu
sd
coeffici
variat
cv
lld
lld
correspond
level
approxim
kul
ige
lld
allergen
solid
phase
rang
fu
yellow
jacket
venom
fu
short
ragwe
correspond
kul
ige
low
level
dilut
curv
exhibit
parallel
curv
construct
use
zero
diluent
calibr
point
assay
refer
curv
low
level
method
capabl
measur
specif
ige
level
lower
manufactur
kul
cutoff
would
seem
particularli
import
research
applic
analysi
certain
highrisk
allergen
clinic
signific
low
level
specif
ige
serum
warrant
studi
allergistsimmunologist
often
consult
patient
rash
recurr
infect
differenti
diagnosi
compris
varieti
disord
rare
syndrom
requir
earli
diagnosi
specif
manag
mo
old
wm
develop
persist
rash
worsen
eczema
later
recurr
sever
skin
infect
skin
abscess
recurr
sinus
chronic
otiti
media
requir
multipl
placement
tympanostomi
tube
yet
persist
tympan
membran
perfor
recurr
wheez
note
yr
age
sever
episod
pneumonia
sinc
yr
age
affect
differ
lobe
fail
shed
primari
teeth
histori
periodont
oral
thrush
develop
scoliosi
multipl
fractur
upper
extrem
rib
yr
staphylococc
bacteremia
osteomyel
acetabulum
spite
antibiot
prophylaxi
continu
recurr
skin
infect
lymphaden
laboratori
evalu
reveal
eosinophilia
normal
level
igg
iga
igm
igg
subclass
except
decreas
mgdl
protect
level
anti
pneumonia
h
influenza
low
antitetanu
antidiphtheria
titer
yr
total
ige
level
iuml
support
diagnosi
hyper
ige
hie
syndrom
decreas
iuml
yr
rast
posit
hd
mite
cat
dog
egg
milk
pollen
flow
cytomerti
nbt
phagocyt
index
normal
low
mgdl
dexa
scan
show
osteopenia
chest
xray
show
bilater
infiltr
atelectasi
scoliosi
thorac
spine
hospit
yr
skin
fair
lichenifi
widespread
maculopapular
erythemat
rash
palm
finger
show
open
crack
pustul
weep
lesion
addit
coars
facial
featur
face
eczemat
conclus
hie
syndrom
autosom
domin
disord
mimic
atop
dermat
sever
cours
multipl
infect
sever
complic
although
markedli
elev
total
ige
level
introduct
mannosebind
lectin
mbl
serum
protein
lectin
complement
pathway
import
innat
immun
thought
particularli
relev
young
children
develop
adapt
immun
defici
mbl
report
populationbas
studi
risk
factor
children
infect
hospit
addit
agedepend
variabl
mbl
previous
note
studi
evalu
preval
mbl
defici
children
establish
recurr
infect
refer
evalu
immunodefici
method
prospect
evalu
mbl
statu
children
refer
recurr
infect
serum
collect
octob
septemb
children
known
primari
secondari
immunodefici
exclud
mbl
analysi
perform
standard
elisa
use
mbl
oligom
assay
perform
chart
laboratori
review
comorbid
diagnos
quantit
immunoglobulin
level
subclass
complement
function
result
twohundr
thirti
five
children
evalu
mean
age
year
rang
year
mean
mbl
ngml
rang
ngml
thirtyon
children
mbl
defici
level
among
group
mean
mbl
level
ngml
rang
ngml
mean
age
group
year
rang
year
children
mbl
defici
children
level
f
ratio
children
abnorm
mbl
level
linear
regress
analysi
show
correl
mbl
level
age
comorbid
diagnos
variabl
includ
asthma
allergi
atop
dermat
none
children
symptom
compat
connect
tissu
diseas
child
abnorm
mbl
level
found
signific
defici
igg
iga
igm
sever
children
low
within
normal
physiolog
rang
concomit
complement
pathway
disord
detect
conclus
studi
reveal
correl
mbl
level
age
children
recurr
infect
mbl
defici
approxim
twice
estim
rate
gener
popul
contrari
previou
studi
signific
immunolog
disord
identifi
therefor
mbl
defici
alon
risk
factor
infect
children
tb
fausnight
hershey
pa
introduct
incid
periop
anaphylaxi
estim
procedur
approxim
case
periop
anaphylaxi
attribut
neuromuscular
agent
littl
inform
report
literatur
regard
pediatr
periop
anaphylaxi
describ
pediatr
patient
suspect
periop
anaphylaxi
rocuronium
method
yearold
girl
histori
sacral
agenesi
neurogen
bladder
schedul
bladder
augment
surgeri
patient
taken
latexfre
oper
room
induct
gener
anesthesia
found
difficult
ventil
also
becam
hypotens
examin
patient
reveal
urticaria
right
arm
given
epinephrin
diphenhydramin
dexamethason
procedur
abort
reaction
believ
either
rocuronium
propofol
result
high
incid
anaphylaxi
neuromuscular
agent
allergi
skin
test
perform
rocuronium
vecuronium
succinylcholin
patient
neg
percutan
skin
test
rocuronium
vecuronium
succinylcholin
neg
intraderm
skin
test
rocuronium
dilut
posit
intraderm
skin
test
rocuronium
dilut
neg
intraderm
skin
test
vecuronium
succinylcholin
dilut
underw
surgeri
week
skin
test
receiv
test
dose
vecuronium
reaction
receiv
dose
vecuronium
multipl
dose
morphin
without
advers
reaction
propofol
avoid
surgeri
complet
without
difficulti
conclus
case
illustr
use
skin
test
neuromuscular
agent
pediatr
patient
introduct
extrapulmonari
pneumocysti
jiroveci
infect
rare
nonhiv
infect
individu
knowledg
report
patient
good
syndrom
report
case
extrapulmonari
pneumocysti
patient
good
syndrom
case
report
african
american
male
patient
histori
good
syndrom
present
left
flank
pain
month
durat
pain
constant
associ
night
sweat
fever
chill
furthermor
patient
also
report
weight
loss
exam
patient
found
multipl
hypopig
area
abdomen
left
lower
extrem
bitempor
wast
sunken
eyebal
oral
thrush
patient
also
found
left
costovertebr
angl
tender
palpabl
solid
fix
mass
along
left
mid
axillari
line
overli
splenic
area
computedtomographi
ct
scan
chest
abdomen
show
x
cm
soft
tissu
mass
left
later
aspect
vertebr
bodi
x
cm
soft
tissu
parasplen
mass
parasplen
mass
involv
inferior
anterior
aspect
left
rib
see
figur
giemsastain
biopsi
parasplen
mass
reveal
pneumocysti
jiroveci
confirm
use
immunohistochem
stain
monoclon
antipnumocysti
antibodi
patient
symptom
night
sweat
loss
appetit
improv
within
hour
follow
initi
trimethoprimsulfamethoxazol
therapi
ct
chest
abdomen
repeat
six
month
post
treatment
confirm
resolut
paravertebr
parasplen
mass
conclus
knowledg
first
case
extrapulmonari
pneumocysti
present
patient
good
syndrom
although
rare
extrapulmonari
pneumocysti
consid
differenti
diagnosi
patient
good
syndrom
chest
abdomin
mass
introduct
cell
regul
cellular
interact
environ
develop
play
critic
role
regul
develop
autoimmun
diseas
report
inflammatori
myositi
caucasian
femal
primari
celldefici
sinc
infanc
method
nine
month
age
patient
develop
lymphoid
interstiti
pneumon
immunolog
evalu
reveal
isol
tcell
defici
first
year
life
failur
thrive
recurr
sinus
oral
candidiasi
fungal
skin
infect
pseudomona
pneumonia
year
autoimmun
condit
character
purpur
rash
nose
face
exposur
area
elbow
knee
finger
raynaud
phenomenon
nasal
septum
perfor
develop
inflammatori
marker
persist
elev
autoantibodi
detect
age
develop
proxim
muscl
weak
distal
joint
contractur
dri
gangren
finger
thrombot
incid
occur
result
serial
immunolog
evalu
reveal
low
normal
low
normal
decreas
lymphocyt
transform
antigen
appropri
mitogen
igg
normal
mgdl
iga
normal
mgdl
igm
normal
mgdl
appropri
antibodi
respons
vaccin
antigen
bone
marrow
thymu
biopsi
normal
evalu
consist
known
primari
secondari
immunodefici
sever
skin
biopsi
reveal
nonspecif
dermat
without
vascul
mri
lower
extrem
show
abnorm
signal
involv
bilater
muscl
thigh
calv
muscl
biopsi
reveal
inflammatori
myositi
plasma
cell
predomin
inconsist
dermatomyos
polymyos
aldolas
iul
crp
mgdl
esr
rf
type
ii
collagen
ab
eiml
ana
anca
ace
within
normal
rang
antibodi
myositi
myositi
relatedantibodi
neg
diagnosi
nonspecif
plasmacel
inflammatori
myositi
made
trial
monthli
ivig
gmkg
result
clinic
improv
conclus
novel
plasma
cell
myositi
occur
child
primari
cell
defici
underscor
role
cell
play
develop
autoimmun
diseas
introduct
incid
hypersensit
reaction
hr
increas
patient
treat
multipl
cours
carboplatin
purpos
investig
evalu
effect
desensit
protocol
character
immun
mechan
carboplatin
hr
method
analyz
ten
consecut
patient
two
year
period
document
hr
carboplatin
requir
continu
treatment
platinum
agent
patient
treat
carboplatin
use
desensit
protocol
skin
test
perform
five
patient
result
ten
patient
success
complet
plan
cours
desensit
carboplatin
without
reaction
four
patient
symptom
first
third
desensit
toler
readministr
infus
without
reaction
subsequ
cours
protocol
modifi
two
patient
extracutan
symptom
desensit
unchang
patient
mild
urticaria
three
patient
toler
subsequ
cours
desensit
without
reaction
fourth
patient
symptom
desensit
longer
requir
carboplatin
five
patient
skin
test
carboplatin
four
posit
wheal
flare
reaction
one
patient
skin
test
respons
carboplatin
becam
neg
desensit
conclus
desensit
protocol
safe
effect
treat
patient
carboplatin
hr
posit
skin
test
carboplatin
suggest
mast
celligemedi
mechan
convers
posit
skin
test
neg
respons
desensit
support
antigenspecif
mast
cell
desensit
hypothesi
associ
food
allergi
acid
reflux
atop
adult
studi
design
retrospect
chart
review
patient
conduct
peopl
test
posit
peopl
test
neg
food
allergi
includ
preval
gastroesophag
reflux
diseas
gerd
total
group
studi
arm
compar
popul
preval
method
result
allergen
specif
ige
test
pharmacia
immunocap
nj
run
food
allergi
review
help
locat
chart
atop
subject
posit
neg
food
allergi
result
review
chart
histori
heartburn
acid
regurgit
diagnosi
gerd
laryngopharyng
reflux
lpr
peptic
ulcer
diseas
pud
popul
preval
ci
acid
reflux
estim
histor
comparison
studi
adult
similar
geograph
locat
result
food
allergi
posit
group
subject
ci
either
histori
heartburn
andor
diagnosi
gerd
lpr
pud
food
allergi
neg
group
ci
acid
relat
disord
total
studi
group
atop
subject
preval
heartburn
gerd
lpr
pud
chi
squar
analysi
preval
acid
reflux
disord
significantli
higher
total
studi
group
compar
popul
preval
preval
acid
reflux
disord
food
allergi
studi
group
popul
show
signific
differ
preval
acid
reflux
disord
significantli
higher
food
allergi
neg
group
compar
preval
popul
signific
differ
preval
acid
reflux
disord
two
studi
group
without
food
allergi
p
conclus
preval
acid
reflux
disord
higher
peopl
food
allergi
compar
popul
miss
statist
signific
patient
without
food
allergi
significantli
higher
preval
acid
reflux
disord
compar
popul
atop
individu
statist
signific
higher
preval
acid
reflux
disord
statist
signific
differ
atop
without
food
allergi
abstract
background
analysi
dispens
pattern
inject
epinephrin
offer
method
studi
characterist
school
children
allerg
anaphylact
reaction
object
analyz
demograph
children
prescrib
inject
epinephrin
massachusett
school
district
divers
racial
ethnic
enrol
pattern
method
school
nurs
school
grade
enrol
student
record
characterist
student
prescrib
inject
epinephrin
includ
number
racial
mix
student
school
student
age
grade
level
race
sex
allerg
disord
requir
epinephrin
survey
school
district
two
predomin
white
suburban
district
enrol
student
one
urban
area
minor
popul
enrol
student
use
epinephrin
peanut
allergi
analyz
detail
result
total
student
three
school
system
dispens
inject
epinephrin
male
outnumb
femal
white
outnumb
nonwhit
two
third
children
dispens
epinephrin
peanut
allergi
second
common
allergi
sting
insect
allergi
rate
dispens
epinephrin
peanut
allergi
lowest
urban
school
district
versu
two
suburban
district
respect
white
peanut
allergi
outnumb
nonwhit
male
outnumb
femal
lowest
rate
prescrib
inject
epinephrin
peanut
allergi
three
school
district
found
nonwhit
school
eightynin
school
children
peanut
allergi
enrol
grade
pk
twice
mani
white
versu
nonwhit
school
children
urban
system
prescrib
inject
epinephrin
peanut
allergi
eight
hispan
asian
student
dispens
inject
epinephrin
peanut
allergi
conclus
first
studi
suggest
may
racial
dispar
preval
childhood
peanut
allergi
one
possibl
explan
dispar
vari
feed
practic
minor
infant
children
may
induc
state
toler
lead
lower
incid
peanut
allergi
fi
hsu
hj
burstein
mc
castel
boston
introduct
trastuzumab
human
kappa
monoclon
antibodi
specif
human
epiderm
growth
factor
receptor
protein
use
treatment
posit
breast
cancer
present
first
report
desensit
trastuzumab
patient
igemedi
reaction
trastuzumab
document
human
antibodi
method
year
old
woman
metastat
invas
ductal
breast
cancer
erpr
posit
strongli
posit
unrespons
convent
therapi
present
anaphylact
reaction
trastuzumab
evalu
rapid
desensit
skin
test
serum
specif
igg
antibodi
patient
previous
receiv
trastuzumab
result
anaphylact
reaction
trastuzumab
consist
diffus
erythema
urticaria
respiratori
distress
laryng
edema
premed
steroid
blockad
slow
infus
prevent
subsequ
reaction
skin
prick
test
trastuzumab
posit
neg
control
confirm
igemedi
mechan
igg
antihuman
antibodi
haha
trastuzumab
confirm
elisa
patient
desensit
trastuzumab
mgkg
intraven
protocol
start
mcgh
increas
rate
everi
minut
final
rate
mgh
total
infus
time
hour
premed
includ
diphenhydramin
prednison
famotidin
montelukast
desensit
confirm
neg
skin
prick
intraderm
test
mgml
mgml
posit
histamin
control
patient
toler
total
weekli
dose
trastuzumab
mgkg
intraderm
skin
test
prior
cours
show
reactiv
indic
resensit
serum
level
tratuzumab
undetect
week
desensit
conclus
allerg
reaction
trastuzumab
rare
includ
anaphylaxi
patient
document
haha
andor
igemedi
reaction
trastuzumab
clinic
symptom
type
imast
cell
mediatorrel
symptom
desensit
allow
continu
administr
treatment
provid
toler
clinic
effect
desensit
patient
ige
haha
antibodi
remain
defin
contrast
report
medic
literatur
detail
medic
aspect
limit
attack
infant
bring
total
report
infant
attack
date
two
infant
suffer
long
term
morbid
die
like
report
medic
literatur
major
adult
long
term
care
facil
although
hospit
overal
individu
stung
die
within
one
week
sting
signific
medic
consequ
sting
report
newspap
report
oppos
report
medic
literatur
conclus
data
suggest
increas
number
fire
ant
attack
occur
medic
facil
chronic
ill
frequent
immobil
patient
come
contact
forag
ant
unattend
infant
privat
home
fire
ant
endem
area
also
appear
risk
factor
determin
individu
stung
sever
injuri
attack
remain
uncertain
presenc
fire
ant
insid
health
care
facil
home
harbing
fire
ant
attack
disabl
infant
occup
hypothes
morbid
determin
number
sting
condit
patient
type
treatment
administ
purpos
determin
gender
confer
risk
posit
penicillin
pcn
skin
test
method
rate
posit
pcn
skin
test
accord
gender
determin
patient
histori
pcn
allergi
undergo
allergi
preoper
evalu
june
june
period
patient
seen
preoper
evalu
clinic
histori
pcn
allergi
compris
studi
popul
univari
logist
regress
analysi
employ
calcul
odd
ratio
confid
interv
ci
gender
differ
rate
posit
pcn
skin
test
multivari
logist
regress
analysi
use
adjust
age
histori
multipl
drug
allergi
pvalu
less
consid
statist
signific
result
patient
underw
skin
test
pcn
patient
chart
avail
review
mean
age
studi
group
year
sixtyfour
patient
posit
skin
test
pcn
femal
male
ci
p
negativeequivoc
pcn
skin
test
femal
versu
male
multivari
logist
regress
analysi
adjust
age
histori
multipl
drug
allergi
femal
gender
like
posit
pcn
skin
test
ci
p
patient
undergo
pcn
skin
test
male
femal
conclus
first
report
show
greater
risk
posit
skin
test
pcn
exist
associ
femal
gender
age
histori
multipl
drug
allergi
unlik
confound
factor
observ
gender
risk
studi
need
identifi
possibl
confound
factor
andor
mechan
explain
risk
fiocchi
pa
restani
cucchiara
g
lombardi
g
magazzu
gl
marseglia
k
pittschiel
tripodi
r
troncon
vierucci
milan
itali
roma
itali
pescara
itali
messina
itali
pavia
itali
bolzano
itali
napoli
itali
firenz
itali
background
cow
milk
substitut
children
allerg
cow
milk
protein
cmp
includ
soybas
formula
cow
milk
hydrolys
neither
rule
sensitis
risk
object
prospect
assess
clinic
toler
ricebas
hydrolys
formula
children
allerg
cow
milk
protein
cmp
consum
rice
openli
patient
method
ninetyseven
children
age
month
immedi
reaction
cow
milk
confirm
dbpcfc
assess
clinic
toler
cow
milk
spt
whole
milk
lactalbumin
ala
lactoglobulin
blg
casein
ca
ca
sigma
chemic
st
loui
mo
whole
milk
ala
blg
ca
specif
ige
determin
perform
use
cap
test
pharmacia
uppsala
sweden
similarli
sensitis
rice
hrf
investig
spt
cap
test
patient
sera
investig
immunoblot
cmp
rice
hrf
heinzplada
milan
itali
dbpcfc
carri
g
rhf
powder
mask
neocat
tm
equival
ml
reconstitut
formula
result
spt
patient
posit
cow
milk
andor
cmp
fraction
mm
wheal
diamet
ige
determin
gave
posit
result
cow
milk
andor
cmp
fraction
patient
test
rice
hrf
immunoblot
posit
ca
ca
ala
blg
bovin
serum
albumin
similarli
although
patient
sera
larg
recogn
rice
one
weakli
react
rhf
challeng
rhf
neg
case
conclus
conclud
despit
frequent
sensitis
rice
children
cma
toler
rice
rhf
clinic
hydrolyz
rice
formula
may
thu
repres
altern
protein
sourc
children
cma
rc
cartwright
wk
dolen
augusta
ga
introduct
convent
treatment
human
semin
fluid
allergi
includ
abstin
barrier
protect
subcutan
immunotherapi
fraction
semin
fluid
treatment
use
local
intravagin
desensit
unfraction
semin
fluid
recent
describ
experi
desensit
method
still
limit
littl
report
longterm
result
method
woman
histori
allerg
rhiniti
asthma
experienc
anaphylaxi
follow
first
unprotect
intercours
sinc
birth
first
child
igemedi
sensit
demonstr
use
specif
ige
test
pharmacia
cap
system
skin
prick
test
use
undilut
semin
fluid
obtain
patient
husband
approv
human
assur
committe
patient
underw
rush
intravagin
desensit
steadili
increas
concentr
semin
fluid
begin
vv
concentr
result
specif
ige
level
human
semin
fluid
kul
skin
prick
test
posit
wheal
mm
diamet
pseudopod
flare
mm
diamet
desensit
success
patient
toler
local
applic
whole
semen
without
signific
reaction
follow
desensit
patient
report
husband
engag
unprotect
intercours
without
local
system
symptom
last
year
sinc
desensit
experienc
anaphylaxi
develop
local
symptom
exposur
semin
fluid
delay
past
day
longest
time
period
exposur
week
becam
pregnant
month
ago
pregnanc
complic
conclus
local
intravagin
desensit
safe
effect
treatment
human
semin
fluid
allergi
patient
delay
semin
fluid
exposur
greater
day
associ
return
symptom
emphas
need
frequent
semin
fluid
exposur
maintain
desensit
l
terracciano
sarratud
fiocchi
p
restani
guerci
milan
itali
background
kiwifruit
allergi
children
seldom
report
reaction
observ
usual
mild
anaphylaxi
describ
document
case
infant
develop
anaphylac
symptom
within
minut
mother
eat
two
kiwifruit
initi
breastfeed
case
histori
fourth
month
boy
admit
emerg
depart
dysphonia
breath
difficulti
generalis
urticaria
angioedema
lip
face
episod
treat
anaphylact
reaction
epinephrin
chlorpheniramin
hydrocortison
sodium
succin
administ
via
percutan
cathet
symptomat
control
achiev
within
minut
day
second
anaphylact
episod
similar
sever
occur
circumst
neither
episod
requir
critic
care
boy
present
two
month
later
clinic
evalu
paediatr
allergi
unit
skin
prick
test
spt
posit
egg
white
yolk
neg
cow
milk
protein
fraction
beef
chicken
pork
codfish
rice
wheat
soybean
maiz
potato
carrot
tomato
bean
pea
celeri
peanut
dermatophagoid
pteronyssinu
farina
grass
banana
spt
kiwifruit
specif
order
exquisit
contact
suspect
induc
posit
wheal
mm
diamet
posit
specif
ige
determin
capfeia
pharmacia
sweden
kiwifruit
kul
cat
dander
kul
egg
white
kul
return
determin
inhal
food
allergen
cutoff
point
kul
total
ige
level
kul
strict
avoid
kiwifruit
breastfeed
mother
prove
effect
noth
untoward
happen
interven
year
current
age
year
boy
free
foodrel
symptom
prickbyprick
test
nativ
allergen
spt
carri
commerci
extract
allergen
associ
literatur
kiwifruit
allergi
neg
comment
report
immedi
reaction
kiwifruit
two
year
case
sever
reaction
via
breastmilk
infant
monosensitis
kiwifruit
indic
nurs
may
repres
hidden
sourc
exposur
older
children
monosensitis
without
prior
sensitis
pollen
describ
major
risk
associ
sever
symptom
sikora
jw
sleasman
n
tangsinmankong
st
petersburg
fl
introduct
treachercollin
syndrom
tc
autosom
domin
disord
abnorm
craniofaci
develop
earli
embryogenesi
known
relationship
new
bone
format
develop
lymphocyt
cytokin
associ
tc
humor
immunodefici
yet
report
present
novel
case
yearold
caucasian
femal
patient
tc
common
variabl
immunodefici
method
patient
present
midfac
hypoplasia
micrognathia
microtia
conduct
hear
loss
cleft
palat
histori
recurr
upper
lower
respiratori
infect
patient
histori
chronic
sinus
recurr
otiti
media
pneumonia
result
bronchiectasi
haemophilu
influenza
staphylococcu
aureu
persist
isol
bronchial
fluid
laboratori
workup
immunodefici
initi
result
immunoglobulin
analysi
reveal
low
igg
mgdl
low
iga
igm
igg
mgdl
low
igg
mgdl
igg
mgdl
low
igg
mgdl
patient
detect
respons
proteinderiv
vaccin
diphtheria
tetanu
polysaccharidederiv
vaccin
pneumococc
baselin
week
immun
b
lymphocyt
enumer
mannosebind
lectin
within
normal
limit
laboratori
find
consist
diagnosi
common
variabl
immunodefici
patient
began
receiv
monthli
dose
mgkgdose
intraven
immunoglobulin
result
clinic
improv
patient
longer
requir
antibiot
therapi
respiratori
infect
pulmonari
function
improv
bronchiectasi
resolv
month
initi
ivig
conclus
find
show
tc
associ
common
variabl
immunodefici
suggest
link
skelet
dysplasia
immunodefici
hartel
jw
sleasman
n
tangsinmankong
st
petersburg
fl
introduct
streptococcu
pneumonia
common
caus
invas
bacteri
infect
human
howev
incid
pneumonia
infect
healthi
adolesc
low
per
year
mannosebind
lectin
mbl
ctype
lectin
play
central
role
innat
immun
respons
activ
classic
complement
pathway
act
opsonin
bind
receptor
sever
studi
demonstr
associ
invas
bacteri
infect
includ
pneumonia
homozyg
mutat
mbl
gene
howev
associ
previous
describ
patient
heterozyg
mutat
method
caucasian
femal
present
second
episod
mening
span
streptococcu
pneumonia
isol
peripher
blood
cultur
occas
lumbar
punctur
reveal
wbc
band
pmn
glucos
mgdl
protein
mgdl
result
consist
bacteri
mening
extens
evalu
predispos
caus
reveal
benign
arnoldchiari
malform
immunolog
evalu
initi
result
evalu
reveal
igg
mgdl
normal
iga
igm
normal
igg
subclass
antibodi
respons
diphtheria
tetanu
vaccin
adequ
antibodi
respons
pneumococc
vaccin
given
year
prior
protect
common
serotyp
test
mcgml
lymphocyt
subset
analysi
within
normal
rang
howelljolli
bodi
detect
peripher
blood
smear
evalu
secondari
immunodefici
neg
includ
hiv
antibodi
elisa
complement
analysi
show
uml
markedli
low
mbl
ngml
genet
analysi
mbl
reveal
heterozyg
mutat
codon
mutat
two
promot
region
homozyg
mutat
hl
variant
heterozyg
mutat
pq
variant
conclus
heterozyg
mutat
mbl
codon
associ
mutat
promot
region
result
sever
impair
mbl
protein
product
may
lead
increas
suscept
invas
bacteri
infect
mening
rational
patient
similar
symptom
may
allerg
nonallerg
mix
rhiniti
trigger
differenti
respond
distinct
medic
assess
st
clinic
patient
popul
character
factor
influenc
appropri
diagnosi
treatment
rhiniti
type
method
use
valid
commerci
questionnair
chart
review
patient
seen
academ
allergi
clinic
assess
number
allerg
vs
irrit
st
demograph
histor
factor
includ
pharmacotherapi
associ
differ
symptom
result
popul
femal
male
consist
individu
mix
rhiniti
histori
women
higher
st
score
men
includ
total
score
vs
unpair
ttest
allergen
score
vs
irrit
score
vs
patient
treat
azelastin
az
intranas
steroid
in
lower
st
score
patient
treat
either
alon
total
st
az
in
allergen
st
az
in
irrit
st
signific
differ
conclus
femal
patient
significantli
higher
symptom
score
total
allerg
irrit
rhiniti
monotherapi
in
az
minim
effect
reduc
st
effect
use
combin
data
demonstr
rhiniti
popul
heterogen
address
differenti
respons
similar
medic
increas
respons
combin
drug
therapi
support
heterogen
pathophysiolog
mix
rhiniti
featur
may
relat
combin
multipl
aeroallergen
air
pollut
exposur
houston
area
introduct
interact
eye
nose
warrant
attent
regard
propag
treatment
allerg
reaction
role
topic
therapi
rhiniti
conjunct
becom
wide
consid
question
therapeut
rout
rais
purpos
elucid
anatom
pharmacokinet
interact
conjunctiv
nasal
mucosa
lead
ration
select
rout
medic
administr
method
studi
investig
effect
ocularli
instil
allergen
induc
sign
symptom
rhinoconjunct
studi
compar
effect
allergen
administ
via
conjunctiv
allergen
challeng
cac
nasal
allergen
challeng
nac
analyz
tear
nasal
secret
ecp
tryptas
studi
also
use
abil
cac
model
induc
rhiniti
sign
symptom
evalu
rel
effect
medic
rout
ocular
v
nasal
spray
v
system
ocular
nasal
spray
v
system
nasal
spray
ocular
v
placebo
result
naccac
studi
reveal
follow
cac
signific
ocular
nasal
sign
symptom
note
follow
nac
nasal
symptom
clinic
signific
nasal
symptom
score
cac
nac
differ
significantli
timepoint
repres
lag
allergen
mediat
movement
eye
nose
measur
level
ecp
tryptas
found
tear
nasal
secret
cac
nasal
secret
except
subject
nac
cac
studi
ocular
therapi
exhibit
greater
efficaci
ocular
itch
relief
p
significantli
differ
nasal
system
therapi
nasal
symptom
relief
eyedropnas
spray
combin
exhibit
significantli
greater
prevent
overal
rhinoconjunct
sign
symptom
nasalsystem
therapi
ocular
therapi
offer
greater
protect
nasal
sign
symptom
compar
placebo
p
conclus
nac
cac
result
support
unidirect
flow
eye
nose
abil
cac
yield
nasal
symptom
efficaci
topic
therapi
tear
due
inflamm
inferior
turbin
would
ocular
symptom
result
nasal
challeng
result
offer
insight
natur
connect
ocular
nasal
mucosa
efficaci
vari
medic
administr
rout
manag
rhinoconjunct
symptom
introduct
asthma
diseas
manag
program
frequent
target
high
util
respons
larg
amount
asthma
cost
identifi
frequent
flier
usual
offer
intervent
includ
case
manag
program
use
approach
usual
demonstr
reduct
util
though
intervent
may
caus
declin
could
also
due
regress
mean
rtm
tendenc
outlier
becom
like
mean
time
studi
measur
rtm
medicaid
hmo
asthma
popul
determin
whether
target
case
manag
effect
independ
phenomenon
hypothes
direct
case
manag
provid
addit
util
reduct
beyond
rtm
method
weight
asthma
util
score
determin
quarterli
member
hmo
asthma
rtm
measur
determin
mani
patient
persist
high
util
quarterli
year
baselin
determin
effect
utilizationdirect
case
manag
number
frequent
flier
baselin
quarter
also
determin
result
total
asthma
frequent
flier
identifi
januari
septemb
individu
continu
frequent
flier
similar
decreas
util
seen
frequent
flier
identifi
begin
quarter
mean
decreas
number
frequent
flier
shown
tabl
repres
substanti
regress
mean
total
number
high
util
baselin
decreas
implement
utilizationdirect
case
manag
independ
regress
mean
also
repres
decreas
health
plan
member
asthma
start
suggest
declin
result
diminish
health
plan
membership
benefit
appear
result
earli
intervent
member
becom
frequent
flier
conclus
utilizationdirect
case
manag
reduc
overal
asthma
util
prevent
member
becom
high
util
earli
stage
program
claim
interven
plan
member
alreadi
high
util
like
take
advantag
regress
mean
studi
indic
high
incid
asthma
among
schoolag
children
preval
increas
signific
number
remain
unidentifi
experi
morbid
includ
school
absente
may
prevent
part
adher
nation
asthma
guidelin
implement
pilot
studi
detect
control
initi
appropri
health
care
among
grade
student
suburban
popul
studi
coordin
middl
school
staff
local
counti
health
depart
screen
paramet
includ
student
questionnair
peak
flow
exercis
peak
flow
assess
frast
spirometri
indic
environment
tobacco
smoke
et
record
result
student
screen
histori
neg
screen
histori
neg
screen
e
histori
posit
screen
histori
suggest
written
screen
neg
screen
exercis
b
histori
posit
screen
c
et
group
b
c
et
group
e
individu
student
result
mail
home
medic
followup
recommend
posit
screen
parent
children
fail
questionnair
exercis
screen
group
b
c
phone
wk
interv
student
ingroup
b
medic
followup
student
group
c
medic
followup
conclus
screen
grade
student
identifi
signific
undetect
known
uncontrol
time
screen
student
strong
suspicion
base
questionnair
accept
exercis
screen
children
screen
suggest
uncontrol
medic
followup
et
increas
home
student
posit
screen
remain
seriou
health
issu
school
screen
merit
mail
phone
followup
insuffici
interven
initi
accept
treatment
refer
redlin
et
al
develop
valid
schoolbas
asthma
allergi
screen
instrument
parent
student
ann
allergi
asthma
immunol
tsanakasjn
et
al
free
run
asthma
screen
test
arch
diseas
american
colleg
allergi
asthma
clinic
immunolog
screen
test
age
acaaiorg
introduct
laboratori
evid
suggest
desloratadin
effect
inhibit
inflammatori
mediat
play
import
role
allerg
also
viral
induc
inflamm
purpos
studi
assess
efficaci
acut
bronchiol
develop
young
children
suffer
concomit
atop
dermat
ad
method
particip
young
boy
gilr
age
suffer
acut
bronchiol
establish
wheez
rhiniti
fever
patient
also
concomit
ad
establish
hanifin
rafka
criteria
patient
alloc
receiv
syrup
formul
desloratadin
eriu
schere
plough
mgday
day
activ
group
desloratadin
treatment
control
group
use
quota
alloc
system
calcul
physic
global
symptom
score
combin
cough
wheez
chest
retract
nasal
flare
block
nose
runni
nose
sore
throat
scale
respiratori
distress
assess
instrument
rdai
examin
patient
baselin
day
therapi
initi
day
normal
bodi
temperatur
respiratori
rate
heart
beat
rate
use
albuterol
result
group
patient
compar
age
gender
famili
histori
asthma
time
onset
acut
respiratori
ill
extent
medic
taken
prior
enter
studi
global
symptom
score
rdai
index
children
evenli
treat
oxygen
oral
theophyllin
mgkgday
adequ
rehydr
day
global
symptom
score
patient
receiv
desloratadin
vs
control
group
day
also
signific
differ
activ
control
group
rdai
index
vs
especi
signific
drop
wheez
score
activ
group
day
respiratoryheart
rate
normal
temperatur
return
normal
use
albuterol
differ
significantli
group
conclus
preliminari
studi
first
show
desloratadin
effect
agent
viral
lower
respiratori
tract
infect
young
children
suffer
ad
encourag
gcp
trial
explor
action
desloratadin
infantil
bronchiol
concomit
ad
hj
su
wt
lin
pj
tsai
cy
huang
pc
wu
tainan
taiwan
increas
preval
childhood
asthma
observ
across
world
found
associ
partli
indoor
pollut
includ
bioaerosol
exposur
meanwhil
adequ
ventil
shown
effect
dilut
indoor
air
pollut
limit
data
avail
address
directli
ventil
rate
implic
childhood
respiratori
symptom
studi
aim
examin
concentr
distribut
select
indoor
air
pollut
includ
bioaerosol
domest
environ
assess
effect
ventil
rate
character
trace
ga
concentr
decay
method
concentr
variat
abovement
air
pollut
studi
subject
chosen
prior
citywid
questionnair
survey
base
posit
respons
inquiri
physiciandiagnos
asthmat
statu
wheez
symptom
past
month
environment
assess
includ
ventil
air
qualiti
measur
conduct
twice
earli
winter
earli
summer
respiratori
health
diari
pefr
peak
expiratori
flow
rate
record
week
concurr
sampl
activ
increas
ventil
rate
statist
associ
decreas
indoor
concentr
tvoc
adjust
sex
age
select
hous
characterist
tvoc
concentr
report
cough
studi
children
nasal
congest
indoor
bacteri
concentr
morn
pefr
less
similar
multivari
logist
regress
data
collect
winter
studi
summer
signific
relationship
ventil
rate
morn
pefr
less
studi
children
multivari
logist
regress
studi
identifi
less
report
childhood
respiratori
symptom
especi
cough
morn
pefr
less
associ
increas
ventil
rate
higher
level
indoor
air
pollut
appear
present
greater
frequenc
symptom
studi
suggest
quantit
proper
manag
ventil
effici
may
benefici
control
childhood
respiratori
ill
adjust
sex
age
environment
tobacco
exposur
use
incens
air
condition
p
ns
statist
signific
whole
model
test
background
moderatetosever
allerg
asthma
substanti
impact
patient
asthmarel
qualiti
life
arql
addit
asthma
symptom
allerg
rhiniti
rhinosinus
relat
comorbid
often
appar
patient
sever
diseas
make
difficult
treat
despit
guidelineconsist
care
mani
patient
still
experi
variabl
asthma
control
signal
unmet
need
within
popul
omalizumab
recent
demonstr
clinic
efficaci
safeti
treat
asthma
object
aim
paper
summar
arql
outcom
associ
omalizumab
therapi
moderatetosever
allerg
asthma
method
perform
systemat
review
arql
data
clinic
studi
report
publish
clinic
trial
omalizumab
arql
measur
juniperasthma
qualiti
life
questionnair
aqlq
result
statist
signific
result
arql
endpoint
consist
favor
omalizumab
placebo
magnitud
chang
arql
consist
align
clinic
endpoint
moder
larg
effect
size
omalizumab
group
maintain
throughout
clinic
trial
program
doubleblind
extens
phase
howev
placebo
group
also
experienc
withingroup
improv
moder
effect
size
metaanalysi
indic
fold
increas
larg
point
improv
overal
aqlq
score
omalizumabtr
group
compar
placebo
stabil
steroidreduct
phase
clinic
trial
conclus
consist
posit
impact
omalizumab
arql
outcom
clinic
trial
program
provid
evid
valu
adjunct
therapi
patient
moderatetosever
allerg
asthma
signific
differ
larg
effect
size
observ
despit
fact
control
group
receiv
activ
guidelineconsist
treatment
produc
substanti
placebo
effect
improv
observ
overal
symptom
activ
emot
environment
dimens
aqlq
indic
omalizumab
produc
benefit
arql
patient
moderatetosever
allerg
asthma
background
omalizumab
monoclon
antiig
antibodi
significantli
improv
asthmarel
qualiti
life
arql
patient
moderatesever
allerg
asthma
express
symptom
despit
moderatehigh
inhal
corticosteroid
ic
dose
mean
score
mask
underli
variabl
arql
outcom
investig
examin
variabl
outcom
elucid
specif
impact
omalizumab
treatment
method
aqlq
data
two
random
doubleblind
placebocontrol
clinic
trial
pool
assess
underli
variabl
mean
score
identifi
key
driver
arql
treatmenteffect
differ
juniperasthma
qualiti
life
questionnair
aqlq
omalizumab
placebo
activ
control
patient
result
correl
aqlq
clinic
outcom
low
moder
best
aqlq
assess
captur
patient
benefit
supplement
clinic
outcom
measur
across
compon
item
aqlq
patient
receiv
omalizumab
improv
patient
receiv
placebo
activ
control
p
omalizumab
patient
report
greatest
improv
reduc
wake
symptom
morn
symptom
domain
vs
p
limit
activ
done
activ
domain
vs
p
fear
medic
avail
emot
domain
vs
p
symptom
expos
dust
environ
domain
vs
p
compar
placebo
activ
control
patient
conclus
arql
assess
provid
complementari
nonoverlap
inform
clinic
benefit
distinct
clinic
outcom
measur
examin
underli
variabl
aqlq
mean
score
itemlevel
respons
extend
previous
publish
result
omalizumab
treatment
effect
show
aggreg
arql
improv
omalizumab
patient
strongli
influenc
symptom
activ
improv
brimer
k
malhi
c
adam
c
dinakar
kansa
citi
mo
introduct
desir
belong
group
power
motiv
except
strong
adolesc
popul
asthma
diseas
make
peopl
feel
differ
percept
may
imping
patient
adher
medic
regimen
hypothes
belong
club
everi
member
asthma
may
encourag
identif
adolesc
asthmat
peer
mitig
percept
differ
object
investig
factor
make
asthmat
adolesc
feel
differ
explor
hypothesi
group
activ
asthma
club
would
help
adolesc
asthmat
feel
less
differ
method
part
ongo
survey
children
asthma
age
year
offer
anonym
questionnair
primari
care
adolesc
clinic
hospit
questionnair
includ
multiplechoic
openend
question
design
explor
feel
respond
respons
numer
talli
report
percentag
result
present
time
survey
propos
complet
one
third
youth
asthma
answer
survey
neg
feel
regard
asthma
nearli
forti
percent
respond
report
diagnosi
made
feel
differ
healthi
peer
fortyf
percent
respond
felt
restrict
exclud
school
activ
athlet
club
due
asthma
onethird
feel
uncomfort
take
inhal
front
friend
respond
indic
enjoy
group
activ
major
respond
rate
play
sport
favorit
group
activ
conclus
almost
forti
percent
asthmat
youth
survey
indic
asthma
made
feel
differ
result
restrictionexclus
school
activ
athlet
club
overwhelm
major
express
prefer
particip
group
activ
particularli
recreat
sport
social
prefer
toward
group
activ
may
incorpor
intervent
asthma
club
help
asthmat
youth
adjust
diseas
treatment
regimen
introduct
airway
hyperrespons
ahr
exagger
narrow
airway
respons
stimuli
allergen
histamin
cold
air
ahr
characterist
featur
asthma
link
chronic
airway
inflamm
phosphodiesteras
enzym
found
key
inflammatori
cell
involv
pathophysiolog
asthma
inhibitor
prevent
breakdown
cyclic
adenosin
monophosph
natur
modul
inflamm
roflumilast
investig
oral
oncedaili
inhibitor
shown
antiinflammatori
activ
vitro
vivo
studi
examin
effect
singl
dose
roflumilast
chang
ahr
follow
allergeninduc
asthmat
reaction
patient
mild
asthma
method
doubleblind
random
crossov
studi
consist
treatment
period
separ
washout
period
total
patient
forc
expiratori
volum
one
second
fev
predict
hyperrespons
histamin
provoc
concentr
caus
drop
fev
pc
fev
mgml
random
receiv
singl
dose
oral
roflumilast
placebo
day
treatment
period
follow
allergen
challeng
min
medic
histamin
provoc
perform
h
intak
studi
drug
result
chang
fev
min
roflumilast
administr
suggest
absenc
direct
acut
bronchodil
allergen
challeng
elicit
earli
late
asthmat
reaction
attenu
singl
dose
roflumilast
histamin
pc
fev
patient
treat
roflumilast
decreas
lesser
extent
patient
treat
placebo
chang
pc
fev
baselin
challeng
mgml
mean
sd
placebo
mgml
roflumilast
magnitud
chang
pc
fev
statist
significantli
differ
placebo
roflumilast
treatment
group
thu
roflumilast
decreas
develop
ahr
approxim
doublingdilut
conclus
singl
dose
oral
roflumilast
attenu
allergeninduc
ahr
data
provid
evid
roflumilast
may
provid
antiinflammatori
activ
vivo
may
effect
treatment
patient
asthma
introduct
past
year
track
pediatr
asthma
admiss
evalu
huntington
memori
hospit
fall
winter
month
octmarch
note
x
increas
number
asthma
admiss
evalu
compar
spring
summer
april
septemb
patient
encounann
allergi
asthma
immunolog
ter
year
analyz
potenti
caus
increas
diesel
particul
estim
increas
fall
versu
spring
found
burbank
citi
adjac
pasadena
pollut
particl
combust
fossil
fuel
may
act
immunoadjuv
allergen
exposur
demonstr
experiment
mice
human
nasal
exposur
studi
method
computer
analysi
asthma
admiss
evalu
calcul
accord
establish
code
acut
chronic
reactiv
airway
diseas
infecti
diseas
patient
analyz
standard
asthma
questionnair
also
pollen
mold
count
well
diesel
particul
meteorolog
condit
studi
result
similar
number
viral
infect
occur
fall
spring
among
preval
pollen
mold
chines
elm
pollen
sept
oct
weed
pollen
juli
dec
newli
recogn
aureobasidium
mold
nov
march
pollen
grain
fragment
releas
respirables
debri
load
allergen
taylor
et
al
taylor
et
al
conidia
aureobasidium
also
respir
size
identifi
sequenc
analysi
fine
particul
air
pollut
contain
diesel
particl
increas
fall
winter
southern
california
conclus
incid
asthma
outbreak
may
vari
air
pollut
level
immedi
environ
pollen
fragment
particl
fossil
fuel
combust
deposit
similar
region
lower
airway
rainfal
increas
fall
winter
coincid
increas
mold
aureobasidium
aureobasidium
recent
discov
high
concentr
pasadena
known
allergen
could
factor
increas
asthma
mixtur
pollen
mold
fine
combust
particl
may
relev
increas
incid
asthma
fall
winter
month
pasadena
background
previous
note
tree
ragwe
pollen
grain
airborn
daili
period
respect
season
aaaai
acaai
grass
level
lower
tree
weed
aaaai
nab
chose
longer
daili
interv
examin
six
hour
tree
one
hour
ragwe
three
hour
method
twentyfour
hour
microscop
slide
sampl
collect
use
burkard
day
air
sampler
slide
examin
x
along
singl
longitudin
travers
presenc
absenc
grass
pollen
note
per
sixhour
segment
six
success
field
result
presenc
airborn
grass
pollen
daili
segment
spars
first
two
week
may
gradual
increas
next
day
detect
daili
segment
end
june
ammophila
arenaria
aa
highli
resili
grass
habitat
europ
north
america
australia
new
zealand
south
africa
mediterranean
use
predominantli
dune
stabil
patient
atop
diseas
includ
allerg
reaction
pollen
transfer
coastal
region
order
minim
pollen
exposur
spite
presenc
aa
pollen
patient
experi
allergi
relief
coast
studi
examin
contradict
presenc
strong
grass
allergen
absenc
allerg
symptom
atop
patient
whether
allerg
crossreact
among
differ
type
grass
pollen
includ
aa
pollen
adult
patient
present
symptom
grass
pollen
allergi
underw
prick
test
rast
test
grass
pollen
mix
extract
aa
pollen
subject
show
posit
result
prick
rast
test
aa
extract
subsequ
test
via
rhinomanometri
reaction
aa
use
prick
test
solut
subject
show
posit
reaction
prick
test
aa
extract
grass
pollen
mix
show
specif
antibodi
sera
show
elev
specif
ige
level
specif
reaction
protein
band
aa
sera
incub
grass
pollen
extract
almost
specif
band
previous
detect
aa
inhibit
patient
high
level
total
specif
ige
aa
show
weak
band
inhibit
demonstr
allergen
aa
compar
data
coastal
mainland
weather
station
june
juli
coastal
wind
speed
averag
ms
inland
wind
speed
averag
ms
high
wind
speed
like
dilut
pollen
concentr
base
find
invers
relationship
wind
speed
pollen
concentr
dispers
ragwe
pollen
hypothes
concentr
aa
pollen
may
similarli
influenc
sensit
patient
report
allerg
symptom
coastal
area
inhabit
aa
plant
indic
natur
condit
either
plant
modifi
pollen
allergen
environment
condit
includ
salt
aerosol
wind
pattern
topographi
light
exposur
caus
modif
pattern
like
becom
dramat
effect
global
climat
chang
transform
natur
environ
find
may
also
becom
relev
grass
allergi
type
asthma
common
chronic
inflammatori
disord
airway
increas
preval
past
decad
character
airway
obstruct
airway
inflamm
airway
hyperrespons
ahr
nonspecif
stimuli
studi
examin
effect
novel
class
molecul
inhibit
antigeninduc
earli
late
allerg
respons
ear
lar
ahr
airway
eosinophilia
mous
guinea
pig
model
asthma
pulmonari
function
measur
consciou
unrestrain
anim
wholebodi
plethysmographi
anim
sensit
ovalbumin
ova
intraperiton
alum
follow
treatment
ip
twice
daili
day
last
dose
anim
challeng
ovalbumin
pulmonari
function
record
ear
lar
hr
later
ahr
follow
bronchoalveolar
lavag
blood
lung
tissu
collect
treatment
significantli
attenu
lar
ovasensit
challeng
mice
guinea
pig
effect
ear
ahr
methacholin
mice
histamin
guinea
pig
prevent
treatment
attenu
rise
total
number
inflammatori
cell
lung
almost
ablat
rise
bal
eosinophilia
lung
due
antigen
sensit
challeng
effect
pulmonari
function
airway
inflamm
ovasensit
challeng
mice
compar
dexamethason
model
asthma
data
suggest
underli
pathophysiolog
chang
allerg
airway
inflamm
therefor
could
prove
benefici
treatment
bronchial
asthma
madison
wi
portland
milwauke
wi
normal
il
denver
co
lo
angel
ca
fremont
ca
introduct
daclizumab
human
monoclon
antibodi
direct
receptor
chain
approv
prevent
renal
allograft
reject
evalu
treatment
asthma
daclizumab
inhibit
activ
human
lymphocyt
block
prolifer
reduc
product
cytokin
recent
report
daclizumab
improv
pulmonari
function
phase
ii
trial
patient
moder
sever
chronic
persist
asthma
jaci
report
addit
data
trial
possibl
role
daclizumab
antiinflammatori
agent
affect
asthma
outcom
method
nonsmok
asthmat
age
baselin
predict
despit
use
mcg
daili
inhal
triamcinolon
taa
equival
enrol
random
multicent
doubleblind
placebocontrol
trial
patient
random
iv
daclizumab
mgkg
follow
mgkg
everi
week
placebo
ad
stabl
dose
taa
start
week
patient
underw
reduct
taa
everi
week
continu
studi
drug
week
result
patient
daclizumab
demonstr
prolong
time
exacerb
requir
system
steroid
rescu
compar
placebo
patient
exacerb
rate
reduc
daclizumab
group
compar
placebo
group
steroidst
steroidtap
phase
vs
patient
daclizumab
demonstr
decreas
peripher
eosinophil
count
baselin
week
mm
vs
placebo
mm
daclizumabtr
patient
elev
baselin
serum
eosinophil
cation
protein
secp
signific
reduct
secp
baselin
day
compar
placebo
patient
p
peripher
eosinophil
decreas
significantli
daclizumab
patient
asthma
exacerb
compar
increas
daclizumabtr
patient
least
one
exacerb
conclus
daclizumab
reduc
time
frequenc
exacerb
treat
asthmat
mechan
effect
remain
fulli
elucid
initi
find
suggest
associ
reduct
circul
eosinophil
eosinophil
product
may
play
role
therapeut
effect
hae
genet
defici
caus
decreas
esteras
inhibitor
level
rare
condit
approxim
preval
individu
manifest
acut
attack
swell
involv
larynx
potenti
life
threaten
condit
gi
tract
caus
syndrom
similar
acut
abdomin
catastroph
skin
soft
tissu
patient
includ
limb
face
extern
genitalia
approv
therapi
acut
attack
usa
pathogenesi
potenti
fatal
condit
thought
due
excess
activ
plasma
kallikrein
specif
highli
activ
ki
pm
recombin
inhibitor
human
plasma
kallikrein
undergo
evalu
hae
cardiopulmonari
bypass
anim
free
product
doubl
blind
randomis
drug
placebo
placebo
control
dose
ascend
studi
acut
attack
hae
run
usa
european
union
four
dose
group
patient
includ
studi
dose
primari
outcom
variabl
proport
patient
achiev
signific
clinic
respons
within
hour
administr
therapi
safeti
secondari
endpoint
includ
site
respons
dose
respons
median
time
signific
respons
site
dose
group
met
primari
endpoint
patient
signific
improv
within
hour
placebo
respons
rate
differ
p
patient
receiv
respond
median
time
minut
differ
proport
case
respond
within
hour
three
anatom
site
time
signific
respons
significantli
differ
dose
group
anatom
site
safeti
profil
compar
patient
treat
placebo
term
sae
ae
conclus
doubl
blind
studi
shown
statist
superior
placebo
least
safe
placebo
drug
effect
treat
hae
site
includ
larynx
repres
import
advanc
manag
hae
ar
among
common
chronic
childhood
disord
effect
treat
intranas
inhal
glucocorticosteroid
ic
recent
evid
suggest
intranas
ic
therapi
may
suppress
hpa
axi
function
decreas
growth
veloc
studi
report
followup
data
children
femal
african
american
age
year
mean
year
entri
enrol
longterm
growth
trial
intranas
taa
treatment
ar
primari
measur
includ
height
veloc
bone
miner
densiti
bmd
serum
osteocalcin
salivari
cortisol
level
subject
follow
expect
ageappropri
growth
veloc
averag
growth
veloc
cmyear
girl
boy
age
year
respect
cmyear
girl
boy
age
year
respect
mean
std
bmd
mean
serum
osteocalcin
level
ngml
mean
salivari
cortisol
level
nml
entri
followup
respect
result
demonstr
signific
effect
one
year
intranas
treatment
taa
growth
veloc
hpa
function
children
ar
patient
male
femal
rang
age
year
year
receiv
dose
rang
inject
week
patient
evalu
symptom
score
pulmonari
function
pft
blood
eosinophil
count
bec
medic
use
allergi
skin
test
st
initi
perform
prick
neg
intraderm
id
wv
neg
id
wv
skin
test
perform
immedi
minut
administr
chang
pft
bec
howev
signific
reduct
symptom
score
includ
nocturn
asthma
exercis
toler
sens
well
addit
parenthet
reduct
nasal
symptom
also
signific
declin
medic
use
especi
albuterol
st
declin
patient
evalu
dramat
mani
sever
individu
allergen
st
went
prick
posit
id
wv
neg
moreov
st
declin
instanc
minut
administr
except
patient
addit
asthma
one
patient
allerg
bronchopulmonari
aspergillosi
anoth
allerg
fungal
sinus
three
patient
test
posit
prick
test
mous
antigen
instanc
becam
neg
administr
patient
toler
without
problem
conclud
administr
associ
improv
symptom
decreas
use
medic
addit
promin
declin
st
mark
minut
administr
compar
immedi
prior
administr
explan
find
appar
appear
safe
administ
patient
even
demonstr
specif
ige
mous
antigen
st
ap
baptist
ts
tang
jl
baldwin
ann
arbor
mi
introduct
academ
medic
institut
pressur
shorten
elimin
resid
elect
rotat
due
feder
workhour
restrict
unknown
affect
knowledg
referr
pattern
resid
faculti
physician
object
studi
examin
factor
associ
resid
faculti
perceiv
knowledg
referr
pattern
toward
allergyimmunolog
ai
method
questionnair
sent
primari
care
physician
one
academ
center
address
past
histori
ai
referr
referr
intent
condit
may
seen
allergist
perceiv
ai
knowledg
independ
variabl
includ
histori
ai
rotat
gender
depart
year
trainingpractic
histori
referr
allergist
result
complet
survey
return
use
logist
regress
forward
select
found
resid
physician
cohort
advanc
year
train
histori
ai
rotat
like
increas
past
histori
referr
allergist
increas
referr
intent
chronic
sinus
allergist
increas
perceiv
ai
knowledg
faculti
physician
cohort
histori
ai
rotat
like
increas
perceiv
knowledg
ai
addit
pediatr
faculti
physician
like
refer
asthma
chronic
eczema
allergist
faculti
depart
final
faculti
physician
past
histori
referr
allergist
like
refer
asthma
allerg
rhiniti
allergist
conclus
factor
associ
resid
faculti
physician
perceiv
knowledg
referr
histori
referr
intent
toward
ai
differ
resid
senior
train
level
histori
ai
rotat
appear
import
faculti
histori
ai
rotat
pediatr
depart
past
histori
referr
allergist
appear
import
given
histori
ai
rotat
may
increas
perceiv
knowledg
referr
pattern
toward
ai
elimin
ai
rotat
medic
institut
may
import
consequ
patient
field
ai
recent
anecdot
report
suggest
hbv
may
effect
treatment
patient
multipl
sclerosi
ms
movement
patient
zealou
lay
practition
receiv
multipl
repeat
bee
sting
sinc
practic
real
risk
possibl
fatal
allerg
reaction
well
emot
econom
cost
properli
conduct
studi
safeti
efficaci
need
purpos
present
phase
pilot
studi
evalu
safeti
hbv
extract
patient
pfm
total
evalu
bee
venom
nonallerg
patient
pfm
year
enrol
randomli
divid
group
receiv
increas
allergen
dose
immun
schedul
one
year
hyperreact
hbv
evalu
questionnair
px
hematolog
metabol
immunolog
test
includ
skin
test
possibl
benefici
respons
therapi
evalu
questionnair
function
neurolog
test
fnt
chang
measur
somatosensoryevok
potenti
sep
prior
complet
studi
seriou
advers
allerg
reaction
observ
subject
even
highest
dose
bee
venom
therapi
although
subject
worsen
neurolog
symptom
cours
bee
venom
therapi
requir
termin
respons
could
ascrib
side
effect
hbv
spontan
worsen
neurolog
diseas
independ
treatment
sinc
correl
event
bee
venom
inject
remain
felt
therapi
beneficialther
chang
either
fnt
sep
measur
studi
present
report
repres
first
control
studi
evalu
safeti
hbv
possibl
adjunct
treatment
multipl
sclerosi
preliminari
safeti
studi
suggest
administr
repeat
inject
hbv
stepup
dosag
regimen
appropri
select
nonhbv
allerg
patient
ms
seriou
advers
allerg
reaction
small
number
subject
studi
permit
conclus
regard
efficaci
therefor
provid
littl
evid
support
use
hbv
treatment
ms
much
larger
care
conduct
multicent
studi
would
requir
establish
efficaci
finegold
new
york
ny
rush
immunotherapi
rit
benefit
induc
immunolog
desensit
shorter
period
time
convent
immunotherapi
howev
increas
risk
system
reaction
util
acceler
schedul
past
radiocontrast
media
reaction
significantli
reduc
use
standard
protocol
modif
protocol
use
prior
rit
oral
premed
consist
mgm
prednison
hour
hour
hour
prior
rit
fexofenadin
mgm
hour
hour
prior
procedur
ranitidin
mgm
hour
prior
rit
patient
toler
premed
well
sign
consent
obtain
prior
rit
patient
desensit
offic
set
appropri
therapi
anaphylaxi
avail
without
indwel
intraven
line
inject
gener
began
dilut
anticip
mainten
solut
doubl
everi
minut
hour
patient
observ
hour
prior
discharg
manner
patient
desensit
half
day
session
patient
inject
week
week
week
dose
increas
full
mainten
dose
reaction
occur
process
appropri
decreas
util
techniqu
patient
treat
averag
age
year
old
year
age
patient
allerg
rhiniti
asthma
insect
allergi
patient
complic
medic
ill
exclud
nine
patient
system
reaction
requir
inject
epinephrin
among
symptom
experienc
wheez
nasal
congest
flush
patient
requir
second
inject
epinephrin
intraven
fluid
hospit
patient
reaction
rate
patient
treat
inject
inject
given
rush
protocol
result
typic
increas
rate
reaction
rit
howev
system
mostli
mild
respond
therapi
one
case
delay
hour
reaction
thu
premed
prevent
system
reaction
seem
modifi
make
rit
offic
set
practic
effect
therapi
previous
shown
oligonucleotid
consist
novel
structur
synthet
immunostimulatori
motif
cpr
r
synthet
purin
moieti
refer
secondgener
immunomodulatori
oligonucleotid
imo
induc
potent
immun
respons
prevent
ovainduc
allerg
asthma
mous
model
present
studi
examin
local
system
immun
respons
imo
follow
intranas
administr
naiv
mice
studi
show
imo
produc
higher
level
serum
local
compar
next
examin
abil
sc
administr
imo
revers
ovainduc
immun
respons
murin
model
asthma
treatment
ovasensit
challeng
mice
imo
either
rout
administr
suppress
level
increas
ifngamma
secret
spleen
cell
cultur
lung
homogen
imo
decreas
level
serum
ige
induc
higher
level
total
ovaspecif
titer
serum
balf
rout
imo
deliveri
show
similar
efficaci
serum
balf
immunoglobulin
level
sc
deliveri
result
stronger
system
effect
spleen
cell
cytokin
product
rout
administr
produc
stronger
local
effect
lung
cytokin
imo
also
decreas
eosinophil
balf
suppress
inflammatori
cell
infiltr
goblet
cell
hyperplasia
lung
effect
lung
superior
administr
imo
sc
administr
studi
understand
effect
low
multipl
dose
singl
higher
dose
administ
imo
naiv
mice
suggest
low
multipl
dose
induc
strong
respons
local
singl
higher
dose
produc
higher
system
respons
find
suggest
secondgener
imo
contain
cpr
dinucleotid
potent
revers
ovainduc
immun
respons
strong
type
cytokin
induct
ovasensit
challeng
mice
deliveri
superior
sc
deliveri
revers
ovainduc
airway
inflamm
mucos
secret
show
ait
medic
inappropri
lack
document
necess
initi
continu
andor
strong
contraind
review
record
method
audit
conveni
sampl
record
document
necess
continu
ait
use
checklist
base
oig
report
includ
follow
criteria
appropri
diagnosi
specif
justif
exclus
strong
contraind
sign
inform
consent
written
physician
order
least
annual
reevalu
continu
ait
result
first
chart
alphabet
file
total
ait
chart
review
patient
f
rang
age
yr
mean
yr
mean
durat
ait
yr
rang
yr
indic
ait
includ
allerg
rhiniti
alon
asthma
chronic
sinus
asthma
alon
venom
anaphylaxi
initi
document
necess
seven
chart
written
order
initi
ait
nine
lack
sign
consent
form
strong
contraind
found
peak
flow
document
show
asthma
case
wellcontrol
three
episod
aitinduc
anaphylaxi
requir
epinephrin
occur
ait
subsequ
resum
welltoler
seventeen
chart
document
reevalu
preced
month
includ
document
reevalu
previou
month
ait
discontinu
ait
consid
patient
yr
ait
respect
still
receiv
mainten
dose
estim
time
complet
review
min
per
chart
interpret
intern
chart
review
adher
ait
practic
paramet
use
checklist
quickli
easili
assess
document
medicar
reimburs
patient
safeti
object
immunotherapi
accept
mode
treatment
children
suffer
allerg
rhiniti
allerg
asthma
studi
demonstr
rapid
allergen
vaccin
rav
safe
convent
allergen
vaccin
cav
children
rav
may
also
improv
patient
adher
studi
design
pediatr
patient
year
age
diagnos
allerg
rhiniti
andor
mild
sever
asthma
underw
rav
hour
period
officebas
set
patient
premed
prednison
antagonist
day
prior
procedur
patient
monitor
reaction
procedur
continu
cav
schedul
adher
review
subsequ
result
total
pediatr
patient
underw
rav
util
hour
protocol
patient
male
femal
patient
allerg
rhiniti
asthma
chronic
sinus
procedur
patient
experienc
system
reaction
none
experienc
true
anaphylaxi
seven
eight
patient
suffer
system
reaction
patient
asthma
inhal
corticosteroid
three
eight
patient
male
five
eight
femal
everi
system
reaction
occur
within
minut
inject
treatment
usual
includ
one
combin
follow
nebul
breath
treatment
albuterol
two
spray
nostril
azelastin
diphenydramin
taken
oral
intramuscularli
everi
patient
treat
discharg
within
two
hour
one
requir
treatment
subcutan
epinephrin
treatment
recurr
symptom
hospit
patient
continu
convent
allergen
immunotherapi
regimen
follow
rapid
protocol
reach
mainten
dose
typic
month
buildup
period
save
patient
reach
efficaci
dosag
almost
immedi
adher
rate
month
respect
conclus
effect
dose
allergen
vaccin
safe
reach
use
hour
protocol
annal
allergi
asthma
immunolog
children
advantag
rav
cav
includ
improv
adher
almost
immedi
clinic
efficaci
decreas
cost
introduct
studi
involv
allergen
immunotherapi
ait
further
understand
cat
allergen
proteas
dust
mite
allergen
impact
data
assess
object
evalu
ait
prescrib
trend
year
focus
new
prescript
publish
data
regard
specif
prescrib
recommend
method
retrospect
review
ait
prescript
central
allergi
extract
laboratori
databas
perform
respect
publish
literatur
find
recommend
regard
ubiquit
natur
cat
allergen
effect
dose
cat
antigen
combin
proteas
contain
extract
suscept
degrad
dust
mite
antigen
dose
use
hous
dust
versu
dust
mite
antigen
result
cat
allergen
includ
new
allergi
immunotherapi
prescript
review
includ
new
prescript
statist
signific
increas
p
past
year
mean
quantiti
cat
antigen
includ
new
prescript
unchang
new
prescript
written
manufactur
recommend
mainten
dose
significantli
less
written
level
p
signific
chang
percentag
extract
combin
antigen
proteas
antigen
suscept
degrad
prescript
contain
alternaria
andor
cockroach
antigen
mix
one
antigen
suscept
degrad
extract
still
combin
mean
volum
dust
mite
mix
contain
prescript
prescript
contain
dust
mite
rose
use
hous
dust
unchang
period
prescript
conclus
although
percentag
cat
contain
extract
increas
significantli
dose
cat
allergen
remain
unchang
despit
publish
literatur
recommend
higher
volum
proteasecontain
allergen
prescrib
pattern
significantli
chang
young
stage
life
crucial
period
aeroallergen
sensit
consid
immatur
neonat
immun
system
may
lead
tcell
anergi
deviat
toward
respons
mice
aim
work
evalu
influenc
oligodeoxynucleotid
contain
cpg
motif
cpgodn
ovalbumin
ova
blomia
tropicali
bt
immun
earli
life
compar
adult
stage
three
day
old
asn
mice
immun
ova
al
oh
boost
day
immun
dai
bled
dai
group
mice
receiv
cpgodn
controlodn
associ
ova
immun
boost
anim
three
group
ova
ovacpg
ovaco
kill
day
old
spleen
collect
prepar
cultur
eight
week
old
femal
asn
mice
immun
ova
al
oh
boost
dai
bled
dai
group
mice
receiv
cpgodn
controlodn
associ
ova
immun
anim
three
group
challeng
month
immun
bled
day
later
similar
protocol
perform
use
blomia
tropicali
bt
extract
place
ova
neonat
adult
coadministr
cpgodn
ova
bt
abl
significantli
decreas
specif
ige
antibodi
level
increas
product
moreov
cpgodn
decreas
specif
level
bt
immun
coadministr
controlodn
neonat
decreas
antiova
product
ovachalleng
month
later
adult
immun
similar
respons
detect
group
receiv
cpgodn
associ
ova
show
decreas
antiova
ige
enhanc
level
analysi
cell
divis
neonat
lymphocyt
flow
cytometri
show
decreas
prolifer
ovacpg
mice
group
ova
stimul
effect
seen
either
b
cell
cell
result
show
immun
allergen
ova
bt
associ
cpgodn
decreas
type
hypersensit
respons
pattern
antibodi
product
suggest
respons
induc
cpgodn
establish
memori
respons
find
may
impli
use
cpgodn
earli
life
seem
benefici
strategi
modul
prevent
develop
allerg
diseas
n
horn
capetand
frieri
east
meadow
ny
introduct
shown
dust
mite
allergen
affect
function
airway
epitheli
cell
winton
et
al
br
j
pharm
previou
experi
show
aggreg
presenc
dermatophagoid
pteronyssinu
dp
capetand
et
al
j
clin
path
hypothes
epitheli
damag
associ
airway
remodel
character
fibroblast
dysregul
evalu
respons
fibroblast
damag
airway
epitheli
cell
bioactiv
serumfre
condit
media
dptreat
cell
dpcm
assay
nhlf
method
experi
use
insulintransferrinselenium
supplement
dmem
dpcm
gener
treat
auml
dp
alkabello
ad
confluent
nhlf
hour
cultur
without
dp
cm
ad
confluent
nhlf
control
cell
morpholog
densiti
evalu
microscopi
mtt
assay
respect
data
analyz
anova
follow
studentneumankeul
snk
p
power
analysi
result
confluent
nhlf
treat
dpcm
show
decreas
cell
densiti
figur
increas
aggreg
rel
cm
alon
nhlf
alon
direct
addit
auml
dp
dp
show
weak
aggreg
aggreg
nhlf
show
viabil
grew
confluenc
subcultur
serumsuppl
media
conclus
nhlf
aggreg
greater
cell
densiti
lower
dpcm
cm
dp
suggest
dptreat
cell
releas
unidentifi
factor
factor
contribut
nhlf
aggreg
possibl
apoptosi
identif
factor
would
increas
understand
fibroblast
respons
epitheli
cell
exposur
dp
may
involv
airway
remodel
featur
chronic
sever
asthma
jt
zimmermann
yc
huang
frieri
east
meadow
ny
introduct
budesonid
demonstr
inhibit
tgf
gmcsf
ragwe
dustmit
dm
stimul
human
alveolar
epitheli
cell
j
allergi
clin
immunol
ann
allergi
asthma
immunolog
rant
product
express
dm
stimul
cell
recent
shown
inhibit
budesonid
allergi
asthma
proc
press
histamin
known
influenc
immun
respons
regul
cytokin
synthesi
allergi
studi
examin
effect
budesonid
presenc
histamin
product
express
cell
method
pulmonari
epitheli
cell
cultur
dmem
hour
presenc
auml
dm
histamin
budesonid
product
measur
sensit
elisa
mrna
measur
qualit
rtpcr
use
standard
primer
gapdh
control
result
cell
stimul
dm
pgml
p
budesonid
alon
decreas
level
pgml
p
combin
histamin
decreas
level
pgml
p
rel
intens
mrna
express
reduc
dmstimul
cell
control
cell
budesonid
conclus
budesonid
combin
histamin
show
greater
inhibit
product
cell
budesonid
alon
possibl
increas
cell
membran
permeabl
cr
oliveira
ae
fusaro
jr
victor
ea
futata
ca
brito
aj
duart
mn
sato
paulo
brazil
antigendriven
bystand
suppress
induc
oral
toler
could
interest
approach
allergi
field
consid
high
incid
new
allergen
sensit
atop
individu
address
influenc
nonrel
allergen
exposur
type
hypersensit
respons
mite
blomia
tropicali
bt
ovalbumin
ova
mice
verifi
oral
toler
effect
btova
coimmun
model
group
mice
immun
bt
extract
two
week
later
submit
ovaimmun
first
immun
ova
coinject
bt
ova
ova
feed
perform
five
day
prior
coimmun
ige
ab
estim
mean
passiv
cutan
anaphylaxi
reaction
specif
ab
cytokin
secret
elisa
mice
sensit
bt
expos
ova
develop
enhanc
ige
respons
ova
respons
observ
ovaimmun
prior
btimmun
coinject
bt
ova
led
domin
ige
respons
toward
ova
bt
viceversa
respons
ova
feed
prior
coimmun
decreas
ige
ab
level
ova
parallel
bystand
suppress
avoid
outcom
btsensit
mice
show
increas
ifn
secret
level
induc
antigenspecif
stimulu
furthermor
effect
oral
toler
also
relat
ova
amount
employ
coimmun
sinc
ova
feed
prior
coimmun
low
amount
ova
led
inhibit
ige
ab
respons
allergen
wherea
inhibit
specif
nonrel
antigen
igg
ab
respons
broken
result
evidenc
depend
allergen
potenti
new
allergen
exposur
may
exert
adjuv
effect
primari
sensit
allergen
bystand
effect
nonrel
allergen
oral
toler
interest
mechan
control
new
aller
rational
regulatori
cell
patient
atop
asthma
undergo
apoptosi
stimul
specif
allergen
antihistamin
use
control
allerg
inflammatori
diseas
influenc
treg
cell
current
unknown
present
studi
investig
influenc
desloratadin
apoptosi
regulatori
cell
atop
patient
dust
mite
induc
allerg
diseas
includ
allerg
asthma
method
patient
posit
skin
prick
test
hous
dust
mite
allergen
clinic
histori
allerg
upper
andor
lower
respiratori
symptom
treat
scheringplough
usa
daili
day
patient
use
system
corticosteroid
theophyllin
medic
stop
least
hour
blood
collect
blood
sampl
treatment
control
group
compris
individu
without
allerg
respiratori
symptom
neg
skin
pricktest
peripher
blood
mononuclear
cell
pbmc
isol
ficol
densiti
gradient
stimul
specif
allergen
dermatophagoid
farina
control
seri
phorbol
myrist
acet
pma
pbmc
label
monoclon
antibodi
annexinvpropidium
iodid
anvpi
test
done
lymphocyt
subpopul
apoptosi
analyz
flow
cytometri
result
treatment
atop
patient
signific
differ
number
cell
cocultur
pbmc
patient
treat
specif
allergen
signific
increas
cell
observ
simultan
treatment
led
signific
increas
express
antiapoptot
protein
cell
data
parallel
decreas
express
cell
also
decreas
treg
cell
late
stage
apoptosi
anv
pi
cell
treat
patient
conclus
antihistamin
prepar
desloratadin
prevent
allergenspecif
apoptosi
regulatori
cell
patient
atop
asthma
type
histamin
receptor
may
involv
regul
apoptosi
andor
surviv
cell
ag
palmacarlo
ml
palmacarlo
lisboa
portug
introduct
solar
urticaria
porphyrin
correspond
sun
sensit
wavelength
due
disturb
posphorin
metabol
photosensit
caus
urticaria
erythema
polymorph
solar
erupt
sever
case
vesicl
bulla
photosensit
confirm
light
test
method
protoporhyrin
rbc
uro
coproporphyrin
urin
copro
protoporhyrin
faec
porphyrin
precursor
studi
un
case
solar
urticaria
seen
last
year
result
patient
femal
male
diagnosi
porphyria
confirm
laboratori
method
clinic
patient
present
solar
urticaria
solar
erythema
polymorph
solar
erupt
patient
femal
male
present
also
neuro
viscer
symptom
abdomin
pain
vomit
asthenia
constip
muscl
pain
paresia
depress
anesthes
reaction
case
symptom
associ
anticoncept
drug
conjunct
clinic
histori
laboratori
data
allow
confirm
diagnosi
case
protoporphyria
erytheropoietica
one
trigger
anticoncept
case
coporporhyria
hereditaria
case
porphyria
variegata
group
compris
one
case
erythropoiet
protoporphyria
induc
estrogen
previous
report
conclus
research
porphyrin
must
done
patient
solar
urticaria
erythema
incid
sun
sensit
mix
hepat
porphyriaalso
present
neuroviscer
symptom
drug
depend
suggest
porphyria
studi
must
mandatori
suspect
case
ar
narayan
j
kaplan
v
sirvan
chandrasekaran
c
goodwin
l
goodwin
l
guida
frieri
east
meadow
ny
manhasset
ny
bayshor
ny
rational
divis
report
nitric
oxid
tracheal
epithelium
mediat
induct
american
journal
respiratori
critic
care
medicin
increas
level
mononuclear
cell
mnc
cystic
fibrosi
cf
patient
note
pediatr
asthma
allergi
immunolog
mnc
cf
increas
stimul
aspergillu
fumigatu
asp
rhdnase
j
clin
allergi
immunol
tnfi
produc
bronchial
epitheli
cell
bec
presenc
mnc
normal
control
nc
rant
chemokin
facilit
leukocyt
migrat
associ
airway
inflamm
cf
asp
sensit
cf
patient
could
amplifi
proinflammatori
cytokin
tnf
rant
method
studi
mrna
protein
express
tnf
rant
yearold
cf
patient
nc
mnc
patient
nc
stimul
asp
bec
rhdnase
mrna
express
studi
real
time
pcr
taqman
chemistri
abi
prism
protein
level
elisa
result
tnfproduct
supernat
mnc
bec
nc
increas
pgml
pgml
rhdnase
wherea
cf
patient
tnfmrna
express
greatli
enhanc
nc
declin
presenc
rhdnase
fold
differ
differ
express
level
nc
fold
differ
rhdnase
treatment
express
mnc
bec
patient
increas
fold
compar
nc
fold
rhdnase
decreas
asp
stimul
level
fold
patient
compar
nc
fold
mnc
bec
rant
product
patient
increas
pgml
decreas
pgml
rhdnase
increas
pgml
pgml
nc
contrast
rant
mrna
express
group
higher
nc
decreas
rhdnase
cf
nc
fold
vs
fold
conclus
rhdnase
increas
decreas
proinflammatori
tnfand
rant
cf
patient
stimul
asp
rhdnase
could
lead
augment
bactericid
activ
epitheli
defens
enhanc
product
decreas
express
product
tnf
rant
case
report
two
steroid
depend
atop
dermat
patient
respond
treatment
omalizumab
patient
yearold
white
male
present
histori
sever
atop
dermat
year
along
concomit
mild
persist
asthma
allerg
rhiniti
previous
receiv
monthli
triamcinolon
inject
methotrex
doxycyclin
limit
respons
present
mild
improv
regimen
altern
day
prednison
fexofenadin
bid
zafirlukast
bid
howev
attempt
wean
prednison
unsuccess
omalizumab
initi
dosag
everi
four
week
patient
remain
prednison
depend
yet
free
atop
dermat
patient
diagnost
work
determin
total
ige
kul
patient
specif
ige
test
posit
grass
mix
weed
mix
mapl
white
pine
peanut
strawberri
gluten
soybean
wheat
oat
dog
dander
specif
ige
test
neg
cat
dander
egg
white
milk
goos
feather
chicken
feather
mold
mix
dust
mix
fish
mix
patient
b
yearold
white
male
present
histori
sever
full
bodi
atop
dermat
along
mild
persist
asthma
allerg
rhiniti
also
receiv
triamcinolon
inject
limit
success
respond
altern
day
prednison
desloratidin
bid
zileuton
bid
attempt
wean
prednison
fail
initi
omalizumab
everi
two
week
atop
dermat
control
daili
desloratidin
omalizumab
everi
two
week
success
wean
corticosteroid
medic
begun
immunotherapi
regimen
patient
b
diagnost
work
determin
total
ige
level
kul
patient
b
specif
ige
test
posit
weed
mix
tree
mix
mapl
peanut
strawberri
dust
mix
cat
dander
dog
dander
egg
white
milk
oat
wheat
goos
feather
chicken
feather
specif
ige
test
neg
grass
mix
white
pine
mold
mix
gluten
soybean
fish
mix
two
case
report
reveal
signific
respons
omalizumab
sever
steroid
depend
atop
dermat
research
strongli
indic
consid
qualiti
life
issu
sever
atop
dermat
potenti
side
effect
longterm
corticosteroid
treatment
eosinophil
esophag
ee
describ
children
character
high
level
eosinophil
eosinophilshigh
power
field
hpf
esophag
mucosa
recent
report
indic
combin
preval
eosinophil
gastrointestin
disord
may
higher
inflammatori
bowel
diseas
ibd
present
symptom
ee
mimick
gastroesophag
reflux
diseas
gerd
patient
age
may
experi
delay
time
onset
symptom
diagnosi
ee
pauciti
data
literatur
regard
delay
time
symptom
onset
diagnosi
ee
report
data
four
children
three
year
age
ee
experienc
signific
diagnost
delay
four
young
children
refer
pediatr
allergi
clinic
diagnosi
ee
tabl
three
patient
male
one
femal
patient
month
age
time
diagnosi
diagnost
delay
month
averag
delay
month
common
present
symptom
vomit
three
four
patient
histori
respiratori
obstruct
symptom
patient
receiv
convent
treatment
reflux
diseas
one
undergon
nissen
fundopl
prior
diagnosi
four
patient
esophag
biopsi
reveal
eosinophilshpf
three
four
patient
famili
histori
atopi
two
patient
known
histori
food
allergi
skin
test
food
posit
two
patient
rast
radioallergoabsorb
test
food
posit
one
patient
recent
data
suggest
diagnost
delay
ibd
decreas
much
hypothes
may
due
part
increas
index
suspicion
health
care
provid
littl
data
avail
regard
diagnost
lag
children
ee
current
believ
chronic
ee
lead
progress
esophag
scar
dysfunct
strictur
format
also
describ
children
less
two
year
age
given
report
increas
incid
allerg
gastrointestin
diseas
past
decad
data
regard
diagnost
delay
condit
may
instrument
improv
health
care
provid
awar
disord
kohlipamnani
e
cooney
p
huynh
f
lobo
new
ct
introduct
cutan
hypersensit
reaction
amprenavir
proteas
inhibitor
report
treat
patient
sever
lifethreaten
rash
treatment
discontinu
requir
case
report
case
success
desensit
amprenavir
recurr
maculopapular
exanthem
hivinfect
patient
late
stage
diseas
limit
antiretrovir
arv
agent
option
method
patient
yearold
caucasian
femal
late
stage
hiv
diseas
absolut
count
cellsmm
hiv
rna
copiesml
multipl
arv
intoler
develop
sever
gener
maculopapular
erupt
spare
mucou
membran
six
day
follow
initi
regimen
compris
amprenavir
lopinavirritonavir
zidovudin
lamivudin
similar
reaction
occur
follow
rechalleng
amprenavir
alon
mg
oral
formul
bid
via
percutan
endoscop
gastrostomi
peg
tube
despit
concurr
administr
oral
prednison
mgday
loratidin
mgday
result
skin
prick
test
amprenavir
mcgml
neg
wherea
intraderm
test
mcgml
posit
mm
wheal
mm
flare
percutan
intraderm
test
normal
salin
nonreact
posit
histamin
control
skin
prick
yield
mm
wheal
mm
flare
subsequ
increment
dose
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
amprenavir
oral
solut
administ
via
peg
tube
minut
interv
tabl
patient
success
toler
amprenavir
desensit
remain
therapi
without
recurr
rash
month
followup
conclus
desensit
may
permit
continu
use
amprenavir
patient
histori
amprenavirinduc
maculopapular
erupt
limit
altern
treatment
option
effort
aim
character
mechan
amprenavir
cutan
hypersensit
reaction
seem
warrant
given
frequenc
reaction
limit
number
arv
agent
avail
patient
late
stage
hiv
diseas
dose
oral
solut
administ
peg
tube
twenti
thirti
minut
interv
introduct
betalactam
bl
allergi
common
drug
allergi
case
ige
antibodi
specif
bl
nucleu
howev
sidechainspecif
ige
scsige
bl
describ
despit
skin
test
st
bl
penicillin
pcn
commonli
perform
report
case
yearold
femal
select
allergi
pip
describ
util
st
agent
confirm
scsige
method
st
prepen
pp
pcn
g
carri
percutan
pc
test
follow
intraderm
id
test
st
also
carri
ampicillin
amp
mgml
pip
mgml
pc
level
mgml
id
levela
nonirrit
concentr
piptazobactam
tbm
mgml
pc
level
mgml
id
level
exclud
possibl
select
allergi
tbm
case
report
yearold
white
femal
crohn
diseas
hospit
treatment
intraabdomin
abscess
immedi
flush
urticaria
infus
piptbm
approxim
year
prior
allergyimmunolog
servic
consult
pcn
st
primari
servic
prefer
empir
treat
piptbm
receiv
imipenem
approxim
month
prior
without
untoward
reaction
st
pp
pcn
g
perform
neg
respons
adequ
control
subsequ
receiv
piptbm
develop
flush
urticaria
initi
infus
consist
igemedi
reaction
two
month
later
st
pp
pcn
g
repeat
addit
st
amp
pip
piptbm
perform
posit
respons
pip
piptbm
neg
respons
pp
pcn
g
amp
impli
select
igemedi
potenti
pip
toler
oral
challeng
pcn
vk
mg
immedi
follow
st
without
untoward
reaction
conclus
describ
case
st
pip
use
diagnos
scsige
patient
prior
reaction
consist
igemedi
pathogenesi
inform
help
identifi
antibiot
safe
receiv
futur
case
support
util
st
bl
addit
pcn
evalu
manag
patient
histori
advers
reaction
bl
may
reflect
presenc
scsige
ar
vaishnav
bs
bochner
baltimor
md
report
case
caucasian
male
histori
asthma
two
episod
eosinophil
pneumonia
chronic
peripher
eosinophilia
baselin
eosinophil
count
around
develop
amnesia
elev
cardiac
enzym
februari
anoth
physician
ad
montelukast
januari
good
respons
advair
decreas
bid
februari
eosinophil
count
increas
soon
develop
left
arm
numb
diplopia
well
left
arm
leg
weak
local
hospit
found
elev
troponin
cpk
cardiac
catheter
show
normal
coronari
arteri
good
left
ventricular
function
soon
discharg
develop
confus
global
amnesia
brain
mri
show
diffus
uptak
consist
global
inflamm
andor
vascul
upon
hear
stori
told
take
mg
prednison
urgent
come
hospit
admiss
within
hour
mental
statu
visual
symptom
improv
physic
examin
unremark
except
subungu
splinter
hemorrhag
montelukast
stop
gmday
solumedrol
iv
start
endomyocardi
biopsi
day
later
show
mild
hypertrophi
fibrosi
without
eosinophil
repeat
brain
mri
mra
normal
chest
ct
show
multipl
patchi
infiltr
new
central
cavitari
lesion
right
lobe
lab
includ
neg
anca
ana
normal
complement
csf
differenti
diagnosi
includ
churgstrauss
syndrom
css
versu
hypereosinophil
syndrom
ihe
myocardi
neurolog
pulmonari
involv
serum
tryptas
normal
fluoresc
situ
hybrid
fusion
gene
base
along
new
pulmonari
cavitari
lesion
chest
ct
diagnosi
css
made
day
iv
steroid
switch
mgday
prednison
upon
discharg
eosinophil
count
mg
prednison
procedur
complet
also
start
aspirin
mg
daili
prevent
thrombot
thromboembol
complic
seen
followup
clinic
cytoxan
mg
daili
start
prednison
taper
toler
treatment
well
far
excel
clinic
laboratori
respons
inhibitor
defici
rare
disord
classifi
acquir
hereditari
form
entiti
distinguish
recurr
angioedema
without
pruritu
urticaria
upper
airway
head
neck
extrem
gi
tract
typic
involv
inherit
form
usual
present
first
second
decad
accompani
famili
histori
acquir
form
commonli
present
fifth
decad
acquir
defici
serolog
evalu
reveal
low
level
normal
level
level
normal
hereditari
form
acquir
form
may
associ
lymphoprolif
disord
autoimmun
diseas
acquir
defici
typic
recogn
underli
malign
condit
diagnos
clinic
regress
report
patient
whose
underli
disord
respond
treatment
methodsa
case
report
old
femal
develop
repeat
episod
facial
angioedema
requir
hospit
preced
one
year
vagu
abdomin
pain
cramp
datalaboratori
investig
patient
reveal
mgdl
mgdl
uml
mgdl
mgdl
activ
normal
mgdl
mgdl
laboratori
evalu
notabl
normal
cbc
diff
comprehens
metabol
panel
amylas
lipas
spep
pattern
ige
elev
kul
hematolog
consult
ct
chest
abdomen
pelvi
nondiagnost
peripher
blood
flow
cytometri
reveal
small
distinct
popul
consist
clonal
bcell
lymphoprolif
disord
repeat
test
show
skew
toward
lamba
light
chain
express
bone
marrow
biopsi
aspir
essenti
normal
except
erythroid
hyperplasia
danazol
treatment
physic
examin
without
mass
lymphadenopathi
patient
remain
asymptomat
begin
danazol
although
elev
rbc
hgb
hct
absolut
lymphocyt
count
develop
conclusionacquir
defici
rare
caus
recurr
angioedema
report
small
cohort
case
present
report
anoth
case
report
reinforc
need
physician
evalu
concomit
lymphoprolif
disord
chronic
urticaria
distress
condit
usual
associ
poor
qualiti
life
poor
respons
symptomat
therapi
wide
varieti
caus
mechan
describ
patient
caus
remain
unknown
rare
case
associ
thyroid
antibodi
respond
thyroxin
even
absenc
overt
thyroid
diseas
case
report
obes
white
femal
present
histori
persist
urticariaangioedema
mo
urticaria
involv
variou
part
bodi
individu
lesion
usual
last
hr
often
accompani
facial
edema
oral
diphenhydramin
qid
caus
littl
improv
patient
could
suspect
offend
factor
review
system
past
medic
histori
unremark
except
hyperthyroid
age
yr
treat
medic
yr
physic
examin
sever
urticari
lesion
though
take
diphenhydramin
thyroid
appear
normal
regard
size
shape
textur
variou
second
gener
antihistamin
doxepin
littl
help
laboratori
evalu
reveal
total
serum
ige
iuml
normal
iuml
uml
normal
uml
high
tsh
iuml
normal
iuml
low
free
ngdl
normal
ngdl
antithyroglobulin
titer
iuml
normal
iuml
antimicrosom
titer
highli
elev
iuml
normal
iuml
consist
hashimoto
thyroid
thyroxin
therapi
initi
dose
mcgd
result
mark
improv
within
one
week
patient
abl
discontinu
doxepin
antihistamin
mark
drop
tsh
iuml
thyroxin
dose
reduc
mcgd
thyroid
function
test
becam
normal
within
two
month
experi
recurr
urticaria
angioedema
mo
followup
far
conclus
patient
chronic
urticariaangioedema
especi
women
screen
thyroid
autoantibodi
posit
thyroxin
therapi
might
bring
impress
remiss
urticaria
hypersensit
pneumon
hp
result
abnorm
immunolog
mediat
respons
environment
antigen
trigger
typic
patient
hp
experi
transient
fever
hypoxemia
muscl
joint
pain
difficulti
breath
fatigu
weight
loss
cough
two
clinic
present
hp
differenti
onset
resolut
symptom
patient
experienc
acut
hp
experi
onset
symptom
hour
follow
exposur
particular
antigen
resolv
day
without
specif
treatment
howev
patient
chronic
hp
experi
symptom
persist
month
year
expos
recogn
caus
hp
yearold
caucasian
male
refer
practic
acut
bronchiti
referr
secondari
histori
allerg
rhiniti
chronic
asthma
gastroesophag
reflux
disord
sinu
surgeri
nonsmok
male
machin
oper
local
factori
well
began
work
presenc
heat
induct
machin
metal
lubric
spray
call
multan
hinkl
surfac
technolog
id
multan
product
contain
naphthen
petroleum
distil
amin
salt
amin
soap
triethanolamin
hexyl
hexylen
glycol
ethanol
sodium
petroleum
sulfon
triazin
lubric
known
irrit
eye
skin
respiratori
tract
recent
studi
indic
thermal
decomposit
triazin
readili
occur
metalwork
result
product
formaldehyd
formaldehyd
known
carcinogen
well
respiratori
skin
eye
digest
tract
irrit
patient
develop
seriou
respiratori
health
problem
result
work
absenc
eventu
hospit
hospit
receiv
high
resolut
ct
scan
show
diffus
ground
glass
appear
multipl
attenu
area
lung
consist
hypersensit
pneumon
patient
treat
corticosteroid
antibiot
eventu
normal
lung
parenchyma
chest
ct
repres
first
report
case
hypersensit
pneumon
result
exposur
metalwork
fluid
respiratori
irrit
multan
aj
ham
pong
f
chan
sl
bahna
ottawa
canada
shreveport
la
sexual
intercours
known
rout
semen
hypersensit
reaction
semin
fluid
protein
contamin
drug
food
report
case
anaphylaxi
cephalexincontain
semen
ingest
histori
present
ill
woman
develop
system
reaction
swallow
semen
sinc
coupl
frequent
practic
fellatio
without
reaction
husband
suspect
cephalexin
take
day
mg
qid
reaction
began
less
min
peak
min
first
itchi
oral
mucosa
follow
wheez
flush
face
upper
chest
nausea
diphenhydramin
mg
administ
po
min
reaction
subsid
hr
past
medic
histori
gener
urticaria
oral
penicillin
yr
earlier
posit
penicillin
skin
test
also
allerg
rhinoconjunct
mild
intermitt
asthma
posit
skin
test
hous
dust
mite
cat
dog
epiderm
pollen
grass
tree
ragwe
also
oral
allergi
syndrom
certain
fresh
fruit
tree
nut
hazelnut
caus
also
diarrhea
colic
neither
patient
husband
ate
nutcontain
food
day
preced
reaction
famili
histori
allerg
rhinoconjunct
mother
sister
brother
evalu
patient
sought
allergi
evalu
yr
reaction
husband
gave
consent
serum
ige
iuml
skin
test
posit
penicilloyl
polylysin
mol
id
neg
cefazolin
mgml
prick
mgml
id
neg
prick
test
husband
semin
plasma
intak
cephalexin
qid
day
use
cephalexin
bioassay
sensit
mcgml
medic
level
husband
urin
min
post
last
dose
mcgml
serum
min
mcgml
undetect
semen
collect
min
conclus
probabl
first
case
report
system
reaction
ingest
semen
reaction
occur
atop
penicillinsensit
woman
seem
caus
cephalexin
excret
semen
urin
contamin
drop
mcg
addit
avoid
penicillin
cephalosporin
advis
avoid
husband
semen
take
drug
least
day
afterward
background
asthma
caus
seriou
morbid
mortal
yet
asthma
educ
evalu
program
urban
rather
rural
focusther
lack
data
rural
north
dakota
nd
nd
survey
aim
studi
knowledg
awar
manag
strategi
asthma
like
use
meter
dose
inhal
spacer
devic
peak
flow
meter
method
qualit
survey
address
attitud
belief
asthma
trigger
knowledg
medic
deliveri
rout
use
hospit
provid
visitsa
simpl
questionnair
selfadminist
rural
clinic
small
town
southeastern
north
question
explor
asthma
knowledg
extent
famili
histori
asthma
factor
aggrav
asthmait
voluntari
popul
survey
includ
patient
famili
teacher
employe
nurs
home
local
hospit
clinic
result
survey
complet
asthma
familyof
famili
histori
person
asthma
morerespond
age
year
femalese
tabl
discuss
survey
rural
comparison
urban
area
may
help
plan
asthma
educ
resourc
deni
asthma
famili
similarli
nonurban
alaskan
nativ
lower
incid
asthma
compar
nonnativesour
result
show
lack
awar
areagrain
dust
exposur
perceiv
asthma
trigger
without
evid
local
research
neededin
studi
smoke
consid
trigger
may
realther
lack
awar
peak
flow
meter
role
asthma
carea
studi
show
compar
area
even
rural
nurs
use
peak
flow
meter
less
often
assess
monitor
asthmathi
suggest
need
comprehens
asthma
educ
program
rural
area
base
nation
guidelinesw
moder
followup
rate
comparison
one
studi
miss
schedul
followup
exercis
induc
asthma
known
group
conclus
need
better
patientprovid
commun
highlight
lack
awar
proven
strategi
combat
asthmath
use
simpl
survey
reveal
mani
unknown
fact
asthma
awar
rural
ndfurther
studi
determin
cost
effect
solut
achiev
nation
target
asthma
manag
essenti
aim
studi
asthma
emphasi
chang
larg
middl
airway
aim
studi
observ
morpholog
chang
small
airway
lung
tissu
salt
guinea
pig
asthma
model
gpam
investig
role
eotaxin
nfb
inflamm
asthma
explor
function
variat
alveolar
type
cell
asthma
evalu
effect
inhal
glucocorticoid
annal
allergi
asthma
immunolog
paramet
salt
asthma
model
method
gpam
establish
ovalbumin
challeng
five
group
divid
control
asthma
day
day
intraperiton
dexamethason
budesonid
inhal
group
express
eotaxin
nfb
determin
immunohistochem
technolog
rtpcr
dna
bind
activ
nfb
electropharet
mobil
shift
assay
balf
phospholipid
concentr
measur
phosphoru
detect
result
signific
inflammatiom
infiltr
eosinophil
lymphocyt
salt
observ
asthma
group
protein
level
eotaxin
nfb
express
salt
significantli
elev
asthma
group
control
mrna
express
eotaxin
lung
tissu
homogen
significantli
increas
asthma
group
dna
bind
activ
nfb
lung
homogen
significantli
increas
asthma
group
balf
surfact
repres
phospholipid
significantli
decreas
asthma
group
glucocorticoid
differ
way
intak
provid
signific
effect
inflammatiom
salt
conclus
widespread
signific
inflamm
eosinophil
infiltr
exist
salt
gpam
indic
asthma
diseas
involv
whole
airway
lung
system
structur
chang
also
impair
function
alveolar
cell
role
small
airway
inflammatiom
may
great
import
eotaxin
activ
mediat
process
inflammatiom
nfb
play
import
role
regul
eotaxin
upregul
mediat
gpam
express
salt
similar
central
airway
recent
report
immunomodulatori
oligonucleotid
imo
consist
novel
structur
synthet
cpr
rpg
r
r
synthet
purin
moieti
stimulatori
motif
effect
prevent
ovainduc
asthma
mous
model
present
studi
examin
whether
novel
imo
revers
establish
allerg
airway
inflamm
mice
balbc
mice
sensit
challeng
ovalbumin
ova
evalu
airway
hyperrespons
ahr
methacholin
follow
ovasensit
mice
random
treat
placebo
mg
mgdose
sc
follow
day
two
day
final
treatment
mice
rechalleng
ova
pulmonari
function
record
mice
treat
either
imo
significantli
protect
earli
ear
late
lar
allerg
respons
airway
hypersensit
hyperreact
methacholin
bal
peribronchi
eosinophilia
bal
serum
total
serum
ige
compar
vehicletr
ovasensit
challeng
anim
signific
increas
immatur
lung
dendrit
cell
togeth
increas
serum
level
signific
decreas
lung
type
cell
compar
vehicletr
ovalbuminsensit
anim
lung
follow
treatment
either
imo
data
suggest
imo
effect
potent
attenu
key
featur
establish
allerg
airway
inflamm
bronchial
asthma
effect
could
mediat
via
decreas
lung
cell
increas
immatur
dendrit
cell
addit
imo
contain
novel
structur
provid
higher
metabol
stabil
may
permit
lower
andor
less
frequent
dose
evalu
safeti
immunopharmacolog
phase
clinic
trial
healthi
human
volunt
introduct
hemoglobinopathi
common
southern
europ
mediterranean
area
frequent
thalassemia
sickl
cell
diseas
asid
major
hematolog
diseas
homozygot
patient
minor
form
frequent
thalassemia
minor
sickl
cell
trait
case
mycrocytosi
decreas
red
cell
volum
mean
corpuscular
volum
abnorm
erythrocyt
found
lead
hemorheolog
disturb
bronchial
circul
bronchial
hypereact
rational
studi
evalu
incid
asthma
hemoglobinopat
patient
allerg
hous
dust
mitesmethodsfrom
patient
seen
last
year
outpati
allergi
clinic
case
hemoglobinopathi
confirm
red
cell
count
hemoglobin
electrophoresi
assay
hemoglobin
f
sickl
cell
testal
patient
allerg
diseas
character
clinic
histori
skin
prick
test
aeroallergen
total
specif
ige
rastcapfeia
respiratori
function
evalu
result
hemoglobinopathi
betathalassemia
case
betadelta
thalassemia
sickl
cell
trait
hemoglobin
asid
case
urticaria
patient
present
respiratori
allergi
rhiniti
case
thalassemia
hemoglobin
c
asthma
without
rhiniti
case
thalassemia
case
sickl
cell
trait
therefor
asthma
present
group
respiratori
allerg
patient
without
hemoglobinopathi
asthma
rhiniti
conclus
preval
asthma
higher
hemoglobinopathi
p
squar
chi
test
hemorheolog
chang
probabl
greater
rigid
red
blood
cell
capillari
bed
contribut
bronchial
hypereact
detect
hemoglobinopathi
must
done
asthmat
patient
slight
anemia
mycrocytosi
investig
role
aspirinexacerb
respiratori
diseas
aerd
risk
factor
develop
airway
remodel
patient
aspirin
intoler
develop
hyperplast
sinus
fibrosi
nasal
polyposi
specul
similar
mechan
could
act
lower
airway
individu
would
demonstr
sever
asthma
evid
airway
remodel
epidemiolog
natur
histori
asthma
outcom
treatment
regimen
tenor
studi
multicent
observ
studi
subject
sever
difficulttotreat
asthma
baselin
data
compar
subject
year
report
asthma
exacerb
follow
aspirin
ingest
primari
measur
asthma
remodel
maxim
achiev
postbronchodil
spirometri
adult
subject
aerd
compar
aspirin
toler
subject
subject
aspirin
intoler
demonstr
evid
airway
remodel
shown
lower
postbronchodil
predict
fev
addit
like
physicianassess
sever
asthma
intub
requir
highdos
inhal
corticosteroid
oral
corticosteroid
previou
month
conclud
aspirin
intoler
associ
remodel
upper
lower
airway
asthma
complex
variabl
diseas
two
main
compon
airway
inflamm
smooth
muscl
dysfunct
accord
nation
intern
asthma
guidelin
subject
persist
asthma
classif
i
one
three
categori
mild
moder
sever
base
upon
lung
function
symptom
nighttim
awaken
medic
exacerb
though
wide
believ
high
degre
variabl
pediatr
adult
subject
asthma
studi
compar
variabl
therefor
analysi
previous
conduct
asthma
studi
undertaken
evalu
pediatr
subject
age
year
adult
subject
previous
receiv
shortact
beta
agoinst
alon
seven
doubleblind
random
trial
analysi
limit
subject
random
placebo
trial
studi
subject
exhibit
mark
fluctuat
asthma
sever
despit
fact
subject
met
criteria
moder
sever
asthma
baselin
week
pediatr
subject
week
adult
spent
intermitt
mild
moder
sever
categori
respect
summari
sever
classif
base
upon
symptom
albuterol
use
present
addit
base
upon
pef
predict
week
spent
intermittentmild
categori
pediatr
adult
subject
respect
howev
fluctuat
pef
occur
frequent
pediatr
subject
adult
subject
experienc
chang
sever
base
pef
week
indic
variabl
pediatr
subject
analysi
clearli
demonstr
asthma
variabl
condit
pediatr
adult
subject
frequent
move
sever
categori
furthermor
mark
differ
sever
classif
pediatr
adult
subject
asthma
sever
consequ
optim
therapi
adequ
assess
discret
pointintim
assess
lung
function
frequenc
albuterol
use
asthma
symptom
especi
pediatr
age
group
studi
suggest
may
associ
singl
nucleotid
polymorph
snp
beta
adrenerg
receptor
gene
respons
beta
adrenerg
bronchodil
polymorph
codon
center
debat
therefor
retrospect
analysi
six
larg
random
trial
conduct
evalu
clinic
respons
salmeterol
administ
fluticason
propion
fsc
bid
week
patient
yr
moder
sever
asthma
differ
polymorph
codon
baselin
demograph
similar
genotyp
subgroup
measur
asthma
improv
baselin
similar
across
subgroup
week
pairwis
comparison
conduct
genotyp
differ
fev
note
tabl
find
retrospect
analysi
show
regardless
genotyp
clinic
respons
salmeterol
ic
similar
chronic
dose
although
prospect
studi
need
fulli
understand
effect
polymorph
respons
therapi
longact
beta
agonist
analysi
suggest
therapi
salmeterol
ic
togeth
appropri
caucasian
patient
differ
genotyp
coronari
arteri
diseas
cad
asthma
commonli
coexist
adult
iv
dipyridamol
thallium
scintigraphi
consid
safe
noninvas
techniqu
evalu
cad
patient
ca
nt
exercis
dipyrdamol
purin
block
reuptak
extracellular
adenosin
increas
serum
adenosin
level
iv
administrationthi
result
transient
coronari
vasodil
increas
sensit
thallium
studi
methylxanthin
revers
effect
endogen
adenosin
competit
antagon
adenosin
local
purinoreceptor
report
case
yrold
femal
year
histori
stabl
mild
persist
asthma
treat
daili
salmeterol
lowdos
fluticason
refer
cardiolog
atyp
chest
pain
within
minut
standard
iv
dose
dipyridamol
patient
report
chest
tight
cough
wheez
symptom
typic
past
asthma
flare
abolish
within
minut
aminophyllin
infus
albuterol
administeredth
stress
test
complet
normal
inhal
adenosin
induc
bronchconstrict
use
probe
bronchial
hyperrespons
commerci
iv
adenosin
prepar
use
treat
supraventricular
tachycardia
report
induc
bronchospasm
known
asthmat
sinc
serum
level
adenosin
transient
increas
follow
iv
dipyridamol
bronchospast
symptom
dipyridamol
stress
test
unexpect
earlier
studi
found
increas
incid
wheez
patient
known
copdasthma
undergo
dipyridamol
stress
test
despit
pretreat
beta
agonist
mark
declin
theophyllin
use
chronic
asthma
recent
year
may
actual
increas
incid
risk
cardiologist
perform
thallium
stress
test
familiar
risk
asthma
flare
dipyridamol
use
iv
aminophyllin
frequent
revers
sever
type
clinic
dipyridamol
reaction
includ
bronchospasm
hand
impress
allergist
rel
unfamiliar
associ
allergist
asthma
specialist
well
asthmat
patient
awar
risk
acut
dipyridamol
induc
bronchospasm
elect
cardiac
stress
test
shown
adhes
molecul
involv
inflammatori
diseas
lung
bronchial
asthma
purpos
studi
measur
establish
possibl
differ
serum
level
solubl
atop
patient
patient
allerg
rhiniti
patient
bronchial
asthma
comparison
patient
without
atopi
patient
asthma
without
rhiniti
whether
differ
level
group
patient
allerg
rhiniti
asthma
comparison
group
patient
allerg
rhiniti
also
comparison
healthi
control
result
studi
substanti
statist
signific
differ
level
group
patient
comparison
healthi
control
statist
signific
differ
level
patient
without
atopi
patient
allerg
rhiniti
bronchial
asthma
comparison
group
patient
allerg
rhiniti
conclus
import
marker
inflamm
patient
allerg
rhiniti
well
bronchial
asthma
atop
statu
influenc
differ
level
although
mean
level
higher
patient
allerg
rhiniti
bronchial
asthma
ngml
comparison
mean
level
patient
allerg
rhiniti
ngml
statist
signific
differ
note
level
group
subject
ie
asthma
contribut
statist
signific
increas
level
k
nadarajah
gr
green
naglak
abington
pa
object
studi
variou
clinic
outcom
penicillin
skin
test
pst
communitybas
hospit
determin
percentag
patient
antibiot
modif
choic
antibiot
use
follow
result
pst
method
studi
retrospect
chart
review
inpati
penicillin
skin
test
period
year
jan
juli
inform
collect
patient
use
detail
data
collect
form
data
summar
use
descript
statist
includ
frequenc
percentag
result
patient
penicillin
skin
test
neg
test
five
posit
test
four
patient
test
indetermin
histamin
control
neg
eighti
six
percent
patient
histori
penicillin
allergi
histori
cephalosporin
allergi
histori
penicillin
cephalosporin
allergi
durat
antibiot
prior
pst
rang
zero
day
reduct
use
vancomycin
reduct
use
floroquinolon
reduct
use
aminoglycosid
follow
pst
aztreonam
use
patient
pst
zero
patient
pst
use
penicillinbas
drug
pst
cephalosporin
use
increas
third
gener
cephalosporin
second
third
gener
cephalosporin
ie
patient
neg
pst
receiv
penicillin
cephalosporin
vancomycin
usag
higher
among
pst
posit
patient
endocard
diagnosi
patient
skin
test
staphylococcu
aureu
enterococcu
common
organ
cultur
seriou
advers
reaction
use
penicillin
cephalosporin
use
follow
neg
pst
advers
reaction
penicillin
skin
test
conclus
popul
studi
pst
lower
usag
vancomycin
floroquinolon
aminoglycosid
increas
use
penicillin
third
gener
cephalosporin
usag
increas
pst
studi
overal
pst
result
antibiot
modif
could
lower
emerg
multidrug
resist
organ
vancomycin
resist
enterococcu
aim
studi
find
new
marker
could
easili
done
predict
possibl
allergi
develop
infant
prevent
procedur
alway
econom
better
treatment
itselffood
allergen
abl
stimul
lymphocyt
even
prenat
period
immunolog
matur
newborn
still
center
interest
depend
mani
differ
factor
question
activ
cord
blood
children
correl
develop
allergi
examin
group
consist
newborn
boy
breastf
children
total
ige
cord
blood
mother
blood
taken
deliveri
measur
use
unicap
immunolog
detect
done
use
fluorocytometri
becton
nad
dako
addit
parent
questionair
famili
atopi
reault
show
posit
famili
atopi
histori
group
elev
level
ige
group
b
symptom
allergi
first
month
life
group
c
correl
antigen
subgroup
frequenc
find
show
unfortun
predict
marker
allergi
develop
rational
etiolog
eosinophil
esophag
ee
unknown
relationship
type
allerg
respons
unclear
comparison
patient
posit
neg
type
allergi
test
may
clarifi
ee
determin
common
food
allergen
method
retrospect
chart
review
medic
record
januari
januari
children
year
age
biopsi
confirm
ee
n
ee
defin
eosinophil
per
high
power
field
esophag
mucos
biopsi
patient
group
accord
posit
n
neg
n
allerg
respons
skin
radioallergosorb
test
cap
rast
pharmacia
skin
test
commerci
extract
hollistersti
laboratori
greer
laboratori
perform
allergist
offic
wheal
greater
neg
control
skin
test
ige
kul
rast
consid
posit
perform
fisher
exact
analysi
determin
associ
exist
type
allerg
respons
factor
age
symptom
peripher
eosinophilia
person
famili
histori
atopi
asthma
allerg
rhinit
atop
dermat
result
ee
patient
posit
type
allerg
respons
significantli
younger
neg
respons
mean
yo
median
yo
rang
yo
versu
mean
yo
median
yo
rang
yo
p
vomit
present
symptom
significantli
increas
allerg
popul
p
abdomin
pain
chief
complaint
significantli
increas
nonallerg
popul
p
person
famili
histori
atopi
peripher
eosinophilia
similar
group
common
allergen
cow
milk
peanut
egg
soybean
wheat
conclus
patient
diagnos
ee
present
young
age
present
symptom
vomit
may
type
allerg
respons
contribut
esophag
eosinophil
inflamm
consist
food
allergi
children
milk
peanut
egg
soybean
wheat
common
food
found
allergi
test
posit
predict
accuraci
food
annal
allergi
asthma
immunolog
test
challeng
remain
develop
specif
plan
confirm
caus
food
oral
challeng
elimin
trial
rational
relationship
specif
ige
igg
level
atop
individu
unknown
increas
antigen
exposur
expect
increas
igg
product
howev
influenc
ige
level
unclear
clarifi
relationship
follow
studi
conduct
method
three
hundr
sixti
tandem
determin
specif
ige
igg
level
individu
collect
use
immunocap
instrument
pharmacia
diagnost
commerci
avail
reagent
subject
ige
level
kul
igg
determin
mgl
specif
allergen
speci
includ
studi
specif
ige
igg
determin
alternaria
alternata
aspergillu
fumigatu
penicillium
notatum
cladosporium
herbarium
feli
domesticu
cani
familari
dermatophagoid
farina
periplaneta
americana
correl
coeffici
calcul
use
excel
microsoft
result
review
data
set
yield
tandem
determin
specif
ige
igg
level
atop
individu
common
ige
sensit
alternaria
sixtyfour
percent
individu
specif
ige
direct
alternaria
lowest
ige
respons
rate
cat
roach
individu
ige
respons
specif
speci
correl
coeffici
cc
calcul
specif
ige
igg
level
posit
eight
speci
test
highest
cc
dog
n
cc
follow
aspergillu
n
cc
penicillium
n
cc
alternaria
n
cc
cladosporium
n
cc
cat
n
cc
roach
n
cc
lowest
correl
dermatophagoid
farina
n
cc
conclus
individu
measur
specif
ige
igg
level
consid
appear
posit
correl
specif
ige
igg
level
mani
allergen
speci
factor
influenc
correl
like
genet
environment
identifi
link
clinic
applic
next
challeng
recent
protein
microarray
test
compet
tradit
allergenspecif
vitro
assay
advantag
microarray
allergi
test
attract
microarray
analysi
alon
effect
reduc
analysi
time
autom
microarray
equip
typic
much
larger
benchtop
counterpart
incorpor
microarray
technolog
autom
microfluid
cartridg
provid
rapid
allergen
test
use
compact
lowcost
desktop
instrument
inject
mold
microfluid
cartridg
fig
contain
array
miniatur
pump
valv
direct
reagent
independ
solid
phase
reaction
area
standard
ige
nibsc
well
allergen
immobil
within
cartridg
form
protein
microarray
small
desktop
analyz
actuat
pump
cartridg
automat
carri
chemiluminescencebas
elisa
reaction
total
ige
quantit
perform
minut
reaction
figb
show
result
imag
dilut
seri
immobil
ige
concentr
rang
iuml
correspond
fg
ng
ige
per
spot
averag
cv
valu
ige
quantit
show
good
linear
fg
sensit
quantit
ige
curv
use
elimin
effect
cartridg
variabl
specif
ige
detect
demonstr
use
extract
pteronyssinu
dp
afumigatu
b
verrucosa
bv
minut
reaction
elisa
techniqu
employ
fig
c
show
result
imag
bv
dp
posit
serum
respect
sensit
dp
specif
ige
test
investig
use
posit
class
serum
sampl
confirm
mast
dilut
class
serum
neg
control
serum
could
detect
cartridg
fold
dilut
result
limit
detect
rang
iuml
dp
specif
ige
demonstr
total
ige
allergenspecif
ige
detect
total
analysi
time
less
minut
conveni
low
cost
system
use
microfluidicbas
microarray
cartridg
rapid
diagnosi
allow
physician
provid
treatment
patient
still
offic
background
accur
allergen
skin
test
ast
basi
optim
care
allerg
patient
complet
test
first
visit
expedit
diagnosi
treatment
offer
patient
pt
effici
use
time
increas
satisfact
appropri
previsit
prepar
necessari
reduc
variabl
affect
ast
outcom
posit
neg
skin
test
control
necessari
assur
ast
reliabl
method
conduct
retrospect
chart
review
sequenti
pt
skin
test
allergi
practic
order
examin
success
previsit
instruct
identifi
medic
may
affect
ast
pt
given
verbal
written
instruct
discontinu
antihistamin
receptor
antagonist
medic
day
visit
underw
ast
adequ
posit
histamin
neg
salinevehicl
control
obtain
result
pt
inadequ
histamin
respons
ihr
pt
use
within
prior
day
pt
taken
recent
past
stop
least
day
prior
test
pt
exposur
use
psychiatr
medic
pt
ihr
also
examin
pt
discontinu
day
also
take
variou
medic
drug
use
treatment
psychiatr
disord
ssri
benzodiazepin
atyp
antidepress
antipsychot
usual
associ
group
pt
prior
use
includ
also
variou
psychiatr
medic
high
preval
psychiatr
medic
use
two
group
contrast
pt
recent
use
psychiatr
medic
conclus
previsit
patient
educ
discontinu
lead
success
first
visit
ast
overwhelm
major
patient
failur
stop
appropri
time
occur
pt
pt
discontinu
recommend
day
interv
still
ihr
anoth
pt
ihr
yet
obviou
use
pt
take
psychiatr
medic
normal
associ
ihr
investig
issu
warrant
blazien
chomicien
l
jurgauskien
n
ciaponien
vilniu
lithuania
background
sublingu
specif
immunotherapi
sit
accept
altern
treatment
subcutan
sit
season
allerg
rhiniti
aim
studi
evalu
chang
allergenspecif
ige
basophil
degranul
test
bdt
year
sit
grass
pollen
mix
method
patient
male
femal
age
year
sensit
grass
pollen
season
allerg
rhiniti
treat
standard
grass
pollen
extract
blood
sampl
collect
year
sit
assess
allergenspecif
ige
use
elisa
method
bdt
use
direct
immunofluoresc
method
employ
monoclon
antibodi
result
sit
well
toler
patient
increas
total
ige
sit
observ
patient
specif
ige
concentr
increas
patient
bdt
result
greater
patient
year
sit
conclus
allergenspecif
ige
bdt
may
serv
marker
indic
clinic
efficaci
sit
season
allerg
rhiniti
patient
ag
palmacarlo
sl
silva
ml
palmacarlo
lisboa
portug
introduct
incid
primari
immunodefici
patient
attend
outpati
center
clinic
allergi
immunolog
depend
recruit
patient
refer
method
last
year
patient
observ
lisbon
clinic
allergi
center
report
allerg
diseas
repeat
infect
refer
specialist
ent
gynaecolog
intern
medicin
pediatr
gp
screen
primari
immunodefici
done
electrophoresi
assay
immunoglobulin
complement
igg
subclass
fluxcytometri
b
nk
cell
result
case
primari
immunodefici
diagnos
humor
deficit
iga
immunodefici
igg
igg
subclass
common
variabl
immunodefici
cvi
igm
complement
case
esteras
inhibitor
defici
cellular
case
mucocutan
candidiasi
fertil
femal
case
defici
combin
case
defici
coupl
ligand
igg
defici
conclus
present
seri
chronic
mucocutan
candidiasi
preval
primari
immunodefici
due
number
patient
refer
gynaecologist
asid
group
decreas
nk
cell
common
immunolog
pattern
humor
immunodefici
frequent
mainli
cvi
iga
igg
igg
subclass
defici
search
immunodefici
must
done
patient
repeat
infect
attend
immunoallergolog
depart
case
atyp
complement
defici
cc
randolph
waterburi
ct
introduct
complemennt
defici
occur
individu
result
decreas
opson
chemotaxi
increas
preval
ofsl
rheumat
disordersa
well
enhanc
vulner
pyogen
infectionther
two
type
defici
type
associ
sle
protein
translat
type
ii
absenc
protein
secretionw
present
year
old
white
femal
otherwis
healthi
recurr
urticaria
angioedema
complement
defici
method
case
report
wf
athlet
present
two
month
histori
recurr
hive
angioedema
associ
ingest
halloween
candi
one
week
evalu
hive
coconut
wellher
histori
othewis
unremark
except
recurr
uti
annual
sinus
pneumonia
well
migrainessh
deni
sexual
activityh
physic
exam
normalresult
evalu
autoimmun
diseas
reveal
normal
esr
ana
dsdna
mono
hepat
serolog
well
lyme
titer
howev
normal
evalu
complement
reveal
normal
normal
normal
father
normal
sister
normal
mother
normal
workup
includ
posit
prick
skin
test
ragwe
ash
grass
start
rhinocort
clarinex
seasonallysh
follow
one
year
resolut
hive
asymptomatich
diagnosi
confirm
pediatr
rheumatologistconclus
present
atyp
case
complement
defici
current
asymptomat
individu
background
diagnos
month
old
male
cgd
aspergillu
brain
abscess
pulmonari
infiltr
review
literatur
suggest
one
youngest
case
cgd
complic
cerebr
aspergillosi
case
report
ten
month
old
male
previous
seen
unexplain
persist
pulmonari
infiltr
sinc
month
age
present
hospit
lethargi
fever
increas
irrit
ct
scan
head
reveal
sever
hydrocephalu
multipl
brain
abscess
found
surgic
exam
cultur
aspergillu
fumigatu
histori
failur
thrive
hypotonia
sinc
birth
famili
histori
signific
parent
second
cousin
famili
histori
recurr
infect
childhood
death
physic
examin
signific
child
weight
height
respect
persist
fever
c
hypotonia
hepatosplenomegali
left
lower
lung
field
rale
initi
immun
workup
normal
except
elev
total
ige
kul
cell
initi
low
later
increas
normal
level
without
intervent
neutrophil
oxidas
activ
assess
dihydrorotamin
dhr
oxid
control
superoxid
product
assess
cytochrom
c
reduct
zero
patient
treat
interferon
presum
cgd
aspergillu
brain
abscess
improv
intraven
voriconazol
caspofungun
respons
organ
recurr
pulmonari
infect
identifi
improv
antifung
therapi
broad
spectrum
antibiot
dhr
test
parent
sibl
normal
antibodi
test
show
complet
defici
protein
normal
level
protein
evalu
exon
gene
encod
protein
normal
conclus
mutat
due
protein
defici
respons
case
cgd
one
previous
report
case
defici
without
exon
mutat
singl
point
mutat
intron
ncfii
gene
identifi
fungal
infect
may
complic
cgd
howev
cerebr
aspergillosi
seldom
encount
case
annal
allergi
asthma
immunolog
report
month
old
cgd
due
defici
without
exon
mutat
complic
cerebr
aspergillosi
introduct
lymphoid
interstiti
pneumonia
uncommon
condit
consid
diseas
per
se
inflammatori
pulmonari
reaction
variou
extern
stimuli
system
diseas
howev
present
time
case
remain
idiopath
present
case
infant
develop
lymphoid
interstiti
pneumonia
associ
deficit
interferonproduct
method
describ
clinic
case
review
medic
literatur
result
present
case
five
month
old
male
histori
cough
respiratori
distress
four
previou
hospit
admiss
regard
pneumon
event
two
month
age
four
sibl
dead
two
abdomin
diseas
one
candidiasi
first
year
life
parent
refer
consanguin
physic
examin
show
malnourish
child
sign
bilater
lung
consolid
oxygen
supplement
intraven
antibiot
start
patient
nt
neonat
histori
relat
present
compliant
chest
film
reveal
diffus
bilater
interstiti
pattern
confirm
pulmonari
ct
scan
sweat
chlorid
test
hiv
epstein
barr
viru
serolog
test
neg
initi
immunolog
evalu
report
slightli
increas
leukocyt
count
hypergammaglobulinemia
lymphocityc
flow
citometri
nitro
blue
tetrazolium
reduct
test
normal
paramet
open
lung
biopsi
show
thick
pulmonar
interstitium
moder
number
lymphocyt
atyp
pattern
patient
discharg
clinic
improv
ambulatori
oxygen
supplement
inhal
fluticasonesalmeterol
ambulatori
followup
evalu
lymphocyt
product
cytokin
found
level
interferon
start
weekli
administr
oral
transfer
factor
patient
show
excel
clinic
improv
evidenc
oxygen
depend
weight
gain
absenc
hospit
admiss
conclus
patient
repres
new
linkag
lymphoid
interstiti
pneumonia
primari
immunodefici
character
interferonproduct
deficit
mayb
non
previous
describ
molecular
defect
probabl
autosom
recess
inherit
pattern
also
confirm
transfer
factor
use
induc
gamma
interferon
endog
product
object
marijuana
schedul
class
psychoact
control
substanc
frequent
use
orient
societi
event
jubil
caus
alter
state
conscienc
euphoria
prolong
use
follow
addict
dependenceit
contain
chemic
entiti
cannabinoid
ie
cannabidiol
cbd
cannabinol
cbn
tetrahydrocannabinol
thc
later
use
associ
crave
use
narcot
enhanc
euphori
effect
activ
ingredi
ie
cannabinoid
thc
liquid
solubl
high
concentr
alter
membran
function
result
alter
immun
cell
respons
cannabinoid
immunosuppress
properti
caus
impair
cellmedi
humor
immun
system
activ
cytokin
product
leukocyt
migrat
natur
killercel
nk
activ
result
reduct
host
resist
bacteri
viral
infect
pm
hiv
infect
higher
risk
develop
aid
infect
opportunist
bacteria
fungi
virus
pm
compar
non
marijuana
smoker
respiratori
illnesscannabinoid
also
characterist
immunomodul
ie
gener
suppress
occasion
enhanc
immunolog
respons
suggest
immunosuppress
effect
cannabinoid
might
use
clinic
exampl
treat
multipl
sclerosisa
per
clinic
respons
cannabinoid
found
exacerb
exist
allergi
antigen
complex
elicit
format
specif
antibodiesmetabolit
hapten
combin
bodi
protein
method
follow
studi
includ
male
year
pm
month
serum
level
tch
time
reduct
prolifer
lymphocyt
proportion
increas
prolifer
b
lymphocyt
reduct
cytotox
activ
lymphocyt
reduct
macrophag
activ
ie
phygocytosi
rational
patient
xla
subject
arthriti
cellul
three
rel
similar
cours
suggest
infecti
etiolog
method
two
brother
cousin
africanamerican
famili
known
carri
xla
diagnos
xla
chronic
treat
ivig
three
develop
arthriti
cellul
lower
extrem
eldest
year
old
wax
wane
arthriti
cellul
refractori
oral
antibiot
attempt
younger
brother
yet
accomplish
pubert
chang
age
percentil
weight
height
also
sever
month
wax
wane
arthriti
cellul
refractori
oral
antibiot
cousin
esophogastroduodenoscopi
show
gastriti
duoden
heavi
growth
organ
visual
specif
stain
h
pylori
cousin
also
experienc
recent
weight
loss
arthritiscellul
result
younger
brother
blood
cultur
grew
curv
gramneg
rod
subsequ
cultur
state
lab
grew
similar
organ
ureaseneg
two
brother
near
complet
sixmonth
cours
ertapenem
gentamicin
resolut
arthriti
cellul
younger
gain
kg
experienc
pubert
chang
age
year
conclus
prior
report
sever
differ
relat
organ
caus
arthriti
cellul
patient
xla
includ
helicobact
campylobact
flexispira
speci
ureaseneg
organ
would
flexispira
may
campylobactor
speci
helicobact
cani
result
famili
suggest
longterm
combin
iv
antibiot
may
indic
patient
syndrom
slow
viru
infect
report
affect
central
nervou
system
parvoviru
herp
cmv
usual
includ
diagnosi
cn
diseas
associ
cn
manifest
immunocompromis
patient
abstract
report
neurolog
manifest
link
ebsteinbarrherp
viru
immun
defici
patient
year
old
femal
present
clinic
histori
chronic
fatigu
symptom
daili
arthralgia
frequent
sinu
infect
idiopath
tremor
past
year
patient
neurolog
evalu
includ
mri
found
within
normal
limit
despit
worsen
tremor
head
arm
full
clinic
laboratori
evalu
perform
reveal
igg
subclass
low
tcell
number
function
low
respons
specif
antibodi
posit
igm
ebv
parvo
cmv
patient
common
immun
defici
coupl
chronic
viral
infect
worsen
tremor
led
us
tri
high
dose
ivig
divid
day
cycl
everi
week
within
three
month
start
ivig
patient
larg
reduct
tremor
neg
igm
parvoviru
herp
cmv
given
find
suggest
ivig
may
play
role
neuroimmun
modul
shown
neuroimmun
diseas
suggest
interact
parvoviru
herp
cmv
part
slow
virus
combin
underli
immun
disord
may
lead
neurolog
present
high
dose
ivig
revers
syndrom
purpos
date
two
patient
older
fifti
year
age
diagnos
velocardiofaci
syndrom
vcf
case
repres
third
patient
method
physic
laboratori
find
patient
present
case
report
result
describ
sixtysixyearold
male
recent
diagnos
vcf
confirm
fluoresc
insitu
hybrid
fish
refer
psychiatrist
comprehens
care
histori
cleft
palat
learn
disabl
child
onset
psychiatr
ill
late
teen
although
histori
cardiac
diseas
patient
agenesi
left
renal
arteri
well
vascular
anomali
includ
hypoplasia
left
segement
anterior
cerebr
arteri
find
includ
hypothyroid
hypoparathyroid
sensorineur
hear
loss
typic
faci
also
suffer
chronic
candidiasi
immunolog
laboratori
studi
reveal
ratio
cell
decreas
percentag
markedli
diminish
b
cell
percentag
decreas
cell
mitogen
respons
markedli
decreas
b
cell
mitogen
respons
nevertheless
total
serum
igg
specif
antibodi
respons
remain
normal
low
serum
igm
conclus
patient
meet
criteria
diagnosi
vcf
third
report
case
diagnos
age
fifti
though
immunolog
find
may
consist
diagnosi
may
due
part
immunolog
senesc
given
age
background
classic
present
patient
xla
mutat
btk
gene
includ
mark
hypogammaglobulinemia
absent
b
cell
signific
sinopulmonari
infect
begin
month
age
typic
md
present
anemia
leukopenia
monocytosi
thrombocytopenia
recurr
infect
skin
rash
hepatosplenomegali
mani
subject
demonstr
chromosom
abnorm
includ
monosomi
describ
case
md
present
featur
condit
clinic
histori
present
year
old
male
suspect
diagnosi
xla
chronic
sinopulmonari
diseas
begin
mo
diffus
bronchiectasi
agammaglobulinemia
absent
b
cell
wbc
cellsul
monocyt
platelet
count
ul
anemia
hepatosplenomegali
skin
rash
bone
marrow
biopsi
show
md
absent
plasma
cell
monosomi
cell
btk
express
sequenc
analysi
normal
conclus
xla
like
primari
immun
defici
would
present
male
clinic
pictur
describ
case
illustr
import
maintain
expand
differenti
diagnosi
patient
presum
primari
immunodefici
j
wang
l
mayer
c
cunninghamrundl
new
york
ny
background
chronic
granulomat
diseas
cgd
usual
result
acut
chronic
infect
defin
spectrum
bacteria
fungi
characterist
includ
inflammatori
disord
includ
genitourinari
mucos
inflamm
resembl
inflammatori
bowel
diseas
gmcsf
use
treatment
mucos
inflamm
glycogen
storag
diseas
ib
crohn
diseas
success
object
explor
use
novel
therapi
treatment
mucos
inflamm
associ
cgd
method
patient
treat
daili
gmcsf
mcgkgdose
subcutan
inject
along
parenter
antibiot
total
parenter
nutrit
day
gmcsf
hydrocortison
enema
ad
due
continu
pain
swell
result
rectal
abdomin
pain
significantli
improv
blood
streak
stool
decreas
toler
regular
diet
discharg
home
day
start
gmcsf
rectal
abdomin
pain
blood
stool
conclus
gmcsf
may
use
therapi
manag
mucos
inflamm
cgd
patient
appear
safe
well
toler
permit
avoid
immun
suppress
altern
introduct
manag
autoimmun
cytopenia
patient
cellular
immunodefici
may
challeng
treatment
cytopenia
corticosteroid
may
potenti
immun
dysfunct
lead
infect
method
describ
monthold
femal
cellular
immunodefici
autoimmun
thrombocytopenia
hemolyt
anemia
treat
steroid
ivig
without
improv
rituximab
monoclon
antibodi
bind
blymphocyt
surfac
antigen
initi
result
patient
present
month
age
failur
thrive
eczema
recurr
bacteri
pneumonia
diagnos
lymphocyt
immunodefici
decreas
absolut
number
lymphocyt
cell
function
markedli
decreas
measur
pha
cona
pwm
develop
chronic
thrombocytopenia
platelet
less
coomb
posit
anemia
hemoglobin
gdl
place
prednison
minim
improv
continu
develop
sever
pneumonia
rituximab
mgm
week
initi
dose
cytopenia
improv
increas
platelet
count
hemoglobin
absolut
count
fell
wean
steroid
perman
also
continu
ivig
prophylact
antibiot
need
rituximab
pend
bone
marrow
transplant
conclus
rituximab
monoclon
anticd
antibodi
may
help
treat
autoimmun
cytopenia
patient
cellular
immunodefici
steroid
need
avoid
ivig
antibodi
replac
substitut
subsequ
humor
antibodi
deplet
due
induc
secondari
b
cell
lymphopenia
introduct
patient
month
old
male
born
full
term
prenat
cours
note
pulmonari
abnorm
left
lower
lobe
approxim
week
age
serial
ultrasound
fetal
mri
consist
diagnosi
congenit
cystic
adenomatoid
malform
ccam
histolog
elect
resect
lesion
perform
month
age
reveal
evid
ccam
silver
stain
reveal
florid
pneumocysti
jiroveci
carinii
infect
patient
complet
asymptomat
differenti
diagnosi
infect
newborn
period
includ
hiv
infect
sever
combin
immunodefici
xlink
hyperigm
syndrom
infect
also
occur
newborn
appar
normal
immun
system
method
immunolog
evalu
perform
evalu
patient
list
diagnos
complet
blood
count
perform
lymphocyt
subset
perform
flow
cytometri
quantit
immunoglobulin
g
e
measur
nephelometri
specif
antibodi
tetanu
diptheria
determin
elisa
hiv
statu
ascertain
western
blot
dna
pcr
dichlorofluorescein
assay
perform
fluorescenceactiv
cell
sorter
techniqu
use
evalu
ligand
lymphocyt
stimul
mitogen
tetanu
perform
result
patient
neg
antibodi
neg
hiv
dna
pcr
result
complet
blood
count
normal
absolut
lymphocyt
count
patient
normal
percentag
number
natur
killer
cell
lymphocyt
stimul
mitogen
tetanu
normal
dcf
assay
normal
fac
reveal
normal
level
ligand
month
age
protect
titer
diptheria
tetanu
titer
iuml
protect
iuml
month
igg
e
normal
respect
conclus
immunolog
test
reveal
evid
sever
combin
immunodefici
hiv
infect
xlink
hyperigm
syndrom
patient
remain
well
clinic
normal
growth
develop
subsequ
infect
pneumocysti
jiroveci
pneumonia
seen
infant
appar
normal
immun
system
commerci
prepar
igg
produc
iv
use
ivig
must
fulfil
regulatori
requir
method
prepar
howev
may
produc
alter
content
function
igg
subclass
disturb
composit
reflect
lower
clinic
effect
product
report
patient
specif
immunodefici
chang
new
ivig
prepar
lessen
clinic
effect
new
product
also
experienc
recoveri
chang
differ
ivig
product
case
yo
male
hx
cervic
lymphadenopathi
associ
recurr
uri
fatigu
cognit
alter
hypercholesterolemia
dx
specif
immunodefici
start
ivig
infus
w
brought
level
normal
valu
mgdl
mgdl
good
clinic
improv
chang
differ
ivig
product
lower
iga
content
initi
symptom
return
decreas
mgdl
mgdl
chang
differ
ivig
product
higher
iga
content
disappear
previou
symptom
case
yo
femal
histori
chronic
yeast
infect
fatigu
joint
pain
asthma
ge
reflux
depress
hypothyroid
shunt
hydrocephali
diagnos
immunodefici
start
ivig
mg
x
kg
x
w
chang
anoth
ivig
lower
iga
content
experienc
worsen
symptom
month
receiv
chang
differ
ivig
product
higher
iga
content
complet
improv
symptom
although
content
iga
product
ugml
significantli
lower
product
total
igg
igg
subclass
distribut
includ
compar
therefor
lack
clinic
effect
product
would
appear
relat
qualit
alter
product
relat
methodolog
prepar
possibl
remov
iga
physicochem
alter
affect
biolog
activ
contribut
lessen
clinic
efficaci
product
present
case
alert
allergistimmunologist
observ
treat
patient
igg
igg
subclass
defici
background
develop
atopi
known
occur
nonatop
recipi
bone
marrow
transplant
bmt
atop
donor
revers
condit
atop
recipi
lose
evid
specif
ige
bmt
nonatop
donor
quit
uniqu
case
report
ph
year
old
male
refer
recurr
nasal
congest
teenag
patient
treat
chronic
allerg
rhiniti
asthma
atop
dermat
diagnos
sever
multipl
food
allergi
skin
test
done
teenag
show
reaction
multipl
pollen
dog
cat
seafood
cashew
walnut
pecan
year
age
underw
allogen
bmt
nonatop
brother
acut
myelogen
leukemia
asthma
atop
dermat
observ
clear
almost
complet
allerg
rhiniti
improv
bmt
blood
type
chang
skin
test
done
current
visit
show
unremark
respons
pollen
cat
dog
dust
mite
food
good
histamin
control
discuss
neg
skin
test
result
suggest
current
nasal
symptom
vasomotor
natur
consid
past
sever
symptom
appear
unlik
lost
specificig
sensit
spontan
transfer
atopi
known
occur
nonatop
recipi
bmt
atop
donor
studi
patient
undergo
allogen
bmt
hematolog
malign
nonatop
recipi
develop
posit
skin
test
profil
similar
atop
donor
possibl
mechan
passiv
transfer
memori
bcell
initi
specificig
product
donor
pattern
revers
mechan
could
occur
recipi
gain
lymphoid
precursor
atop
tendenc
lead
clear
atopi
literatur
yield
one
report
asthma
resolv
highdos
chemotherapi
autolog
stem
cell
transplant
author
suggest
chemotherapi
could
result
immun
system
reconstitut
normal
tcell
repertoir
resolut
asthma
introduct
primari
central
nervou
system
cn
lymphoma
constitut
small
percentag
central
nervou
system
tumor
adult
seen
frequent
aid
patient
immunodefici
state
extrem
rare
children
even
primari
immunodefici
present
femal
combin
immunodefici
develop
eber
ebvassoci
larg
bcell
lymphoma
confin
cn
method
patient
femal
evalu
combin
immunodefici
present
institut
acut
fever
seizur
activ
result
patient
histori
recurr
pneumonia
otiti
media
sinus
upper
respiratori
infect
also
exhibit
failur
thrive
chronic
diarrhea
sensorineur
deaf
found
combin
immunodefici
sever
neutropenia
lymphopenia
low
iga
low
igm
poor
specif
antibodi
respons
protein
polysaccharid
antigen
respons
candida
delay
hypersensit
skin
test
hiv
test
neg
thought
acut
meningoenceph
caus
fever
seizur
activ
howev
bacteri
viral
fungal
studi
neg
receiv
multipl
anitbacteri
antifung
antivir
agent
die
secondari
brainstem
compress
due
sever
cerebr
edema
autopsi
reveal
eber
larg
bcell
lymphoma
involv
brain
spinal
cord
tumor
cell
found
elsewher
conclus
case
repres
rare
manifest
combin
immunodefici
develop
primari
cn
lymphoma
tumor
cell
found
eber
ebvassoci
ebv
known
associ
lymphoma
especi
aid
immunocompromis
patient
primari
tumor
site
sever
combin
immun
defici
patient
involv
cn
immunodefici
cancer
registri
institut
v
litvinova
g
muzlaev
krasnodar
russian
feder
introduct
glyoma
one
preval
diseas
among
brain
tumor
malign
previou
investig
shown
immun
disord
patient
glyoma
tumor
time
suggest
possibl
antitumor
activ
proinflammatori
cytokin
tnf
penetr
via
haematoencephal
barrier
induc
lysi
tumor
cell
aim
investig
studi
serum
spinal
fluid
concentr
one
key
immunoregulatori
cytokin
gamma
ifn
patient
glyoma
tumor
method
concentr
gamma
ifn
studi
serum
spinal
fluid
patient
glyoma
eliza
method
control
paramet
studi
patient
brain
trauma
result
shown
concentr
gamma
ifn
serum
spinal
fluid
time
higher
trauma
patient
p
serum
level
gamma
ifn
glyoma
patient
accordingli
trauma
concentr
spinal
fluid
studi
cytokin
time
higher
control
patient
conclus
proinflammatori
cytokin
gamma
ifn
may
involv
pathogenesi
glyoma
particip
possibl
antitumor
factor
immun
glyoma
patient
arreymensah
ru
sorensen
new
orlean
la
rational
immunodefici
need
rule
infant
present
failur
thrive
patient
tcell
lymphopenia
hypogammaglobulinemia
pancytopenia
may
primari
immunodefici
scid
secondari
immunodefici
may
need
manag
differ
method
evalu
cellular
antibodymedi
immun
month
old
aaf
admit
failur
thrive
chronic
diarrhea
ohistori
duoden
atresia
correct
creat
blind
duoden
loop
anastomosi
stomach
jejunum
birth
mass
hypogastrium
result
immunolog
evalu
reveal
lymphopenia
rang
anemia
hemoglobin
retic
anc
rang
thrombocytopenia
mitogen
respons
normal
pha
cona
pwm
immunoglobulin
igg
iga
igm
ige
iuml
total
protein
albumin
immunoglobul
halflif
studi
day
patient
metabol
imbal
hypokalemia
hyponatremia
hypocalcemia
blood
stool
urin
cultur
normal
stool
ova
parasit
viru
neg
hivpcr
radiolog
evalu
superior
mesenter
vein
thrombosi
chronic
malrot
volvulu
dilat
duoden
blind
loop
possibl
lymphat
obstruct
patient
improv
clinic
immunolog
marker
normal
surgic
remov
adhes
obstruct
conclus
patient
secondari
immunodefici
due
lymphangiectasia
lymphangiectasia
consid
presenc
lymphopenia
normal
lymphocyt
function
hypogammaglobulinemia
accompani
hypoproteinemia
hypoalbuminemia
hypogammaglobulinemia
hypoproteinemia
secondari
gastrointestin
loss
immunolog
compon
delet
syndrom
also
known
digeorg
syndrom
dg
hypoplasia
thymu
quit
variabl
among
patient
provid
opportun
determin
relationship
thymic
function
cell
receptor
tcr
repertoir
divers
use
novel
measur
repertoir
divers
base
length
polymorph
call
ham
distanc
tcrbv
repertoir
divers
dg
found
differ
control
subject
overal
skew
receptor
express
expect
clinic
outcom
also
great
intraindividu
variabl
dg
tcr
repertoir
degre
repertoir
divers
directli
correl
thymic
output
measur
cell
receptor
excis
circl
trec
ie
greater
thymic
output
result
divers
repertoir
see
figur
result
demonstr
quantit
relationship
thymic
function
repertoir
divers
human
may
reflect
balanc
thymic
output
peripher
expans
maintain
adequ
tcr
repertoir
addit
may
suggest
basi
wherein
limit
repertoir
divers
mediat
immun
defici
autoimmun
tcr
repertoir
divers
dg
measur
ham
distanc
correl
thymic
output
measur
trec
plot
logarithm
scale
sabra
sabra
hj
castro
j
malkarai
ji
mendezinocencio
g
santo
ja
bellanti
rio
de
janeiro
brazil
washington
dc
major
investig
effort
laboratori
direct
studi
nonig
mechan
role
immunopathogenesi
food
allergi
fa
previous
report
cytokin
alter
associ
sever
clinic
entiti
overlap
diseas
manifest
affect
mucosalassoci
lymphoid
tissu
malt
gi
tract
galt
skin
salt
nasal
nalt
bronchial
tissu
balt
object
present
studi
evalu
specif
immunolog
alter
group
patient
nonig
fa
peripher
blood
lymphocyt
subset
analys
perform
patient
fa
document
doubleblind
placebocontrol
foodchalleng
dbpcfc
patient
treat
aminoacid
base
formula
aabf
receiv
open
challeng
use
panel
commonli
offend
allergen
food
allergen
normal
dietth
clinic
pictur
patient
fa
link
maltrel
manifest
galt
symptom
diarrhea
vomit
abdomin
pain
ftt
balt
symptom
asthma
salt
symptom
eczema
nalt
symptom
rhiniti
edema
ascit
anaphylaxi
subject
normal
serum
ige
eosinophil
level
neg
ige
food
rast
test
normal
mean
low
level
peripher
blood
abnorm
ratio
observ
patient
ageand
gendermatch
control
reveal
ratio
rang
patient
anaphylaxi
ratio
patient
respond
well
aabf
open
challeng
common
offend
food
regular
diet
milk
soy
wheat
egg
nut
beef
chicken
reveal
multipl
food
allergi
two
year
followup
aabf
regimen
patient
remain
well
allerg
multipl
food
low
level
remain
uniqu
immunolog
alter
patientsthes
studi
suggest
abnorm
low
distribut
may
play
pathogenet
role
nonig
mediat
fa
sinc
lymphocyt
play
role
immunolog
toler
tempt
specul
low
level
may
signal
failur
develop
patient
predispos
develop
allergi
multipl
food
compon
background
mix
connect
tissu
diseas
mctd
diseas
taht
caus
controversi
author
consid
distinct
rheumat
diseas
other
believ
earli
stage
fulli
defin
autoimmun
diseas
distinct
featur
presenc
small
nuclear
rnp
autoantibodi
clinic
featur
involv
raynaud
phenomenon
swollen
hand
sclerodactyli
esophag
hypomotil
polyarthr
myositi
allof
present
other
well
dein
rheumat
diseas
aew
case
describ
pediatr
popul
objet
determin
frecuenc
mix
connect
tissu
diseas
mexicanchildren
tertiari
level
institut
accord
kasakawa
criteria
alarconsegovia
criteria
sharp
criteria
establish
diagnosi
well
defin
autoimmun
entiti
made
follow
method
medic
chart
assess
diagnosi
mctd
hospit
result
case
autoinmun
diseas
treat
system
lupu
erythematosu
sle
rheumatoid
arthriti
ra
scleroderma
dermatomyos
found
four
case
complet
kasakawa
criteria
diagnosi
probabl
accord
alarconsegovia
sharp
criteria
one
develop
sle
one
year
follow
case
fulfil
diagnosi
criteria
mctd
raynaud
phenomenon
rnp
antibodi
posit
arthriti
lymphadenopathi
restrict
pulmonari
diseas
sclerodactili
muscl
weak
develop
full
blown
sle
year
follow
discuss
diseas
extrem
rare
children
conclud
least
pediatr
age
diseas
may
exist
earli
stage
defin
autoimmun
diseas
terminolog
un
differenti
connect
tissu
diseas
appropri
defin
case
baysan
hy
song
gupta
l
yel
irvin
ca
hereditari
angioedema
hae
autosom
domin
diseas
character
episod
angioedema
skin
mucosa
respiratori
gastrointestin
system
hae
caus
quantit
type
andor
function
type
ii
defici
plasma
protein
inhibitor
earli
compon
classic
complement
pathway
attack
hae
may
lifethreaten
even
caus
death
airway
involv
report
yearold
femal
patient
hae
type
ii
seven
affect
famili
member
two
die
laryng
angioedema
patient
histori
recurr
swell
eyelid
lip
tongu
extrem
respiratori
distress
sinc
five
year
age
hospit
sever
occas
one
requir
intub
assist
ventil
laboratori
studi
attack
reveal
normal
serum
complement
level
complement
level
decreas
mgdl
mgdl
esteras
function
impair
n
greater
contrast
normal
quantit
esteras
patient
longterm
danazol
treatment
ten
year
experienc
side
effect
notabl
hirsut
current
limit
efficaci
safe
treatment
option
hae
treatment
choic
acut
attack
prophylaxi
appear
inhibitor
concentr
yet
licens
us
present
patient
emphas
need
establish
correct
diagnosi
appropri
manag
plan
recurr
angioedema
j
hajsam
l
ponomarjev
krasnodar
russian
feder
background
previou
investig
indic
posit
effect
ncir
differ
chronic
inflammatori
infecti
diseas
nevertheless
mechan
clinic
efficaci
ncir
remain
still
unknown
aim
investig
studi
immun
disord
patient
chronic
tonsil
immunomodulatori
effect
complex
treatment
combin
ncir
method
children
chronic
tonsil
age
year
old
observ
cell
receptor
hladr
studi
use
flow
cytometri
method
cytokin
gamma
ifn
investig
eliza
method
treatment
includ
tradit
method
combin
ncir
control
group
without
tonsil
consist
children
age
result
shown
chronic
tonsil
dcreas
number
hladr
cell
decreas
cell
mainli
due
decreas
cell
time
shown
increas
number
cell
chronic
tonsil
determin
increas
serum
proinflammatori
cytokin
level
time
p
time
level
gamma
ifn
lower
control
time
studi
treatment
method
includ
ncir
result
increas
number
cell
level
decreas
pgml
pgml
time
serum
concentr
gamma
ifn
increas
time
accordingli
conclus
chronic
tonsil
shown
immun
disord
cell
subpopul
cytokin
product
efficaci
ncir
mainli
depend
normalis
cellular
subpopul
increas
concentr
gamma
ifn
introduct
viral
hepat
character
suppress
function
relat
diseas
sever
aim
research
determin
total
ige
concentr
level
patient
viral
hepat
c
vhc
mix
viral
hepat
vhbc
investig
correl
cell
paramet
method
patient
vhc
patient
vhbc
confirm
pcr
examin
evalu
serum
total
ige
level
perform
elisa
kit
produc
vectorbest
russia
immunophenotyp
peripher
blood
mononuclear
cell
pbmc
done
cytometri
monoclon
antibodi
hladrantigen
result
level
serum
total
ige
patient
vhc
vhbc
significantli
increas
group
studi
especi
acut
hepat
c
muml
p
compar
control
group
analysi
pbmc
subpopul
patient
vhc
vhbc
done
relat
total
ige
level
group
muml
group
ii
muml
patient
viral
hepat
high
total
ige
level
content
ratio
significantli
decreas
compar
control
group
p
notabl
chang
found
patient
acut
vhc
vhbc
increas
content
seen
group
low
high
level
total
ige
content
patient
high
level
total
ige
also
increas
p
conclus
patient
vhc
vhbc
significantli
greater
level
total
ige
compar
control
group
p
increas
total
ige
level
patient
viral
hepat
associ
imbal
tlymphocyt
subpopul
includ
decreas
increas
band
nkcell
titl
occup
airway
allergi
among
health
care
worker
hcw
latex
allergi
introduct
last
year
frequenc
latex
allergi
increas
health
care
worker
hcw
risk
group
diseas
latex
allergi
symptom
occur
differ
organ
includ
skin
conjunct
nose
bronchi
studi
aim
aim
studi
estim
incid
airway
allergi
group
hcw
latex
allergi
materi
method
investig
carri
group
hcw
age
averag
age
two
hundr
eight
women
forti
four
men
group
investig
consist
questionair
examin
skin
prick
test
latex
patch
test
rubber
addit
sige
latex
spirometri
result
seventi
eight
hcw
report
undesir
effect
contact
latex
product
fourti
hcw
report
symptom
airway
nose
bronchi
latex
allergi
spt
andor
sige
anamnesi
posit
diagnos
case
symptom
concern
skin
nose
conjunct
case
skin
conjunct
case
nose
conjunct
case
nose
skin
case
bronchi
skin
nose
conjunct
case
skin
case
conclus
incid
occup
airway
allergi
group
health
care
worker
latex
allergi
high
case
latex
allergi
symptom
usual
affect
skin
sometim
includ
also
organ
conjunct
nose
seldom
bronchi
incid
anaphylaxi
increas
food
allergi
anaphylaxi
network
wish
expand
use
inject
epinephrin
first
respond
allerg
emerg
indiana
first
respond
basic
emt
advanc
emt
paramed
use
inject
epinephrin
permit
paramed
advanc
emt
respond
bill
introduc
expand
use
inject
epinephrin
em
personnel
event
allerg
emerg
sponsor
indiana
allergi
asthma
immunolog
societi
emerg
medic
servic
commiss
indiana
juli
senat
bill
took
effect
permit
first
respond
administ
without
restrict
inject
epinephrin
legisl
pass
becam
respons
medic
director
md
ambul
servic
state
implement
chang
attempt
assess
impact
legisl
survey
md
state
month
passag
bill
md
notifi
legisl
memo
public
meet
addit
md
receiv
copi
legisl
md
respond
survey
result
unawar
legisl
awar
legisl
implement
awar
legisl
implement
restrict
basic
emt
awar
legisl
implement
level
conclus
twentyf
percent
md
unawar
legisl
among
implement
chang
major
permit
use
basic
emt
allergist
lay
organ
em
commission
need
assur
implement
legisl
md
within
state
khadavi
b
silverman
schneider
great
neck
ny
brooklyn
ny
rabbit
anaphylaxi
extrem
rare
one
document
case
upon
inhal
describ
patient
sever
anaphylaxi
upon
consumpt
rabbit
femal
histori
asthma
allerg
rhiniti
present
evalu
patient
complain
worsen
asthma
rhiniti
symptom
home
upon
exposur
outdoor
pollen
histori
reveal
famili
rabbit
pet
laboratori
test
show
total
ige
kul
rast
result
normal
tree
ragwe
mold
kiul
posit
result
found
ragwe
dust
cockroach
cat
dog
mous
peanut
rabbit
epithelium
kiul
class
iv
among
environment
control
measur
famili
advis
elimin
rabbit
home
environ
could
potenti
trigger
daughter
allergi
symptom
two
day
later
patient
present
emerg
room
wheez
cough
angioedema
hand
face
treat
albuterol
diphenhydramin
oral
steroid
parent
said
follow
instruct
know
anaphylaxi
occur
question
reveal
famili
consum
pet
rabbit
night
preced
anaphylact
reaction
first
time
daughter
ate
rabbit
parent
assum
exposur
live
rabbit
would
worsen
allergi
asthma
symptom
never
expect
allerg
reaction
via
ingest
advis
feed
daughter
rabbit
given
prescript
selfinject
epinephrin
demonstr
either
complet
ident
partial
similar
cross
reactiv
inhal
food
allergen
note
previous
certain
food
garlic
crustacean
protein
physician
need
advis
food
allerg
patient
allerg
reaction
develop
upon
inhal
food
seen
peanut
also
respiratori
sensit
allergen
lead
allerg
symptom
upon
ingest
nsouli
j
scheiner
j
malkarai
ja
bellanti
burk
va
washington
dc
safeti
select
coxii
inhibitor
patient
known
nsaidinduc
allerg
reaction
definit
establish
still
open
debat
present
report
describ
two
patient
hypersensit
reaction
naproxen
first
character
system
anaphylact
reaction
second
local
urticaria
follow
ingest
drug
first
case
yo
wf
histori
osteoarthr
minut
ingest
mg
naproxen
develop
gener
pruritu
urticaria
laryng
edema
hypotens
treat
er
epinephrin
diphenhydramin
iv
corticosteroid
epicutan
intraderm
skin
test
celecoxib
reveal
neg
result
similar
control
oral
challeng
celecoxib
well
toler
patient
without
advers
respons
second
case
yo
wf
known
histori
chronic
urticaria
osteoarthr
requir
regular
use
naproxen
complet
allerg
immunolog
workup
neg
upon
discontinu
drug
resolut
urticaria
oral
challeng
celecoxib
well
toler
patient
without
advers
sequela
two
case
report
exemplifi
two
extrem
spectrum
advers
allerg
reaction
naproxen
nonselect
coxi
coxii
inhibitor
one
system
second
local
suggest
pathogenesi
symptom
like
pseudoallerg
natur
immunologicallymedi
dissimilar
chemic
structur
naproxen
celecoxib
togeth
differ
mechan
action
suggest
absenc
allerg
reaction
challeng
celecoxib
coxii
inhibitor
may
relat
lack
crossreact
two
drug
although
find
suggest
oral
celecoxib
could
possibl
safe
altern
patient
naproxeninduc
drug
reaction
would
prudent
first
conduct
care
challeng
drug
wellequip
medic
set
clinic
accept
toler
could
safe
assess
introduct
fix
remov
dentur
made
cast
alloy
mani
orthodont
applianc
also
fabric
metal
biomateri
document
vitro
vivo
metal
restor
releas
metal
ion
mainli
due
corros
metal
ion
may
distribut
system
local
could
pay
signific
role
induct
oral
orand
system
immunoinflammatori
condit
studi
determin
frequenc
sensit
metal
salt
clinic
characterist
group
patient
complaint
relat
advers
effect
dental
alloy
method
patient
women
men
age
year
symptom
assum
advers
effect
dental
alloy
studi
patient
studi
base
metal
salt
includ
cu
co
cr
mg
mn
ni
ti
zn
use
patch
test
patch
test
substanc
salt
petrolatum
patch
test
conduct
accord
recommend
icdrg
occlus
time
day
patch
test
read
remov
patch
finn
chamber
scanpor
epitest
ltd
oy
tulusa
finland
day
later
total
number
percentag
irrit
allerg
patch
test
reaction
calcul
result
patient
sensit
base
metal
use
dental
restor
note
symptom
includ
burn
mouth
metal
tast
electr
sensat
dri
mouth
tast
irrit
patient
symptom
local
gingiv
anomali
tongu
stomat
lichenoid
reaction
often
seen
frequent
patch
test
reaction
caus
ni
cr
co
conclus
studi
demonstr
higher
frequenc
hypersensit
reaction
ni
cr
co
group
patient
often
symptom
burn
mouth
metal
tast
electr
sensat
local
gingiv
anomali
tongu
wy
mak
kearney
b
silverman
schneider
brooklyn
ny
process
intraven
drug
desensit
often
involv
simpl
tediou
calcul
miscalcul
may
aris
due
human
error
patient
truli
allerg
drug
question
error
life
threaten
fatal
propos
use
spreadsheet
minim
calcul
error
spreadsheet
microsoft
excel
ibm
lotu
corel
quattro
pro
use
extens
financ
tediou
repetit
calcul
properti
spreadsheet
make
ideal
tool
assist
drug
desensit
protocol
chose
microsoft
excel
avail
institut
gener
templat
initi
creat
equat
specif
cell
base
protocol
list
patterson
allerg
diseas
edit
middleton
allergi
principl
practic
edit
input
specif
number
amount
drug
volum
diluent
key
cell
spreadsheet
program
automat
calcul
protocol
given
intraven
drug
exampl
pipericillin
protocol
list
find
use
spreadsheet
minim
calcul
error
henc
reduc
likelihood
avoid
reaction
also
decreas
prepar
time
desensit
protocol
recommend
use
allergist
perform
drug
desensit
state
year
ago
infest
home
across
northeast
southeast
midwestern
state
insect
fall
winter
month
becom
increasingli
common
last
year
sever
investig
publish
case
report
patient
allerg
rhiniti
conjunct
asthma
symptom
associ
suspect
inhal
exposur
high
level
protein
beetl
report
seri
patient
present
spectrum
variou
allergi
complaint
rang
symptom
allerg
rhiniti
asthma
urticaria
angioedema
acut
anaphylaxi
document
elev
serum
tryptas
exposur
high
number
multicolor
asian
ladybeetl
malb
method
perform
western
blot
patient
serum
wholebodi
ladybeetl
extract
made
confirm
h
axyridi
obtain
one
infest
home
region
result
blot
patient
serum
reveal
ige
bind
differ
protein
molecular
weight
approxim
kd
serum
two
patient
bound
kd
protein
possibl
similar
kd
protein
previous
identifi
yarbrough
et
al
jaci
ige
four
patient
bound
kd
protein
previous
report
lastli
serum
two
patient
reveal
ige
bind
kd
protein
possibl
similar
heavier
protein
mention
abstract
magnan
et
al
jaci
conclus
present
five
patient
specif
ige
malb
allerg
symptom
exposur
high
level
malb
conclud
malb
like
signific
sourc
sever
differ
allergen
protein
malb
increasingli
becom
signific
caus
wide
varieti
hypersensit
reaction
across
unit
state
multipl
expos
subject
sever
entomologist
report
beetl
bite
human
specul
wide
rang
igemedi
symptom
includ
urticaria
angioedema
anaphylaxi
occur
exposur
protein
inhal
direct
contact
possibl
inocul
protein
skin
bite
scratch
beetl
case
report
literatur
review
cs
taylor
ramesh
getzvil
ny
buffalo
ny
introduct
lentil
belong
legum
famili
stapl
ingredi
ethnic
indian
diet
lentil
shown
caus
allerg
reaction
even
anaphylaxi
howev
littl
research
done
distinguish
type
lentil
use
commonli
indian
diet
variou
hypersensit
lentil
includ
black
gram
phaseolu
mungo
mung
bean
split
chick
pea
bengal
gram
case
report
report
indian
boy
present
sever
atop
dermat
sinc
age
four
month
dermat
exacerb
ingest
pea
bean
resolv
avoid
nine
month
age
child
introduc
boil
mung
bean
subsequ
develop
lip
swell
within
minut
similar
reaction
occur
split
chick
pea
physic
exam
consult
reveal
sever
eczema
skin
test
use
commerci
extract
reveal
respons
peanut
never
eaten
peanut
soybean
pea
egg
subsequ
skin
test
follow
visit
prepar
reagent
reveal
much
greater
respons
mung
bean
chick
pea
split
chick
pea
black
gram
patient
develop
system
respons
test
requir
epinephrin
discuss
legum
allergi
peanut
soy
pea
rare
unit
state
report
asia
mediterranean
area
report
one
case
seri
patient
lentil
allergi
react
one
lentil
five
percent
cross
reactiv
peanut
legum
soy
pea
howev
extent
cross
reactiv
peanut
legum
subgroup
ie
lentil
well
document
also
appear
confus
label
variou
lentil
use
ethnic
diet
conclus
case
present
make
allergist
awar
mani
differnt
type
lentil
caus
hypersenst
reaction
import
consid
ethnic
dietari
habit
evaul
food
allergi
background
epinephrin
drug
choic
treatment
anaphylaxi
howev
frequent
underutil
one
possibl
reason
fear
advers
cardiac
effect
common
side
effect
epinephrin
palpit
tachycardia
sweat
nausea
vomit
respiratori
difficulti
pallor
dizzi
weak
tremor
headach
nervous
anxieti
arrhythmia
previou
studi
show
administr
epinephrin
small
number
healthi
adult
caus
signific
cardiac
advers
event
vital
sign
chang
clinic
signific
purpos
retrospect
analysi
determin
safeti
profil
epinephrin
larg
number
patient
administ
epinephrin
treatment
anaphylaxi
occur
physician
offic
method
patient
allergi
offic
administ
epinephrin
acut
anaphylaxi
select
retrospect
analysi
chart
review
advers
event
vital
conduct
vital
sign
side
effect
monitor
everi
minut
minimum
minut
administr
epinephrin
result
patient
age
receiv
inject
epinephrin
inject
epinephrin
patient
puls
systol
blood
pressur
determin
patient
concurr
diastol
blood
pressur
found
betweem
common
report
side
effect
tremor
headach
pallor
rise
blood
pressur
heart
rate
epinephrin
transient
return
normal
within
minut
observ
seriou
side
effect
patient
respond
epinephrin
abl
go
home
conclus
retrospect
analysi
reveal
administr
epinephrin
safe
effect
treatment
acut
anaphylaxi
outpati
set
use
epinephrin
treatment
anaphylaxi
lifesav
use
treat
noncardiac
elderli
patient
anaphylact
reaction
encourag
purpos
clinic
pathway
establish
decreas
use
vancomycin
surgic
patient
selfreport
penicillin
pcn
allergi
method
institut
develop
preoper
evalu
poe
clinic
elect
surgic
patient
june
onsit
sameday
allergi
consult
penicillin
skin
test
made
avail
preoper
patient
selfreport
pcn
allergi
review
antibiot
recommend
actual
administr
vancomycin
complianc
surgeon
recommend
juli
result
time
patient
seen
preoper
medic
exam
poe
clinic
evalu
pcn
allergi
patient
met
irb
standard
particip
studi
mean
age
patient
year
top
three
surgic
specialti
repres
poe
clinic
orthoped
urolog
neurosurgeri
patient
underw
skin
test
pcn
allergi
eightyf
percent
patient
histori
pcn
allergi
recommend
use
lactam
cefazolin
recommend
avoid
lactam
fortythre
one
posit
skin
test
pcn
patient
patient
actual
receiv
preoper
antibiot
patient
receiv
cefazolin
receiv
clindamycin
receiv
ciprofloxacin
receiv
levofloxacin
patient
receiv
one
antibiot
prophylaxi
patient
receiv
vancomycin
conclus
establish
clinic
pathway
preoper
clinic
includ
allergi
test
consult
reduc
vancomycin
use
surgic
patient
histori
penicillin
allergi
h
yarmohammadi
nowakwegrzyn
new
york
ny
introduct
anticonvuls
hypersensit
syndrom
potenti
fatal
drug
reaction
cutan
system
reaction
aren
oxideproduc
anticonvuls
case
hallmark
featur
fever
rash
lymphadenopathi
accompani
multi
organsystem
abnorm
fatal
outcom
often
associ
liver
failur
recognit
syndrom
may
variabl
present
key
prompt
discontinu
drug
close
monitor
manag
case
male
receiv
dilantin
seizur
prophylaxi
follow
craniopharyngioma
resect
fourteen
day
later
readmit
fever
csf
leak
surgic
site
start
ceftriaxon
vancomycin
empir
lp
pan
cultur
done
continu
low
grade
fever
day
admiss
develop
maculopapular
rash
trunk
day
lft
increas
cbc
show
eosinophilia
antibiot
stop
lft
continu
rise
day
dilantin
stop
lft
normal
day
fever
stop
rash
disappear
case
yo
girl
admit
hospit
gener
rash
facial
edema
fever
degre
c
develop
prurit
maculopapular
erythemat
rash
trunk
face
week
prior
admiss
develop
high
fever
three
month
prior
visit
start
phenytoin
control
grand
mal
seizur
physic
exam
reveal
cervic
axillari
lymphadenopathi
elev
wbc
eosinophilia
elev
lft
phenytoin
stop
upon
admiss
hour
later
continu
fever
elev
lft
develop
erythema
mouth
treatment
ivig
prednison
initi
resolut
symptom
seen
within
day
therapi
conclus
time
recognit
anticonvuls
hypersensit
syndrom
import
accur
diagnosi
prevent
potenti
fatal
reexposur
influenc
subsequ
anticonvuls
treatment
option
ivig
prednison
consid
situat
prompt
improv
lft
clinic
symptom
observ
recent
publish
result
telephon
survey
preval
seafood
allergi
us
indic
seafood
allergi
signific
health
concern
aim
present
studi
retrospect
review
data
topic
interview
subiect
attend
allergi
outpati
suspect
food
allergi
year
older
reaction
food
report
patient
frequent
women
patient
report
reaction
seafood
overal
preval
seafood
reaction
fish
shellfish
includ
mollusk
case
reaction
fish
quit
possibl
shellfish
also
includ
patient
often
unabl
tell
role
finfish
shellfish
apart
probabl
due
fact
seafood
dish
complet
seafood
meal
itali
gener
includ
shell
finfish
less
half
case
convinc
relationship
ingest
seafood
reaction
reaction
report
gastrointestin
non
lifethreaten
angioedema
mild
oral
allergi
syndrom
acut
urticaria
asthma
rhinoconjunct
gastrointestin
reaction
might
true
igemedi
allerg
reaction
also
toxic
conclus
even
select
popul
like
attend
allergi
clinic
use
broad
definit
advers
reaction
seafood
allergi
appear
rare
phenomenon
limit
clinic
impact
preval
moder
sever
reaction
angioedema
asthma
whole
select
popul
clopidogrel
plavix
antithrombot
agent
current
use
prevent
thrombot
cardiovascular
event
inhibit
adenosin
diphosph
adp
depend
platelet
activ
clinic
use
patient
aspirin
intoler
develop
neutropenia
ticlopidin
report
case
clopidogrel
caus
rash
urticaria
often
patient
told
allerg
clopidogrel
take
despit
fact
workup
ever
perform
elucid
whether
reaction
inde
immunolog
natur
review
literatur
reveal
report
attempt
desensit
patient
clopidogrel
presum
immunolog
drug
reaction
present
case
yearold
femal
initi
took
clopidogrel
mg
po
daili
transient
ischem
attack
toler
medicin
five
day
replac
aspirinwarfarin
combin
took
next
five
day
reintroduct
clopidogrel
week
later
unev
develop
prurit
maculopapular
rash
day
restart
therapi
time
take
medic
cardiopulmonari
gastrointestin
complaint
discontinu
clopidogrel
asymptomat
consult
skin
test
done
use
clopidogrel
prepar
concentr
mgml
mgml
time
control
skin
test
three
nonatop
subject
perform
produc
reaction
either
epicutan
intraderm
test
contrast
patient
posit
skin
reaction
concentr
intraderm
test
patient
hospit
oral
desensit
clopidogrel
dilut
prepar
hospit
pharmaci
patient
toler
initi
dose
mg
serial
threefold
increas
concentr
given
everi
minut
total
cumul
dose
mg
reach
patient
toler
entir
procedur
suffer
advers
reaction
upon
continu
treatment
demonstr
util
oral
desensit
clopidogrel
patient
posit
skin
test
requir
medic
lamotrigin
nonaromat
anticonvuls
desir
pharmacolog
profil
common
idiosyncrat
reaction
children
rash
sever
cutan
advers
reaction
system
hypersensit
reaction
uncommonli
report
method
case
present
caucasian
femal
prescrib
lamotrigin
escal
dose
first
gener
seizur
week
later
develop
pink
rash
cheek
gradual
progress
trunk
hand
feet
three
day
later
seen
er
treat
possibl
streptococcalpharyng
fever
rash
oral
penicillinv
treatment
initi
rash
continu
spread
bodi
mild
pruriti
sore
lip
mouth
blister
note
left
ear
hand
feet
later
lamotrigin
discontinu
oral
steroid
prescrib
continu
develop
new
blister
rash
hemorrhag
plaqu
dysuria
later
transfer
institut
physic
examin
signific
afebril
girl
without
pallor
icteru
bilater
conjunct
without
kerat
evid
tender
cervic
lymphadenopathi
palpabl
multipl
ulcer
lip
gingiva
seen
sever
targetoid
lesion
trunk
extrem
note
along
hemorrhag
plaqu
extrem
superfici
slough
distal
finger
toe
note
nikolski
sign
demonstr
system
examin
unremark
laboratori
test
hemoglobin
wbcnormal
rang
without
eosinophilia
normal
ptaptt
inr
liver
function
test
show
elev
normal
bilirubin
urin
analysi
normal
serolog
cmv
ebv
hsv
hepat
b
neg
skin
biopsi
show
full
thick
epiderm
necrosi
sub
epiderm
cleft
aggress
support
therapi
initi
corticosteroid
continu
five
day
prior
discharg
hospit
rash
dri
lesion
fade
blister
oral
ulcer
heal
liver
enzym
decreas
conclus
report
occurr
stevensjohnson
syndrom
lamotrigin
young
child
literatur
sever
reaction
associ
higher
dose
rapid
escal
dose
concomit
use
valproat
earli
recognit
withdraw
medic
necessari
improv
outcom
introduct
patient
histori
penicillin
pcn
allergi
neg
pcn
skin
test
major
minor
determin
patient
toler
pcn
administr
without
risk
immedi
reaction
fact
middleton
allergi
principl
practic
report
lifethreaten
falseneg
reaction
report
pcn
administ
neg
pcn
skin
test
describ
case
patient
histori
pcn
allergi
neg
pcn
skin
test
major
minor
determin
experienc
lifethreaten
anaphylact
shock
administ
piperacillintazobactam
case
histori
woman
crohn
diseas
admit
treatment
enterocutan
fistula
three
month
admiss
patient
report
sever
reaction
either
piperacillintazobactam
intraven
iv
lorazepam
need
respiratori
support
intens
care
unit
order
delin
problem
allergi
consult
obtain
serum
ige
antibodi
pcn
measur
commerci
cap
system
radioallergosorb
test
rast
fluoroenzymeimmunoassay
feia
pharmacia
upjohn
uppsala
sweden
pcn
skin
test
major
minor
determin
neg
skin
test
prick
intraderm
piperacillintazobactam
also
neg
five
minut
receiv
gram
piperacillintazobactam
iv
patient
report
feel
lighthead
flush
nauseat
diaphoret
blood
pressur
decreas
baselin
heart
rate
appear
toxic
wheez
rash
note
physic
examin
patient
treat
iv
epinephrin
diphenhydramin
dexamethason
recov
without
sequela
serum
tryptas
drawn
hour
begin
reaction
elev
ngml
decreas
ngml
hour
later
complement
level
normal
conclus
despit
high
neg
predict
valu
neg
pcn
skin
test
major
minor
determin
report
lifethreaten
falseneg
reaction
report
pcn
administ
neg
pcn
skin
test
physician
need
cautiou
administ
piperacillintazobactam
blactam
patient
histori
sever
reaction
anaphylaxi
past
pcn
administr
majmundar
da
khan
dalla
tx
introduct
varieti
advers
drug
reaction
report
therapi
allopurinol
success
protocol
desensit
allopurinol
develop
report
case
patient
success
desensit
allopurinol
develop
dress
four
month
allopurinol
therapi
method
year
old
man
refer
depart
remot
histori
rash
fever
result
hospit
initi
allopurinol
due
sever
gouti
arthriti
unrespons
colchicin
requir
chronic
steroid
recommend
attempt
allopurinol
desensit
base
histori
prior
reaction
slow
desensit
protocol
perform
begin
allopurinol
increas
dose
weekli
patient
toler
entir
desensit
protocol
without
advers
reaction
initi
daili
allopurinol
mg
per
day
result
four
month
desensit
daili
allopurinol
use
patient
develop
fever
acut
maculopapular
erupt
back
abdomen
without
mucos
involv
laboratori
demonstr
eosinophilia
cellsmm
elev
ast
alt
ggt
ul
treat
prednison
day
taper
weekli
week
success
resolut
symptom
eosinophilia
transamin
conclus
desensit
allopurinol
safe
accomplish
allergist
need
cogniz
potenti
delay
seriou
drug
reaction
dress
wiskott
aldrich
syndrom
immunodefici
character
eczema
pyogen
infect
mix
immunodeficiencyw
describ
male
sevenmonth
old
perinat
anteced
without
import
ulcer
site
applic
bcg
nonblood
rel
healthi
parent
twomonthsold
initi
continu
fever
quantifi
treat
multipl
antibiot
without
resolut
hospit
plaquetopenia
anemia
diagnos
receiv
red
globul
platel
transfus
one
week
present
dissemin
dermatosi
character
erythema
desquam
fourmonthag
present
right
axillari
adenomegali
hepatoesplenomegali
recurr
bilater
media
otiti
hospit
institut
malnutrit
bad
gener
condit
febril
dissemin
dermatosi
affect
head
trunk
extrem
character
erythema
desquam
addit
left
ankl
cellul
right
axillari
adenomegali
hepatoespenomegali
hospit
present
left
hand
cellul
hairi
skin
abscess
oral
candidiasi
requir
surgic
treatment
econdari
compartiment
syndrom
cellul
left
ankl
persist
hemogram
report
thrombocytopenia
normal
platelet
volum
blood
cultiv
posit
gramposit
bacteria
isoaglutinin
normal
immunoglobulin
elev
age
rang
receiv
antimicrobi
antifung
treatment
die
autopsi
timic
alymphoplasia
report
cortic
lymphoid
depopul
lymphat
ganglia
spleen
diseas
dissemin
cytomegal
inclus
multifoc
pulmonari
pneumocystosi
bcgiti
diseas
graft
versu
guest
previou
featur
conclud
compat
mix
immunodefici
wiskottaldrich
syndrom
particular
characterist
make
case
interest
patient
cours
cellular
immun
deficienci
thrombocytopenia
eczema
even
nt
platelet
size
diminish
consid
patient
sever
wiskott
aldrich
syndrom
moment
await
result
genet
studi
uasp
gene
background
hypersensit
mosquito
bite
hmb
disord
character
necrot
skin
reaction
system
gener
symptom
subsequ
mosquito
bite
suggest
hmb
associ
chronic
epsteinbarr
viru
ebv
infect
natur
killer
cell
leukemialymphoma
describ
korean
child
hmb
associ
chronic
ebv
infect
natur
killer
cell
lymphocytosi
case
male
admit
welldemarc
necrot
skin
lesion
sever
swell
right
ear
lobe
develop
mosquito
bite
suffer
sever
similar
symptom
sinc
last
summer
complic
deep
scar
skin
hepatosplenomegali
peripher
lymphadenopathi
detect
laboratori
test
show
wbc
neutrophil
lymphocyt
total
eosinophil
count
ige
prist
ium
immunoglobulin
level
normal
specif
ige
aed
communi
cap
neg
lymphocyt
subset
analysi
demonstr
increas
nk
cell
decreas
cell
igm
antinuclear
antigen
ebna
igm
viral
capsid
antigen
vca
igm
antiearli
antigen
ea
dr
ebv
neg
level
antivca
igg
uml
antiea
dr
igg
uml
antiebna
igg
uml
increas
type
eb
viru
demonstr
blood
mononuclear
cell
dna
pcr
method
eber
situ
hybrid
neg
necrot
tissu
immunostain
nkcell
marker
reveal
mani
immunoreact
cell
perivascular
inflammatori
infiltr
tissu
skin
patch
test
mosquito
allergen
aed
togoi
culex
pipien
show
posit
respons
c
pipien
introduct
scimitar
syndrom
congenit
anomali
result
anomal
pulmonari
venou
return
right
lung
inferior
vena
cava
recurr
respiratori
infect
associ
scimitar
syndrom
method
report
yearold
adolesc
femal
present
immunolog
clinic
recurr
pneumonia
result
patient
present
numer
recurr
pneumonia
multipl
er
visit
hospit
complain
intermitt
chest
pain
cough
fatigu
exercis
intoler
patient
larg
secundum
atrial
septal
defect
surgic
correct
year
age
cardiac
echo
obtain
year
age
reveal
rvh
normal
year
age
known
atop
asthmat
previou
immunolog
workup
normal
iga
igg
igm
present
clinic
pulmonari
function
fvc
review
previou
chest
radiograph
show
chronic
chang
opac
partial
obscur
right
hemidiaphragm
high
resolut
chest
ctscan
show
larg
irregular
venou
structur
extend
right
chest
join
inferior
vena
cava
liver
consist
scimitar
syndrom
patient
refer
pediatr
cardiolog
recommend
surgic
correct
conclus
scimitar
syndrom
may
present
recurr
pneumonia
chronic
lung
diseas
high
resolut
chest
ct
scan
may
use
delin
disord
background
laryngomalacia
common
caus
stridor
infant
rare
report
exist
clinic
relev
laryngomalacia
adult
object
present
case
laryngomalacia
adult
signific
respiratori
symptom
initi
attribut
asthma
method
yearold
femal
histori
allerg
rhiniti
gastroesophag
reflux
diseas
present
allergi
clinic
recommend
regard
prior
diagnosi
asthma
poorli
control
inhal
fluticason
montelukast
albuterol
patient
clinic
diagnos
asthma
age
due
exercis
relat
symptom
symptom
progress
intermitt
trial
variou
inhal
steroid
provid
minim
relief
evalu
patient
describ
constant
wheez
occur
inhal
origin
throat
symptom
respond
albuterol
use
three
four
time
day
rhiniti
control
longterm
highdos
antireflux
therapi
baselin
spirometri
normal
histamin
bronchoprovac
fiberopt
laryngoscopi
perform
evalu
result
histamin
challeng
posit
decreas
mgml
histamin
howev
laryngoscopi
reveal
redund
airway
tissu
notabl
right
arytenoid
cartilag
consist
laryngomalacia
prolaps
laryng
vestibul
significantli
obstruct
airway
inspir
patient
refer
otolaryngolog
surgic
excis
use
carbon
dioxid
laser
perform
subsequ
improv
symptom
decreas
asthma
medic
use
conclus
report
unusu
case
laryngomalacia
adult
present
asthma
success
treat
laser
surgic
excis
laryngoscopi
patient
reveal
redund
airway
tissu
notabl
right
arytenoid
c
kuhl
davi
ca
mather
ca
c
kuhl
uc
davi
medic
center
sacramento
ca
sacramento
va
hospit
mather
ca
background
wheez
uncommon
manifest
phrenic
nerv
dysfunct
object
offer
descript
wheez
attribut
phrenic
nerv
dysfunct
remind
clinician
dyspnea
wheez
caus
cor
pulmonal
caus
phrenic
nerv
dysfunct
method
old
male
nonsmok
present
chronic
dyspnea
occasion
wheez
last
decad
patient
remot
histori
pericardi
strip
presum
tubercul
pericard
also
nonproduct
cough
orthopnea
dyspnea
exacerb
put
hand
head
bend
treat
inhal
corticosteroid
bronchodil
without
relief
result
repeat
chest
xray
show
chronic
elev
right
hemidiaphragm
pulmonari
function
test
show
restrict
pattern
fev
fvc
tlc
dlcova
bronchodil
respons
left
heart
catheter
normal
right
heart
catheter
show
elev
pulmonari
arteri
pressur
subsequ
diagnos
cor
pulmonal
cardiopulmonari
exercis
test
show
increas
minut
ventil
achiev
predominantli
increas
respiratori
rate
rather
increas
tidal
volum
suggest
restrict
interstiti
lung
diseas
chest
ct
show
left
ventricular
enlarg
evid
interstiti
lung
diseas
fluoroscop
sniff
test
perform
show
paradox
movement
diaphragm
diagnos
diaphragmat
dysfunct
result
phrenic
nerv
injuri
prior
pericardi
strip
conclus
wheez
chronic
dyspnea
relat
phrenic
nerv
dysfunct
review
discuss
variou
caus
phrenic
nerv
dysfunct
includ
autoimmun
caus
offer
patient
histori
prior
cardiothorac
surgeri
present
recalcitr
dyspnea
wheez
may
benefit
evalu
phrenic
nerv
dysfunct
background
sudden
sensorineur
hear
loss
ssnhl
defin
loss
least
db
contigu
frequenc
time
cours
hour
fewer
etiolog
ssnhl
includ
viral
infect
ototox
drug
autoimmun
diseas
trauma
neoplasm
vascular
occlus
viral
labyrinth
common
caus
case
sudden
hear
loss
herp
infect
report
approxim
case
caus
viral
infect
typic
sensorineur
hear
loss
recurr
report
case
recurr
ssnhl
oral
herp
lesion
preced
onset
symptom
three
consecut
episod
case
report
male
histori
hypertens
hypothyroid
chronic
tinnitu
left
ear
sinc
gunshot
wound
year
prior
present
clinic
complaint
recurr
episod
sensorineur
hear
loss
first
episod
bilater
hear
loss
occur
month
prior
otolarnolgologist
treat
steroid
taper
valacyclovir
hear
loss
resolv
one
day
therapi
sinc
initi
present
patient
report
three
subsequ
episod
ssnhl
two
episod
respond
prednison
valacyclovir
one
episod
respond
steroid
alon
oral
herpet
lesion
preced
least
three
episod
one
day
prior
hear
loss
laboratori
data
signific
elev
varicellazost
igg
hsv
igg
hsv
igm
perform
rpr
nonreact
ana
neg
mri
head
normal
audiogram
demonstr
increas
speech
discrimin
improv
rest
laboratori
data
unremark
patient
maintain
daili
valacyclovir
therapi
episod
hear
loss
conclus
patient
experienc
hear
loss
concomit
evid
stomat
suggest
caus
effect
relationship
found
antivir
therapi
effect
treatment
ssnhl
patient
demonstr
absenc
symptom
antivir
prophylaxi
conclud
like
etiolog
recurr
hear
loss
secondari
recurr
herp
simplex
infect
abstract
ill
describ
first
time
chines
literatur
kimm
szeto
definit
histolog
descript
publish
kimura
ill
endem
asia
rare
case
report
kimura
diseas
extrem
sporad
rest
world
etiolog
diseas
ignor
believ
aberr
immun
reaction
unknown
antigen
stimulu
howev
epstein
barr
viru
human
herp
viru
candida
albican
involv
certain
case
mast
cell
implic
pathogenesi
cytokin
pattern
product
interleukin
rant
regul
synthesi
ige
orchestr
eosinophil
infiltr
hand
suggest
eosinophil
undergon
acceler
apoptosi
ill
case
report
yearold
boy
month
evolut
presenc
bilater
subcutan
nodul
cm
parotid
submaxillari
gland
present
hypereosinophilia
total
eosinophil
high
ige
total
ige
normal
renal
function
neg
mycot
parasit
teststh
histopatholog
find
reveal
presenc
eosinophil
infiltr
capillari
prolifer
fibrosi
discuss
clinic
characterist
nodul
togeth
hypereosinophilia
extrem
high
ige
characterist
histolog
lesion
diagnosi
kimura
diseas
usual
clinic
present
consist
sever
indol
subcutan
nodul
grow
slowli
volum
locat
neck
head
accompani
satelann
allergi
asthma
immunolog
lite
adenophati
increment
salivari
gland
renal
affect
half
patient
laboratori
detect
hypereosinophilia
elev
total
ige
histolog
lesion
show
hyperplast
lymphoid
tissu
prolif
germin
center
infiltr
eosinophil
interfollicular
perivascular
zone
sometim
form
eosinophil
abscess
prolifer
poscapillari
venul
moment
treat
prednison
great
improv
clinic
evolut
first
case
report
literatur
mexico
introduct
incid
cow
milk
protein
allergi
cmpa
approxim
present
primarili
first
year
life
manifest
cmpa
neonat
period
includ
gastroenter
colic
lethargi
metabol
acidosi
hematochezia
melena
appear
nonig
mediat
ige
mediat
reaction
neonat
period
urticaria
angioedema
unusu
case
africanamerican
male
present
day
histori
rash
swell
erythema
overli
multipl
joint
histori
fever
diarrhea
eczema
medic
prior
admiss
besid
mother
histori
childhood
asthma
famili
histori
atopi
food
allergi
fed
cow
milkbas
formula
similac
sinc
birth
exclus
physic
examin
reveal
diffus
erythemat
rais
macularpapular
rash
area
duski
exfoli
angioedema
overli
joint
periorbit
area
figur
laboratori
evalu
includ
cbc
diff
hgb
electrophoresi
lumbar
punctur
urinalysi
c
q
qualit
quantit
c
c
c
cultur
blood
csf
urin
within
normal
percutan
allergi
skin
test
cow
milk
allergi
perform
reveal
reaction
cow
milk
extract
greer
lenoir
nc
posit
histamin
neg
salin
control
rast
test
show
kul
lactoglobulin
kul
cow
milk
place
element
formula
skin
lesion
swell
resolv
complet
within
hour
week
followup
patient
thrive
without
complaint
conclus
earli
sensit
cow
milk
protein
neonat
period
may
occur
result
ige
mediat
urticaria
angioedema
rash
may
misdiagnos
erythema
multiform
anaphylactoid
purpura
sinc
hemorrhag
lesion
cockad
pattern
common
physician
awar
reaction
may
occur
earli
recognit
manag
may
initi
neonat
periorbit
angioedema
exfoli
urticari
rash
rational
two
patient
present
invas
fungal
cn
infect
found
nk
cell
dysfunct
hypogammaglobulinemia
method
case
report
result
patient
year
old
caucasian
male
present
headach
doubl
vision
periorbit
swell
bilater
sinu
diseas
ct
scan
biopsi
show
invas
rhinocerebr
mucormycosi
continu
deterior
spite
iv
intrathec
amphotericin
b
hyperbar
oxygen
mani
debrid
procedur
left
orbit
exenter
immun
evalu
reveal
low
igg
low
igm
bare
detect
nk
cell
kill
activ
neutrophil
respiratori
burst
normal
continu
worsen
despit
ivig
replac
intoler
side
effect
ifna
gmcsf
mcg
qod
initi
order
boost
nk
cell
activ
result
stabil
infect
discharg
oral
antifung
therapi
posaconazol
ivig
gmcsf
sixteen
month
later
continu
remain
stabl
clinic
radiograph
ivig
gmcsf
patient
caucasian
male
present
headach
mental
statu
chang
ataxia
head
ct
scan
show
left
mass
effect
edema
underw
surgic
debrid
ventricul
zygomycet
famili
mucormycosi
found
start
iv
amphotericin
b
oral
posaconazol
immun
evalu
reveal
low
igg
igm
low
nk
cell
activ
neutrophil
respiratori
burst
normal
start
ivig
gmcsf
nk
cell
function
improv
significantli
remain
clinic
stabl
ivig
gmcsf
persist
radiograph
evid
enlarg
ventricl
conclus
hypogammaglobulinemia
usual
associ
invas
cn
fungal
infect
suggest
nk
cell
dysfunct
like
respons
clinic
cours
patient
nk
cell
defici
report
associ
recurr
mucos
candidiasi
suggest
import
role
cell
control
fungi
spectrum
clinic
present
nk
cell
defici
known
sinc
normal
includ
immun
system
evalu
patient
illustr
import
includ
function
nk
cell
assess
evalu
immun
function
introduct
report
case
success
system
hydrocortison
desensit
sinc
allerg
reaction
system
desensit
corticosteroid
rare
document
method
present
patient
multipl
medic
problem
histori
radiocontrast
induc
anaphylactoid
reaction
corticosteroid
allergi
patient
undergo
cardiac
catheter
corticosteroid
desensit
perform
prior
procedur
result
skin
test
radiocontrast
consid
help
therefor
patient
suspect
reaction
radiocontrast
gener
premed
corticosteroid
antihistamin
decreas
risk
sever
reaction
sinc
patient
experienc
allerg
reaction
corticosteroid
previous
skin
test
two
differ
corticosteroid
least
reactiv
skin
test
reveal
posit
immedi
reaction
hydrocortison
cardiac
catheter
contrast
consid
absolut
necessari
case
corticosteroid
desensit
perform
halflif
hydrocortison
shortest
among
test
corticosteroid
minut
protocol
develop
short
interv
escal
dose
dose
dilut
yield
total
volum
avoid
fluid
overload
patient
renal
failur
desensit
patient
develop
pruritu
erythema
rd
th
dose
resolv
immedi
diphenhydramin
desensit
patient
continu
hydrocortison
intraven
everi
four
hour
one
hour
prior
procedur
patient
premed
hydrocortison
diphenhydramin
administ
radiocontrast
without
advers
reaction
conclus
success
desensit
patient
corticosteroid
premed
hydrocortison
diphenhydramin
administ
radiocontrast
case
illustr
intraven
desensit
may
suitabl
approach
therapi
corticosteroid
allerg
patient
requir
system
corticosteroid
administr
autoimmun
neutropenia
defin
decreas
absolut
number
peripher
neutrophil
caus
immunologicallymedi
mechan
autoantibodi
direct
neutrophil
lead
peripher
destruct
neutrophil
andor
inhibit
myelopoesi
bone
marrow
although
recurr
aphthou
stomat
often
herald
sign
neutropenia
diagnosi
requir
demonstr
specif
antineutrophil
antibodi
act
promot
immun
destruct
clearanc
neutrophil
mononuclear
phagocyt
present
case
report
describ
rare
clinic
associ
ra
adult
yrold
black
male
present
year
histori
recurr
repeat
pain
multipl
oral
ulcer
initi
oral
ulcer
occur
monthli
basi
time
ulcer
oral
mucosa
tongu
began
appear
weekli
later
continu
past
medic
histori
reveal
drug
allergi
posit
histori
hypertens
physic
exam
reveal
otherwis
healthi
male
lymphoadenopathi
splenomegali
laboratori
workup
reveal
hiv
neg
viral
cultur
h
simplex
neg
mild
increas
cyroglobulin
neg
anti
dsdna
neg
antismith
rnp
neg
wbc
count
neutrophil
anc
lymphocyt
monocyt
platelet
bone
marrow
biopsi
reveal
normal
product
neutrophil
direct
neutrophil
antibodi
assay
reveal
elev
valu
n
although
follow
initi
prednison
mg
immedi
increas
anc
seen
level
fell
dosag
taper
figur
show
time
cours
doserespons
relationship
anc
prednison
dosag
case
report
illustr
import
recognit
relationship
ra
neutropenia
associ
masquerad
clinic
entiti
background
dyspnea
wheez
decreas
suggest
asthma
essenti
clinician
consid
broad
differenti
diagnosi
outcom
could
catastroph
correct
diagnosi
miss
case
present
present
case
yo
filipino
femal
refer
clinic
evalu
cough
short
breath
wheezi
respir
associ
chang
voic
qualiti
nasal
palat
pruritu
postnas
drainag
initi
evalu
reveal
mold
spore
hypersensit
prick
punctur
test
spirometri
obstruct
pattern
l
l
predict
revers
post
nebul
albuterol
initi
diagnosi
allerg
rhiniti
adult
onset
asthma
made
start
salmeterol
budesonid
montelukast
pirbuterol
symptom
persist
rabeprazol
ad
treat
possibl
laryngopharyng
reflux
repeat
spirometri
reveal
l
prompt
treatment
system
corticosteroid
improv
fiberopt
laryngoscopi
within
normal
limit
high
resolut
comput
tomographi
obtain
show
mass
left
side
trachea
obstruct
airway
bronchoscopi
reveal
tumor
cm
vocal
cord
appear
adenoid
cystic
carcinoma
confirm
patholog
tumor
resect
remov
cm
trachea
reanastomosi
follow
week
cours
radiat
therapi
medic
discontinu
symptom
wheez
dyspnea
cough
complet
resolv
repeat
spirometri
within
normal
limit
remain
asymptomat
surveil
bronchoscopi
neg
recurr
discuss
adenoid
cystic
carcinoma
acc
uncommon
form
malign
neoplasm
occur
within
salivari
gland
tracheobronchi
acc
typic
present
symptom
cough
dyspnea
hoars
due
slow
growth
acc
rel
indol
cours
recent
studi
cohort
acc
patient
surviv
year
year
standard
therapi
surgic
resect
often
follow
radiotherapi
conclus
patient
fail
convent
therapi
asthma
import
entertain
diagnosi
systemat
approach
establish
correct
diagnosi
ipex
extrem
rare
hereditari
condit
character
immun
dysfunct
polyendocrinopathi
enteropathi
xlink
recess
inherit
lead
death
without
prompt
diagnosi
patient
usual
present
month
sever
diarrhea
failur
thrive
earli
onset
iddm
children
die
one
year
without
bone
marrow
transplant
immunolog
evalu
typic
normal
except
elev
ige
eosinophilia
autoantibodi
report
case
ipex
infant
present
birth
die
day
multiorgan
system
failur
male
infant
born
week
due
chorioamnion
prom
birth
copiou
green
fluid
appear
rectum
ng
tube
evolv
secretori
diarrhea
workup
fistula
neg
week
patient
develop
ascit
explor
laparotomi
reveal
inflam
appendix
laparotomi
patient
stool
output
never
toler
enter
feed
remain
intub
problem
apnea
coagulapathi
patholog
appendix
show
excess
lymphocyt
immun
system
investig
show
elev
ige
igg
serum
antienterocyt
igg
antibodi
posit
patient
neg
mother
base
data
ipex
suspect
autopsi
seem
confirm
autopsi
scarc
patient
ipex
find
reveal
mani
organ
affect
fibrosi
lymphocyt
infiltr
pancrea
gi
tract
pancrea
reveal
almost
complet
loss
exocrin
structur
invas
fibrosi
chronic
inflammatori
cell
mucosa
gi
tract
stomach
rectum
show
columnar
epithelium
taken
fibrosi
capillari
chronic
inflamm
inflammatori
cell
lymphocyt
plasma
cell
immunochemistri
lymphoreticular
system
consist
lymphoid
pauciti
thymu
lymph
node
spleen
preliminari
data
suggest
patient
splice
mutat
gene
ipex
extrem
rare
diseas
often
difficult
diagnos
patient
aliv
infant
present
earli
infanc
diarrhea
endocrinopathi
without
prompt
diagnosi
death
inevit
result
one
must
awar
atyp
present
consid
patient
total
villou
atrophi
one
clinic
featur
iddm
autoimmun
introduct
digeorg
syndrom
dg
character
thymic
hypoplasia
parathyroid
hypoplasia
conotrunc
cardiac
defect
wide
varieti
clinic
manifest
also
increas
risk
autoimmun
phenomena
later
life
due
thymic
hypoplasia
case
report
yearold
aa
girl
tetralog
fallot
repair
age
development
delay
asthma
recurr
sinopulmonari
infectionsskin
abscess
gerd
arthralgia
seizur
disord
due
hypox
encephalopathi
cardiac
surgeri
present
allergyimmunolog
clinic
immun
workup
histori
document
hypocalcemia
age
develop
persist
annular
patch
left
leg
skin
biopsi
appear
consist
sarcoid
dermat
evid
sarcoidosi
except
slightli
elev
ace
level
given
lack
system
involv
skin
lesion
treat
resolv
spontan
age
develop
swell
right
mandibl
bone
biopsi
reveal
garr
osteomyel
steril
hyperprolif
osteomyel
like
trigger
dental
cari
elev
esr
polyclon
hypergammaglobulinemia
igg
normal
crp
immun
workup
reveal
decreas
cell
ratio
slightli
elev
b
cell
highnorm
rang
nk
cell
normal
rang
cell
cytokin
product
respons
mitogen
excess
product
proinflammatori
cytokin
respons
lp
conjunct
facial
dysmorph
dg
suspect
fish
analysi
reveal
microdelet
repeat
workup
reveal
evid
system
sarcoidosi
autoantibodi
screen
neg
includ
lupu
anticoagul
treat
inhibitor
secondari
gerd
mild
thrombocytopenia
joint
symptom
resolv
concurr
declin
esr
igg
level
month
conclus
recurr
infect
fragment
care
result
chronic
inflamm
henc
overstimul
immun
system
may
led
dg
patient
develop
atyp
autoimmun
phenomena
unusu
clinic
manifest
case
illustr
import
recogn
phenotyp
featur
dg
earli
life
provid
close
monitor
coordin
care
rational
report
case
patient
celiac
diseas
continu
symptom
fever
nausea
vomit
night
sweat
fatigu
despit
gluten
free
diet
whose
symptom
respons
antihistamin
method
case
report
result
yearold
white
male
suffer
mononucleosi
episod
prostat
began
suffer
fatigu
fever
follow
chronic
fatigu
syndrom
center
novemb
patient
place
famvir
allevi
sore
throat
later
place
interferon
gamma
discontinu
due
increas
fever
nausea
vomit
stop
medic
symptom
abat
sometim
patient
father
diagnos
celiac
sprue
april
patient
develop
prurit
rash
right
arm
biopsi
reveal
subepiderm
vesicl
pmn
tip
dermal
papilla
may
develop
oral
ulcer
well
joint
pain
patient
underw
endoscopi
biopsi
reveal
intraepitheli
lymphocytosi
duodenum
patient
strict
gluten
free
diet
sinc
octob
report
symptom
improv
skin
lesion
itchi
eye
oral
ulcer
howev
begun
suffer
constip
continu
intermitt
night
sweat
fever
nausea
vomit
februari
pruritu
allevi
hydroxyzin
regimen
benadryl
pepcid
start
aid
pruritu
patient
report
improv
symptom
pruriti
sweat
emesi
conclus
diagnosi
celiac
diseas
cd
patient
persist
nausea
vomit
sporad
fever
fatigu
despit
maintain
strict
gluten
free
diet
shown
improv
symptom
antihistamin
patient
histori
chronic
infect
prostat
chronic
ebv
patient
also
report
allevi
symptom
interferon
therapi
suggest
autoimmun
compon
current
ill
cd
preval
unit
state
much
higher
thought
us
celiac
diseas
associ
increas
risk
lymphoma
malabsorpt
lead
neurolog
diseas
rare
case
cd
associ
pruritu
respond
antihistamin
rational
eosinophil
cystiti
rel
rare
condit
children
adult
vari
cours
usual
respond
shortterm
nsaid
steroid
therapi
report
man
sever
case
respond
prolong
oral
steroid
case
report
year
old
caucasian
man
prior
esophag
cancer
sp
esophagectomi
diabet
hypertens
allerg
rhiniti
chronic
obstruct
pulmonari
diseas
present
suprapub
pain
urinari
frequenc
dysuria
hematuria
urinalysi
show
numer
red
blood
cell
bacteria
malign
cell
eosinophil
treat
antibiot
resolut
symptom
sever
week
later
experienc
sever
suprapub
pain
hematuria
result
symptomat
drop
hemoglobin
underw
cystoscopi
biopsi
reveal
chronic
cystiti
inflammatori
infiltr
contain
numer
eosinophil
unrespons
treatment
nsaid
intravesicular
dmso
refer
servic
start
prednison
mgday
dysuria
hematuria
persist
prednison
doubl
plu
third
gener
quinolon
ad
three
week
later
hematuria
dysuria
resolv
asymptomat
antibiot
stop
prednison
gradual
taper
sever
week
whenev
steroid
dose
drop
mgday
experienc
exacerb
symptom
last
three
year
dose
prednison
kept
symptom
abat
renal
function
stabl
conclus
eosinophil
cystiti
uncommon
diagnosi
unknown
etiolog
describ
patient
debilit
suprapub
pain
symptomat
anemia
hematuria
associ
eosinophil
cystiti
three
year
sinc
first
saw
continu
therapi
mg
prednisoneday
prevent
exacerb
case
uniqu
sever
hematuria
experienc
prolong
rel
low
steroid
dose
need
suppress
exacerb
propos
eosinophil
cystiti
patient
sever
hematuria
may
otherwis
candid
cystectomi
trial
prolong
oral
prednison
may
benefici
rational
allerg
reaction
insulin
occur
frequent
past
porcin
bovin
prepar
contrast
allerg
reaction
human
insulin
prepar
report
patient
treat
insulin
insulin
allergi
may
manifest
immediatetyp
igemedi
reaction
delay
type
hypersensit
serum
sick
vari
sever
mild
discomfort
lifethreaten
event
present
case
illustr
insulin
allergi
may
complic
hospit
often
misdiagnos
method
yo
diabet
femal
histori
insulin
allergi
evalu
patient
long
stand
diabet
control
oral
hypoglycem
requir
insulin
acut
ill
hospit
patient
unabl
recal
previou
type
insulin
receiv
previou
hospit
patient
complain
vagu
symptom
fatigu
parasthesia
sweat
anxieti
palpit
one
occas
patient
syncop
episod
hypotens
anoth
occas
patient
develop
rash
dyspnea
receiv
sq
insulin
physcian
intrepret
find
may
due
hypoglycem
allerg
reaction
suspect
patient
never
underw
test
recent
hospit
patient
histori
review
formal
allergi
consult
obtain
underw
epicutan
intraderm
test
human
insulin
prepar
insulin
antibodi
level
also
obtain
result
patient
neg
epicutan
test
human
insulin
prepar
howev
intraderm
test
patient
posit
reaction
lispro
nph
lent
neg
intraderm
test
insulin
glargin
regular
insulin
igg
ige
insulin
antibodi
test
result
conclus
hospit
patient
receiv
multipl
medic
commonli
experi
pharmacolog
advers
andor
allerg
reaction
necessari
obtain
thorough
histori
document
reaction
patient
experi
determin
type
event
occur
suspicion
drug
allergi
skin
test
andor
rast
assay
may
provid
insight
possibl
ige
mediat
reaction
case
advis
patient
may
use
regular
insulin
hospit
insulin
glargin
use
help
achiev
optim
glycem
long
term
control
background
hereditari
angioedema
type
iii
hae
iii
recent
describ
form
angioedema
occur
exclus
femal
character
normal
inhibitor
inh
protein
function
hae
iii
thought
xlink
autosom
domin
mode
inherit
evalu
year
old
femal
recurr
facial
swell
abdomin
pain
laryng
edema
famili
histori
similar
symptom
sever
femal
rel
case
report
year
old
african
american
femal
present
two
year
histori
recurr
lip
tongu
facial
swell
also
abdomin
pain
diarrhea
short
breath
episod
associ
hive
symptom
predat
menarch
correl
menstrual
cycl
time
present
describ
increas
frequenc
symptom
respond
antihistamin
diphenhydramin
cetirizin
prednison
patient
medic
problem
famili
histori
signific
recurr
episod
facial
lip
tongu
swell
matern
aunt
grandmoth
great
grandmoth
patient
great
grandmoth
requir
tracheal
intub
ventil
support
upper
airway
compromis
patient
physic
exam
unremark
laboratori
valu
drawn
acut
episod
swell
reveal
inh
function
normal
inh
protein
normal
mgml
mgdl
normal
mgdl
dna
sequenc
exon
investig
possibl
unusu
inh
mutat
normal
bind
abnorm
kallikrein
inhibit
neg
lab
test
includ
normal
mast
cell
tryptas
mcgl
neg
rf
ana
normal
angiotensin
convert
enzym
ul
normal
ul
posit
skin
prick
test
varieti
food
patient
toler
base
two
case
report
treatment
hae
iii
androgen
patient
start
danazol
daili
symptomat
improv
conclus
hae
iii
rare
diseas
affect
femal
exclus
clinic
indistinguish
inh
defici
mechan
inherit
remain
elucid
unclear
danazol
appear
amelior
symptom
even
though
evid
annal
allergi
asthma
immunolog
inhibitor
dysfunct
disord
believ
first
kindr
hae
iii
report
unit
state
r
dworski
peter
nashvil
tn
fourmonthold
femal
ident
twin
evalu
noisi
breath
recurr
cyanosi
deliv
week
estim
gestat
age
uncompl
pregnanc
birth
intub
hour
respiratori
distress
remaind
neonat
period
unev
age
week
develop
noisi
breath
often
associ
cyanosi
particularli
supin
posit
cri
treatment
inhal
albuterol
prednisolon
ineffect
respiratori
infect
symptom
gastroesophag
reflux
diseas
growth
normal
twin
sibl
well
famili
histori
neg
allergi
respiratori
condit
initi
diagnos
tracheomalacia
howev
histori
cyanot
episod
prompt
search
definit
diagnosi
underw
bronchoscopi
show
tracheomalacia
breath
spontan
circumferenti
narrow
lower
trachea
like
due
compress
echocardiogram
reveal
doubl
aortic
arch
find
confirm
comput
tomographi
angiographi
demonstr
presenc
vascular
ring
compos
doubl
patent
aortic
arch
give
rise
ipsilater
carotid
subclavian
arteri
airway
normal
aortic
inlet
narrow
markedli
level
two
arch
surgic
divis
ductu
ligament
distal
anterior
vascular
arch
perform
aortic
arch
abnorm
suspect
infant
hoars
cough
noisi
breath
especi
inspir
sometim
also
expir
diagnosi
also
consid
older
children
recurr
bronchiti
pneumonia
respiratori
symptom
frequent
gastrointestin
manifest
diagnosi
usual
occur
first
year
life
surgeri
often
treatment
choic
postop
complic
rel
rare
outcom
surgeri
judg
month
includ
least
one
winter
season
malacia
delay
extub
recoveri
follow
surgeri
surgic
cure
occur
approxim
patient
surgeri
probabl
less
success
children
doubl
arch
malacia
thatayatikom
aj
white
st
loui
mo
background
common
variabl
immunodefici
cvid
commonest
symptomat
primari
antibodi
defici
syndrom
b
lymphocyt
produc
low
level
immunoglobulin
lead
recurr
bacteri
infect
although
hypogammaglobulinemia
suscept
recurr
infect
seen
patient
associ
condit
noninfecti
granulomat
diseas
well
describ
cvid
corticosteroid
therapi
use
improv
subset
cvid
granulomat
diseas
howev
treatment
remain
problemat
new
therapeut
agent
need
tumor
necrosi
factor
tnf
demonstr
primari
mediat
granuloma
format
mainten
therefor
antitnf
medic
potenti
therapeut
agent
granulomat
diseas
case
report
caucasian
male
cvid
sever
granulomat
diseas
treat
success
infliximab
chimer
antitnf
monoclon
antibodi
patient
initi
present
high
fever
chill
abdomin
pain
subsequ
develop
acut
respiratori
failur
adult
respiratori
distress
syndrom
patient
hospit
requir
intens
care
ventilatori
support
diagnost
test
reveal
elev
sediment
rate
posit
epsteinbarr
viru
ebv
capsid
igm
antibodi
imag
studi
demonstr
bilater
diffus
pulmonari
infiltr
hepatosplenomegali
open
lung
liver
biopsi
reveal
noncas
granulomat
lesion
without
evid
ebv
infect
high
dose
corticosteroid
therapi
given
partial
improv
high
dose
infliximab
given
weekli
remark
improv
patient
abl
wean
ventil
success
within
week
prednison
dose
dramat
decreas
infliximab
infus
everi
week
low
dose
prednison
continu
followup
liver
biopsi
month
infliximab
show
granulomat
lesion
infliximab
discontinu
month
treatment
seriou
infect
complic
period
treatment
conclus
antitnf
therapi
may
safe
effect
treatment
may
allow
corticosteroid
dose
reduct
futur
clinic
studi
antitnf
therapi
cvid
granulomat
diseas
warrant
background
chrugstrauss
syndrom
disord
character
hypereosinophilia
system
vascul
occur
individu
asthma
objet
present
pediatr
case
suffer
system
vascul
case
fulfil
churgstrauss
syndrom
clinic
criteria
histophatolog
find
compat
diagnosi
case
year
femal
came
institut
diagnosi
sever
asthma
chronic
sinusisit
polyp
requir
high
dose
steroid
histori
administr
antileukotrien
receptor
antagonist
month
admiss
present
weight
loss
fatigu
cephalea
cough
physic
examin
pallor
respiratori
difficulti
sign
bronchospasm
evid
tachycardia
hepatomegali
also
document
laboratori
test
show
anemia
eosinophilia
anca
sgot
stgop
ige
elev
uiml
chestx
ray
show
patchi
opac
lung
cardiomegali
pulmonari
scintigraphi
report
low
perfus
lung
predominantli
left
lungechocardiographi
demonstr
sign
myocard
eyect
fraction
open
lung
biopsi
execut
vascul
fibrinoid
chang
affect
small
medium
vessel
report
treatment
start
oral
prednison
mgkgd
cyclophosphamid
puls
satisfactori
evolut
discuss
knowledg
first
pediatr
case
css
report
mexico
fulil
follow
criteria
asthma
eosinophilia
system
vascul
involv
heart
liver
lung
diseas
extrem
rare
special
mexico
aggress
treatment
necessari
case
favor
outcom
introduct
wheez
asthma
wellknown
aphor
among
physician
principl
exist
patient
present
lip
swell
allergist
offic
describ
patient
present
fluctuat
lip
swell
ultim
found
cheiliti
granulomatosa
case
histori
male
histori
allerg
rhiniti
asthma
present
allergi
clinic
lower
lip
swell
occasion
upper
lip
swell
receiv
allergen
immunotherapi
dust
mite
tree
swell
wax
wane
year
becam
persist
previou
six
month
deni
tonguethroat
swell
dysphagia
respiratori
distress
trigger
swell
use
topic
lip
fail
treatment
includ
loratadin
ranitidin
cetirizin
fexofenadin
montelukast
place
oneweek
cours
prednison
decreas
lip
swell
recur
complet
treatment
physic
exam
signific
diffus
firm
lower
lip
edema
time
normal
size
oral
lesion
tongu
swell
patch
test
standard
panel
preserv
oral
flavor
dental
acryl
neg
punch
biopsi
reveal
noncas
epithelioid
granulomat
inflamm
consist
granulomat
cheiliti
place
minocyclin
mg
mouth
twice
daili
littl
benefit
cours
oral
prednison
result
improv
lip
swell
conclus
melkerssonrosenth
syndrom
mr
rare
syndrom
character
triad
recurr
facial
paralysi
chronic
edema
face
lip
hypertrophi
fissur
tongu
cheiliti
granulomatosa
consid
monosymptomat
form
mr
manifest
chronic
swell
lip
caus
granulomat
inflamm
swell
typic
tender
may
either
soft
firm
allergist
often
consult
lip
swell
thought
due
angioedema
howev
case
illustr
lip
swell
angioedema
one
must
consid
diagnos
melkerssonrosenth
syndrom
cheiliti
granulomatosa
progress
multifoc
leukoencephalopathi
pml
disord
nervou
system
affect
individu
immun
suppress
associ
hiv
infect
present
nearli
patient
acquir
immun
defici
syndrom
jc
viru
common
human
polyomaviru
caus
demyelin
disord
progress
symptom
reflect
multifoc
distribut
brain
lesion
includ
mental
deterior
vision
loss
speech
disturb
ataxia
paralysi
ultim
coma
rare
case
seizur
may
occur
known
treatment
pml
report
yearold
yo
male
month
weight
loss
sudden
onset
confus
lethargi
progress
loss
cognit
requir
hospit
upon
question
found
recurr
upper
respiratori
tract
infect
sinc
infanc
success
treat
antibiot
child
atop
dermat
exercis
induc
asthma
myringotomi
tube
place
twice
yo
underw
nasal
polypectomi
yo
squamou
cell
carcinoma
remov
develop
benign
cervic
lymphadenopathi
common
wart
year
later
develop
hsv
esophag
remaind
histori
unremark
normal
develop
growth
histori
drug
abus
multipl
sexual
partner
homosexu
contact
physic
examin
thin
ill
appear
oral
ulcer
gener
scanti
lymphoadenopathi
multipl
common
wart
feet
occasion
ronchi
brain
mri
show
demyelin
process
consist
pml
pcr
jc
viru
posit
hiv
pcr
neg
total
immunoglobulin
count
low
report
year
old
femal
year
histori
moder
persist
asthma
start
xolair
sq
q
wk
present
presum
allerg
reaction
three
hour
second
xolair
inject
patient
report
develop
dizzi
short
breath
felt
like
allerg
reaction
evalu
observ
two
hour
emerg
depart
treat
physician
report
wheez
felt
need
treatment
rule
psychogen
factor
given
placebo
inject
next
schedul
visit
ten
minut
later
report
develop
throat
tight
short
breath
chang
peak
flow
lung
clear
symptom
resolv
complet
within
minut
receiv
placebo
epinephrin
nebul
normal
salin
patient
inform
react
placebo
inject
well
placebo
epinephrin
albuterol
counsel
patient
return
offic
everi
week
next
three
week
receiv
blind
inject
subsequ
react
either
dose
placebo
xolair
sinc
toler
monthli
xolair
inject
without
incid
case
illustr
import
rule
psycholog
caus
presum
allerg
reaction
introduct
latex
allergi
type
ige
mediat
hipersensit
occur
special
high
risk
popul
like
patient
undergon
variou
surgeri
case
year
old
boy
asthma
allerg
rhiniti
sinc
penicillin
allergi
retrospect
mother
refer
lip
edema
balloon
inflatingat
year
age
left
orchiorrhaphi
cryptorchi
surgeri
sacral
giant
melanocit
naevusdur
fourth
surgic
intervent
colloc
tissu
expand
patient
present
perior
fingertip
cyanosi
gener
cutan
rash
sever
mmhg
hr
xmin
treat
iv
fluid
steroid
antihistamin
inhal
racem
epinephrineat
icu
final
outcom
satisfactori
laboratori
total
ige
skin
prick
test
glove
extract
raw
natur
latex
extract
purifi
latex
protein
pseudoevein
molecular
hevein
hev
b
modifi
hevein
posit
western
blot
protein
extract
latex
posit
elisa
purifi
latex
protein
posit
last
surgeri
withdraw
tissu
expand
perform
latex
free
surgic
equip
without
problem
discuss
patient
risk
factor
latex
allergi
atopi
repetit
exposur
latex
articl
surgeri
present
mild
manifest
latex
allergi
till
final
develop
fullblown
anaphylaxi
diagnosi
made
base
clinic
histori
skin
prick
test
western
blot
protein
extract
elisa
purifi
latex
protein
favor
outcom
withdraw
latex
last
surgeri
introduct
churgstrauss
syndrom
css
form
primari
vascul
rare
diagnosi
elderli
patient
case
report
year
old
woman
present
week
histori
fatigu
vomit
diarrhea
abdomin
pain
right
lower
leg
paresthesia
prior
admiss
treat
left
neck
erythema
adenopathi
presum
cellul
good
health
histori
atopi
age
develop
chronic
sinus
requir
bilater
sinu
surgeri
polypectomi
new
onset
asthma
requir
system
steroid
control
prednison
taper
month
prior
admiss
object
find
includ
coalesc
nonblanch
petechia
abdomen
peripher
eosinophilia
normochrom
normocyt
anemia
ana
p
canca
neg
ct
show
ascit
pleural
effus
egd
reveal
duoden
ulcer
eosinophil
infiltr
biopsi
echo
show
pericardi
effus
septal
motion
abnorm
troponin
without
cad
consist
subepicardi
myocard
emg
confirm
right
peron
neuropathi
skin
biopsi
reveal
dens
superfici
midderm
perivascular
interstiti
eosinophil
infiltr
addit
evalu
exclud
malign
infect
abpa
treatment
prednison
initi
rapid
clinic
improv
ensu
persist
acr
criteria
css
discuss
churgstrauss
syndrom
rare
form
vascul
mean
age
onset
within
third
fifth
decad
uncommon
caus
system
vascul
patient
older
form
frust
css
variant
earli
manifest
syndrom
hidden
oral
system
steroid
employ
treatment
worsen
asthma
often
associ
css
variant
make
expedi
identif
css
challeng
delay
recognit
contribut
relentless
progress
entiti
result
system
vascul
multiorgan
involv
earli
diagnosi
especi
prodrom
eosinophil
phase
essenti
untreat
css
high
rate
morbid
mortal
therefor
css
form
frust
variant
must
integr
compon
differenti
diagnosi
patient
present
adult
onset
asthma
andor
recurr
sinus
common
variabl
immunodefici
cvid
preval
primari
immunodefici
diseas
cvid
heterogen
group
immunolog
disord
unknown
etiolog
character
impair
antibodi
respons
hypogammaglobulinemia
normal
b
cell
common
immunolog
defect
patient
cvid
defect
antibodi
format
mani
differ
immun
system
defect
report
group
patient
patient
realli
identifi
molecular
diagnosi
cvid
consist
sever
differ
genet
defect
immunolog
defect
cvid
failur
blymphocyt
differenti
plasmacel
b
lymphocyt
patient
fail
differenti
igproduc
cell
stimul
pokewe
mitogen
vitro
even
cocultur
normal
cell
overwhelm
bodi
literatur
suggest
patient
cvid
intact
b
lymphocyt
immatur
phenotyp
howev
function
classif
cvid
patient
basi
vitro
ig
product
time
consum
recent
propos
new
classif
base
quantit
repartit
memori
b
cell
accord
dual
express
igd
present
case
yr
old
boy
present
soon
life
frequent
infect
particular
sever
pneumonia
meningoencef
sepsi
bronchiti
otiti
linfoaden
also
thalassemia
intermedia
clinic
manifest
suggest
immunodefici
reason
year
age
serum
immunoglobulin
antibodi
detect
show
reduct
subclass
cell
normal
total
igg
iga
igm
normal
ratio
normal
isohemagglutinin
vitro
cell
function
also
defect
antibodi
product
tetanu
diphtheria
pertussi
immun
laboratori
find
allow
howev
sure
diagnosi
cvid
new
immunolog
evalu
age
year
old
onset
splenomegali
enlarg
lymph
node
demonstr
b
memori
defect
sever
deficit
lymphocyt
function
vitro
also
possibl
find
sever
defici
cd
cell
mean
defect
memori
b
cell
therfor
label
condit
cvid
past
two
decad
conflict
view
regard
clinic
import
igg
subclass
defici
children
subclass
play
vital
role
immun
respons
polysaccharid
antigen
isol
subclass
defici
may
widespread
often
asymptomat
children
howev
associ
subclass
andor
immunoglobulin
class
may
signific
symptomat
outcom
report
patient
diagnos
famili
dysautonomia
fd
age
five
week
present
sever
hypotonia
tachypnea
hinder
poor
pulmonari
function
hospit
fifteen
time
recurr
pneumonia
includ
four
lengthi
intens
care
admiss
daili
inhaledcorticosteroid
brochodil
therapi
initi
along
chest
therapi
via
high
frequenc
chest
wall
oscil
immunoglobulin
level
measur
recent
point
low
level
total
iga
antibodi
mgdl
n
mgdl
n
mgdl
n
mgdl
n
total
iga
mgdl
n
sinc
receiv
monthli
ivig
therapi
recurr
pulmonari
infect
slowli
wean
daili
brochodil
therapi
current
accept
theori
low
subclass
level
may
associ
increas
risk
bacteri
infect
select
group
fd
patient
may
distinct
suscept
popul
level
critic
older
brother
also
diagnos
fd
demonstr
iga
level
slightli
higher
nevertheless
lower
end
normal
rang
suffer
less
invas
less
frequent
bacteri
infect
may
support
genet
associ
fd
hypogammaglobulinemia
altern
may
signal
fd
patient
may
prolong
variant
transient
hypogammaglobulinemia
infanc
followup
immun
profil
studi
postivig
trough
level
broader
investig
fd
popul
necessari
determin
sever
preval
find
pulmonari
failur
domin
caus
death
patient
fd
prompt
diagnosi
effect
treatment
associ
immun
defici
may
proven
essenti
effort
enhanc
prolong
live
hassan
ja
grant
galveston
tx
rational
common
variabl
immunodefici
cvid
rare
primari
immunodefici
present
young
adult
repeat
sinopulmonari
infect
result
profound
hypogammaglobulinemia
first
describ
suri
et
al
ann
acad
med
singapor
describ
young
man
diagnos
untreat
cvid
eventu
cours
case
descript
caucasian
male
hospit
secondari
chronic
pneumonia
respiratori
failur
note
nonexist
level
immunoglobulin
histori
reveal
ivig
treatment
age
stop
year
due
noncompli
although
untreat
deni
recurr
sinus
otiti
media
bronchiti
almost
year
note
recent
inabl
keep
basebal
practic
last
ten
healthi
sibl
patient
start
monthli
ivig
infus
note
hypertens
tachycardia
tachypnea
month
satur
room
air
histori
acut
dyspnea
calf
muscl
right
abdomin
pain
admit
hospit
pulmonari
thromboembol
rule
laboratori
data
humor
function
pneumococc
tetanu
toxoid
hepvac
undetect
cell
function
mump
candida
ppd
normal
immunoglobulin
igg
iga
igm
undetect
flow
cytometri
b
nk
cell
marker
normal
mild
decreas
ratio
high
resolut
ct
thorax
bronchiectasi
bronchial
wall
thicken
obstruct
chang
airtrap
minut
walk
desatur
nc
bnp
echocardiogramestim
ef
sever
pulmonari
hypertens
cardiac
catheter
normal
coronari
arteri
sever
pulmonari
hypertens
pa
pressur
conclus
cvid
patient
reason
good
prognosi
treatment
untreat
cvid
associ
chronic
lung
infect
bronchiectasi
pulmonari
hypertens
right
heart
failur
although
lung
transplant
becam
avail
earli
eighti
nejm
extrem
invas
life
save
procedur
undertaken
patient
cvid
endstag
pulmonari
hypertens
thorax
lung
transplant
may
way
ensur
surviv
patient
introduct
chronic
eosinophil
pneumonia
cep
rare
disord
unknown
etiolog
character
chronic
relaps
interstiti
lung
diseas
blood
tissu
eosinophilia
cep
occur
often
women
preexist
atop
diseas
patient
cep
respond
rapidli
system
corticosteroid
often
relaps
short
lowdos
cours
therapi
uncommon
extrapulmonari
involv
arthralgia
cutan
purpura
pericard
hepat
report
present
case
patient
cep
pericardi
effus
case
report
patient
nonsmok
woman
past
medic
histori
signific
allerg
rhiniti
asthma
initi
present
fourmonth
histori
worsen
short
breath
dyspnea
exert
dri
nonproduct
cough
weight
loss
approxim
five
pound
symptom
refractori
increas
dosag
inhal
fluticason
develop
intermitt
fever
chest
xray
reveal
bilater
apic
infiltr
treatment
levofloxacin
seven
day
result
improv
symptom
roentograph
find
thereaft
present
chest
abdomin
pain
hypotens
hypoxia
blood
work
reveal
white
cell
count
cmm
differenti
signific
eosinophilia
absolut
eosinophil
count
cmm
chest
ct
show
dens
consolid
predominantli
along
peripher
aspect
upper
superior
segment
lower
lobe
pericardi
effus
moder
pericardi
effus
without
evid
tamponad
confirm
echocardiogram
left
upper
lobe
wedg
biopsi
find
includ
signific
tissu
eosinophilia
scatter
foci
activ
organ
exud
evid
granulomat
necrot
vascul
patient
treat
cep
sixmonth
cours
prednison
start
mg
daili
result
rapid
improv
pulmonari
system
symptom
background
immunologist
consult
evalu
immunodefici
patient
recurr
skin
infect
disord
phagocyt
system
may
associ
cutan
infect
method
case
report
case
african
american
girl
twin
present
recurr
skin
abscess
month
age
first
buttock
abscess
requir
incis
drainag
oral
antibiot
month
later
develop
anoth
abscess
found
neutropen
absolut
neutrophil
count
anc
cyclic
neutropenia
consid
pediatrician
monitor
cbc
show
persist
neutropenia
anc
month
age
hospit
fever
neutropenia
immunolog
consult
evalu
neutropenia
rest
past
medic
histori
unremark
healthi
appear
growth
paramet
appropri
age
physic
examin
unremark
immunoglobulin
band
tcell
marker
nitroblu
tetrazolium
complement
assay
hemoglobin
platelet
peripher
smear
normal
antibodi
hiv
cmv
ebv
parvoviru
undetect
antineutrophil
antibodi
posit
establish
diagnosi
primari
autoimmun
neutropenia
abscess
heal
oral
antibiot
sever
neutropenia
anc
persist
three
subsequ
month
without
infect
twin
b
also
found
persist
sever
neutropenia
without
morbid
suggest
primari
primari
less
known
among
physician
typic
diagnos
extens
investig
exclud
caus
neutropenia
exact
incid
unknown
usual
seen
children
month
age
often
sever
neutropenia
selflimit
bacteri
infect
clinic
cours
presenc
antibodi
neutrophil
antigen
diagnost
famili
occurr
primari
report
literatur
conclus
primari
may
remain
diagnos
due
lack
characterist
clinic
featur
although
benign
clinic
cours
like
sever
infect
includ
pneumonia
sepsi
mening
report
genet
may
play
role
diseas
present
primari
twin
background
atop
dermat
ad
chronic
inflamatori
diseas
skin
affect
wordl
populationth
natur
histori
ad
patient
evolv
coexist
allerg
diseas
allerg
rhiniti
allerg
conjunct
asthma
sublingu
immunotherapi
demonstr
util
patient
howev
semirush
immunotherapi
pollen
show
util
one
anim
case
publish
year
ago
case
report
infant
refer
us
began
one
year
skin
lesion
compat
ad
six
month
later
began
perenni
rinhorrea
nasal
itch
multipl
treatment
topic
corticosteroid
moistur
antihistamin
topicsystem
antibiot
demonstr
util
evalu
reveal
ad
lession
affect
total
bodi
surfac
clinic
featur
allerg
rhiniti
ar
lab
test
reveal
eosinophylia
blood
cell
count
normal
level
total
ige
specif
ige
dermatophagoid
pteronissinu
dpt
high
skin
prick
test
reveal
result
ad
environment
control
oral
costicosteroid
transfer
factor
despit
treatment
improv
observ
consid
dpt
princip
factor
mainten
ad
lession
ar
episod
absenc
sublingu
immunotherapi
hospit
decid
semirush
immunotherapi
schedul
began
ml
wv
concentr
dpt
ml
wv
concentr
two
month
receiv
three
dose
per
week
local
system
advers
event
report
ad
lesion
ar
symptomatolog
disappear
first
month
treatment
time
exacerb
document
conclus
semirush
immunotherapi
use
safe
treatment
ad
patient
specif
ige
aeroallergen
demonstr
introduct
eosinophil
gastrointestin
disord
rare
group
disord
involv
entir
gastrointestin
tract
present
vari
may
includ
vomit
dysphagia
abdomin
pain
diarrhea
failur
thrive
diagnosi
made
endoscop
biopsi
reveal
eosinophil
rich
inflamm
absenc
known
caus
eosinophilia
peripher
eosinophil
ige
may
elev
normal
report
patient
eosinophil
gastroenter
associ
ampullari
tubulovil
adnenoma
method
white
male
allerg
rhiniti
famili
histori
atopi
admit
profus
wateri
diarrhea
deni
new
medic
eat
raw
food
recent
travel
eosinophil
elev
wbc
ige
elev
multipl
stool
specimen
neg
ova
parasit
enter
pathogen
serolog
neg
strongyloid
trichinella
e
histolytica
toxocara
ast
alt
bilirubin
elev
ct
scan
show
dilat
billiari
duct
possibl
ampullari
mass
biopsi
ampullari
mass
reveal
tubulovil
adenoma
biopsi
duodenum
termin
ileum
colon
rectum
remark
focal
eosinophil
cryptiti
chronic
inflamm
lamina
propria
consist
eosinophil
scatter
lymphocyt
histiocyt
specimen
neg
parasit
infect
includ
duoden
aspir
empir
start
metronidazol
singulair
gradual
improv
symptom
eosinophil
liver
test
two
month
discharg
patient
remain
diarrhea
free
normal
eosinophil
count
conclus
report
patient
eosinophil
gastroenter
ampullari
tubulovil
adenoma
obstruct
biliari
system
uniqu
present
illustr
divers
natur
gastrointestin
manifest
seen
eosinophil
gastroenter
background
zonisamid
antiseizur
medic
chemic
classifi
sulfonamid
unrel
ant
seizur
agent
report
case
hypersensit
agent
child
method
case
report
result
patient
girl
develop
peel
lip
three
week
start
zonisamid
one
week
later
develop
rash
began
face
gener
sever
day
neck
trunk
extrem
respiratori
distress
joint
complaint
angioedema
associ
episod
fever
prompt
referr
hospit
day
rash
rash
macularpapular
without
discret
urticari
lesion
rash
coalesc
underli
erythema
face
chest
neck
patient
known
histori
seizur
disord
asthma
mild
eczema
gastro
esophag
reflux
develop
delay
lactos
intoler
failur
thrive
medic
lansoprazol
topiram
albuterol
lab
reveal
normal
white
cell
count
elev
sed
rate
elev
lft
ie
sgot
sgpt
new
medic
zonisamid
discontinu
treat
iv
steroid
hydroxyzin
rash
start
fade
day
patient
fever
resolv
third
hospit
day
liver
enzym
return
normal
day
conclus
rel
new
antiseizur
agent
associ
hypersensit
reaction
children
introduct
kawasaki
diseas
kd
acut
chilhood
vascul
addit
diagnost
criteria
broad
rang
nonspecif
clinic
featur
may
observ
includ
asept
mening
vomit
diarrhea
abdomin
pain
steril
pyuria
arthralgia
arthrti
pulmonari
infiltr
pleural
effus
nonspecif
paralyt
ileum
manifest
gastrointestin
vascul
describ
child
develop
featur
kawasaki
diseas
includ
rare
report
patient
report
yearold
femal
present
day
high
fever
nonsuppur
cervic
lymphadenopathi
petequi
rash
leg
swell
feet
distend
abdomen
vomit
obnubil
hypoact
incongru
speech
fisur
lip
distend
abdomen
lab
test
show
anemia
high
wbc
count
thrombocytopenia
hypoalbuminemia
lactat
dehydrogenas
ldh
glutamin
transferas
ggt
csf
total
protein
glucos
cell
pm
mn
seric
complement
cultur
neg
develop
myocard
aneurysm
right
left
coronari
arteri
day
present
cardiac
failur
pleural
effus
paralyt
ileum
hydrop
vesicular
mechan
ventilatori
assist
requir
first
dose
intraven
immunoglobulin
ivig
infus
heparin
hydrocortison
day
second
dose
ivig
infus
fever
abdomin
vascul
steroid
ware
discontinu
heparin
suspend
aspirin
ad
antiaggreg
discuss
patient
present
unusu
sever
present
kd
pleural
effus
nonspecif
ileum
cardiac
failur
secondari
myocard
asept
mening
thrombocytopenia
manifest
rare
report
time
present
devast
evolut
complic
resolv
lastest
studi
shown
treatment
ivig
plu
corticosteroid
significantli
reduc
serum
concentr
proinflamatori
cytokin
case
antiinflamatori
dose
aspirin
contraind
steroid
use
satisfactori
outcom
limit
data
avail
nonrespond
patient
guid
therapi
although
multipl
dose
ivig
suffici
patient
remain
refractori
therapi
need
corticosteroid
control
vascul
process
eosinophilia
defin
absolut
eosinophil
count
x
seen
associ
broad
spectrum
disord
rang
allerg
malign
idiopath
hypereosinophil
syndrom
he
consid
patient
eosinophil
count
x
month
without
commonli
recogn
caus
eosinophilia
evid
organ
damag
otherwis
explain
clinic
set
potenti
aggress
diseas
mean
surviv
less
year
without
treatment
present
year
old
male
hors
breeder
eosinophilia
last
year
prior
come
institut
underw
extens
medic
evalu
includ
bone
marrow
gi
biopsi
multipl
imag
studi
mri
ct
scan
chest
head
well
detail
evalu
cardiac
statu
test
normal
patient
empir
start
treatment
possibl
he
includ
trial
prednison
hydroxyurea
interferon
alfa
imatinib
without
last
resolut
eosinophilia
caus
signific
side
effect
profound
depress
immun
statu
final
light
patient
profess
strongyloid
enzym
immunoassay
done
found
remark
posit
duoden
drainag
confirm
infest
nematod
within
week
start
treatment
ivermectin
eosinophil
count
came
eventu
normal
learn
one
persist
exclud
common
caus
eosinophilia
consid
he
case
parasit
infest
prematur
treatment
immunosuppressor
result
worsen
infect
potenti
poor
even
fatal
outcom
stool
evalu
might
sensit
enough
detect
parasit
therefor
necessari
complet
diagnost
work
appropri
serolog
doxil
pegyl
liposom
form
doxorubicin
use
success
cancer
chemotherapi
agent
mani
type
tumor
hypersensit
reaction
occur
usual
first
infus
appear
rate
relat
symptom
includ
dyspnea
tachypnea
facial
swell
chill
hive
chest
pain
back
pain
report
case
hypersensit
reaction
doxil
yearold
woman
hodgkin
lymphoma
first
outpati
doxil
infus
mgmin
develop
urticaria
chest
tight
dyspnea
back
pain
reaction
persist
despit
medic
antihistamin
steroid
immedi
resolv
paus
infus
mg
doxil
infus
discontinu
six
day
later
admit
complet
half
dose
neg
intraderm
skin
test
dilut
doxil
premed
diphenydramin
dexamethason
acetaminophen
famotidin
doxil
infus
start
mgmin
soon
stop
due
flush
hand
face
infus
decreas
mgmin
abl
toler
slow
infus
mild
toler
symptom
symptom
worsen
infus
stop
minut
complet
mg
infus
doxil
hour
preinfus
postinfus
complement
level
drawn
second
administr
doxil
preinfus
bb
level
normal
preinfus
level
high
indic
might
residu
persist
complement
activ
caus
first
doxil
infus
postinfus
bb
level
normal
howev
postinfus
level
significantli
increas
suggest
complement
activ
second
doxil
infus
given
reaction
first
doxil
infus
neg
skin
test
doxil
highli
unlik
doxil
hypersensit
igemedi
process
therefor
patient
similar
doxil
hypersensit
suggest
slow
rate
infus
mgmin
toler
mild
symptom
minut
paus
sever
symptom
continu
premed
entir
lengthi
infus
introduct
eosiniphil
esophag
ee
isol
sever
esophag
eosinophilia
patient
usual
young
male
present
vomit
epigastr
chest
pain
dysphagia
obstruct
respiratori
problem
often
initi
misdiagnos
treat
gastroesophag
reflux
diseas
gerd
distinct
two
diseas
made
biopsi
esophag
mucosa
eosinophil
esophag
mucosa
indic
patholog
gerd
typic
present
eosinophil
per
high
power
field
hpf
ee
often
present
greater
eosinophil
per
hpf
case
report
patient
one
half
year
old
boy
experienc
sever
symptom
gerd
age
month
vomit
meal
least
time
per
day
cough
lie
night
regurgit
phlegm
earli
morn
complain
discomfort
lower
chest
eat
weight
remain
pound
last
six
month
patient
diagnos
asthma
age
half
howev
famili
histori
asthma
allergi
patient
initi
experienc
improv
lansoprazol
symptom
recur
medic
discontinu
subsequ
cours
ineffect
physic
exam
normal
bar
slightli
edemat
nasal
turbin
endoscop
biopsi
show
numer
eosinphil
later
clarifi
eosinophil
per
hpf
distal
esophagu
patient
show
allergi
milk
wheat
radioallergosorb
rast
test
patient
start
swallow
fluticason
puff
twice
daili
advis
see
nutritionist
regard
wheat
milk
elimin
diet
conclus
ee
import
differenti
gerdlik
symptom
childhood
avoid
misdiagnosi
critic
evalu
number
eosinophil
present
biopsi
specimen
help
differenti
gerd
ee
children
ee
increas
risk
develop
esophag
dysmotil
esophag
strictur
patient
often
posit
skin
prick
rast
test
food
aeroallergen
altern
treatment
food
elimin
diet
glucocorticoid
system
topic
effect
treat
symptom
may
respond
reflux
medic
introduct
asherton
introduc
term
catastroph
antiphospholipid
syndrom
cap
describ
patient
share
clinic
evid
multipl
three
organ
involv
andor
histopatholog
evid
multipl
vessel
occlus
case
report
present
year
old
femal
lumbar
pain
arthralgia
weight
loss
fever
malais
raynaud
phenomenom
alopecia
oral
ulcer
hepatomegali
arriv
polypn
tachycardia
basal
hypoventil
hepatomegali
evid
hb
leucocyt
total
lymphocyct
total
neutrophyl
platelet
coomb
posit
urin
exam
proteinuria
leucocyturia
erythrocyturia
creatinin
diagnos
sle
pericard
cardiac
failur
acut
pulmonari
edema
urinari
tract
infect
pneumonia
requir
mechan
ventil
inotrop
support
intraven
gammaglobulin
hydrocortison
acut
renal
failur
hemodialysi
begun
improv
suddenli
present
seizur
crisi
stupor
livido
reticulari
skin
acrocyanosi
extern
opthamalplexia
bilater
facial
diplexia
ocular
fundu
arteriolar
vasospasm
right
faciocorpor
hemiparesia
cortic
progress
medular
annal
allergi
asthma
immunolog
segment
chang
ct
show
multipl
left
frontooccipit
pariet
hypodens
suggest
lacunar
infarct
diagnos
neurolupu
cap
initi
anti
anti
clp
neg
later
positiv
urinari
tract
infect
contraind
high
dose
steroid
intraven
gamaglobulin
anticoagul
start
signific
improv
current
patient
evolv
satisfactori
way
discuss
literatur
establish
catastroph
ap
character
elev
mortal
patient
damag
evid
cn
pn
kidney
skin
presenc
posit
antiphospholipid
antibodi
energ
antiinflamatori
immunoregulatori
immunosupress
therapi
function
affect
organ
complet
recov
case
exemplifi
therapi
cap
undertaken
suffici
earli
manner
given
elev
mortal
syndrom
patient
white
male
nonsmok
physician
highdos
regimen
advair
singulair
present
histori
progress
chest
tight
pulmonari
function
test
show
normal
fev
lung
function
past
whenev
inhal
steroid
dosag
lower
patient
experienc
reoccurr
asthma
symptom
despit
consist
normal
lung
function
result
rule
possibl
psycholog
induc
asthma
exacerb
patient
fraction
concentr
exhal
nitric
oxid
feno
level
measur
patient
feno
level
elev
ppb
valu
greater
ppb
describ
consist
airway
inflamm
increas
patient
inhal
steroid
patient
remiss
symptom
within
week
case
illustr
increasingli
common
clinic
pictur
symptomat
asthmat
may
normal
spirometri
elev
feno
devic
measur
feno
becom
avail
outpati
clinic
set
elev
feno
may
excel
diagnost
marker
assess
whether
airway
inflamm
adequ
treat
situat
spirometri
valu
within
normal
rang
introduct
autoimmun
thrombocytopen
purpura
atp
character
thrombocytopenia
megakaryocyt
hyperplasia
first
choic
treatment
consist
intraven
gamma
globulin
ivig
corticosteroid
antid
antibodi
second
line
measur
immunosuppress
drug
splenectomi
danazol
case
report
year
old
male
present
first
year
life
ecchymosi
sever
part
bodi
intermitt
april
present
ephistaxi
lower
gastrointestin
bleed
complet
blood
count
show
platelet
count
prednison
start
mgkg
improv
time
danazol
antid
antibodi
ivig
gkg
ad
subsequ
platelet
averag
count
diminish
patient
transfer
hospit
admiss
present
cushingoid
habitu
figur
acanthosi
nigrican
immunolog
test
aan
immunoglobulin
anticardiolipin
glycoprotein
show
alter
bone
marrow
aspir
demonstr
megakaryocyt
hypercellurar
prednison
dose
tamper
patient
present
secondari
glaucoma
patient
continu
treatment
danazol
ivig
dosag
hydroxychloroquin
cyclophosphamid
improv
thu
month
immunosuppress
treatment
splenectomi
perform
obtain
partial
improv
time
ranitidin
hydroxychloroquin
suspend
cyclophosphamid
chang
azathioprin
last
platelet
count
conclus
chronic
atp
childhood
present
case
account
approxim
total
atp
patient
chronic
atp
respond
convent
treatment
therapeut
challeng
patient
use
first
choic
second
choic
drug
improv
consequ
splenectomi
indic
obtain
desir
respons
first
use
immunosuppress
drug
common
diseas
could
good
altern
atp
resist
convent
treatment
import
laboratori
test
patient
background
budesonid
corticosteroid
avail
inhal
jet
nebul
indic
treatment
asthma
children
object
evalu
distribut
clinic
efficaci
inhal
budesonid
administ
nebul
modifi
commerci
devic
method
year
old
male
sever
persist
asthma
underw
lefort
procedur
multipl
craniofaci
abnorm
extern
devic
maintain
mouth
open
imped
proper
use
control
medic
result
develop
increas
asthma
symptom
subsequ
treat
nebul
budesonid
deliv
modifi
jet
nebul
end
plastic
tube
flowbi
manner
perform
dynam
ventil
imag
administ
mci
nebul
technetium
dilut
two
ml
normal
salin
imag
obtain
five
minut
three
second
per
frame
spirometri
monitor
possibl
given
obstruct
natur
facial
devic
result
patient
demonstr
improv
asthma
symptom
ventil
scan
show
patient
breath
technetium
dtpa
special
devic
deliveri
full
lung
volum
within
second
conclus
report
success
treatment
patient
unabl
use
commerci
avail
method
administr
inhal
steroid
rational
hp
nonig
mediat
inflammatori
respons
lung
due
varieti
organ
antigen
includ
metal
work
fluid
widerang
clinic
featur
includ
acut
subacut
chronic
form
elev
antineutrophil
cytoplasm
antibodi
platypnea
defin
dypsnea
induc
upright
posit
reliev
recumb
previous
report
patient
hp
case
white
male
tool
dye
machinist
present
progress
cough
weak
dyspnea
exert
platypnea
symptom
began
week
earlier
coryza
diffus
myalgia
lost
bodi
weight
sinc
symptom
onset
examin
reveal
puls
respiratori
rate
right
basilar
crackl
rest
puls
ox
room
air
drop
upon
ambul
pft
reveal
sever
obstruct
predict
signific
revers
dlco
adjust
va
hemoglobin
hemoglobin
normal
leukocyt
count
differenti
canca
panca
antimpo
perform
elisa
echocardiogram
show
ef
mild
pulmonari
hypertens
shunt
present
chest
roentogram
normal
chest
ct
reveal
diffus
groundglass
pattern
scatter
centrilobular
opac
biopsi
consist
hp
remov
work
exposur
metal
work
fluid
full
recoveri
lung
function
resoulut
symptom
conclus
hp
present
constel
symptom
without
singl
uniqu
identifi
pattern
platypnea
elev
anca
observ
wide
rang
disord
exclud
patient
platypnea
associ
hereditari
hemorrhag
telangiectasia
pulmonari
avm
hepatopulmonari
syndrom
recurr
pulmonari
emboli
patent
foramen
oval
elev
anca
associ
wegen
granulomatosi
goodpastur
syndrom
churgstrauss
vascul
druginduc
vascul
inflammatori
bowel
diseas
other
elisa
specif
modal
anca
indirect
immunofluoresc
less
sensit
possibl
hp
consid
patient
either
two
abnorm
rational
heart
diseas
lead
caus
death
america
person
year
age
coronari
athersclerosi
autopsi
present
elderli
commonli
atyp
myocardi
infarct
silent
unrecogn
framingham
cohort
patient
older
estim
present
dyspnea
without
associ
chest
pain
present
case
unstabl
angina
present
exerciseinduc
asthma
case
yearold
white
male
moder
persist
asthma
hypertens
dyslipidemia
long
histori
allerg
rhiniti
present
abrupt
increas
usual
exerciseinduc
asthma
symptom
four
week
prior
asthma
diagnos
age
spirometi
show
moder
obstruct
signific
incomplet
revers
remot
histori
pipe
cigar
smoke
quit
age
wellcontrol
sinc
time
recent
regimen
consist
fluticason
mcgsalmeterol
mcg
disku
one
inhal
twice
daili
typic
exerciseinduc
asthma
symptom
includ
dyspnea
exert
chest
tight
without
radiat
reliev
rest
albuterol
amount
exert
need
trigger
symptom
howev
much
less
previous
experienc
remain
constant
four
week
prior
present
one
week
prior
normal
ecg
evalu
primari
care
provid
six
month
prior
normal
nuclear
cardiac
stress
test
physic
examin
unremarkal
except
moder
decreas
aerat
pit
edema
lower
extrem
cardiolog
perform
nuclear
stress
test
next
day
abnorm
catheter
reveal
steonsi
proxim
lad
succ
underw
cabg
well
followup
conclus
elderli
present
mani
challeng
diagnostician
includ
multipl
comorbid
well
atyp
often
late
diseas
present
key
rais
suspicion
cardiac
involv
case
recognit
patient
cardiac
risk
factor
set
abrupt
onset
exercis
symptom
lack
asthma
symptom
nocturn
cough
cold
urticaria
uncommon
form
physic
urticaria
case
cold
urticaria
angioedema
provid
addit
inform
regard
unusu
disord
pediatr
popul
otherwis
healthi
femal
present
complaint
urticaria
precipit
cold
exposur
preced
week
recent
ill
past
medic
histori
signific
cat
allergi
multipl
occas
patient
note
erythema
pruritu
arm
face
walk
freezer
aisl
groceri
store
urticaria
would
develop
region
scratch
spontan
resolv
hour
one
occas
urticaria
appear
diffus
take
shower
patient
swim
urticaria
resolv
within
hour
patient
given
diphenhydramin
mother
three
day
prior
present
patient
experienc
upper
lip
angioedema
erythema
globu
sensat
difficulti
swallow
drink
strawberri
slushi
patient
deni
respiratori
complaint
time
symptom
annal
allergi
asthma
immunolog
resolv
spontan
famili
histori
signific
matern
histori
season
allergi
upon
physic
exam
patient
well
appear
discret
urticaria
calf
patient
mother
note
recent
would
appear
cold
raini
day
attribut
fact
patient
pant
left
lower
leg
expos
remaind
exam
normal
dermatograph
absent
laboratori
evalu
consist
cryoglobulin
strawberri
rast
neg
applic
ice
cube
patient
forearm
minut
result
centimet
wheal
note
minut
ice
remov
diagnosi
cold
urticaria
associ
angioedema
made
patient
mother
opt
use
diphenhydramin
need
epinephrin
autoinjector
dispens
month
symptom
onset
patient
complaint
pruritu
hand
becam
cold
urticaria
note
month
followup
patient
deni
symptom
preced
month
neg
ice
cube
test
cold
urticaria
pediatr
popul
rare
entiti
well
understood
case
cold
urticaria
angioedema
offer
addit
insight
unusu
disord
khuntia
mcmorri
ann
arbor
mi
introduct
chronic
granulomat
diseas
cgd
heterogen
group
disord
character
genet
defect
abil
phagocyt
gener
microbicid
reactiv
superoxid
anion
metabolit
manifest
earli
life
primarili
recurr
infect
caus
catalaseproduc
bacteria
staphylococcu
aureu
burkholderia
cepacia
serratia
marcescen
fungu
aspergillu
fumigatu
diseas
may
inherit
xlink
autosom
recess
manner
xlink
diseas
account
case
us
incid
cgd
live
birth
averag
age
present
year
xlink
year
autosom
recess
diseas
case
report
year
old
male
histori
three
separ
episod
pneumonia
begin
age
episod
result
hospit
admiss
intraven
antibiot
therapi
fail
oral
antibiot
therapi
extens
pulmonari
evalu
initi
third
episod
pneumonia
includ
chest
ct
viral
bacteri
immunodefici
studi
cbc
complement
immunoglobulin
flow
cytometri
viral
bacteri
studi
normal
ct
scan
reveal
dens
nodular
opac
right
upper
lobe
surround
groundglass
opacif
mild
bronchiectasi
subsequ
bronchoscopi
demonstr
necrot
granulomat
inflamm
open
lung
biopsi
grew
burkholderia
cepacia
tissu
cultur
clinic
histori
tissu
histopatholog
atyp
organ
found
cultur
suggest
underli
immunodefici
neutrophil
oxid
burst
assay
perform
demonstr
minim
neutrophil
activ
upon
stimul
suggest
diagnosi
cgd
chemillusc
assay
verifi
diagnosi
cgd
minim
fluoresc
note
flow
cytometri
neutrophil
stimul
dna
analysi
demonstr
defici
result
one
autosom
recess
less
clinic
sever
form
diseas
conclus
case
cgd
unusu
delay
present
demonstr
import
complet
immunolog
evalu
includ
evalu
neutrophil
disord
cgd
patient
age
present
recurr
recalcitr
episod
pneumonia
especi
atyp
organ
burkholderia
cepacia
found
cultur
autoimmun
may
play
role
develop
prematur
ovarian
failur
pof
exact
mechan
well
understood
pof
mainli
diagnos
year
age
women
complain
secondari
amenorrhea
pof
report
combin
presenc
ana
autoimmun
diseas
rare
jra
report
two
case
pof
posit
ana
pediatr
patient
one
clinic
featur
jra
first
patient
african
american
girl
height
percentil
weight
percentil
tenosynov
wrist
arthriti
knee
elbow
past
two
year
refer
evalu
manag
menarch
yet
laboratori
investig
reveal
posit
ana
second
patient
african
american
girl
percentil
height
weight
refer
immunolog
clinic
chief
complaint
primari
amenorrhea
delay
develop
secondari
sexual
characterist
found
posit
ana
without
clinic
find
jra
patient
tanner
stage
breast
tanner
stage
pubic
axillari
hair
elev
fsh
lh
karyotyp
small
uteru
small
ovari
pelvic
ultrasound
antiovarian
antibodi
detect
two
patient
bone
age
significantli
delay
pof
karyotyp
normal
women
frequent
seen
combin
elev
serum
ana
clinic
spectrum
rheumatoid
diseas
associ
pof
rang
asymptomat
ana
posit
typic
present
jra
women
pof
monitor
emerg
autoimmun
disord
includ
jra
women
jra
follow
menstrual
irregular
sign
pof
introduct
mani
u
militari
personnel
deploy
middl
east
continu
develop
infect
leishmaniasi
parasit
transmit
sand
fli
pentaval
antimoni
use
effect
treatment
leishmaniasi
mani
year
unit
state
sodium
stiboglucon
pentostam
pentaval
antimoni
choic
current
administ
ind
protocol
side
effect
therapi
includ
myalgia
arthralgia
rash
malais
abdomin
pain
pancreat
hypersensit
reaction
true
incid
hypersensit
reaction
current
known
case
report
two
u
soldier
receiv
pentostam
treatment
cutan
leishmaniasi
evalu
clinic
walter
reed
armi
medic
center
experienc
urticaria
angioedema
wheez
dyspnea
medic
infus
cours
daili
therapi
due
concern
potenti
igemedi
reaction
skin
test
perform
inform
consent
skin
test
includ
prick
test
full
strength
follow
intraderm
id
test
soldier
old
male
report
lip
swell
throat
tingl
dyspnea
chest
pain
hour
treatment
skin
test
lot
use
treatment
cours
show
posit
valu
respect
id
soldier
old
male
report
diffus
pruritu
hive
dyspnea
chest
pain
minut
infus
skin
test
show
posit
valu
respect
id
due
clinic
symptom
posit
skin
test
therapi
discontinu
case
one
control
individu
show
neg
test
prick
full
strength
id
id
conclus
skin
test
pentostam
may
provid
object
tool
accur
classif
advers
reaction
igemedi
relianc
skin
prick
test
alon
may
suffici
detect
pentostam
skin
test
reactiv
patient
react
id
test
prospect
studi
includ
preand
posttreat
skin
test
provid
inform
valu
skin
test
provid
object
evid
igemedi
process
determin
incid
hypersensit
pentostam
introduct
girl
histori
multipl
infect
hospit
respiratori
distress
hypoxia
past
medic
histori
signific
hypothyroid
psoriasi
asthma
multipl
pneumonia
cbc
reveal
absenc
lymphocyt
laboratori
b
cell
subset
show
bcell
low
cell
cell
inadequ
lymphocyt
present
mitogen
antigen
studi
serum
immunoglobulin
normal
antibodi
streptococcu
pneumonia
tetanu
antibodi
rsv
influenza
mycoplasma
absent
chest
xray
reveal
interstiti
infiltr
bilater
high
resolut
ct
scan
reveal
septal
thicken
confirm
interstiti
infiltr
open
lung
biopsi
consist
nonspecif
inflamm
extens
lymphocyt
infiltr
bal
fluid
biopsi
neg
bacteria
fungi
opportunist
pathogen
clinic
cours
patient
improv
antibiot
steroid
start
patient
improv
rapidli
discharg
home
biochem
analysi
demonstr
defici
adenosin
deaminas
ada
form
sever
combin
immun
defici
scid
patient
start
replac
ada
adagen
repeat
high
resolut
ct
scan
show
improv
howev
patient
continu
steroid
depend
control
pulmonari
symptom
lymphocyt
number
remain
low
despit
effect
ada
replac
absenc
serum
datp
remain
clinic
stabl
receiv
adagen
inject
twice
weekli
discuss
ada
defici
condit
lead
accumul
metabolit
datp
toxic
lymphocyt
diseas
commonli
present
first
year
life
scid
fatal
unless
treat
case
unusu
due
late
onset
sever
diseas
normal
serum
immunoglobulin
presenc
protect
antibodi
despit
adequ
replac
ada
patient
continu
profoundli
lymphopen
like
due
steroid
although
yet
complet
understand
underli
lung
diseas
suspect
patient
autoimmun
process
caus
interstiti
inflamm
background
atop
dermat
broad
rang
differenti
diagnos
human
sarcopt
infest
character
sever
prurit
lesion
variabl
appear
distribut
may
masquerad
eczema
infest
may
difficult
confirm
erad
anim
transmiss
report
sourc
human
infect
object
report
case
persist
sarcopt
infest
masquerad
eczema
associ
delusion
parasitosi
method
femal
refer
allergi
clinic
evalu
two
year
histori
recurr
prurit
rash
thought
refractori
atop
dermat
previou
ineffect
treatment
includ
topic
steroid
cream
lindan
topic
antifung
multipl
otc
antiitch
prepar
initi
evalu
widespread
excori
papul
variou
stage
heal
bodi
reput
dog
diagnos
recalcitr
mang
necessit
give
medic
bath
twice
daili
result
clinic
diagnosi
subacut
sarcopt
infect
made
patient
prescrib
two
cours
elimit
follow
oral
ivermectin
rash
quickli
resolv
except
postinflammatori
hyperpigment
three
week
resolut
primari
lesion
complain
prurit
erupt
occur
easili
access
area
began
bring
medicin
bottl
skin
debri
scab
examin
scrape
koh
prepar
skin
biopsi
examin
microscop
show
evid
sarcopt
reinfest
diagnosi
delusion
parasitosi
made
conclus
anim
human
transmiss
sarcopt
infect
seen
patient
rare
respond
quickli
appropri
treatment
despit
erad
infect
develop
delusion
parasitosi
rare
psychiatr
disord
character
fix
fals
belief
infest
insect
creatur
display
classic
matchbox
sign
sampl
skin
scab
detritu
brought
examin
current
receiv
psychiatr
care
background
thimeros
mercuri
deriv
use
sinc
commonli
use
preserv
ophthalm
solut
otic
drop
vaccin
due
bactericid
properti
object
report
first
case
gener
reaction
thimeros
found
influenza
vaccin
method
present
patient
develop
gener
maculopapular
erupt
receiv
thimeros
contain
influenza
vaccin
patch
test
perform
determin
allergi
thimeros
result
patch
test
confirm
type
iv
cell
mediat
sensit
thimeros
support
prior
histori
reaction
thimeros
contain
contact
len
solut
patient
ask
avoid
thimerosalcontain
product
includ
vaccin
unless
benefit
clearli
outweigh
potenti
risk
reaction
conclus
physician
need
awar
thimeros
found
mani
product
includ
vaccin
clinician
also
awar
allerg
reaction
occur
exposur
thimeros
even
vaccin
first
case
report
literatur
gener
reaction
thimeros
influenza
vaccin
angioedema
rare
condit
describ
literatur
exist
inherit
acquir
form
defect
innat
immun
system
particularli
complement
system
incit
culprit
acquir
form
esteras
inhibitor
defici
divid
two
class
gener
commonli
seen
forth
decad
life
type
acquir
angioedema
describ
associ
lymphoprolif
disord
type
relat
excess
complement
activ
consumpt
due
autoantibodi
case
old
man
refer
outsid
physician
manag
idiopath
edema
first
experienc
facial
edema
april
attribut
sweet
myrrh
root
ingest
subsequ
novemb
develop
diffus
swell
upper
extrem
tongu
without
airway
compromis
minim
workup
time
inconclus
fortun
remain
asymptomat
januari
time
experienc
two
episod
tongu
swell
without
etiolog
seen
local
emerg
depart
treat
diphenhydramin
corticosteroid
epinephrin
occas
gradual
improv
symptom
patient
medic
commonli
associ
angioedema
report
insect
envenom
subsequ
seen
primari
care
physician
order
number
laboratori
test
includ
significantli
suppress
light
find
refer
clinic
evalu
time
present
offic
patient
symptom
free
physic
exam
within
normal
limit
laboratori
evalu
essenti
unremark
except
complement
studi
list
tabl
case
demonstr
elderli
patient
evid
idiopath
swell
arriv
diagnosi
acquir
angioedema
base
clinic
present
confirmatori
serum
complement
level
low
time
present
allow
us
delin
etiolog
complement
defici
fact
patient
present
swell
age
pauciti
famili
histori
idiopath
angioedema
make
diagnosi
acquir
angioedema
probabl
measur
serum
level
confirm
diagnosi
introduct
certain
diseas
wide
believ
allerg
etiolog
includ
atop
dermat
episod
wheez
might
result
interplay
genet
environment
factor
least
partial
describ
child
rare
chromosom
disord
present
typic
featur
atop
dermat
recurr
mild
wheez
materi
method
new
born
africanamerican
male
note
unusu
facial
featur
immedi
birth
babi
born
natur
without
antenat
neonat
problem
physic
examin
infant
unusu
facial
characterist
tight
taut
facial
skin
rel
diminish
facial
pad
fat
point
chin
markedli
hyperton
extrem
addit
cardiac
exam
reveal
mumur
consist
uncompl
asd
frequent
reassess
infant
outpati
clinic
done
child
repeat
bout
wheez
attack
facial
rash
compat
diagnosi
atop
dermat
wheez
treat
clinic
nebula
bronchodil
atop
dermat
respond
reason
topic
steroid
applic
moistur
need
chromosom
analysi
peripher
blood
chid
confirm
diagnosi
delet
long
arm
q
chromosom
xy
del
karyotyp
analys
mother
father
normal
child
exhibit
featur
development
delay
seizur
activ
antiepilept
drug
a
institut
initi
eeg
normal
subsequ
eeg
show
find
static
encephalopathi
ct
scan
brain
reveal
absent
corpu
callosum
neurolog
evalu
physiotherapi
request
improv
fine
motor
skill
seem
suffer
seriou
infecti
immunodefici
ill
cbc
normal
continu
fair
gain
weight
height
head
circumfer
atop
dermat
wheez
episod
remain
control
hospit
breakthrough
seizur
dehydr
gastroenter
subsequ
echocardiographi
confirm
closur
asd
conclus
child
chromosom
anamoli
atop
dermat
mild
intermitt
wheez
report
despit
multipl
congenit
problem
child
continu
stabl
clinic
cours
etoposid
chemotherapeut
agent
use
treat
mani
solid
tumor
malign
hypersensit
reaction
well
describ
report
death
anaphylaxi
suggest
hypersensit
anaphylactoid
type
reaction
may
occur
first
dose
case
report
cutan
complic
includ
stevensjohnson
syndrom
radiat
recal
diffus
erythema
four
case
diffus
erythemat
papul
develop
etoposid
therapi
rash
spontan
resolv
within
three
week
biopsi
demonstr
keratinocyt
starburst
pattern
report
first
case
immedi
etoposid
induc
skin
reaction
evolv
long
last
hyperpig
plaqu
pretreat
abl
prevent
immedi
late
reaction
subsequ
exposur
etoposid
year
old
femal
ovarian
cancer
treat
bleomycin
etoposid
vinblastin
three
hour
initi
third
dose
etoposid
patient
develop
prurit
erythemat
macul
chest
abdomen
face
extrem
infus
stop
decadron
administ
fortyeight
hour
prurit
macul
becam
hyperpig
plaqu
chest
abdomen
extrem
face
pruritu
resolv
slow
taper
prednison
darken
plaqu
treat
multipl
topic
prepar
persist
three
month
biopsi
demonstr
superfici
perivascular
infiltr
lymphocyt
eosinophil
suggest
drug
erupt
etoposid
consid
essenti
patient
allergi
consult
literatur
support
cautiou
readministr
etoposid
pretreat
slower
infus
rate
prevent
immedi
hypersensit
could
guarante
prevent
late
hyperpig
reaction
patient
pretreat
prednison
cetirizin
etoposid
administ
icu
slower
rate
infus
etoposid
toler
without
immedi
pruritu
erythemat
reaction
patient
develop
delay
darken
plaqu
cautiou
administr
etoposid
premed
slow
rate
infus
prevent
immedi
late
reaction
previous
experienc
patient
eosinophil
normal
compris
peripher
white
blood
lymphocyt
peripher
blood
eosinophilia
defin
absolut
eosinophil
count
often
caus
atopi
helminth
infect
collagen
vascular
diseas
less
common
caus
includ
adren
insuffici
neoplast
process
eosinophilia
character
mild
moder
sever
although
sever
eosinophilia
report
associ
adult
hiv
infect
studi
hivinfect
children
shown
peripher
blood
eosinophilia
featur
pediatr
hiv
infect
report
unusu
case
sever
peripher
blood
eosinophilia
adolesc
male
subsequ
found
hivinfect
previous
healthi
male
present
week
histori
fever
diarrhea
cough
vomit
abdomin
pain
anorexia
weight
loss
previou
month
patient
recent
emigr
guyana
deni
sexual
activ
intraven
drug
abus
hiv
risk
factor
known
matern
hiv
infect
repeat
stool
specimen
neg
ova
parasit
serolog
e
histolytica
cani
stercorali
neg
abdomin
ultrasound
chest
xray
serum
electrolyt
liver
function
test
within
normal
limit
total
white
blood
cell
eosinophil
absolut
eosinophil
count
elisa
western
blot
posit
human
immunodefici
viru
tlymphocyt
count
rna
level
copiesml
patient
symptom
resolv
next
day
without
treatment
start
combin
antiretrovir
therapi
zidovudin
lamivudin
abacavir
efavirenz
absolut
eosinophil
count
continu
slowli
decreas
last
count
three
month
follow
introduct
antiretrovir
therapi
sever
peripher
blood
eosinophilia
may
present
featur
hiv
infect
adolesc
hiv
test
consid
case
common
caus
eosinophilia
atopi
parasit
infect
exclud
triad
asthma
well
describ
adult
pediatr
literatur
case
highlight
success
treatment
sever
pediatr
asthmat
nasal
polyp
aspirin
sensit
yearold
femal
present
sever
persist
asthma
eib
allerg
rhiniti
chronic
sinus
nasal
polyp
histori
pneumonia
asthma
symptom
minim
age
age
start
flovent
requir
increas
amount
inhal
oral
steroid
requir
cours
oral
steroid
per
year
age
addit
snore
fatigu
chronic
nasal
congest
rhinorhea
sneez
despit
treatment
withallegra
rhinocort
receiv
immunotherapi
age
clinic
improv
sinc
age
recurr
sinus
requir
polypectomi
note
aspirin
caus
nasal
stuffi
mild
wheez
therefor
avoid
exam
allerg
shiner
denni
line
boggi
turbin
nasal
polyp
diffus
wheez
evalu
sever
airway
obstruct
increas
albuterol
chest
ct
mosaic
pattern
due
sever
air
trap
level
sleep
studi
show
sever
hypopnea
pansinus
ct
multipl
posit
spt
eosinophil
count
ige
normal
sweat
chlorid
ph
probeth
differenti
diagnosi
includ
churgstrauss
abpa
cystic
fibrosi
bronchiol
obliteran
triad
asthma
thorough
evalu
diagnos
triad
asthma
week
treatment
oral
prednison
improv
inhal
control
therapi
increas
place
xolair
polypectomi
underw
aspirin
desensit
one
year
start
treatment
remain
requir
albuterol
requir
prednison
eib
allerg
rhiniti
congest
markedli
improv
episod
sinus
repeat
sleep
studi
normal
conclus
treat
sever
pediatr
asthmat
nasal
polyp
aspirin
sensit
frequent
report
pediatr
popul
rais
question
incid
optim
long
term
treatment
triad
asthma
differ
adult
onset
diseas
aa
white
ra
simon
la
jolla
ca
background
human
diseas
mold
tradit
isol
infect
allerg
diseas
hypersensit
pneumon
specif
diseas
patholog
find
list
well
describ
report
case
acut
eosinophil
pneumonia
relat
mold
exposur
case
present
year
old
woman
develop
dri
cough
short
breath
stachybotri
mold
discov
home
chest
radiograph
show
bilater
upper
lobe
infiltr
worsen
two
week
later
treatment
macrolid
flouroquinolon
antibiot
ineffect
white
blood
cell
count
eosinophil
erythrocyt
sediment
rate
mmhr
aspergillu
ige
neg
treatment
prednison
led
complet
resolut
chest
radiograph
abnorm
improv
pulmonari
function
test
patient
given
diagnosi
acut
eosinophil
pneumonia
mold
like
causal
factor
discuss
disput
amongst
health
care
profession
regard
signific
environment
mold
contamin
etiolog
human
diseas
case
repres
well
character
diseas
occur
set
mold
exposur
causal
relationship
establish
tempor
relationship
mold
contamin
symptom
onset
diseas
progress
compel
interestingli
recent
report
mold
contamin
lead
nonspecif
interstiti
pneumoniafibrosi
describ
observ
patient
clinic
similar
patholog
biopsi
tempor
relationship
mold
exposur
knowledg
acut
eosinophil
pneumonia
report
conjunct
mold
exposur
conclus
case
highlight
new
condit
mold
may
causal
role
mechan
unknown
like
nonig
mediat
immunolog
pathway
public
awar
mold
health
concern
increas
perhap
similar
case
emerg
histori
mold
exposur
offer
patient
time
evalu
lung
diseas
stronger
correl
may
emerg
scuba
dive
commonli
practic
activ
normal
carri
minim
risk
sever
allerg
reaction
anaphylaxi
howev
occur
activ
could
particularli
danger
swimmer
submerg
also
lack
proxim
medic
care
report
case
anaphylaxi
occur
scuba
dive
result
unsuspect
hypersensit
latex
compon
scuba
dive
suit
yrold
white
male
develop
sever
gener
urticari
rash
angioedema
lip
eyelid
difficulti
breath
within
minut
appli
suit
enter
water
rescu
transport
nearbi
emerg
depart
receiv
epinephrin
antihistamin
corticosteroid
iv
fluid
gradual
improv
hour
period
patient
deni
stung
marin
aquat
organ
prior
histori
allergi
medic
usag
prior
reaction
sinc
subsequ
investig
reveal
scuba
dive
suit
contain
latex
brazilian
rubber
specif
ige
rast
found
strongli
posit
class
v
latex
therefor
patient
advis
use
suit
made
neopren
synthet
rubber
polychloropren
nonlatex
contain
product
case
report
illustr
import
dilig
search
hidden
sourc
latex
product
produc
lifethreaten
allerg
reaction
sensit
patient
consider
debat
concern
safeti
immun
eggallerg
children
combin
mmr
vaccin
concern
deriv
possibl
anaphylact
reaction
sinc
mmr
vaccin
prepar
attenu
virus
grown
chick
embryo
fibroblast
cell
cultur
previous
report
safe
administr
mmr
vaccin
sever
eggallerg
children
without
develop
advers
reaction
nsouli
tm
et
al
ann
allergi
asthma
immunol
find
consist
current
report
committe
infecti
diseas
american
academi
pediatr
present
case
report
describ
anaphylact
reaction
egg
allerg
yroldwhit
male
consist
gener
urticaria
angioedema
wheez
immedi
follow
administr
second
mmr
vaccin
histori
hive
follow
ingest
egg
confirm
posit
specif
ige
rast
test
patient
anaphylact
reaction
necessit
emerg
treatment
includ
epinephrin
diphenhydramin
corticosteroid
addit
iv
fluid
although
administr
mmr
vaccin
eggallerg
children
consid
absolut
contraind
present
case
report
suggest
caution
observ
administ
mmr
vaccin
patient
care
medic
observ
includ
togeth
readi
avail
emerg
medic
equip
p
buddiga
r
turbin
baisr
l
bielori
newark
nj
introduct
sarcoidosi
chronic
granulomat
diseas
unknown
etiolog
may
multiorgan
system
manifest
character
histopatholog
evid
nonnecrot
granuloma
case
report
year
old
african
american
woman
year
histori
type
ii
diabet
mellitu
hypertens
sinus
recalcitr
multipl
cours
antibiot
month
admit
hospit
complaint
right
eye
proptosi
diplopia
headach
right
facial
numbnessh
exam
consist
ipsilater
mild
optic
neuropathi
complet
sixth
vi
nerv
palsi
trigemin
ophthalm
maxillari
divis
numbnessct
mri
face
orbit
brain
reveal
extens
process
infiltr
ethmoid
maxillari
frontal
sinus
orbit
deep
facial
structureschest
ct
reveal
bilater
interstiti
nodul
symmetr
hilar
adenopathi
differenti
diagnos
includ
sarcoidosi
lymphomatumor
wegen
granulomatosi
fungal
infectionlabspurifi
protein
deriv
testneg
neg
antineutrophil
cytoplasm
autoantibodiesneg
angiotensin
convert
ul
fungal
anaerob
acidfast
bacilli
cultur
sinu
secretionsnegethmoid
adenoid
maxillari
sinu
biopsiesmultipl
nonnecrot
granuloma
basi
compat
clinic
radiograph
find
histopatholog
evid
exclus
diseas
similar
find
diagnosi
sarcoidosi
establish
start
parenter
methylprednisolon
subsequ
taper
oral
prednison
daysconcomitantli
start
methotrex
steroid
spare
agentmost
recent
chest
xray
month
treatment
reveal
near
complet
resolut
hilar
lymphadenopathyat
month
optic
neuropathi
facial
dysesthesia
resolv
left
mild
persist
vi
nerv
dysfunct
conclus
sarcoidosi
manifest
sinus
uncommon
present
mechan
involv
thought
consequ
destruct
cilia
mucu
produc
gland
granulomat
processreview
literatur
indic
eighth
case
report
illustr
high
index
suspicion
etiolog
must
maintain
refractori
respons
multipl
cours
antibiot
treatment
sinus
jb
hein
p
patel
l
bielori
newark
nj
introduct
cid
may
result
opportunist
infect
cryptococc
mening
present
unusu
case
cryptococc
mening
hivneg
patient
sever
lymphocytopenia
case
yearold
male
three
year
histori
sarcoidosi
present
acut
onset
rightsid
bodi
numb
patient
prednison
mgday
month
prior
present
ct
mri
scan
show
vascular
defect
mening
enhanc
hydrocephalu
mass
lesion
gallium
scan
reveal
normal
uptak
liver
spleen
mild
uptak
lung
nasopharyng
region
asymmetr
uptak
bilater
kidney
patient
initi
wbc
cellsmm
compos
neutrophilsmm
eosinophilsmm
basophilsmm
lymphocytesmm
basophilsmm
repeat
studi
reveal
total
lymphocyt
count
decreas
cellsmm
pan
b
cell
decreas
cellsmm
pan
cell
decreas
cellsmm
count
cellsmm
count
cellsmm
ratio
igg
level
normal
mgdl
elisa
neg
hiv
rna
pcr
detect
serum
ace
level
ul
csf
ace
level
ul
csf
obtain
lumbar
punctur
stain
posit
india
ink
cultur
reveal
cryptococcu
neoforman
patient
respond
amphotericin
b
lipid
complex
mgkgday
neurolog
statu
eventu
return
baselin
conclus
sever
lymphopenia
patient
caus
predisposit
infect
cryptococcu
neoforman
etiolog
profound
lymphopenia
like
multifactori
includ
mild
sarcoidosi
activ
lung
uptak
gallium
scan
chronic
corticosteroid
therapi
howev
cryptococcu
becam
entrench
patient
csf
infect
like
depress
peripher
lymphocyt
number
even
case
demonstr
import
explor
broad
differenti
diagnosi
face
lymphocytopenia
background
isosulfan
blue
common
dye
use
sentinel
lymph
node
dissect
usag
procedur
dye
increas
number
although
rare
sever
case
anaphylact
reaction
report
object
report
patient
anaphylact
reaction
isosulfan
blue
undergo
breast
cancer
excis
sentinel
lymph
node
biopsi
method
patient
yearold
woman
breast
cancer
underw
breast
mass
excis
sentinel
lymph
node
biopsi
use
lymphazurin
blue
dye
isosulfan
blue
histori
penicillin
induc
hive
drug
allergi
soon
dye
inject
becam
flush
hypotens
tachycard
hypotens
refract
fluid
challeng
treat
epinephrin
well
intraven
steroid
cimetidin
relief
symptom
subsequ
evalu
allergi
skin
test
isosulfan
blue
dilut
undilut
perform
use
histamin
posit
control
salin
neg
control
procedur
also
perform
two
control
subject
result
patient
posit
skin
test
wheal
flare
isosulfan
blue
undilut
control
appropri
posit
histamin
neg
salin
control
subject
neg
respons
dye
salin
posit
respons
histamin
conclus
isosulfan
blue
dye
may
caus
anaphylact
reaction
patient
undergo
sentinel
lymph
node
dissect
posit
skin
test
result
dye
plu
neg
skin
test
respons
control
suggest
reaction
may
immunoglobulin
e
ig
e
mediat
eosinophil
duoden
ed
glutensensit
enteropathi
gse
celiac
diseas
cd
distinct
clinic
entiti
welldefin
clinic
laboratori
paramet
ed
rare
condit
unknown
etiolog
manifest
eosinophil
infiltr
gastrointestin
tract
peripher
eosinophilia
gse
cd
form
nonig
food
allergi
caus
immun
hypersensit
ingest
gluten
simultan
occurr
two
entiti
howev
rare
event
follow
present
case
report
entiti
found
patient
yo
white
hispan
male
present
sever
chronic
colicki
abdomin
pain
headach
month
durat
hematolog
immunolog
studi
within
normal
limit
serum
ige
level
iuml
n
iuml
antiendosomi
ab
igg
antigliadin
uml
n
uml
skin
test
food
inhal
allergen
weakli
posit
biopsi
inferior
third
esophagu
reveal
chronic
moder
esophag
biopsi
gastric
antrum
reveal
lymphat
hyperplasia
duoden
biopsi
show
shorten
villi
presenc
eosinophil
follow
treatment
esomeprazol
mg
bid
famotidin
mg
qd
montelukast
md
qd
lactobacillu
diet
free
gluten
rofecoxib
mg
qd
betamethason
day
betamethason
patient
improv
partial
resolut
symptom
presenc
duoden
eosinophil
persist
despit
gluten
free
diet
continu
requir
repeat
burst
prednison
sinc
knowledg
rare
find
ed
occur
associ
gse
high
index
suspicion
simultan
occurr
ed
rais
case
gse
fail
respond
convent
gluten
free
regimen
report
evalu
month
old
male
present
pustular
rash
choke
episod
birth
age
week
experienc
two
pneumonia
one
fleet
infiltr
requir
intub
persist
eosinophilia
eosinophil
pustul
biopsi
note
persist
subsequ
rsv
pneumonia
recurr
drain
otiti
media
led
referr
physic
examin
show
thrive
male
infant
multipl
erythemat
papul
pustul
along
scalp
face
axilla
trunk
eosinophilia
confirm
quantit
immunoglobulin
abnorm
igg
ige
iuml
peanut
cap
rast
kual
hib
postvaccin
titer
cell
enumerationstimul
nbt
normal
hiv
test
stool
eosinophil
p
hemoccult
neg
cxr
hrct
ekg
echocardiogram
normal
pustul
cultur
bacteria
viru
fungu
neg
skin
biopsi
reveal
numer
eosinophil
pustul
dermi
epidermi
perifollicular
region
stain
neg
histiocyt
infiltr
nemo
defectincontinentia
pigmenti
consid
test
neg
karyotyp
xy
bone
marrow
biopsi
reveal
numer
eosinophil
differ
stage
matur
myeloprolif
neoplast
chang
bronchoscopi
remark
eosinophil
balf
ph
probe
imped
evalu
neg
egd
biopsi
normal
except
mild
eosinophil
infiltr
proxim
distal
esophagu
clinic
pictur
recurr
prurit
crop
steril
pustul
characterist
skin
biopsi
demonstr
eosinophil
infiltr
diagnosi
eosinophil
pustulosi
ep
childhood
made
despit
longterm
sequela
endorgan
involv
ep
degre
durat
eosinophilia
presenc
eosinophil
airway
esophagu
rais
concern
eosinophil
syndrom
follow
cardiac
cn
pulmonari
gi
system
warrant
infant
pneumonia
felt
due
aspir
ear
infect
result
humor
immun
nadir
drain
pustul
extern
auditori
canal
immunoglobulin
level
monitor
case
illustr
heterogen
eosinophil
diseas
rais
question
drive
mechan
behind
malign
benign
diseas
introduct
behcet
diseas
chronic
relaps
vasculit
diseas
character
recurr
oral
genit
gastrointestin
ulcer
wide
varieti
skin
lesion
uveiti
arthriti
pediatr
case
behcet
diseas
uncommon
estim
preval
children
age
although
diseas
children
show
similar
characterist
adult
diagnosi
behcet
diseas
pediatr
popul
remain
challeng
report
describ
year
old
girl
refer
pediatr
immunolog
clinic
evalu
recurr
pain
oral
ulcer
sinc
age
genit
ulcer
oral
ulcer
would
last
two
week
heal
spontan
would
reappear
week
later
patient
histori
raynaud
phenomenon
last
year
recent
onset
joint
pain
physic
examin
reveal
white
elliptoid
lesion
mm
diamet
erythemat
base
tongu
soft
palat
skin
examin
signific
hyperpig
patch
neck
abdomen
back
erythemat
serpigen
lesion
palm
punctuat
necrot
lesion
fingertip
pathergi
test
posit
laboratori
investig
unremark
cultur
oral
ulcer
remain
neg
patient
diagnos
juvenil
behcet
diseas
start
immunosuppress
therapi
low
dose
prednison
respond
conclus
behcet
diseas
difficult
diagnosi
make
pediatr
popul
case
demonstr
children
recurr
oral
ulcer
may
initi
manifest
behcet
import
clinic
marker
diseas
rational
relaps
polychondr
uncommon
sever
inflammatori
condit
unknown
etiolog
present
varieti
manner
report
year
old
patient
initi
present
sign
symptom
anaphylaxi
shellfish
later
diagnos
relaps
polychondr
case
report
year
old
africanamerican
boy
year
histori
asthma
fish
shrimp
allergi
present
pediatr
intens
care
unit
episod
sever
short
breath
symptom
start
shortli
accident
exposur
shrimp
intens
care
unit
note
wheez
stridor
initi
chest
xray
well
subsequ
fiber
optic
laryngoscopi
show
subglott
stenosi
intub
receiv
mechan
ventil
greater
week
extub
state
felt
fine
continu
demonstr
audibl
stridor
pulmonari
function
test
demonstr
extrathorac
obstruct
laryngoscopi
continu
show
subglott
stenosi
esophagogastroduodenoscopi
show
eros
esophag
consist
reflux
initi
lab
test
demonstr
normal
eosinophil
count
elev
ige
iuml
posit
immunocap
test
multipl
food
patient
discharg
home
minim
stridor
wheez
next
nine
month
sever
stridor
wax
wane
gener
worsen
spite
strict
elimin
diet
antireflux
therapi
receiv
emerg
tracheostomi
patient
admit
hospit
time
complain
bilater
knee
pain
well
signific
weight
loss
physic
exam
demonstr
arthriti
effus
knee
well
unilater
auricular
chondriti
bilater
episcler
antibodi
type
ii
collagen
posit
euml
diagnosi
relaps
polychondr
suggest
conclus
relaps
polychondr
rare
inflammatori
disord
cartilag
connect
tissu
unknown
etiolog
wide
array
present
complaint
well
relaps
natur
disord
often
caus
signific
delay
diagnosi
treatment
case
period
nine
month
initi
present
time
diagnosi
polychondr
could
made
dk
geller
ballow
buffalo
ny
introduct
yo
male
previous
diagnos
panda
present
immunolog
clinic
ivig
patient
healthi
age
develop
facial
motor
tic
associ
group
beta
hemolyt
strep
pharyng
treat
antibiot
tic
resolv
complet
multipl
recurr
associ
strep
viral
infect
tic
improv
resolv
complet
infect
free
histori
vocal
tic
attent
deficithyperact
disord
obsession
think
compuls
behavior
laboratori
multipl
throat
cultur
posit
group
beta
hemolyt
strep
posit
antistreptolysin
antideoxyribonucleas
b
titer
discuss
panda
identifi
subgroup
children
obsess
compuls
disord
andor
tic
disord
whose
symptom
seem
trigger
streptococc
infect
propos
pathophysiolog
immunemedi
mechan
antistreptococc
antibodi
antistreptolysin
antideoxyribonucleas
b
cross
react
basal
ganglia
genet
suscept
host
studi
look
immunomodulatori
therapi
includ
ivig
neuropsychiatr
symptom
includ
tic
disord
secondari
poststreptococc
autoimmun
plan
trial
ivig
patient
given
recurr
natur
tic
relat
streptococc
viral
infect
introduct
chronic
granulomat
diseas
cgd
inherit
disord
phagocyt
cell
respiratori
burst
result
lifethreaten
infect
pulmonari
infect
primari
caus
death
greater
case
role
surgeri
manag
entiti
remain
undefin
case
report
lobectomi
perform
yearold
male
present
persist
opac
medial
right
lobe
fever
cough
malais
rapid
onset
respiratori
failur
skin
abcess
concomit
familiar
histori
unremark
chest
tube
place
first
instanc
order
drain
empyema
progress
observ
ct
scan
show
necrot
pneumonia
right
lung
mediastin
retroperiton
limphadenopathi
bronchopleur
fistula
second
surgic
intervent
undertaken
correct
fistula
pleural
debrid
done
time
serratia
marcens
isol
blood
cultur
lung
primari
immunodefi
suspect
evalu
show
nbt
reduct
dyhidrorhodamin
assay
dhra
nt
demonstr
effect
oxid
burst
subsecu
manag
base
specif
antibiot
serratia
prophylaxi
tmpsmz
itraconazol
transfer
factor
improv
ifn
level
initi
patient
mother
show
dhra
two
granulocyt
popul
without
oxid
burst
x
link
cgd
consist
medic
progress
observ
next
day
conclus
despit
poor
util
show
surgic
procedur
complic
pneumonia
cgd
patient
mani
seri
attend
unusu
natur
pulmonari
infect
high
mortal
morbid
associ
thorac
surgeri
manag
case
show
aggress
approach
diagnosi
combin
procedur
use
immunocompet
patient
pneumonia
may
improv
clinic
condit
cgd
patient
background
takayasu
arter
larg
vessel
vascul
primarili
affect
aorta
branch
preval
women
second
third
decad
life
initi
symptom
system
often
selflimit
diseas
may
progress
undetect
year
sign
vascular
insuffici
develop
arter
commonli
seen
aortic
arch
branch
although
diseas
panarter
vascular
compromis
occur
mani
organ
patholog
involv
vessel
show
intim
prolifer
fibrosi
scar
elast
lamina
case
report
report
case
year
old
southeast
asian
woman
present
diplopia
ptosi
dizzi
progress
dyspnea
past
medic
histori
signific
rheumat
fever
complic
aortic
valv
insuffici
hypertens
physic
find
admiss
includ
hypertens
asymmetr
upper
extrem
blood
pressur
left
arm
hg
right
arm
mm
annal
allergi
asthma
immunolog
hg
wide
puls
pressur
harsh
diastol
murmur
admiss
lab
show
anemia
hemoglobin
hematocrit
elev
erythrocyt
sediment
rate
transesophag
echocardiographi
reveal
sever
dilat
aortic
root
aneurysm
secondari
sever
chronic
aortic
valv
insuffici
calcifi
aortic
leaflet
typic
rheumat
heart
diseas
resect
aortic
valv
aneurysm
perform
patholog
examin
aortic
aneurysm
reveal
intim
adventiti
fibrosi
focal
chronic
inflamm
partial
loss
fibrosi
media
find
compat
heal
takayasu
arter
patient
start
prednison
mouth
daili
takayasu
arter
discharg
stabl
condit
discuss
case
takayasu
arter
masquerad
rheumat
heart
diseas
episod
rheumat
fever
like
initi
present
takayasu
arter
system
symptom
diseas
overlap
takayasu
arter
insidi
diseas
often
lead
delay
diagnosi
consider
morbid
patient
sinc
takayasu
arter
may
go
undiagnos
ischem
symptom
develop
physician
alert
possibl
diseas
young
women
avert
end
organ
damag
achiev
earli
remiss
drug
therapi
present
fifteen
year
old
boy
dissemin
papillomatosi
idiopath
lymphocytopenia
icl
wart
present
sinc
one
year
old
progress
worsen
fifti
wart
hand
leg
multipl
wart
ten
wart
recent
appear
lip
around
mouth
past
medic
histori
signific
hospit
blood
transfus
never
problem
infect
benign
cours
chicken
pox
spontan
resolv
cimetidin
six
month
without
improv
sever
topic
therapi
includ
imiquimod
fail
total
lymphocyt
count
normal
rang
count
normal
rang
natur
killer
cell
cell
normal
hiv
test
neg
serum
immunoglobulin
normal
well
lymphocty
prolifer
studi
reveal
absent
respons
antigen
candida
tetanu
normal
respons
mitogen
studi
show
caus
lymphocytopenia
case
show
diagnosi
idiopath
lymphocytopenia
consid
patient
widespread
viral
infect
whose
hiv
test
neg
appropri
evalu
count
pursu
j
ko
nowakwegrzyn
new
york
ny
introduct
approxim
children
moder
sever
atop
dermat
ad
food
allergi
complementari
altern
medicin
cam
util
estim
patient
allergi
present
case
yearold
boy
ad
refer
receiv
diagnosi
food
allergi
cam
practition
methodscas
yearold
boy
refer
evalu
mild
ad
possibl
food
hypersensit
ad
start
year
age
limit
face
initi
breastf
switch
milkbas
formula
month
age
solid
introduc
month
age
without
difficulti
immedi
reaction
note
worsen
ad
due
food
patient
present
naturopath
allergi
evalu
base
electroderm
skin
test
result
report
allerg
milk
egg
peanut
rice
beef
toler
previous
restrict
milk
egg
week
without
notic
chang
ad
limit
cheek
control
topic
pimecrolimu
result
weight
height
percentil
physic
exam
normal
except
cm
dri
erythemat
patch
cheek
mildli
dri
skin
flexorextensor
surfac
arm
skin
prick
test
reveal
neg
test
milk
egg
peanut
dust
mite
serum
ige
test
also
neg
sinc
evid
ige
sensit
commonli
allergen
food
recommend
continu
unrestrict
diet
discontinu
use
sippi
cup
ad
subsequ
improv
skin
care
regimen
postbath
moistur
topic
pimecrolimu
prn
asthma
allergi
reason
cam
use
us
electroderm
skin
test
method
util
naturopath
doctor
detect
allergen
sensit
howev
two
doubleblind
trial
examin
atop
nonatop
patient
electroderm
test
correl
skin
prick
test
result
regardless
interoper
variabl
conclus
allergi
patient
seek
cam
treatment
import
physician
awar
safeti
efficaci
altern
medic
practic
use
electroderm
skin
test
proven
detect
allergen
sensit
use
modal
discourag
ee
mcginte
ke
sullivan
philadelphia
pa
introduct
hematopoiet
stemcel
transplant
caus
profound
tcell
immunodefici
due
rigor
condit
involv
follow
transplant
tcell
compart
initi
reconstitut
expans
matur
donorderiv
tcell
howev
thymopoiesi
necessari
gener
naiv
tcell
divers
repertoir
factor
affect
thymic
function
impact
abil
bodi
reconstitut
immun
system
report
case
sever
tcell
immunodefici
two
stemcel
transplant
neuroblastoma
patient
histori
thymic
hemorrhag
secondari
mediastin
surgeri
case
femal
histori
highrisk
neuroblastoma
refer
immunolog
evalu
due
signific
infecti
histori
sinc
complet
neuroblastoma
therapi
initi
present
month
age
right
atrial
mass
presum
atrial
myxoma
underw
mediastin
surgeri
resect
tumor
found
neuroblastoma
extend
right
adren
gland
along
vena
cava
ct
scan
follow
surgeri
reveal
area
hemorrhag
right
thymu
subsequ
receiv
highdos
chemotherapi
two
autolog
stemcel
transplant
infect
histori
signific
multipl
episod
upper
respiratori
ill
sinus
otiti
media
requir
myringotomi
tube
placement
two
occas
immunolog
evalu
reveal
dramat
low
absolut
lymphocyt
count
deficit
primarili
tcell
compart
reduc
prolifer
respons
mitogen
immunoglobulin
level
normal
form
protect
titer
diphtheria
tetanu
pneumococc
serotyp
conclus
stemcel
transplant
often
result
sever
tcell
immunodefici
thymu
play
import
role
reconstitut
tcell
compart
naiv
tcell
gener
hematopoiet
stemcel
restor
tcr
divers
case
illustr
damag
thymu
significantli
impair
abil
reconstitut
tcell
compart
ak
knight
c
cunninghamrundl
new
york
ny
rational
first
case
report
oxcarbazepin
induc
immunoglobulin
defici
method
yo
white
femal
refer
investig
low
serum
immunoglobulin
found
part
evalu
chronic
bacteri
vagin
take
oxcarbazepin
chronic
pain
discontinu
immunoglobulin
level
b
cell
number
test
interv
specif
antibodi
respons
pneumococc
vaccin
test
result
present
oxcarbazepin
immunoglobulin
level
low
igg
iga
igm
mgdl
b
cell
defici
b
cell
normal
cellscu
mm
antibodi
respons
one
month
pneumococc
vaccin
poor
protect
antibodi
serotyp
protect
antibodi
respons
pneumococc
serotyp
continu
iga
defici
conclus
patient
initi
evalu
suggest
diagnosi
common
variabl
immun
defici
hypogammaglobulinemia
specif
antibodi
defici
howev
defect
revers
oxcarbazepin
discontinu
unclear
persist
iga
defici
preexist
condit
possibl
predispos
advers
reaction
oxacarbazepin
induc
oxacarbazepin
immunoglobulin
defici
known
though
rare
reaction
carbazepin
parent
drug
oxacarbazepin
advers
reaction
occur
deriv
oxcarbazepin
well
secondari
hypogammaglobulinemia
consid
diagnos
primari
immunodefi
cvid
commit
patient
lifelong
immunoglobulin
therapi
introduct
interferon
glatiram
acet
copaxon
indic
treatment
relapsingremit
multipl
sclerosi
ms
anaphylact
reaction
report
rare
complic
interferon
copaxon
use
report
case
interferon
rebif
copaxon
hypersensit
associ
posit
skin
test
desensit
interferon
betaseron
case
report
patient
yearold
woman
asthma
allerg
rhiniti
diagnos
ms
oct
uncompl
pregnanc
subsequ
place
rebif
one
month
start
therapi
patient
develop
wheez
gener
urticaria
receiv
dose
rebif
symptom
recur
next
day
neurologist
stop
rebif
start
copaxon
two
month
later
develop
episod
gener
urticaria
patient
evalu
center
underw
skin
test
interferon
intramuscular
avonex
interferon
subcutan
rebif
betaseron
copaxon
posit
skin
prick
reaction
copaxon
posit
intraderm
skin
test
avonex
strength
rebif
betaseron
hr
intraderm
reaction
interferon
formul
continu
progress
upto
hr
neurologist
felt
would
benefit
betaseron
therapi
posit
intraderm
skin
test
betaseron
suffici
warrant
desensit
prevent
immedi
hypersensit
reaction
underw
subcutan
desensit
shown
tabl
desensit
halt
minut
patient
develop
itch
hand
return
hr
restart
administ
ml
strength
betaseron
increas
dose
given
patient
receiv
full
therapeut
dose
mg
ml
sinc
done
well
daili
dose
betaseron
mil
unit
conclus
report
ms
patient
develop
urticaria
asthma
exacerb
respons
rebif
urticaria
copaxon
skin
test
confirm
igemedi
allerg
reaction
underw
success
desensit
betaseron
knowledg
report
desensit
betaseron
well
extens
previou
report
case
system
reaction
interferon
copaxon
pentoxifyllin
ptx
phosphodiesteras
inhibitor
use
ischem
vascular
diseas
effect
red
blood
cell
platelet
use
system
inflammatori
diseas
sarcoidosi
abil
inhibit
product
cytokin
tumor
necrosi
factor
tnfa
decid
offer
trial
patient
chronic
urticaria
sinc
agent
increas
intracellular
camp
shown
inhibit
mast
cell
degranul
report
case
yearold
femal
histori
allerg
rhiniti
hypothyroid
diabet
mellitu
recurr
episod
chronic
urticaria
sinc
adolesc
known
allergi
variou
antibiot
otherwis
unremark
histori
famili
histori
social
histori
treat
fexofenadin
qd
azelastin
nasal
spray
zafirlukast
bid
hydroxychloroquin
bid
levothyroxin
qd
doxepin
qh
metformin
bid
spironolacton
qd
time
initi
evalu
physic
exam
notabl
scatter
cm
urticari
skin
lesion
well
area
hypo
hyperpigment
previou
excori
nasal
turbin
mildli
congest
dull
membran
previou
skin
biopsi
show
urticaria
increas
number
mast
cell
workup
includ
normal
cbc
urinalysi
spep
complet
chemistri
profil
well
neg
ana
antithyroid
antibodi
pentoxifyllin
tid
ad
patient
regimen
urticaria
resolv
within
week
longer
visibl
month
followup
pentoxifyllin
safe
medic
side
effect
may
benefit
patient
chronic
urticaria
via
sever
mechan
includ
inhibit
mast
cell
degranul
secret
variou
cytokin
chemokin
benefici
effect
pentoxifyllin
treatment
patient
urticaria
seen
patient
studi
indic
determin
patient
urticaria
like
benefit
pentoxifyllin
well
elucid
mechan
action
pentoxifyllin
amelior
symptom
chronic
urticaria
cm
mjaan
boguniewicz
denver
co
report
case
male
sinc
age
year
suffer
recurr
episod
left
tongu
swell
onset
swell
usual
abrupt
gener
occur
night
awaken
sleep
describ
sensat
pain
tongu
deni
pruritu
throat
lip
eyelid
swell
cough
dyspnea
wheez
rash
itchywateri
eye
episod
occur
infrequ
approxim
everi
spring
tend
resolv
spontan
within
hour
howev
occas
swell
last
day
patient
current
episod
present
week
progress
today
report
pain
increas
swell
child
report
benefit
oral
antihistamin
treat
dexamethason
initi
episod
experienc
gradual
resolut
swell
never
treat
topic
system
epinephrin
addit
cours
system
steroid
famili
histori
angioedema
child
refer
evalu
immunologicallerg
etiolog
unilater
tongu
swell
laboratori
studi
obtain
earli
cours
current
episod
reveal
follow
level
mgdl
level
mgdl
level
mugml
level
mugml
esteras
inhibitor
function
normal
esteras
inhibitor
level
mgdl
unitsml
ana
neg
betatryptas
ngml
total
tryptas
ngml
normal
initi
evalu
reveal
mark
swell
along
erythemat
violac
discolor
left
later
anterior
portion
child
tongu
remaind
examin
normal
patient
refer
pediatr
otolaryngolog
clinic
presumpt
diagnosi
glossal
hemangioma
versu
lymphangioma
underw
magnet
reson
imag
studi
reveal
poorli
defin
masslik
enlarg
anterior
left
aspect
tongu
treat
five
day
cours
prednisolon
initi
regress
lesion
plan
surgic
excis
carri
without
complic
conclus
rare
case
illustr
uniqu
present
glossal
hemangioma
present
recurr
angioedema
highlight
differenti
diagnos
laboratori
studi
clinic
featur
oropharyng
swell
sever
tongu
swell
rare
skin
condit
leprosi
need
consid
differenti
diagnosi
appar
urticaria
angioedema
atyp
appear
respons
therapi
year
old
male
origin
lao
present
chronic
recurr
nonprurit
indur
plaqu
face
trunk
refer
allergi
primari
physician
diagnosi
urticaria
angioedema
rule
allerg
reaction
food
otherwis
healthi
medic
neg
person
famili
histori
atopi
move
unit
state
southeast
asia
visit
sever
week
treat
prednison
hydroxyzin
without
benefit
skin
test
food
neg
cbc
differenti
sediment
rate
antinuclear
antibodi
liver
function
test
normal
neg
skin
punch
biopsi
indur
area
back
show
granuloma
cluster
acidfast
organ
afb
stain
consist
tuberculoid
leprosi
patient
defici
could
treat
dapson
treat
altern
minocyclin
rifampin
clofazimin
mg
daili
subsequ
start
prednison
determin
revers
reaction
lesion
continu
improv
patient
rare
condit
leprosi
confus
urticaria
angioedema
patient
present
atyp
appar
urticaria
angioedema
especi
respons
standard
pharmacolog
treatment
poor
skin
biopsi
indic
may
diagnost
case
introduct
cutan
flush
face
toddler
within
minut
eat
specif
food
prompt
parent
clinician
alik
pursu
food
allergi
test
auriculotempor
syndrom
also
known
frey
syndrom
isol
transient
facial
erythema
distribut
auriculotempor
nerv
follow
mastic
report
child
refer
food
allergi
test
diagnos
auriculotempor
syndrom
case
histori
yo
wf
prior
fullterm
forcepsassist
deliveri
histori
facial
flush
within
minut
follow
ingest
specif
food
flush
induc
varieti
food
specif
spaghetti
cracker
potato
chip
hard
candi
typic
resolv
within
minut
eat
child
respiratori
gastrointestin
distress
flush
episod
angioedema
urticaria
rash
elsewher
bodi
within
ten
minut
eat
lollipop
clinic
erythemat
warm
macular
erupt
appear
bandlik
region
anterior
ear
extend
tempor
bone
mandibl
respons
occur
bilater
mildli
greater
intens
right
side
face
sweat
symptom
develop
flush
began
diminish
thirti
minut
observ
discuss
auriculotempor
syndrom
commonli
seen
patient
undergon
facial
surgeri
specif
parotid
gland
believ
secondari
disrupt
fiber
auriculotempor
nerv
theoriz
nerv
regener
follow
injuri
may
join
parasympathet
fiber
salivari
gland
sympathet
fiber
eccrin
sweat
gland
mastic
could
result
flush
sweat
cutan
distribut
auriculotempor
nerv
extend
tempor
region
mandibl
anterior
ear
although
rare
children
auriculotempor
syndrom
associ
forcep
deliveri
therapi
seldom
benefit
need
syndrom
often
resolv
spontan
mani
year
conclus
auriculotempor
syndrom
lead
cutan
erupt
tempor
relat
ingest
food
allergist
maintain
awar
rare
syndrom
minim
food
allergi
test
elimin
unnecessari
food
provoc
challeng
restrict
diet
alahmad
ss
mace
toronto
canada
introduct
ranitidin
wellknown
antagonist
anaphylact
reaction
seldom
report
despit
widespread
use
drug
report
patient
anaphylact
reaction
ranitidin
method
report
case
anaphylact
reaction
ranitidin
result
femal
histori
urticaria
one
year
period
present
episod
anaphylact
reaction
increas
sever
year
ranitidin
ingest
first
two
episod
occur
one
hour
ranitidin
ingest
began
sensat
burn
itch
head
follow
dizzi
hypotens
near
loss
conscious
patient
signific
pulmonari
laryng
symptom
fourth
episod
occur
minut
take
ranitidin
tablet
character
sever
hypotens
two
episod
manag
emerg
depart
skin
prick
test
crush
ranitidin
tablet
demonstr
posit
mm
wheal
respons
neg
control
investig
carcinoid
syndrom
system
mastocytosi
neg
conclus
ige
mediat
allergi
ranitidin
possibl
anaphylactoid
reaction
ranitidin
well
recogn
entiti
howev
knowledg
case
anaphylact
reaction
ranitidin
describ
hypersensit
reaction
ranitidin
consid
patient
suspect
drugrel
allergi
introduct
sever
combin
immun
defici
scid
cystic
fibrosi
cf
may
present
infanc
histori
failur
thrive
diarrhea
recurr
respiratori
infect
although
cf
common
genet
diseas
occur
caucasian
incid
birth
scid
rare
condit
estim
occur
birth
report
case
xlink
scid
diagnosi
cf
origin
entertain
due
similar
present
mislead
laboratori
result
case
caucasian
male
month
histori
recurr
respiratori
ill
fever
loos
stool
thick
nasal
discharg
failur
thrive
second
admiss
respiratori
infect
relev
lab
result
consist
cultur
grew
parainfluenza
viru
np
wash
pseudomona
aeruginosa
deep
throat
cultur
chest
xray
show
patchi
infiltr
borderlin
sweat
test
mmoll
despit
treat
broad
spectrum
antibiot
coverag
albuterol
pulmozym
respiratori
symptom
improv
physic
exam
reveal
thin
infant
palpabl
though
small
lymph
node
cervic
groin
diffus
scatter
rhonchi
liver
edg
palpabl
cm
costal
margin
quant
immunoglobulin
obtain
result
igg
iga
igm
review
chest
xray
signific
absent
thymic
shadow
lymphocyt
count
sinc
admiss
rang
flow
cytometri
reveal
count
count
lymphocyt
tcell
stimul
test
markedli
diminish
antigen
mitogen
presum
diagnosi
xlink
scid
made
patient
undrew
haploident
bone
marrow
transplant
subsequ
cf
gene
analysi
result
neg
discuss
outlin
case
essenti
recogn
similar
present
symptom
cf
rel
common
genet
diseas
scid
uncommon
one
although
pseudomona
seen
increas
frequenc
patient
cf
essenti
recogn
also
lead
pathogen
affect
patient
antibodi
defici
review
literatur
reveal
previou
case
individu
scid
report
increas
sweat
chlorid
explan
would
occur
immunodefici
previous
associ
form
dwarfism
report
first
describ
case
common
variabl
immun
defici
patient
seckel
syndrom
bird
head
dwarfism
diagnosi
seckel
dwarfism
autosom
recess
disord
made
month
age
boy
base
intrauterin
growth
retard
proport
dwarfism
microcephali
micrognathia
narrow
face
birdlik
larg
eye
beak
nose
hematolog
abnorm
report
estim
patient
child
develop
thrombocytopenia
age
year
age
pancytopenia
hypocellular
bone
marrow
low
count
note
bactrim
neupogen
begun
signific
infect
rotaviru
salmonella
gastroenter
occur
time
along
frequent
otiti
lead
pe
tube
placement
age
subsequ
resolv
never
opportunist
infect
thrush
age
year
requir
monthli
red
cell
transfus
sever
anemia
sever
month
transfus
blood
bank
report
longer
detect
blood
group
antibodi
crossmatch
led
measur
immunoglobulin
igm
undetect
low
iga
mgdl
low
igg
mgdl
demonstr
protect
titer
pneumococc
serotyp
either
conjug
unconjug
pneumococc
vaccin
respons
diphtheria
tetanu
rubeola
influenza
vaccin
adequ
total
hemolyt
complement
normal
remain
lymphocytopen
alc
low
five
dose
ivig
monthli
platelet
remain
kul
improv
anemia
although
mechan
bone
marrow
failur
patient
presum
chromosom
breakag
demonstr
child
karyotyp
chromosom
fragil
delet
detect
date
hypogammaglobulinemia
investig
patient
undergo
frequent
transfus
lose
blood
group
antibodi
suspicion
immun
defici
remain
particularli
high
patient
sever
growth
retard
dwarfism
nl
rider
craig
hershey
pa
object
studi
assess
effect
physician
univers
primari
care
clinic
diagnos
manag
adult
patient
asthma
retrospect
chart
review
adult
patient
clinic
perform
chart
evalu
use
survey
instrument
develop
nation
asthma
educ
prevent
program
naepp
consist
queri
chart
evalu
met
entri
criteria
overal
complianc
naepp
recommend
adher
asthma
guidelin
follow
area
diagnosi
treatmentdiseas
control
monitor
educ
data
suggest
opportun
improv
care
provid
patient
asthma
especi
area
asthma
educ
monitor
even
univers
outpati
facil
data
also
suggest
naepp
guidelin
effect
incorpor
primari
care
practic
bm
wahler
l
sherwood
craig
hershey
pa
object
aim
evalu
adher
nation
heart
lung
blood
institut
nhlbi
nation
asthma
educ
prevent
program
naepp
diagnosi
manag
guidelin
regard
asthma
admiss
teach
hospit
method
retrospect
chart
review
patient
age
year
admit
hershey
medic
center
primari
diagnosi
asthma
asthma
exacerb
conduct
use
questionnair
focus
key
aspect
asthma
care
outlin
naepp
guidelin
result
overal
complianc
guidelin
maxim
area
complianc
note
regard
pharmacolog
treatment
util
much
lower
level
complianc
note
area
patient
educ
instruct
written
action
plan
prior
discharg
provis
peak
flow
meter
home
use
assess
asthma
symptom
sever
inhal
steroid
prescript
discharg
conclus
adequ
care
term
pharmacolog
treatment
given
suboptim
care
area
guidelin
exist
continu
room
improv
regard
asthma
manag
notabl
area
educ
document
trigger
prepar
discharg
adequ
tool
monitor
control
symptom
background
asthma
one
common
problem
childhood
respons
signific
proport
absenc
school
chronic
ill
object
studi
carri
among
schoolag
children
year
tehran
school
order
determin
frequenc
asthma
method
accord
recommend
questionnair
design
contain
standard
question
student
given
necessari
inform
complet
questionnair
guidanc
high
school
student
complet
questionnair
parent
primari
school
student
complet
result
seven
hundr
eight
children
children
asthma
preval
higher
boy
compar
girl
preval
diseas
estim
guidanc
school
high
school
primari
student
base
survey
common
clinic
manifest
asthma
includ
prolong
cough
last
day
exerciseinduc
wheez
dyspnea
follow
repeat
dyspnea
wheez
base
drug
respons
receiv
solbutamol
preval
asthma
evalu
rang
primari
school
guidanc
school
high
school
conclus
preval
asthma
high
among
student
tehran
school
need
care
screen
programm
either
inform
given
patient
parent
diseas
us
asthma
common
chronic
diseas
childhood
affect
approxim
million
children
reason
inadequ
asthma
control
includ
inappropri
therapi
incorrect
inhal
techniqu
poor
complianc
treatment
exposur
environment
trigger
rate
asthma
preval
hospit
death
highest
among
children
resid
inner
citi
import
risk
factor
asthmarel
mortal
includ
poor
black
commun
braddock
north
braddock
rankin
among
poorest
allegheni
counti
design
area
greatest
health
risk
recent
statist
demonstr
increas
number
asthma
hospit
commun
children
per
doubl
averag
allegheni
counti
greater
seventim
overal
us
rate
asthma
hospit
goal
assess
asthmat
sever
appropri
treatment
provid
asthma
educ
ensur
access
healthcar
asthmat
children
live
medic
underserv
predominantli
africanamerican
commun
twentyseven
asthmat
children
identifi
children
assess
age
year
age
year
year
age
base
nhlbi
guidelin
sever
child
asthma
determin
mildintermitt
asthma
mildpersist
asthma
moderatepersist
asthma
severepersist
asthma
appropri
treatment
base
sever
also
determin
found
children
mildintermitt
asthma
children
mildpersist
asthma
children
moderatepersist
asthma
children
severepersist
asthma
receiv
inappropri
treatment
furthermor
inappropri
treat
children
undertr
follow
assess
patient
parent
educ
regard
asthma
trigger
pathophysiolog
use
peak
flow
meter
inhal
techniqu
pharmacolog
treatment
patient
also
schedul
outpati
followup
care
result
demonstr
inappropri
treatment
especi
undertreat
may
signific
caus
increas
asthma
morbid
popul
underscor
need
aggress
educ
innov
method
ensur
health
care
w
lile
kengleong
fc
stephani
e
philip
singapor
background
asthma
admiss
import
indic
asthma
morbid
littl
known
risk
factor
associ
asthma
admiss
among
highrisk
asthmat
purpos
characteris
profil
highrisk
asthmat
previou
asthma
hospit
identifi
predictor
risk
factor
associ
asthma
hospit
method
data
consecut
highrisk
asthmat
enrol
asthma
program
octob
may
retriev
prospect
databas
highrisk
asthmat
defin
patient
clinic
diagnosi
asthma
least
one
hospit
admiss
exacerb
asthma
preced
month
least
one
sever
exacerb
asthma
preced
month
requir
unschedul
visit
nebulis
comparison
made
among
highrisk
asthmat
least
one
hospit
asthma
past
month
prior
asthma
program
enrol
hospit
statist
analys
perform
use
spss
version
window
result
among
highrisk
asthmat
least
one
asthma
hospit
past
month
prior
enrol
asthma
program
hospit
significantli
associ
femal
gender
asthma
admiss
v
without
asthma
admniss
significantli
higher
proport
asthmat
formal
educ
v
primari
educ
v
secondari
educ
v
hospit
asthma
compar
tertiari
educ
v
admit
predominantli
lower
incom
group
poor
inhal
techniqu
ownership
asthma
action
plan
v
hospit
also
younger
median
age
v
lower
first
peak
flow
read
v
conclus
among
highrisk
asthmat
certain
popul
subgroup
greater
risk
hospit
asthma
intervent
aim
reduc
asthma
morbid
take
find
consider
introduct
associ
asthma
symptom
air
qualiti
well
establish
controversi
exist
concern
role
variou
air
qualiti
indic
associ
san
antonio
air
qualiti
emerg
depart
ed
visit
asthma
militari
medic
center
defin
object
studi
determin
correl
select
air
qualiti
indic
san
antonio
ed
visit
asthma
gener
popul
pediatr
popul
method
select
air
qualiti
indic
air
qualiti
index
aqi
ozon
aqi
particul
matter
pollen
count
mold
spore
count
daili
high
temperatur
number
daili
ed
visit
code
asthma
obtain
retrospect
pediatr
visit
patient
yearsold
evalu
subgroup
pearson
correl
coeffici
r
calcul
data
pair
result
day
studi
period
visit
asthma
visit
pediatr
number
daili
visit
rang
visit
pediatr
visit
r
valu
visit
pediatr
visit
aqi
ozon
aqi
particul
matter
total
pollen
grainsm
mold
sporesm
daili
high
temperatur
respect
addit
calcul
r
valu
sameday
air
qualiti
indic
ed
visit
r
valu
also
calcul
averag
air
qualiti
indic
ed
visit
averag
r
valu
visit
pediatr
visit
averag
aqi
ozon
aqi
particul
matter
total
pollen
grainsm
mold
sporesm
daili
high
temperatur
respect
conclus
signific
correl
select
air
qualiti
indic
ed
visit
asthma
either
gener
popul
pediatr
visit
studi
provid
evid
air
qualiti
link
ed
visit
asthma
san
antonio
degre
air
qualiti
san
antonio
affect
asthma
symptom
remain
unclear
introduct
aim
studi
evalu
level
exhal
air
patient
suffer
chronic
cough
method
studi
perform
young
mean
age
year
nonsmok
patient
chronic
cough
refer
allergi
clinic
evalu
bronchial
provoc
challeng
histamin
perform
accord
method
ryan
exhal
measur
onlin
use
chemiluminesc
analyz
siever
usa
patient
rest
spirometri
within
normal
valu
result
signific
bronchoconstrict
respons
histamin
concentr
equal
lower
mgml
found
patient
patient
significantli
greater
mean
concentr
exhal
air
ppb
ppb
p
receiv
oper
characterist
roc
curv
analysi
reveal
possibl
identifi
among
patient
suffer
chronic
cough
signific
bronchial
hyperreact
use
ppb
cutoff
valu
exhal
concentr
specif
bronchial
hyperreact
sensit
conclus
assess
concentr
help
assess
bronchial
hyperreact
patient
chronic
cough
l
abetz
j
bousquet
e
junip
e
bateman
h
boushey
w
buss
clark
r
pauwel
pedersen
manchest
unit
kingdom
montpeli
franc
ancast
canada
cape
town
south
africa
san
francisco
ca
madison
wi
london
unit
kingdom
ghent
belgium
kold
denmark
introduct
acq
develop
measur
asthma
control
use
clinic
practic
clinic
trial
reliabl
valid
respons
previous
demonstr
origin
item
acq
item
minu
question
item
minu
short
act
bronchodil
use
question
version
data
gain
optim
asthma
control
goal
studi
use
assess
predict
valu
acq
item
version
determin
asthma
control
statu
method
receiv
oper
characterist
curv
roc
curv
plot
true
posit
rate
versu
fals
posit
rate
differ
acq
cutpoint
use
determin
optimum
cut
point
total
control
wellcontrol
asthma
score
item
version
acq
examin
interv
result
predict
total
control
asthma
area
roc
curv
arocc
item
version
respect
predict
wellcontrol
asthma
arocc
item
version
predict
model
item
version
provid
best
arocc
item
version
best
cutoff
point
predict
total
control
asthma
arocc
correspond
sensit
specif
respect
item
version
best
cutoff
point
arocc
sensit
specif
best
cutoff
point
predict
wellcontrol
asthma
item
version
point
item
version
respect
conclus
result
indic
sensit
specif
acq
predict
asthma
control
statu
yo
black
male
asthma
allerg
rhiniti
develop
gradual
worsen
cough
product
clear
yellow
sputum
despit
treatment
high
dose
fluticason
salmeterol
monteleukast
prn
albuterol
asthma
histori
signific
intub
age
pneumonia
age
physic
exam
reveal
pale
turbin
expiratori
wheez
pulmonari
function
test
show
sever
obstruct
lung
defect
improv
bronchodil
ratio
chest
ct
reveal
signific
bronchiectasi
right
middl
lobe
lingula
lower
lobe
evalu
bronchiectasi
show
normal
quantit
immunoglobulin
subclass
humor
respons
render
innat
immunodefici
less
like
diagnosi
allerg
bronchopulmonari
aspergillosi
entertain
ige
aspergillu
titer
neg
sinu
ct
fail
show
activ
diseas
yet
patient
report
chronic
yellow
nasal
discharg
despit
cours
antibiot
although
sexual
activ
sever
male
partner
hiv
test
neg
time
month
apart
evalu
cystic
fibrosi
cf
show
symptom
malabsorpt
neg
sweat
test
test
reveal
normal
antitrypsin
level
panca
esr
ace
level
neg
sputum
afb
mycobacteria
help
exclud
condit
defici
vascul
sarcoidosi
chronic
infect
definit
answer
diagnosi
cf
pursu
genet
screen
well
map
neg
diagnosi
primari
ciliari
dyskinesia
entertain
howev
mucos
biopsi
nose
reveal
structur
abnorm
final
sperm
analysi
reveal
azoospermia
confirm
diagnosi
young
syndrom
rare
diseas
featur
similar
cf
includ
bronchiectasi
chronic
sinus
azoospermia
young
syndrom
howev
obstruct
process
rather
lack
va
deferen
result
azoospermia
normal
sweat
chlorid
genet
pancreat
test
case
demonstr
import
investig
persist
product
cough
asthmat
patient
differenti
diagnosi
well
appropri
work
bronchiectasi
final
diagnosi
import
sinc
appropri
manag
situat
may
affect
long
term
outcom
ag
palmacarlo
ml
palmacarlo
lisboa
portug
introduct
bronchial
challeng
current
done
allerg
asthma
allergen
histamin
metacholinebronchi
reactiv
allergen
histamin
probabl
variabl
purpos
evalu
dose
allergen
histamin
trigger
signific
bronchial
obstruct
alway
correl
asthmat
patient
method
vitalograph
model
compact
use
throughout
studi
allergen
challeng
done
acqueou
solut
hous
dust
mite
bronchial
challeng
placebo
sodium
chlorid
histamin
allergen
done
patient
provoc
histamin
allergen
threshold
dose
induc
decreas
greater
determin
case
well
histamin
allergen
second
challeng
done
patient
suprathreshold
dose
histamin
allergen
correspond
doubl
threshold
result
provoc
done
patient
either
histamin
allergen
allerg
non
allerg
threshold
dose
histamin
ug
allerg
patient
ug
non
allerg
patientsin
allerg
patient
histamin
threshold
challeng
mean
decreas
suprathreshold
dose
decreas
allergen
challeng
decreas
supra
threshold
dose
decreas
non
allerg
patient
chang
allergen
challeng
good
correl
constrict
induc
histamin
allergen
either
threshold
supra
threshold
dose
p
observ
threshold
dose
histamin
allergen
conclus
result
confirm
bronchial
obstruct
trigger
allergen
mediat
sensit
evalu
roughli
compar
challeng
point
better
sensit
supra
threshold
dose
allergen
mediat
allergen
histamin
challeng
nt
give
inform
introduct
peak
expiratori
flow
rate
pfr
forc
expiratori
volum
first
second
current
use
function
evalu
asthmat
patient
degre
correl
obstruct
restrict
mix
spirometr
ventilatori
pattern
well
known
purpos
studi
evalu
correl
pfr
marker
global
airway
obstruct
compar
asthmat
patient
obstruct
restrict
method
asthmat
patient
male
femal
studi
spirometri
vitalograph
compact
absenc
bronchodilatori
antiinflammatori
therapi
patient
classifi
function
pattern
accord
vc
normal
vc
greater
expect
valu
greater
obstruct
vc
greater
greater
restrict
vc
less
greater
mix
vc
less
less
present
call
function
emphysema
result
accord
criteria
patient
normal
restrict
obstruct
mix
group
correl
pfr
statisc
signific
p
correl
coeffici
variabl
function
normal
patient
r
restrict
patient
obstruct
mix
subgroup
function
emphysema
subgroup
correl
coeffici
r
allow
defin
pfr
conclus
report
two
usual
assay
global
bronchial
obstruct
depend
balanc
restrict
either
intersti
fibrosi
hyperinfl
obstruct
close
mark
obstruct
coexist
restrict
pattern
function
emphysema
practic
pfr
valu
sever
case
ventilatori
failur
dispers
valu
standard
error
regress
allow
correl
data
patient
introduct
tenor
studi
longitudin
observ
natur
histori
subject
sever
difficulttotreat
asthma
analysi
assess
associ
previou
futur
asthma
exacerb
tenor
method
subject
elig
analysi
year
age
baselin
least
one
followup
assess
year
year
recent
asthma
exacerb
past
month
defin
asthmarel
emerg
room
er
visit
night
hospit
unschedul
physician
offic
contact
composit
measur
least
one
previou
exacerb
event
rel
risk
rr
confid
limit
ci
gener
compar
exacerb
year
rel
year
exacerb
rate
defin
number
event
divid
total
patient
followup
time
adjust
perform
baselin
characterist
result
subject
elig
analysi
rr
year
vs
year
ci
unschedul
offic
contact
ci
composit
exacerb
measur
ci
er
visit
ci
night
hospit
subject
exacerb
composit
measur
year
similarli
high
rate
year
compar
patient
without
event
year
went
exacerb
year
see
tabl
conclus
tenor
subject
experienc
asthma
exacerb
year
statist
significantli
increas
risk
subsequ
exacerb
follow
year
compar
subject
experienc
exacerb
year
increas
risk
consist
asthma
exacerb
outcom
elev
hospit
due
asthma
assess
recent
asthmarel
healthcar
use
critic
compon
clinic
evalu
subject
sever
difficulttotreat
asthma
fund
genentech
inc
novarti
pharmaceut
corp
background
preliminari
studi
investig
yoga
breathwork
asthma
promis
sever
random
control
trial
shown
benefit
yoga
postur
andor
breath
versu
control
control
case
involv
intervent
usual
care
studi
advanc
field
provid
activ
control
method
random
control
doubleblind
clinic
trial
conduct
octob
march
determin
effect
feasibl
yoga
breathwork
intervent
improv
clinic
indic
qualiti
life
adult
patient
mild
moder
asthma
random
assign
made
either
yoga
intervent
includ
postur
breathwork
stretch
control
condit
outcom
measur
assess
includ
mini
asthma
qualiti
life
questionnair
miniaqlq
rescu
inhal
use
spirometri
symptom
diari
health
care
util
result
sixtytwo
particip
random
intervent
control
group
complet
final
followup
measur
intentiontotreat
analysi
perform
signific
withingroup
differ
postbronchodil
morn
symptom
score
appar
intervent
control
group
week
howev
signific
differ
group
observ
outcom
measuresconclus
iyengar
yoga
confer
appreci
benefit
mild
moder
asthma
circumst
yoga
benefit
asthma
manag
remain
determin
order
investig
asthma
mortal
trend
u
hispan
popul
collect
graph
data
nation
center
health
statist
mortal
data
hispan
popul
avail
entir
unit
state
sinc
readili
avail
asthma
sinc
data
indic
decreas
death
asthma
decreas
nonhispan
popul
rate
death
asthma
decreas
hispan
popul
per
nonhispan
popul
decreas
rate
nonhispan
white
decreas
rate
death
asthma
twice
high
among
hispan
women
men
rate
death
asthma
nonhispan
black
twice
high
nonhispan
white
nation
center
health
statist
data
dictat
racial
terminolog
data
peopl
hispan
origin
includ
peopl
race
data
affect
underreport
hispan
origin
death
certif
undercoverag
censu
result
popul
estim
net
correct
thu
rate
death
asthma
lower
decreas
faster
among
hispan
rest
popul
unit
state
allerg
rhiniti
asthma
highli
preval
diseas
often
coexist
patient
rhiniti
symptom
shown
impact
lower
airway
impact
rhiniti
asthma
control
may
greatest
patient
sever
rhiniti
symptom
therefor
analysi
perform
determin
impact
baselin
rhiniti
sever
asthma
control
patient
asthma
allerg
rhiniti
receiv
either
fluticason
propion
aqueou
nasal
spray
fpan
montelukast
mon
ad
fluticason
propionatesalmeterol
mcg
fsc
total
patient
year
persist
asthma
season
allerg
rhiniti
receiv
fpan
qd
mon
qd
placebo
pbo
addit
fsc
bid
week
baselin
total
nasal
symptom
score
tnss
rang
analysi
restrict
patient
whose
preenrol
asthma
therapi
includ
fsc
regardless
baselin
rhiniti
sever
patient
asthma
allerg
rhiniti
mon
ad
fsc
result
addit
improv
overal
asthma
control
compar
fsc
alon
data
suggest
optim
treatment
individu
condit
goal
treatment
patient
coexist
allerg
rhiniti
asthma
introduct
recent
studi
demonstr
parainfluenza
coronavirus
import
trigger
asthma
parainfluenza
virus
one
main
trigger
virusinduc
asthma
summer
parainfluenza
virus
often
caus
sever
low
respiratori
tract
infect
immuncompromis
patient
patient
bone
marrow
transplant
retrospect
studi
found
pediatr
bmt
patient
hpiv
infect
viral
respiratori
infect
develop
pneumonia
die
virus
contribut
fatal
asthma
materi
method
amplif
virus
primer
anneal
specif
region
viral
genom
hngene
spike
glycoprotein
gene
coronaviru
nucleocapsid
glycoprotein
gene
coronaviru
use
pcrdiagnost
perform
nasal
throat
swab
taken
children
atop
asthma
exacerb
result
total
sampl
includ
neg
control
test
pcr
posit
respiratori
virus
sampl
note
children
asthma
exacerb
includ
test
sampl
detect
posit
sampl
coronaviru
coronaviru
detect
studi
neg
control
sampl
taken
children
atop
asthma
remiss
control
found
neg
viral
pcr
conclus
respiratori
virus
import
factor
asthma
exacerb
children
frequent
detect
among
posit
sampl
although
less
often
posit
infect
studi
frequenc
detect
coronavirus
may
influenc
season
activ
virus
introduct
budapest
children
come
regular
supervis
special
train
paediatrician
paediatrician
respons
averag
children
often
seen
age
year
method
questionnair
sent
district
paediatrician
budapest
budapest
budapest
total
number
children
practic
number
asthmat
assess
diagnosi
asthma
everi
case
establish
paediatr
hospit
special
allergi
pulmonolog
outpati
clinic
result
repli
receiv
paeditrician
respons
supervis
children
diagnos
asthma
repli
sent
physician
total
children
care
includ
asthmat
preval
end
paediatrician
children
answer
note
asthmat
preval
asthma
conclus
current
survey
preval
asthma
childhood
far
largest
made
increas
preval
diagnosi
asthma
base
clinic
investig
note
differ
investig
year
highli
signific
panel
report
guidelin
diagnosi
manag
asthma
avail
sinc
standard
improv
qualiti
asthma
care
howev
asthma
remain
lead
caus
hospit
new
york
citi
children
implement
guidelin
fulli
embrac
primari
care
set
attempt
increas
primari
care
practition
complianc
guidelin
extens
train
hospit
base
pediatr
clinic
school
base
health
clinic
brooklyn
inner
citi
particip
april
march
program
part
new
york
citi
educ
qualiti
improv
project
equip
initi
asthma
physician
specialist
asthma
educ
train
primari
care
physician
nurs
practition
guidelin
train
reinforc
monthli
luncheon
session
clinic
exam
room
also
suppli
asthma
educ
materi
peak
flow
meter
asthma
action
plan
goal
identifi
asthmat
document
asthma
sever
give
persist
asthmat
written
manag
plan
util
appropri
control
medic
complianc
measur
track
asthma
visit
asthma
intak
form
prior
project
consist
attempt
made
clinic
regularli
classifi
asthmat
sever
provid
written
asthma
action
plan
place
patient
control
medic
onset
project
total
asthma
visit
evalu
school
base
health
center
hospit
base
pediatr
clinic
sever
classifi
asthma
visit
patient
classifi
persist
receiv
updat
written
manag
plan
asthma
visit
place
control
medic
asthma
manag
program
demonstr
success
improv
primari
care
practition
complianc
naepp
asthma
guidelin
studi
need
determin
complianc
guidelin
persist
cessat
extens
train
complianc
improv
asthma
outcom
numer
studi
associ
asthma
obes
although
obes
identifi
risk
factor
asthma
limit
inform
impact
obes
childhood
asthma
studi
examin
effect
bodi
composit
asthma
sever
pulmonari
function
children
retrospect
review
chart
asthmat
children
age
year
refer
communitybas
pediatr
pulmonolog
practic
data
includ
asthma
primari
diagnosi
baselin
spirometri
avail
asthma
sever
classifi
bodi
mass
index
bmi
classifi
normal
overweight
obes
spirometri
result
review
eightyf
patient
review
thirtyon
patient
normal
weight
overweight
obes
baselin
characterist
age
gender
raceethn
similar
asthma
sever
classif
differ
normal
overweight
obes
children
overal
classifi
intermitt
persist
mild
asthma
persist
moderatesever
asthma
children
intermitt
asthma
receiv
control
therapi
compar
persist
mild
moderatesever
asthma
although
healthcar
util
asthma
emerg
room
visitsadmiss
significantli
differ
children
intermitt
persist
mild
moderatesever
asthma
differ
normal
overweight
obes
children
compar
spirometri
result
show
compar
peak
expiratori
flow
rate
pfr
group
predict
normal
weight
predict
overweight
obes
mean
forc
vital
capac
fvc
mean
forc
expiratori
volum
second
respect
differ
forc
expiratori
flow
midlung
volum
predict
studi
retrospect
review
asthmat
children
compar
bmi
asthma
sever
spirometri
found
differ
asthma
sever
classif
normal
overweightobes
patient
regardless
bmi
indic
spirometri
similar
studi
need
examin
impact
obes
differ
asthma
relat
diseas
outcom
object
investig
effect
budesonid
formoterol
levalbuterol
alon
combin
product
express
ragwe
ra
stimul
cell
method
cell
cultur
duplic
hour
degre
celciu
co
serum
free
dmem
without
follow
ra
x
budesonid
x
formoterol
x
levalbuterol
product
express
measur
sensit
elisa
mrna
assay
cell
supernat
pellet
result
product
express
cell
rose
markedli
presenc
ra
pgml
amolml
signific
inhibit
follow
addit
budesonid
combin
budesonid
formoterol
budesonid
levalbuterol
budesonid
formoterol
levalbuterol
p
combin
treatment
budesonid
levalbuterol
versu
budesonid
alon
reach
signific
product
express
p
budesonid
formoterol
compar
budesonid
alon
reach
signific
product
p
conclus
combin
therapi
budesonid
long
short
act
betaagonist
show
greater
effect
inhibit
compar
budesonid
alon
synergist
effect
distal
airway
may
prevent
subset
asthmat
develop
airway
remodel
g
tamura
sano
k
hirata
ishioka
nakashima
miyamoto
sendai
japan
tokyo
japan
osaka
japan
hiroshima
japan
hamamatsu
japan
tulobuterol
tape
world
first
longact
transderm
prepar
design
releas
tulobuterol
optim
fashion
appli
daili
bedtim
blood
concentr
tulobuterol
peak
earli
morn
kept
effect
level
hour
tulobuterol
tape
milder
less
frequent
advers
event
convent
oral
tulobuterol
prepar
use
bedtim
prevent
mark
drop
peak
expiratori
flow
pef
earli
morn
consequ
tulobuterol
tape
commonli
use
japan
longact
present
studi
evalu
efficaci
longact
compar
effect
two
differ
dose
administ
tulobuterol
tape
dose
mgday
patient
persist
asthma
alreadi
use
inhal
corticosteroid
studi
random
doubleblind
doubledummi
parallelgroup
multicent
trial
durat
mean
pef
mgday
group
significantli
increas
baselin
valu
week
week
week
lmin
week
respect
increas
mean
morn
pef
mgday
group
significantli
higher
mgday
group
everi
point
determin
mean
even
pef
significantli
increas
treatment
group
compar
baselin
valu
everi
point
determin
although
increas
mgday
group
greater
mgday
group
point
determin
differ
group
statist
signific
week
safeti
profil
two
treatment
similar
patient
persist
asthma
requir
inhal
shortact
receiv
inhal
corticosteroid
tulobuterol
tape
mgday
significantli
improv
pef
compar
tulobuterol
tape
mgday
introduct
averag
children
admit
annual
asthma
children
hospit
requir
admiss
pediatr
intens
care
unit
picu
admiss
highest
month
august
septemb
octob
aeroallergen
alternaria
ragwe
predomin
season
allergi
allergen
may
account
increas
number
picu
admiss
asthma
object
hypothes
season
increas
admiss
rate
could
relat
allergen
sensit
particularli
alternaria
andor
ragwe
predomin
late
summer
fall
method
data
collect
retrospect
chart
review
patient
admit
picu
asthma
exacerb
skin
prick
test
spt
within
one
year
picu
admiss
criteria
inclus
studi
result
higher
preval
admiss
picu
asthma
exacerb
august
septemb
octob
admiss
admiss
p
sixtyon
subject
met
oneyear
spt
criteria
analysi
subject
admit
august
septemb
octob
categor
group
other
categor
group
b
sensit
total
aeroallergen
tress
grass
weed
ragwe
outdoor
mold
indoor
mold
alternaria
cat
dog
roach
dust
mite
compar
two
group
statist
signific
aeroallergen
sensit
alternaria
ragwe
subject
admit
picu
august
septemb
octob
group
subject
admit
month
year
group
b
conclus
asthma
exacerb
requir
picu
admiss
preval
month
august
septemb
octob
increas
rate
picu
admiss
correl
aeroallergen
sensit
preval
allergen
august
septemb
octob
therefor
suspect
factor
viral
upper
respiratori
infect
addit
aeroallergen
sensit
may
contribut
sever
asthma
exacerb
late
summer
fall
month
k
kuzum
shigenobu
ehim
japan
infantil
wheez
may
result
differ
phenotyp
aim
studi
evalu
risk
factor
allergi
result
allergyrel
blood
test
among
infant
differ
type
allergi
symptom
infant
examin
physic
birth
month
age
questionnair
number
sibl
famili
histori
allergi
feed
method
given
allerg
diseas
diagnos
month
age
subject
divid
group
infant
atop
dermat
ad
group
infant
ad
wheez
aw
group
infant
wheez
w
group
infant
without
allerg
symptom
c
group
risk
factor
evalu
patient
group
aw
group
w
group
given
allergyrel
blood
test
total
serum
ige
level
rast
egg
white
milk
hous
dust
mite
month
age
result
blood
test
control
subject
month
age
compar
group
shown
male
infant
aw
group
c
group
p
aw
vs
c
p
vs
c
number
sibl
greater
w
aw
group
c
group
p
w
vs
w
vs
c
p
aw
vs
p
aw
vs
c
rate
posit
famili
histori
allerg
diseas
high
aw
group
compar
w
c
group
p
vs
c
aw
vs
c
p
aw
vs
w
rate
breastfeed
month
age
high
group
compar
other
p
vs
c
patient
w
group
lower
level
total
serum
ige
month
age
compar
patient
aw
p
w
vs
aw
w
vs
also
patient
w
group
lower
level
rast
egg
white
month
age
compar
patient
aw
p
w
vs
aw
w
vs
median
total
serum
ige
level
month
age
higher
aw
w
compar
c
p
aw
vs
c
vs
c
conclus
two
differ
phenotyp
wheez
infant
month
age
wheez
ad
might
allergyrel
wheez
without
ad
may
relat
factor
compar
c
group
p
b
p
c
p
p
compar
group
p
p
p
p
compar
aw
group
f
p
g
p
h
p
group
infant
atop
dermat
aw
group
infant
atop
dermat
wheez
w
group
infant
wheez
c
group
infant
without
allerg
symptom
rast
radioallergosorb
test
na
data
avail
r
amelio
c
capristo
capasso
miraglia
del
giudic
n
maiello
f
decimo
napl
itali
napoli
itali
forc
oscil
techniqu
fot
consid
sensibl
specif
method
estim
breath
function
asthmat
children
age
year
nt
need
special
collabor
aim
studi
valu
baselin
respiratori
resist
fot
preschoolag
children
asthma
high
dose
budesonid
flunisolid
treatment
purpos
asthmat
children
age
year
select
first
examin
patient
show
basal
valu
fot
frequenc
chang
major
equal
mcg
salbutamol
treatment
day
studi
children
select
nt
take
system
inhal
steroid
cromon
leukotrien
antagonist
teophyllin
antihistamin
nt
present
upper
lower
airway
infect
two
week
runin
select
patient
took
least
time
per
week
patient
divid
two
group
group
children
inhal
flunisolid
salbutamol
mcg
bid
day
follow
two
week
inhal
flunisolid
mcgkgdose
salbutamol
mcg
pmdispac
prn
group
ii
children
inhal
budesonid
mg
bid
salbutamol
mcg
bid
day
follow
two
week
inhal
budesonid
mg
bid
salbutamol
mcg
pmdispac
prn
moreov
gave
diarycard
simpl
symptom
score
get
real
percept
symptom
cours
studi
howev
treatment
children
ritir
studi
result
obtain
statist
analys
student
test
signific
pre
valu
reduct
obtain
vs
group
quick
action
group
ii
reduc
airway
resist
p
children
treat
flunisolid
lower
frequenc
breathless
nocturn
cough
lower
salbutamol
use
budesonid
group
pn
conclus
fot
actual
safeti
method
valu
efficaci
inhal
steroid
preschoolag
children
asthma
introduct
approxim
us
adult
louisiana
la
adult
current
asthma
current
smoke
cigarett
accord
behavior
risk
factor
surveil
system
brfss
purpos
studi
compar
asthmat
smoker
vs
nonsmok
la
us
address
whether
asthmat
smoker
util
medic
care
servic
er
outpati
clinic
whether
abl
fulli
particip
activ
daili
live
compar
nonsmok
asthmat
method
brfss
statebas
telephon
survey
us
adult
survey
collect
selfreport
inform
modifi
risk
factor
chronic
diseas
studi
analyz
data
brfss
survey
use
sa
softwar
data
current
asthmat
cigarett
smoker
us
louisiana
asthmat
current
smoke
significantli
higher
nation
averag
p
within
past
year
averag
number
emerg
room
visit
due
asthma
similar
locat
la
us
nation
smoker
visit
er
significantli
frequent
nonsmok
ns
p
la
smoker
visit
er
twice
often
nonsmok
ns
p
number
annual
routin
outpati
checkup
asthma
similar
base
locat
la
us
smoker
nonsmok
similar
number
checkup
nation
ns
louisiana
ns
number
day
asthmat
unabl
perform
usual
activ
significantli
fewer
la
nation
la
us
p
smoker
significantli
higher
number
miss
day
nation
ns
p
la
signific
differ
number
miss
day
base
smoke
statu
ns
conclus
even
though
louisiana
lower
preval
asthmat
compar
nation
averag
significantli
asthmat
smoker
asthmat
smoker
la
us
util
er
nonsmok
counterpart
smoker
nonsmok
similar
number
routin
outpati
visit
asthmat
smoker
miss
day
significantli
differ
nation
level
research
shown
young
age
highli
associ
improp
use
children
use
mdi
hold
chamber
arch
pediatr
adolesc
med
object
studi
compar
health
outcom
achiev
children
asthma
use
inhal
corticosteroid
icss
deliv
nebul
compar
outcom
children
use
icss
deliv
nonnebul
devic
method
use
manag
care
organ
databas
pharmetr
integr
outcom
databas
identifi
children
age
year
asthma
diagnosi
asthmarel
hospitalizationemerg
depart
ed
visit
juli
june
prescript
claim
ic
within
day
discharg
compar
rel
risk
hospit
recurr
day
cox
proport
hazard
regress
covariatessex
age
current
prior
asthma
medic
prior
oral
corticosteroid
shortact
adrenerg
agonist
use
initi
type
index
event
patient
receiv
nebul
ic
vs
ic
age
group
year
year
result
patient
claim
ic
receiv
nebul
ic
age
year
receiv
nonnebul
ic
age
year
postindex
hospit
rate
refil
rate
higher
patient
use
nebul
ic
model
risk
adjust
patient
use
nebul
ic
risk
reduct
hospit
recurr
vs
use
nebul
ic
hr
ci
age
group
patient
nebul
ic
risk
reduct
compar
patient
use
nebul
ic
hr
ci
age
group
patient
nebul
ic
risk
reduct
hr
ci
conclus
actual
practic
treatment
nebul
ic
asthma
exacerb
associ
signific
reduct
recurr
hospit
visit
young
children
possibl
due
improv
techniqu
complianc
introduct
tenor
multicent
cohort
studi
patient
sever
difficulttotreat
asthma
object
tenor
studi
better
understand
natur
histori
patient
sever
difficulttotreat
asthma
analysi
assess
frequenc
skin
test
popul
character
differ
posit
st
neg
st
subject
method
subject
ask
whether
ever
skin
test
test
result
st
compar
st
never
test
stnd
use
clinic
asthmarel
characterist
subject
year
age
includ
analysi
result
subject
elig
analysi
skin
test
past
stnd
frequenc
allergist
site
pulmonologistoth
site
test
posit
allergist
pulmonologistoth
baselin
ige
st
subject
iuml
vs
iuml
st
p
tabl
shown
age
asthma
onset
durat
asthma
rate
atop
disord
rate
asthma
trigger
aeroallergen
differenti
st
st
group
diseas
sever
evalu
fev
healthcar
util
medic
use
howev
similar
two
group
gener
stnd
like
valu
closer
st
group
suggest
major
test
would
st
administ
test
conclus
preval
st
subject
allergi
pulmonari
practic
high
demonstr
major
sever
difficulttotreat
patient
allerg
asthma
st
patient
show
differ
clinic
characterist
compar
st
includ
greater
likelihood
asthma
symptom
trigger
aeroallergen
data
also
show
clinic
profil
stnd
patient
may
similar
st
patient
suggest
util
univers
allerg
evalu
sever
asthmat
fund
genentech
novarti
pharmaceut
corp
background
current
nation
guidelin
diagnosi
manag
asthma
naepp
epr
classifi
asthma
sever
base
frequenc
asthma
symptom
medic
use
measur
lung
function
spirometri
peak
expiratori
flow
variabl
recent
util
spirometri
measur
assign
asthma
sever
come
question
evalu
correl
spirometri
measur
asthma
sever
schoolag
children
mostli
naiv
antiinflammatori
therapi
method
children
particip
schoolbas
lowincom
asthma
mobil
van
program
breathmobil
recruit
referr
school
nurs
commun
public
health
clinic
parent
respons
flyer
asthma
screen
questionnair
spirometri
perform
children
greater
year
age
part
comprehens
asthma
evalu
asthma
sever
assign
base
symptom
accord
naepp
epr
result
april
april
children
evalu
breathmobil
patient
diagnos
asthma
classif
sever
symptom
frequenc
accord
naepp
epr
guidelin
result
mild
intermitt
mi
mild
persist
mip
moder
persist
mop
sever
persist
sp
percentag
patient
mean
lung
function
baselin
evalu
without
bronchodil
challeng
shown
tabl
statist
signific
differ
p
sever
group
pronounc
compar
sever
persist
group
intermitt
group
howev
mean
valu
appear
normal
degre
asthma
given
current
accept
cutoff
valu
fvc
conclus
studi
airflow
impair
correl
asthma
sever
although
normal
even
children
sever
persist
asthma
therefor
normal
lung
function
measur
may
mislead
sole
criteria
asthma
sever
classif
perhap
higher
cutoff
point
might
better
indic
asthma
sever
children
asthma
frequent
chronic
diseas
childhoodour
main
know
preval
bronchial
asthma
children
year
north
zone
mexico
citi
compar
preval
obtain
written
questionnair
versu
video
questionnair
group
year
accord
methodolog
propos
isaac
materi
method
mean
valid
standard
questionnair
isaac
appli
children
year
questionnair
year
fill
parent
group
year
answer
questionnair
video
questionnair
accord
isaac
specif
base
studi
popul
calcul
statcal
program
size
sampl
choos
hazard
sampl
children
year
group
year
sex
elementari
high
school
measur
central
tendenc
use
result
final
sampl
size
group
children
adolesc
men
women
preval
asthma
diagnosi
teenag
p
ic
children
p
ic
wheez
last
month
p
ic
children
p
ic
year
wheez
induc
exercis
appear
p
ic
teenag
p
ic
group
sever
asthma
show
nocturn
awak
p
number
crisi
last
year
children
teenag
respect
p
video
questionnair
teenag
ic
answer
affirm
display
shaken
breath
last
year
rest
ic
last
month
exercis
question
confirm
display
symptom
ic
last
year
ic
last
month
wideawak
night
ic
last
year
last
month
conclus
preval
asthma
diagnosi
higher
teenag
group
children
group
preval
asthma
higher
also
group
rational
investig
relationship
pet
exposur
healthcar
util
hcu
cohort
pediatr
patient
sever
difficulttotreat
asthma
epidemiolog
natur
histori
asthma
outcom
treatment
regimen
tenor
observ
studi
hypothes
pet
exposur
would
increas
hcu
due
increas
airway
inflamm
method
tenor
multicent
cohort
studi
patient
sever
difficulttotreat
asthma
children
age
interview
baselin
regard
asthmarel
hcu
previou
month
patient
pet
exposur
ppe
compar
patient
pet
exposur
pnpe
respons
analyz
use
fisher
exact
test
result
ppe
less
like
sever
asthma
physician
assess
vs
addit
ppe
less
like
emerg
room
er
visit
vs
hospit
vs
previou
month
pnpe
ige
level
iuml
vs
ppe
pnpe
similar
regard
presenc
allerg
rhiniti
skin
test
posit
compar
pnpe
fewer
ppe
two
pet
er
visit
hospit
tabl
among
ppe
differ
ige
level
asthma
sever
relat
number
pet
conclus
pet
exposur
associ
reduc
hcu
tenor
pediatr
cohort
pronounc
effect
seen
reduc
er
visit
hospit
need
multipl
pet
ppe
significantli
lower
ige
level
compar
pnpe
regardless
number
pet
data
support
hypothesi
exposur
pet
may
paradox
protect
individu
develop
sever
asthma
altern
data
may
reflect
selfselect
patient
sever
allerg
asthma
like
avoid
pet
howev
may
confound
factor
famili
pet
confer
protect
effect
asthma
sever
introduct
asthma
chronic
obstruct
airway
diseas
phosphodiesteras
involv
pathophysiolog
diseas
express
abundantli
key
inflammatori
cell
inhibitor
investig
antiinflammatori
agent
prevent
breakdown
cyclic
adenosin
monophosph
natur
modul
inflamm
roflumilast
investig
oral
oncedaili
inhibitor
demonstr
vitro
vivo
antiinflammatori
activ
may
translat
clinic
efficaci
asthma
therapi
studi
examin
abil
roflumilast
exert
direct
acut
bronchodilatori
activ
patient
mild
moder
asthma
method
doubleblind
random
placebocontrol
crossov
studi
consist
three
treatment
period
one
day
separ
washout
period
treatment
period
patient
forc
expiratori
volum
one
second
fev
predict
receiv
either
oral
roflumilast
roflumilast
placebo
fev
measur
twice
prior
administr
period
h
follow
treatment
h
patient
inhal
salbutamol
metereddos
inhal
fev
measur
min
later
advers
event
vital
sign
electrocardiogram
result
monitor
throughout
studi
result
median
baselin
fev
similar
three
treatment
period
dose
roflumilast
lead
statist
signific
differ
versu
placebo
timeaverag
fev
first
h
drug
intak
p
thu
evid
direct
acut
bronchodilatori
effect
either
singl
dose
roflumilast
contrast
inhal
shortact
bronchodil
salbutamol
led
distinct
improv
fev
versu
baselin
treatment
group
median
fev
increas
roflumilast
roflumilast
placebo
group
respect
roflumilast
well
toler
conclus
oral
oncedaili
roflumilast
exhibit
direct
acut
bronchodilatori
activ
patient
mild
moder
asthma
could
achiev
shortact
agonist
data
support
propos
mechan
action
roflumilast
antiinflammatori
agent
south
africa
guadalajara
spain
munich
germani
weinheim
germani
budapest
hungari
konstanz
germani
introduct
phosphodiesteras
found
key
inflammatori
cell
involv
pathophysiolog
chronic
obstruct
pulmonari
diseas
asthma
inhibitor
enzym
antiinflammatori
agent
prevent
breakdown
cyclic
adenosin
monophosph
natur
modul
inflamm
roflumilast
investig
oral
oncedaili
inhibitor
demonstr
vitro
vivo
antiinflammatori
activ
studi
examin
doserel
efficaci
roflumilast
patient
asthma
method
patient
stabl
asthma
forc
expiratori
volum
second
fev
predict
enrol
random
doubleblind
doserang
find
studi
singleblind
placebo
runin
period
three
week
patient
receiv
oral
roflumilast
daili
n
respect
week
efficaci
assess
chang
baselin
spirometr
lung
function
fev
forc
vital
capac
fvc
well
morn
even
peak
expiratori
flow
pef
record
patient
diari
safeti
toler
paramet
monitor
throughout
studi
result
treatment
roflumilast
led
dosedepend
statist
signific
increas
fev
fvc
p
morn
pef
p
last
visit
fev
improv
baselin
ml
ml
ml
patient
treat
roflumilast
daili
respect
similarli
dosedepend
improv
lmin
lmin
lmin
morn
pef
baselin
reach
roflumilast
well
toler
dose
level
test
frequent
drugrel
advers
event
headach
follow
gastrointestin
disord
diarrhea
nausea
clinic
relev
chang
vital
sign
electrocardiogram
laboratori
paramet
conclus
oral
oncedaili
roflumilast
associ
dosedepend
clinic
relev
improv
lung
function
patient
stabl
asthma
roflumilast
well
toler
jl
izquierdo
ed
bateman
p
magyar
u
harnest
p
hofbauer
varga
c
schmidwirlitsch
bredenbroek
td
bethk
guadalajara
spain
cape
town
south
africa
budapest
hungari
munich
germani
weinheim
germani
tatabanya
hungari
konstanz
germani
introduct
phosphodiesteras
inhibitor
new
class
antiinflammatori
agent
therapeut
use
inflammatori
airway
diseas
sever
studi
investig
oral
oncedaili
inhibitor
roflumilast
provid
clinic
meaning
improv
patient
chronic
obstruct
pulmonari
diseas
asthma
studi
examin
longterm
safeti
toler
roflumilast
week
patient
asthma
method
patient
persist
stabl
asthma
fev
predict
random
particip
doubleblind
random
doserang
find
studi
treat
oral
roflumilast
daili
week
patient
complet
studi
perprotocol
continu
treatment
openlabel
extens
studi
patient
receiv
oral
roflumilast
daili
extens
period
advers
event
ae
clinic
laboratori
paramet
vital
annal
allergi
asthma
immunolog
sign
ecg
assess
throughout
extens
period
result
total
patient
enrol
extens
studi
overal
common
ae
relat
respiratori
system
small
number
patient
experienc
ae
assess
least
like
relat
studi
medic
frequent
drugrel
advers
event
headach
diarrhea
nausea
report
patient
respect
ae
mild
moder
intens
transient
durat
patient
discontinu
studi
due
ae
ae
lead
discontinu
assess
relat
unlik
relat
studi
drug
patient
report
seriou
ae
assess
relat
unlik
relat
roflumilast
clinic
relev
chang
clinic
laboratori
paramet
vital
sign
ecg
physic
examin
occur
conclus
oral
oncedaili
roflumilast
administ
week
well
toler
patient
persist
stabl
asthma
studi
provid
evid
roflumilast
associ
low
incid
ae
mostli
mild
moder
intens
transient
natur
thu
support
potenti
therapeut
use
roflumilast
asthma
pari
franc
madrid
spain
guadalajara
spain
harrow
unit
kingdom
weinheim
germani
augsburg
germani
munich
germani
kaufbeuren
germani
konstanz
germani
introduct
asthma
inhal
corticosteroid
ic
mainstay
mainten
treatment
new
therapeut
agent
need
target
key
inflammatori
process
asthma
effect
ic
overcom
known
limit
ic
phosphodiesteras
inhibitor
antiinflammatori
agent
prevent
breakdown
cyclic
adenosin
monophosph
natur
modul
inflamm
roflumilast
investig
oral
oncedaili
inhibitor
potenti
use
antiinflammatori
asthma
therapi
studi
compar
standard
corticosteroid
treatment
twicedaili
inhal
beclomethason
dipropion
bdp
oral
oncedaili
roflumilast
patient
asthma
method
random
doubleblind
doubledummi
studi
patient
forc
expiratori
volum
one
second
fev
predict
receiv
either
oral
roflumilast
daili
inhal
bdp
twice
daili
week
mean
chang
lsmean
sem
lung
function
paramet
fev
forc
vital
capac
fvc
morn
even
peak
expiratori
flow
pef
baselin
determin
week
treatment
symptom
score
rescu
medic
use
assess
result
roflumilast
bdp
improv
fev
baselin
clinic
meaning
level
respect
p
similarli
roflumilast
bdp
improv
fvc
respect
p
well
morn
even
pef
p
roflumilast
statist
noninferior
bdp
roflumilast
bdp
led
statist
signific
compar
improv
asthma
symptom
use
rescu
medic
advers
event
gener
mild
moder
common
drugrel
advers
event
report
roflumilast
group
nausea
headach
diarrhea
clinic
relev
chang
vital
sign
ecg
laboratori
paramet
conclus
roflumilast
provid
clinic
meaning
improv
lung
function
paramet
reduc
asthma
symptom
decreas
need
rescu
medic
oral
oncedaili
roflumilast
effect
inhal
twicedaili
bdp
treatment
asthma
oral
roflumilast
well
toler
rational
evalu
medic
claim
commerci
health
plan
permit
assess
therapeut
intervent
resourc
util
studi
investig
impact
control
therapi
children
start
asthma
mainten
medic
risk
obtain
prescript
oral
corticosteroid
oc
shortact
betaagonist
saba
ad
anoth
asthma
therapi
evalu
method
retrospect
observ
studi
util
medic
pharmaci
claim
larg
repres
manag
care
plan
children
age
year
old
asthma
diagnosi
initi
pharmaci
claim
one
follow
regimen
fluticasonesalmeterol
singl
inhal
fsc
fluticason
propion
alon
fp
montelukast
mon
inhal
corticosteroid
plu
montelukast
icsmon
ic
plu
salmeterol
separ
inhal
icssal
includ
analysi
subject
exclud
receiv
asthma
control
medic
month
prior
initi
therapi
regress
use
estim
incid
rate
ratio
irr
oc
saba
use
neg
binomi
odd
ratio
ad
control
add
ed
hospit
ip
event
logist
model
control
demograph
precontrol
asthmarel
medic
event
baselin
total
health
care
cost
result
ratio
tabl
confid
interv
exclud
uniti
indic
significantli
increas
use
likelihood
event
compar
fsc
cohort
control
children
start
fsc
less
like
add
anoth
control
mon
fp
icssal
less
use
oc
saba
cohort
studi
month
initi
control
therapi
addit
children
treat
ic
mon
significantli
greater
edip
visit
compar
fsc
conclus
use
fp
sal
fsc
singl
inhal
assur
children
get
optim
inhal
corticosteroid
therapi
well
benefit
long
act
bronchodil
avoid
potenti
select
discontinu
ic
multipl
control
cohort
nayak
r
nathan
j
william
kundu
lloyd
banerji
normal
il
colorado
spring
co
bridgewat
nj
introduct
inhal
corticosteroid
ic
recommend
firstlin
therapi
sever
persist
asthma
system
exposur
ic
may
suppress
hypothalamicpituitaryadren
hpa
axi
function
particularli
dose
requir
control
sever
asthma
ciclesonid
cic
hydrofluoroalkan
hfa
meter
dose
inhal
mdi
novel
effect
ic
convert
lung
activ
metabolit
desisobutyryl
ciclesonid
descic
previous
shortterm
studi
cic
shown
effect
serum
urinari
cortisol
level
may
attribut
low
oral
bioavail
high
serum
protein
bind
high
clearanc
rate
cic
activ
metabolit
hpa
axi
analysi
part
longterm
studi
evalu
safeti
cic
beclomethason
dipropion
bdp
hfamdi
patient
sever
persist
asthma
method
multicent
doubleblind
parallelgroup
extens
doubleblind
trial
patient
year
sever
persist
asthma
patient
random
ratio
cic
bdp
receiv
cic
g
bid
exactu
bdp
g
bid
exactu
week
dose
medic
could
titrat
g
bid
need
asthma
control
hpaaxi
function
assess
select
center
subset
patient
baselin
end
studi
month
earli
termin
measur
peak
serum
cortisol
induc
low
dose
cosyntropin
urinari
free
cortisol
correct
creatinin
result
data
avail
small
number
patient
center
evalu
hpaaxi
tabl
mean
baselin
level
chang
baselin
end
studi
valu
lowdos
cosyntropin
peak
serum
cortisol
level
cic
bdp
compar
likewis
baselin
level
mean
chang
baselin
end
studi
valu
urinari
free
cortisol
correct
creatinin
compar
among
two
treatment
group
conclus
find
demonstr
cic
daili
month
safe
signific
effect
hpaaxi
function
long
rahman
boston
wilmington
de
introduct
littl
inform
avail
regard
relationship
asthma
sever
diseas
control
complianc
medic
method
physician
percept
regard
variabl
determin
internetbas
gener
asthma
medic
usag
survey
patientspecif
asthma
medic
usag
survey
decemb
physician
pcp
pediatrician
allergist
immunologist
pulmonologist
patientspecif
survey
base
chart
inform
randomli
chosen
patient
per
physician
control
medic
result
patient
categor
physician
mild
intermitt
mild
moder
sever
persist
asthma
respect
overal
patient
categor
control
asthma
compliant
current
regimen
wors
asthma
control
decreas
complianc
increas
physician
visit
associ
increas
asthma
sever
classif
physician
report
patient
sever
persist
diseas
control
asthma
contrast
patient
mild
intermitt
asthma
patient
mild
intermitt
asthma
mild
moder
sever
persist
asthma
mean
physician
visit
asthma
respect
within
past
year
physician
percept
patient
complianc
vari
less
across
group
patient
sever
persist
asthma
patient
mild
intermitt
asthma
rate
compliant
incid
allerg
rhiniti
similar
among
sever
level
rang
patient
sever
persist
asthma
like
comorbid
condit
includ
hypertens
chronic
obstruct
pulmonari
disord
chronic
bronchiti
osteoporosi
compar
patient
asthma
sever
level
conclus
decreas
asthma
control
rate
complianc
well
increas
physician
visit
comorbid
medic
condit
may
associ
increas
asthma
sever
classif
rational
children
asthma
frequent
comorbid
allerg
condit
requir
medic
purpos
studi
assess
whether
control
asthma
medic
select
would
reduc
util
intranas
steroid
in
prescript
nonsed
antihistamin
nsa
children
treat
comorbid
allergi
method
observ
retrospect
studi
util
pharmetr
integr
outcom
databas
contain
administr
medic
pharmaci
claim
data
manag
care
plan
across
unit
state
children
age
year
old
new
diagnosi
asthma
identifi
observ
month
initi
diagnosi
treatment
asthma
postindex
four
cohort
establish
base
control
medic
dispens
montelukast
mon
fluticason
propion
fp
fpmon
fpsalmeterol
singl
inhal
fsc
result
baselin
comorbid
diagnosi
allerg
rhiniti
observ
children
pattern
use
in
nsa
similar
month
month
initi
asthma
diagnosi
treatment
children
diagnosi
allerg
rhiniti
nearli
twice
like
receiv
nsa
in
treatment
cohort
use
similar
amount
allergi
medic
presenc
absenc
diagnosi
allerg
rhiniti
alter
find
adjust
odd
ratio
ci
use
nsa
in
rel
use
fsc
postindex
period
mon
fp
fpmon
tabl
show
percent
children
dispens
nsa
andor
in
number
unit
allergi
medic
also
similar
across
cohort
conclus
use
mon
fp
fpmon
fsc
asthma
alter
rate
quantiti
either
intranas
corticosteroid
nonsed
antihistamin
dispens
children
period
although
allerg
rhiniti
common
comorbid
pediatr
asthma
select
regimen
contain
montelukast
reduc
use
either
nsa
in
compar
asthma
treatment
fp
fsc
rational
medic
complianc
recogn
signific
challeng
pediatricsth
purpos
studi
compar
inhal
corticosteroid
ic
persist
pediatr
patient
use
singl
inhal
contain
inhal
corticosteroid
fluticason
propion
fp
inhal
longact
betaagonist
salmeterol
sal
fsc
patient
receiv
fp
alon
fp
sal
separ
inhal
ic
montelukast
mon
method
retrospect
prepost
databas
studi
util
medic
pharmaci
claim
total
subject
year
age
diagnosi
asthma
group
cohort
fsc
fp
icssal
icsmon
patient
control
month
prior
index
event
first
prescript
medic
interest
subject
requir
continu
enrol
month
preand
month
postindex
subject
cystic
fibrosi
copd
bronchopulmonari
dysplasia
respiratori
distress
syndrom
exclud
ic
refil
rate
measur
persist
compar
fsc
ic
compon
cohort
followup
period
result
mean
refil
rate
followup
period
significantli
greater
p
fsc
compar
mean
ic
refil
rate
fp
alon
cohort
ic
sal
ic
mon
cohort
patient
fsc
fill
ic
prescript
patient
fp
alon
icssal
ic
mon
mean
refil
gener
higher
median
fill
consider
number
children
one
fill
fsc
fp
ic
sal
ic
mon
conclus
patient
use
fsc
like
fill
inhal
corticosteroid
often
compar
patient
use
ic
sal
separ
inhal
icsmon
fp
monotherapi
improv
persist
ic
shown
studi
decreas
morbid
mortal
asthma
use
fsc
singl
inhal
assur
children
get
optim
inhal
corticosteroid
therapi
well
benefit
long
act
bronchodil
avoid
select
discontinu
ic
may
occur
two
medic
dispens
nation
health
interview
survey
nhi
estim
million
unit
state
resid
asthma
noncompli
treatment
estim
consequ
noncompli
includ
absenc
work
school
increas
emerg
room
visit
sever
attack
increas
drug
side
effect
greater
cost
care
death
question
complianc
man
sever
prednison
depend
eosinophil
asthma
persist
symptom
despit
treatment
fluticason
propionatesalmeterol
xinafo
bid
prednison
qd
budesonid
mcgpuff
puff
bid
discontinu
budesonid
prednison
initi
methylprednisolon
bid
hour
qd
beclomethason
dipropion
puff
hfa
bid
spacer
clinic
improv
unexpectedli
abrupt
increas
predict
sputum
eosinophil
count
decreas
sudden
improv
chang
methylprednisolon
complianc
prednison
fluticason
question
evalu
complianc
patient
blood
urin
sputum
test
synthet
corticosteroid
without
knowledg
use
mass
spectrometri
blood
level
methylprednisolon
prednisolon
document
use
methylprednisolon
recent
discontinu
prednison
urin
level
methylprednisolon
prednisolon
prednison
confirm
recent
use
prednison
sputum
test
reveal
beclomethason
fluticason
methylprednisolon
confirm
complianc
inhal
fluticason
beclomethason
time
test
thu
contrari
clinic
suspicion
patient
inde
compliant
inhal
glucocorticoid
prednison
subsequ
methylprednisolon
knowledg
first
case
report
document
complianc
inhal
oral
corticosteroid
analysi
synthet
corticosteroid
concentr
blood
urin
well
sputum
complianc
could
document
certainti
could
potenti
minim
advers
effect
needless
escal
steroid
dose
reduc
cost
treatment
minim
morbid
mortal
well
rational
burden
pediatr
asthma
extend
beyond
children
asthma
diagnosi
children
wheez
frequent
delay
diagnosi
asthma
may
imped
institut
appropri
therapi
reduc
diseas
morbid
observ
studi
design
assess
treatment
pattern
children
year
old
receiv
asthma
medic
without
diagnosi
asthma
compar
children
diagnos
asthma
children
without
claim
asthma
method
retrospect
crosssect
studi
util
pharmetr
integr
outcom
databas
contain
administr
medic
pharmaci
claim
data
manag
care
plan
across
unit
state
three
cohort
select
children
asthma
diagnosi
dx
cohort
children
prescript
claim
asthma
control
rescu
medic
without
asthma
diagnosi
rx
cohort
children
neither
asthma
diagnosi
prescript
claim
asthma
medic
control
cohort
util
asthma
medic
asthma
specif
cost
total
cost
care
assess
result
total
children
identifi
dx
cohort
rx
cohort
control
cohort
potenti
asthma
cohort
total
annual
nonasthma
relat
cost
dx
cohort
rx
cohort
control
total
healthcar
charg
dx
rx
cohort
retrospect
asthma
relat
nonasthma
charg
significantli
higher
dx
rx
cohort
compar
control
cohort
rx
cohort
ratio
saba
prescript
claim
asthma
control
claim
higher
dx
cohort
conclus
children
treat
asthma
medic
without
asthma
diagnosi
consum
greater
health
care
resourc
resembl
pattern
health
care
util
children
asthma
diagnosi
close
control
children
treatment
absenc
asthma
diagnosi
appear
undertr
control
therapi
recommend
nation
intern
guidelin
background
recent
retrospect
studi
assess
asthma
variabl
innerc
patient
month
month
enrol
naepp
guidelinesdirect
clinic
manag
educ
program
guidelinesdirect
care
improv
asthma
symptom
outcom
signific
variabl
diseas
indic
observ
period
present
analysi
evalu
resourc
util
associ
variabl
method
econom
end
point
includ
hospitalemerg
depart
ed
visit
total
unschedul
offic
visit
sick
visit
day
lost
work
school
collect
innerc
patient
age
year
femal
minor
treat
primari
care
physician
enrol
guidelinesdirect
asthma
clinic
manag
educ
program
aim
minim
barrier
adher
patient
stratifi
group
high
variabl
asthma
low
variabl
asthma
variabl
defin
number
fluctuat
naepp
symptom
class
postintervent
period
high
variabl
patient
fluctuat
higher
mean
low
variabl
patient
fluctuat
lower
mean
result
guidelinesdirect
therapi
associ
improv
asthma
treatment
period
group
patient
highvari
group
ed
visit
sick
visit
total
unschedul
visit
offic
visit
compar
patient
lowvari
group
see
tabl
conclus
despit
guidelinesdirect
therapi
overal
improv
asthma
control
patient
experienc
variabl
asthma
indic
even
diseas
stabl
symptom
continu
fluctuat
result
asthma
variabl
may
contribut
increas
resourc
util
introduct
inhal
corticosteroid
ic
consid
firstlin
therapi
patient
persist
asthma
ic
lead
oropharyng
advers
event
may
affect
treatment
outcom
adher
occurr
local
advers
event
depend
upon
sever
factor
includ
dosag
durat
ic
treatment
ciclesonid
cic
hydrofluoroalkan
hfa
meter
dose
inhal
mdi
novel
effect
ic
rel
low
oropharyng
deposit
cic
convert
lung
activ
metabolit
desisobutyrylciclesonid
descic
furthermor
cic
undergo
limit
convers
oropharynx
may
account
improv
safeti
profil
oropharyng
safeti
profil
analysi
part
longterm
studi
evalu
safeti
cic
hfamdi
vs
beclomethason
dipropion
bdp
hfamdi
patient
sever
persist
asthma
method
multicent
doubleblind
parallelgroup
extens
doubleblind
studi
patient
year
sever
persist
asthma
patient
random
ratio
cic
bdp
receiv
cic
g
bid
bdp
g
bid
exactu
week
dose
medic
could
titrat
g
bid
need
asthma
control
oropharyng
advers
event
monitor
suspect
oral
fungal
infect
verifi
posit
cultur
result
incid
oral
candidiasi
lower
subject
receiv
cic
compar
receiv
bdp
tabl
incid
pharyng
hoars
respect
cic
group
respect
bdp
group
local
advers
event
resolv
without
sequela
withdraw
due
oropharyng
treatmentemerg
advers
event
conclus
treatment
cic
twicedaili
incid
oropharyng
advers
event
low
cic
treatment
result
much
lower
incid
oral
candidiasi
compar
similar
dose
bdp
reflect
better
local
toler
object
determin
preval
asthma
asthmarel
morbid
treatment
asthmarisk
factor
select
popul
method
routin
health
screen
includ
test
asthma
conduct
new
orlean
center
creativ
art
high
school
particip
identifi
medic
asthma
tool
addit
complet
isaac
questionnair
preval
data
includ
lifetim
wheez
month
wheez
previou
asthma
diagnosi
asthmarel
morbid
includ
sleep
disturb
wheez
exercis
asthma
attack
rate
night
awaken
result
particip
age
year
african
american
white
male
femal
cumul
asthma
preval
lifetim
wheez
wheez
girl
report
time
often
ci
wheez
time
month
signific
associ
race
wheez
last
month
p
white
report
time
often
ci
asthma
morbid
report
follow
night
cough
b
wheez
exercis
parent
less
educ
high
school
less
time
like
ci
children
develop
wheez
past
month
higher
bodi
mass
index
bmi
associ
wheez
exercis
p
increas
ci
among
current
asthma
medic
use
bronchodil
antiinflammatori
medic
three
report
use
spacer
report
use
peak
flow
meter
conclus
asthma
preval
higher
school
popul
nation
averag
less
parent
educ
femal
gender
bmi
associ
greater
asthma
morbid
major
particip
current
asthma
report
receiv
episod
inadequ
treatment
inhal
corticosteroid
object
determin
preval
asthma
asthma
relat
symptom
assess
sever
among
new
orlean
school
children
method
seven
elementari
middl
high
school
new
orlean
particip
screen
student
femal
male
age
fall
questionnair
design
intern
studi
asthma
allergi
childhood
isaac
determin
asthma
preval
sever
children
isaac
questionnair
valid
protocol
use
children
countri
asthma
defin
current
wheez
purpos
studi
data
enter
use
spss
sa
softwar
analysi
result
tabl
presenc
asthma
symptom
ethnic
conclus
asthma
preval
significantli
higher
innerc
school
children
new
orlean
compar
nation
preval
vs
asthma
preval
sever
differ
significantli
africanamerican
caucasian
children
new
orlean
even
remov
effect
gender
age
video
effect
method
teach
pollen
identif
project
digit
imag
offer
threedimension
view
uniqu
pollen
detail
similar
focus
microscop
nation
allergi
nab
current
provid
pollen
count
media
report
level
obtain
standard
count
method
rather
forecast
base
histor
pollin
predict
weather
pattern
american
colleg
allergi
asthma
immunolog
american
academi
allergi
asthma
immunolog
interest
ensur
consist
count
accur
report
practic
organ
offer
pollen
identif
train
conjunct
annual
meet
use
video
initi
train
session
experienc
counter
advanc
cours
certifi
pollen
count
station
unit
state
canada
approxim
current
activ
locat
nab
requir
demonstr
abil
count
accur
identifi
pollen
test
slide
updat
recertif
process
use
interact
web
site
current
develop
ongo
pollen
identif
train
essenti
continu
success
aeroallergen
network
observ
found
video
provid
qualiti
emul
microscop
view
enhanc
depth
detail
individu
pollen
characterist
video
receiv
highest
possibl
rate
cours
attende
conclus
video
play
posit
role
pollen
identif
train
continu
educ
experienc
counter
diagnosi
treatment
mold
allergi
complic
genet
divers
individu
fungal
speci
influenc
endogen
fungal
proteas
extract
composit
potenc
studi
examin
biochem
compar
mold
extract
differ
sourc
compat
allergen
immunotherapi
mixtur
essenti
clinic
effect
product
composit
comparison
extract
prepar
alternaria
aspergillu
penicillium
sourc
materi
us
allergen
manufactur
reveal
variabl
sdspage
protein
band
pattern
notic
differ
total
protein
carbohydr
concentr
alt
level
alternaria
extract
correl
close
total
protein
level
igebind
potenc
measur
elisa
inhibit
immunoblot
profil
fungal
extract
close
relat
one
anoth
compar
sdspage
pattern
suggest
similar
allergen
antigen
epitop
may
retain
molecul
vari
size
parallel
elisa
inhibit
doserespons
curv
provid
statist
evid
repertoir
ige
epitop
conserv
mani
product
variat
potenc
fungal
extract
differ
manufactur
may
result
differ
sourc
materi
andor
condit
extract
storag
stabil
compat
allergen
mixtur
contain
mold
extract
assess
storag
month
use
specif
immunoblot
elisa
procedur
grass
mite
allergen
compromis
mix
mold
extract
stabil
glycerin
alternaria
extract
differ
sourc
produc
similar
effect
grass
allergen
ad
compar
strength
degrad
effect
caus
aspergillu
penicillium
product
close
relat
total
fungal
protein
concentr
extract
ratio
structur
epitop
cat
ragwe
fungal
allergen
stabl
mix
proteasecontain
mold
extract
indic
presenc
natur
proteas
inhibitor
allergen
protein
sequenc
distinct
recogn
enzym
allergen
extract
label
weightvolum
pnu
regulatori
requir
determin
activ
alumadsorb
allergen
extract
label
pnu
felt
depot
formul
purpos
studi
develop
method
measur
import
allergen
protein
specif
ige
bind
capabl
alumadsorb
allergen
extract
begin
assess
potenc
nonstandard
extract
allergen
protein
adsorb
alum
particl
make
measur
difficult
studi
allergen
releas
center
alum
precipit
allergen
extract
use
citrat
buffer
ph
major
allergen
content
sever
lot
product
measur
use
monoclon
antibodi
elisa
group
grass
cyn
bermuda
bet
v
birch
ole
e
oliv
pla
l
english
plantain
assay
develop
valid
alkabello
optim
citrat
releas
buffer
direct
bind
ige
perform
immobil
serial
dilut
extract
microtit
plate
ad
specif
atop
sera
enzym
label
antiig
method
use
abl
measur
vitro
allergen
activ
alumadsorb
extract
major
allergen
content
success
measur
extract
amount
relat
pnu
content
expect
variabl
major
allergen
within
particular
extract
speci
higher
standard
extract
adjust
potenc
extract
demonstr
specif
ige
bind
abil
bind
assay
ige
bind
capabl
variou
dilut
relat
major
allergen
content
conclus
method
develop
releas
adsorb
allergen
protein
alum
extract
extract
analyz
major
allergen
protein
abil
bind
ige
major
allergen
content
current
use
monitor
activ
aqueou
glycerin
extract
studi
demonstr
implement
test
procedur
improv
consist
qualiti
alumadsorb
extract
introduct
speci
smut
rust
fungi
ustilago
maydi
corn
smut
basidiomycet
fungu
infect
ear
corn
respons
percentag
grain
loss
unit
state
eaten
delicaci
mexico
grow
larg
tumorlik
structur
call
gall
dispers
sootlik
spore
respons
common
name
smut
readili
airborn
believ
causal
agent
allerg
rhinoconjunct
corn
smut
ad
standard
screen
panel
patient
present
evalu
rhiniti
region
middl
tennesse
method
use
greer
corn
smut
extract
wv
patient
test
prickpunctur
method
hollistersti
devic
neg
intraderm
test
perform
posit
neg
control
assess
base
current
nation
recommend
wheal
mm
greater
neg
control
consid
posit
prickpunctur
test
wheal
mm
greater
neg
control
consid
posit
intraderm
test
result
patient
test
novemb
march
met
criteria
prickpunctur
posit
met
criteria
intraderm
posit
patient
prick
posit
corn
smut
follow
prick
posit
test
dust
mite
cat
local
grass
mix
local
tree
mix
local
weed
mix
mold
mix
cockroach
dog
discuss
allergi
test
aeroallergen
avail
limit
number
antigen
standard
time
pass
relev
antigen
discov
import
elucid
assess
reveal
signific
presenc
corn
smut
ige
larg
account
intraderm
posit
may
may
reflect
clinic
sensit
number
provid
clinician
may
compar
preval
geograph
area
studi
need
determin
associ
corn
smut
ige
clinic
symptom
h
antihistamin
mainstay
therapi
allerg
disord
includ
skin
diseas
common
sideeffect
market
antihistamin
sedat
especi
clinic
symptom
requir
higher
dose
recommend
condit
commonli
encount
dermatolog
disord
present
studi
describ
pharmacolog
new
nonsed
h
antihistamin
bind
clone
human
h
receptor
similar
affin
ki
nm
refer
antihistamin
cetirizin
ki
nm
loratadin
ki
nm
vivo
protect
rat
guinea
pig
lethal
shock
induc
compound
histamin
respect
ed
mgkg
respect
compound
least
effect
cetirizin
loratadin
rat
inhibit
histamineand
allergeninduc
cutan
reaction
ed
mgkg
similar
potenc
cetirizin
ed
mgkg
loratadin
ed
mgkg
even
guinea
pig
compound
inhibit
histamineand
allergeninduc
skin
reaction
ed
mgkg
similar
extent
loratadin
cetirizin
howev
dog
potent
inhibit
ascari
allergeninduc
wheal
reaction
ed
mgkg
cetirizin
ed
mgkg
loratadin
ed
mgkg
fail
occupi
central
h
receptor
guinea
pig
cerebellum
mgkg
contrast
loratadin
ed
mgkg
vitro
vivo
cardiovascular
safeti
experi
indic
lack
intrins
capac
prolong
qtinterv
even
high
dose
character
potent
nonsed
cardiosaf
h
antihistamin
select
clinic
develop
mainli
field
dermatolog
compound
suitabl
tool
explor
activ
select
h
antihistamin
variou
indic
without
contamin
sed
activ
often
observ
market
antihistamin
increas
dose
ciu
repres
one
clinic
perplex
disord
allergistimmunologist
face
previous
report
clinic
efficaci
fxt
prozac
ssri
wide
use
treatment
depress
manag
ciu
nsouli
tm
et
al
ann
allergi
asthma
immunol
present
report
addit
case
ciu
respond
dramat
follow
use
fxt
yrold
femal
yrold
male
present
ciu
month
durat
respect
requir
oral
corticosteroid
cs
therapi
control
ciu
failur
high
dose
hydroxyzin
ranitidin
agent
tabl
test
food
latex
allergi
viral
hepat
autoimmun
thyroid
diseas
parasit
infect
neg
skin
biopsi
perform
subject
consist
urticari
vascul
follow
one
week
oral
fxt
mg
qd
subject
mg
qd
subject
strike
complet
resolut
urticaria
patient
observ
within
day
time
possibl
success
taper
cs
patient
maintain
fxt
therapi
complet
control
ciu
favor
respons
fxt
therapi
patient
addit
first
case
report
suggest
drug
may
new
therapeut
applic
manag
recalcitr
ciu
background
ipratropium
bromid
nasal
spray
ib
indic
treatment
rhinorrhea
caus
common
cold
cc
season
perenni
allerg
rhiniti
ar
adult
children
age
symptom
rhinorrhea
cc
ar
children
similar
adult
yet
littl
data
use
ib
children
year
age
object
evalu
safeti
efficaci
ib
nasal
spray
yearold
children
symptom
rhinorrhea
cc
ar
method
total
children
cc
ar
treat
openlabel
multicent
studi
cc
patient
receiv
ib
nasal
spray
mcg
per
nostril
tid
day
ar
patient
receiv
ib
nasal
spray
mcg
per
nostril
tid
day
effect
measur
use
global
assess
questionnair
daili
symptom
score
report
parent
result
global
assess
questionnair
parent
found
ib
either
use
somewhat
use
cc
ar
group
respect
regard
effect
cc
ar
parent
report
ib
either
good
effect
excel
effect
treat
rhinorrhea
moreov
cc
ar
parent
found
administr
nasal
spray
either
extrem
easi
easi
eightyon
percent
cc
ar
parent
report
would
use
ib
child
allergi
symptom
daili
symptom
score
none
unbear
rhinorrhea
decreas
p
cc
p
baselin
compar
averag
ontreat
score
decreas
also
seen
stuffi
nose
sneez
nasal
spray
well
toler
advers
event
ae
report
cc
ar
patient
ae
mostli
mild
moder
potenti
system
anticholinerg
seriou
ae
report
conclus
ib
nasal
spray
administ
dose
either
mcg
per
nostril
tid
easi
use
safe
effect
therapi
control
rhinorrhea
children
year
age
common
cold
allerg
rhiniti
chronic
idiopath
urticaria
ciu
repres
one
clinic
perplex
disord
allergistimmunologist
face
pathogenesi
condit
deriv
releas
potent
vasoact
substanc
includ
histamin
product
arachidon
acid
metabol
eg
prostaglandin
thromboxan
form
action
enzym
cyclooxygenas
cox
respons
pseudoallerg
inflammatori
respons
although
number
therapeut
option
exist
owe
plethora
mediat
produc
treatment
focus
larg
use
antihistamin
unsurprisingli
time
without
complet
resolut
symptom
present
report
success
use
inhibitor
treatment
chronic
urticaria
yo
white
hispan
femal
present
month
histori
chronic
urticaria
predominantli
sole
feet
unknown
precipit
factor
failur
respond
prior
treatment
cetirizin
steroid
benadryl
ebastin
epinastin
patient
receiv
blood
transfus
year
ago
prior
histori
allergi
skin
test
reveal
reaction
dust
mite
pollen
cockroach
shellfish
reaction
corn
milk
ige
iu
nv
iu
aso
ui
nv
ui
week
treatment
rofecoxib
vioxx
mg
benadryl
rash
resolv
vioxx
continu
week
complet
resolut
symptomatolog
case
illustr
addit
select
inhibitor
ie
rofecoxib
antihistamin
may
effect
regimen
patient
ciu
fail
respond
adequ
convent
therapi
introduct
elderli
asthmat
patient
whose
symptom
control
inhal
corticosteroid
ic
therapi
may
still
breathless
exert
random
elderli
asthmat
patient
stabil
mediumdos
ic
therapi
two
group
treat
one
group
mediumdos
ic
therapi
plu
montelukast
leukotrien
receptor
antagonist
increaseddos
ic
therapi
compar
effect
treatment
regimen
exercis
toler
method
subject
patient
bronchial
asthma
male
femal
year
stabil
ic
therapi
fluticason
proprion
fp
mgday
three
month
low
peak
expiratori
flow
pef
rate
predict
variabl
randomli
divid
two
group
patient
treat
ic
therapi
plu
montelukast
mgday
fp
mgday
montelukast
group
increaseddos
ic
therapi
mgday
fp
f
group
pulmonari
function
test
sixminut
walk
test
respiratori
ga
analysi
increment
cycl
ergomet
exercis
conduct
exhal
nitric
oxid
level
measur
two
week
studi
treatment
result
pulmonari
function
test
show
signific
increas
maxim
midexpiratori
flow
mmf
forc
expiratori
flow
vital
capac
group
p
signific
chang
f
group
exhal
level
decreas
significantli
group
ppb
group
ppb
f
group
p
sixminut
walk
distanc
extend
group
f
groupth
peak
oxygen
uptak
increas
significantli
group
p
f
group
peak
peak
exercis
load
also
increas
significantli
group
w
p
f
group
conclus
result
indic
concomit
administr
montelukast
effect
dose
escal
ic
exercis
toler
elderli
asthmat
patient
mediumdos
ic
therapi
e
meltzer
luo
l
shen
z
guo
c
schemm
huang
k
chen
p
king
r
nave
banerji
rohatagi
san
diego
ca
bridgewat
nj
konstanz
germani
introduct
inhal
corticosteroid
ic
firstlin
treatment
persist
asthma
ciclesonid
cic
novel
effect
ic
develop
freeli
circul
unbound
ic
avail
caus
system
advers
effect
hypothalamicpituitaryadren
hpa
axi
suppress
henc
import
determin
free
fraction
ic
plasma
separ
studi
protein
bind
activ
metabolit
cic
desisobutyrylciclesonid
descic
evalu
effect
inhal
cic
hpa
axi
function
determin
method
human
plasma
protein
bind
descic
ngml
determin
use
equilibrium
dialysi
dialyz
sampl
analyz
liquid
chromatographi
tandem
mass
spectroscopi
determin
free
bound
descic
separ
clinic
studi
effect
cic
hfa
daili
placebo
pbo
via
metereddos
inhal
exactu
dose
day
week
basal
hpa
axi
function
areaunderthecurv
serum
urinari
cortisol
correct
creatinin
stimul
lowdos
cosyntropin
serum
cortisol
investig
patient
year
persist
asthma
result
mean
human
plasma
protein
bind
descic
studi
measur
serum
cortisol
differ
pbo
cic
similar
result
observ
urinari
cortisol
correct
creatinin
studi
measur
lowdos
cosyntropinstimul
peak
serum
cortisol
week
treatment
signific
differ
mean
chang
baselin
versu
placebo
either
conclus
favor
pharmacokinet
profil
cic
particular
high
protein
bind
descic
may
explain
lack
hpaaxi
suppress
appear
result
greater
system
safeti
purpos
unschedul
offic
ed
visit
urgent
asthma
care
ongo
point
concern
determin
prevent
variabl
regard
unschedul
visit
could
signific
impact
asthma
cost
qualiti
life
object
research
address
follow
question
stratifi
race
gender
age
metropolitanrur
place
resid
comorbid
adult
asthma
fewer
ed
unschedul
offic
visit
urgent
asthma
care
identifi
primari
care
provid
b
health
insur
method
univari
stratifi
bivari
conting
tabl
analys
perform
weight
behavior
risk
factor
surveil
survey
brfss
data
result
adult
asthma
identifi
primari
care
provid
like
unschedul
offic
visit
ed
visit
urgent
asthma
care
also
true
adult
asthma
health
insur
unschedul
offic
visit
ed
visit
relationship
held
stratifi
race
gender
age
relationship
also
held
metropolitan
resid
analysi
inconclus
rural
resid
exist
comorbid
conclus
despit
race
gender
age
metropolitan
resid
primari
care
provid
health
insur
impact
whether
adult
asthma
like
unschedul
offic
ed
visit
urgent
asthma
care
investig
need
examin
factor
impact
adult
asthma
rural
resid
comorbid
bukstein
ga
cherayil
madison
wi
brookfield
wi
introduct
cost
plan
process
prior
author
nonformulari
medic
estim
per
request
cost
physician
process
request
extens
studi
method
drbukstein
board
certifi
allergist
develop
data
collect
tool
form
util
physician
nurs
document
time
spent
process
prior
author
data
collect
includ
class
medicin
requir
pa
nurs
time
spent
call
patient
pharmacist
health
plan
nurs
time
spent
complet
form
nurs
time
clarifi
inform
pa
well
physician
time
spent
complet
pa
activ
result
data
collect
week
request
processedth
class
medicin
often
process
antihistamin
compris
request
nurs
call
track
call
patient
common
call
document
averag
call
per
day
per
nurs
nurs
spent
averag
minut
per
patient
call
call
health
plan
averag
call
per
nurs
per
day
time
spent
call
minut
per
call
physician
call
document
includ
call
averag
call
per
physician
per
day
call
averag
minut
per
calloften
result
prior
author
known
day
request
origin
request
grant
day
retrospect
review
reveal
approv
first
time
process
salari
benefit
calcul
nurs
physician
hourli
rate
defin
per
hour
nurs
per
hour
physician
cost
time
spent
prior
author
calcul
week
studi
period
hour
spent
nurs
call
hour
spent
physician
call
time
period
total
nurs
physician
cost
specialti
practic
per
prior
author
conclus
substanti
cost
process
prior
author
request
nonformulari
drug
physician
offic
side
manag
care
well
insur
side
process
specialti
physician
differ
process
obtain
nonformulari
medic
sinc
almost
request
grant
introduct
diabet
mellitu
advers
impact
cours
outcom
myocardi
infarct
mi
one
mechan
underli
phenomenon
alter
cours
inflamm
repar
process
follow
myocardi
necrosi
abnorm
wound
heal
tissu
repar
immun
respons
diabet
patient
intens
studi
cellular
molecular
mechan
still
unclear
transform
growth
factorbeta
tgfbeta
multifunct
cytokin
play
critic
role
coordin
cours
inflamm
repar
act
potent
depressor
inflamm
stimul
regener
studi
investig
dynam
serum
concentr
activ
form
period
day
onset
mi
diabet
nondiabet
patient
result
nondiabet
signific
increas
observ
day
greater
control
pgml
respect
increas
reach
peak
day
pgml
day
decreas
level
less
day
still
greater
healthi
control
pgml
diabet
concentr
day
pgml
pgml
mi
similar
diabet
without
mi
pgml
day
increas
level
pgml
fold
greater
diabet
without
mi
thu
diabet
patient
serum
concentr
activ
form
much
greater
nondiabet
mi
patient
diabet
mellitu
associ
reduc
significantli
delay
increas
conclus
tgfbeta
defici
may
factor
associ
low
activ
tissu
repar
mi
diabet
patient
introduct
helicobact
pylori
hp
common
gastrointestin
infect
worldwid
infect
develop
chronic
gastriti
peptic
ulcer
diseas
pathogenesi
ulcer
mechan
hp
lifelong
persist
gastric
mucosa
local
immun
disturb
induc
infect
well
known
mechan
resist
elimin
infect
extens
studi
studi
base
phenomenolog
find
absenc
low
hp
colon
subject
spontan
produc
high
level
aim
investig
analysi
efficaci
recombin
interleukin
roncoleukin
biotech
russia
treatment
hpassoci
gastric
ulcer
diseas
method
patient
randomli
divid
two
group
first
group
patient
treat
standard
therapi
includ
two
antibiot
claritromycin
amoxicillin
proton
pomp
inhibitor
receptor
antagonist
patient
second
group
treat
therapi
instead
antibiot
receiv
mg
roncoleukin
four
six
area
submuc
use
gastroscop
method
mg
roncoleukin
dissolv
ml
nacl
ml
human
albumin
infus
intraven
procedur
perform
three
time
interv
hour
result
immunolog
find
demonstr
roncoleukin
result
increas
hladr
cell
level
increas
serum
concentr
fold
fold
ifn
fold
level
tnf
profoundli
decreas
one
month
end
treatment
group
treat
hp
erad
achiev
comparison
control
patient
treat
group
ulcer
epithel
period
day
normal
treatment
control
group
day
p
conclus
immunotherapi
effect
method
treatment
helicobact
pyloriassoci
gastric
ulcer
diseas
compar
tradit
method
treatment
employ
antibiot
introduct
role
differ
cytokin
growth
factor
appreci
progress
essenti
hypertens
particip
tgf
pathogenesi
essenti
hypertens
especi
process
fibrosi
hypertrophia
vascular
smooth
muscular
fiber
cardiomyocyt
activ
reninangiotensin
system
recogn
addit
effect
myocyt
cultur
aim
investig
studi
serum
tgf
level
patient
essenti
hypertens
materi
method
patient
essenti
hypertens
male
femal
averag
age
year
studi
patient
suffer
left
ventricl
hypertrophi
document
echocardiographi
control
group
consist
healthi
volunt
similar
investig
patient
sex
age
patient
serum
concentr
tgf
determin
use
elisa
biomedica
biosourc
result
increas
serum
concentr
growth
factor
note
studi
group
compar
control
group
averag
concentr
patient
essenti
hypertens
pmoll
level
control
group
pmoll
concentr
tgf
essenti
hypertens
patient
pgml
control
group
pgml
posit
correl
concentr
spearmen
rank
coeffici
correl
conclus
increas
serum
concentr
growth
factor
tgf
coinfluenc
patient
essenti
hypertens
suggest
role
growth
factor
pathogenesi
arteri
hypertens
u
kaza
c
lauter
bloomfield
hill
mi
royal
oak
mi
introduct
studi
examin
referr
pattern
allergi
immunolog
inpati
consult
commun
hospit
consequ
invalu
part
physician
housestaff
educ
miss
object
examin
number
inpati
allergi
immunolog
consult
reason
consult
outcom
patient
order
improv
physician
educ
method
perform
retrospect
chart
review
inpati
allergi
immunolog
consult
year
determin
reason
consult
recommend
made
follow
outcom
patient
result
review
total
inpati
allergi
immunolog
consult
time
period
inpati
consult
asthma
drug
allergi
rash
time
period
inpati
consult
rash
drug
allergi
asthma
top
three
reason
consult
remain
although
order
chang
consult
immun
defici
angioedema
rash
increas
wherea
consult
asthma
allergi
decreas
total
consult
number
consult
remain
despit
increas
overal
number
hospit
admiss
greater
consult
allergist
recommend
follow
time
period
studi
greater
patient
improv
less
improv
remaind
case
improv
applic
conclus
conclus
believ
identifi
reason
inpati
allergi
immunolog
consult
examin
common
recommend
well
outcom
patient
valuabl
guid
educ
physician
incorpor
inform
grand
round
resid
confer
physician
benefit
learn
allergist
help
manag
common
allerg
immunolog
problem
patient
hospit
high
percentag
provid
follow
advic
allergist
indic
allergist
great
deal
educ
valu
offer
physician
complementari
altern
medicin
cam
gener
experienc
increas
popular
util
allergyasthma
patient
remain
uncertain
privat
allergi
practic
survey
use
cam
allergyasthma
patient
use
similar
questionnair
assess
current
interest
cam
allergyasthma
patient
compar
data
survey
analyz
complet
questionnair
sequenti
survey
administ
result
compar
questionnair
report
indic
studi
period
major
patient
want
discuss
cam
respect
equal
number
studi
period
discuss
cam
primari
care
provid
sixteen
percent
respond
sought
cam
practition
gener
medic
need
vs
howev
increas
patient
see
cam
practition
allergi
andor
asthma
sixtytwo
percent
would
like
consid
pursu
cam
allergi
specialti
practic
provid
ask
regard
prefer
treatment
state
combin
tradit
cam
prefer
tradit
cam
knowdoctor
choic
patient
seek
chiropract
care
compar
result
acupunctur
first
choic
cam
modal
surpass
vitaminminer
therapi
current
second
third
choic
vitaminminer
therapi
deep
tissu
massag
number
small
impress
current
two
half
time
sinc
patient
practic
seek
cam
allergyasthma
care
outsid
practic
result
demonstr
half
patient
interest
pursu
tradit
cam
option
within
offic
given
trend
begun
discuss
concept
integr
allergi
us
mean
integr
evidencedbas
cam
modal
within
tradit
allergyasthma
practic
introduct
clinic
immun
knowledg
complex
demand
ongo
train
nation
basic
immun
vaccin
safeti
educ
limit
within
tradit
medic
nurs
provid
educ
project
immun
readi
pir
peerreview
webbas
interact
cours
develop
respons
deficit
need
standard
resourc
provid
initi
sustain
train
safe
effect
immun
servic
design
medic
personnel
divers
educ
prepar
current
pir
offer
cours
modul
address
hour
instruct
specif
vaccin
respect
diseas
gener
inform
immun
healthcar
vaccin
procedur
method
user
complet
pretest
establish
baselin
knowledg
interact
modul
follow
posttest
observ
chang
baselin
cours
sequenc
anonym
user
score
data
collect
part
qualiti
assur
cours
valid
process
learn
gain
indic
lgi
calcul
base
averag
mean
pretest
posttest
score
modul
lgi
modul
demonstr
substanti
increas
user
vaccin
knowledg
compar
pre
posttest
effect
method
assess
learn
gain
find
support
pir
success
valid
distancelearn
tool
establish
document
core
knowledg
medic
personnel
administ
vaccin
research
need
assess
effect
knowledg
acquisit
retent
addit
varianc
vaccin
deliveri
train
approach
learn
may
valu
resourc
support
smallpox
influenza
pandem
emerg
prepared
plan
time
train
introduct
varianc
practic
guidelin
prescript
autoinject
epinephrin
well
document
among
practic
physician
famili
patient
effect
patient
educ
requir
provid
compet
current
studi
design
survey
resid
physician
percept
regard
autoinject
epinephrin
educ
use
patient
educ
requir
method
resid
primari
care
disciplin
tertiari
care
medic
center
invit
complet
voluntari
anonym
questionnair
total
survey
distribut
return
emerg
medicin
famili
practic
intern
medicin
pediatr
resid
complet
questionnair
due
small
sampl
size
respons
physician
variou
disciplin
review
whole
result
respond
report
previous
prescrib
autoinject
epinephrin
allerg
emerg
major
prescrib
report
train
inadequ
respond
report
train
respond
report
train
less
need
ensur
profici
respond
report
train
adequ
ensur
profici
none
report
expertis
prescrib
report
either
staff
alway
demonstr
proper
medic
use
patient
interestingli
provid
report
train
proper
use
tabl
summar
resid
train
patient
educ
practic
addit
physician
knowledg
deficit
includ
proper
site
medic
administr
proper
interv
replac
medic
proper
place
medic
storag
conclus
resid
survey
previous
prescrib
autoinject
epinephrin
identifi
train
defici
prescrib
report
standard
care
requir
demonstr
proper
medic
use
alway
met
clear
need
improv
autoinject
epinephrin
educ
resid
train
program
r
bloebaum
rk
calabres
houston
tx
new
york
ny
introduct
pneumocysti
carinii
pneumonia
pcp
major
caus
morbid
mortal
patient
aid
advers
reaction
occur
frequent
effect
medic
prevent
treatment
pcp
trimethoprimsulfamethoxazol
tmpsmx
look
immedi
safeti
efficaci
three
protocol
desensit
aid
patient
method
retrospect
chart
review
identifi
patient
aid
experienc
previou
mild
moder
hypersensit
reaction
tmpsmx
requir
desensit
patient
receiv
one
three
desensit
protocol
base
ill
sever
ward
attend
prefer
intraven
iv
desensit
oral
desensit
oral
desensit
result
patient
receiv
desensit
complet
success
subject
reaction
desensit
process
howev
seven
subject
steroid
treatment
diseas
remain
five
success
patient
mild
reaction
treat
symptomat
acetaminophen
antihistamin
eleven
patient
fail
complet
desensit
six
stop
attend
physician
four
drop
voluntarili
one
patient
expir
desensit
extens
diseas
complic
relat
admit
diagnosi
protocol
equal
success
compar
immedi
success
rate
protocol
protocol
protocol
iv
desensit
protocol
frequent
use
intens
care
unit
critic
ill
patient
two
patient
count
success
desensit
die
day
post
protocol
complet
secondari
extens
comorbid
condit
unrel
desensit
conclus
given
insignific
differ
success
iv
desensit
oral
desensit
protocol
believ
either
may
use
effect
patient
mild
moder
hypersensit
reaction
tmpsmx
oral
desensit
protocol
may
use
safe
outpati
set
given
appropri
lab
follow
moral
e
gonzalez
contrera
lopez
g
lopez
mexico
citi
mexico
introduct
davi
describ
job
syndrom
two
women
dr
buckley
report
two
children
known
hyperig
syndrom
job
syndrom
buckley
syndrom
defin
primari
immunodefici
domin
autosom
character
multisystemat
alter
immunolog
skelet
dermal
dental
diagnost
criteria
level
ige
uiml
chronic
dermat
recur
respiratori
infect
cold
abscess
pneumatocel
infect
caus
candida
final
craniofaci
alter
anoth
front
extraordinari
high
level
ige
report
patient
allerg
ill
increas
risk
anaphylaxi
job
syndrom
criteria
objet
determin
allerg
patient
ige
level
higher
uiml
diagnost
job
syndrom
materi
method
retrospect
revis
realiz
may
april
file
patient
treat
allergi
servic
instituto
nacion
de
pediatria
total
ige
greater
uiml
mean
page
recollect
date
result
nine
women
men
includ
age
rang
year
averag
age
year
diagnos
allergi
rhiniti
allergi
asthma
topic
dermat
coexist
patient
present
hereditari
anteced
atop
cutan
test
posit
greater
reactiv
dermatophagoid
one
syndrom
hyper
ige
detect
other
diagnos
found
allerg
hunter
syndrom
toxocariasi
conclus
patient
allergi
total
level
ige
elev
uiml
without
correspond
job
syndrom
multiallerg
clinic
entiti
propos
level
greater
uiml
introduct
home
monitor
lung
function
asthmat
patient
use
extens
clinic
research
set
howev
littl
attent
given
devic
qualiti
control
object
purpos
studi
determin
accuraci
precis
use
airwatch
system
enact
health
manag
system
palo
alto
ca
usa
method
subject
includ
studi
submit
spirometri
follow
american
thorac
societi
guidelin
at
use
collin
gs
pft
system
afterward
peak
expiratori
flow
rate
pef
forc
expiratori
volum
one
second
determin
use
airwatch
pef
measur
devic
compar
use
two
sampl
ttest
pearson
correl
coeffici
result
total
patient
femal
enrol
mean
age
year
year
measur
rang
l
mean
l
l
mean
l
collin
airwatch
respect
pef
rang
lmin
mean
lmin
collin
lmin
airwatch
mean
lmin
signific
differ
note
pef
measur
p
pearson
correl
r
two
devic
howev
observ
differ
measur
concern
regarless
degre
obstruct
high
low
flow
rate
result
chang
conclus
airwatch
show
great
util
measur
compar
collin
spiromet
although
airwatch
abl
assess
lung
function
home
daili
basi
reliabl
pef
measur
introduct
epidemiolog
data
show
poorli
control
asthma
seriou
public
health
problem
degre
implement
naepp
guidelin
primari
care
practic
remain
defin
object
survey
determin
introduct
assess
tool
primari
care
practic
along
special
design
program
implement
guidelin
would
improv
diagnosi
therapi
method
asthma
care
network
acn
program
design
assist
healthcar
provid
assess
manag
patient
asthma
employ
team
special
train
respiratori
care
associ
rca
rn
rt
visit
primari
care
offic
inform
staff
variou
compon
naepp
guidelin
assist
implement
total
primari
care
provid
site
recruit
part
acn
program
data
patient
visit
collect
analyz
march
januari
program
assess
tool
survey
asthma
control
medic
prescrib
pattern
outcom
measur
includ
degre
symptom
control
limit
activ
sleep
disrupt
use
rescu
medic
util
urgent
care
servic
data
collect
offic
visit
assess
form
ova
complet
patient
physician
rca
provid
inform
educ
devic
train
use
inhal
spacer
ce
cours
staff
discuss
pathophysiolog
assess
manag
asthma
result
total
ova
form
complet
among
patient
includ
adult
older
year
age
children
year
age
rang
report
symptom
consist
lack
asthma
control
approxim
survey
group
marker
uncontrol
asthma
result
assess
control
medic
use
increas
icscontain
medic
conclus
inform
provid
primari
care
health
care
provid
result
consider
increas
prescript
control
therapi
particular
increas
use
ic
control
medic
consist
naepp
guidelin
background
patient
allerg
rhiniti
ar
demonstr
symptom
allergi
fruit
veget
nut
case
oral
allergi
syndrom
oa
typic
hypersensit
plant
food
base
crossreact
pollenallergen
specif
immunoglobulin
e
ige
antibodi
homolog
food
protein
product
cytokin
allerg
rhiniti
patient
without
sensit
food
fruit
veget
allergen
assess
method
fifti
five
patient
age
year
allerg
rhiniti
observ
group
patient
ar
group
ii
patient
ar
oa
sensit
pollen
allergen
test
skin
prick
test
allerg
reaction
food
patient
oa
prove
posit
histori
oral
symptom
caus
eat
fruit
veget
posit
skin
prick
test
respect
food
allergen
blood
eosinophil
count
total
ige
level
determin
peak
allerg
rhiniti
symptom
interferon
level
measur
elisa
result
patient
sensit
grass
pollen
tree
pollen
react
pollen
grass
tree
weed
patient
oa
skin
test
often
posit
birch
alder
mugwort
common
food
product
implic
oa
hazelnut
appl
carrot
peanut
allergi
fruit
veget
confirm
posit
prick
test
season
blood
eosinophil
count
total
ige
level
elev
patient
increas
product
pcgml
group
pcgml
group
ii
pcgml
level
increas
pcgml
group
pcgml
group
ii
pcgml
level
ifn
decreas
pcgml
group
group
ii
pcgml
sit
pollen
allergen
clinic
manifest
allerg
rhiniti
oa
decreas
patient
conclus
allerg
rhiniti
patient
sensit
food
allergen
may
caus
oa
patient
associ
increas
function
activ
respons
patient
knowledg
improv
allergen
immunotherapi
cc
randolph
waterburi
ct
introduct
consensu
object
paramet
improv
immunotherapi
similarli
littl
known
regard
patient
knowledg
immunotherapi
util
two
publish
questionnair
assess
clinic
improv
base
symptom
medic
score
knowledg
immunotherapi
method
chart
patient
estim
allerg
rhiniti
concomit
asthma
retrospect
prospect
review
immunotherapi
inhal
month
year
mean
year
age
rang
mean
male
femal
caucasian
orient
afroamerican
complet
symptom
medic
survey
everi
month
rang
improv
use
declin
likert
scale
mean
indic
improv
symptom
andor
medic
complet
question
survey
knowledg
immunotherapi
question
regard
outcom
immunotherapi
year
onset
immun
durat
onset
immun
danger
immunotherapi
extract
vial
correct
respons
record
perfect
respons
question
correct
respons
conclus
major
immunotherapi
patient
improv
symptom
medic
score
mean
year
complet
knowledg
rational
immunotherapi
educ
repeat
survey
patient
immunotherapi
assur
comprehens
knowledg
immunotherapi
achiev
better
outcom
recommend
investig
uniqu
studi
symptom
medic
score
use
rhiniti
sinus
questionnair
approv
acaai
comprehens
questionnair
assess
knowledg
conduct
period
ie
everi
month
provid
object
paramet
improv
refer
j
nathan
r
glassheim
j
patient
receiv
immunotherapi
report
effect
assess
rhiniti
outcom
questionnair
raq
privat
protein
involv
parasit
invas
host
erythrocyt
lead
vaccin
candid
erythrocyt
stage
malaria
infect
increas
number
vaccin
clinic
trial
undertaken
use
variou
formul
comparison
humor
respons
among
trial
limit
lack
univers
refer
standard
specif
antibodi
purpos
studi
develop
human
refer
standard
antibodi
measur
absolut
quantiti
unit
could
facilit
comparison
interstudi
vaccin
respons
method
formul
refer
standard
pool
human
plasma
sampl
known
contain
high
titer
antibodi
specif
antibodi
within
pool
plasma
captur
adsorb
nickel
resin
process
immobil
metal
affin
chromatographi
imac
intact
antibodyantigen
complex
separ
nickel
resin
total
igg
complex
measur
enzymelink
immunosorb
assay
elisa
result
antibodi
quantit
method
yield
concentr
mcgml
antibodi
refer
standard
conclus
refer
standard
character
studi
may
use
quantit
work
standard
antibodi
respons
futur
vaccin
clinic
trial
involv
standard
may
facilit
clinic
develop
candid
vaccin
malaria
infect
background
specif
immunotherapi
sit
current
one
effect
wide
use
treatment
method
allerg
diseas
includ
asthma
efficaci
sit
depend
correct
choic
patient
sever
asthma
patient
condit
sit
begun
accord
recommend
sit
approv
use
patient
mild
moder
asthma
method
sit
salin
extract
hous
dust
allergen
administ
patient
mild
persist
allerg
asthma
inject
perform
subcutan
per
day
cours
consist
pnu
allergen
last
day
patient
repeatedli
survey
month
sit
complet
dyspnea
attack
occur
daytim
night
assess
influenc
physic
exert
dyspnea
lung
function
also
number
util
shortact
betaagonist
per
day
pulmonari
function
measur
perform
assess
concomit
allerg
rhiniti
patient
receiv
treatment
includ
cromon
util
inhal
corticosteroid
among
dose
mcg
per
day
mcg
per
day
sit
efficaci
assess
clinic
symptom
pulmonari
function
measur
amount
concomit
therapi
receiv
result
number
daytim
dyspnea
attack
reduc
per
month
month
follow
sit
patient
reduc
concomit
asthma
therapi
month
dyspnea
attack
increas
per
month
still
significantli
less
prior
sit
nocturn
symptom
follow
pattern
occur
per
month
prior
sit
per
month
month
sit
per
month
end
sixth
month
sit
patient
symptom
bronchial
obstruct
month
sit
pulmonari
function
approach
normal
valu
although
patient
return
asthma
therapi
nasal
congest
decreas
point
p
clinic
improv
still
present
month
sit
recur
month
sit
conclus
sit
may
effect
treatment
method
improv
asthma
allerg
rhiniti
month
follow
brief
cours
allow
decreas
amount
symptomat
treatment
safe
therapeut
vaccin
alter
allerg
respons
peanut
would
serv
seriou
unmet
medic
need
peanut
allergi
respons
larg
associ
downstream
event
relat
antigen
specif
ige
crosslink
ige
receptor
subsequ
degranul
mast
cell
basophil
clinic
studi
ragwe
shown
link
immunostimulatori
dna
iss
allergen
decreas
ige
recognit
allergen
gener
immunogen
gener
protect
respons
reduc
harm
respons
test
approach
peanut
immunotherapi
focus
clinic
relev
allergen
ara
h
proof
concept
iss
oligonucleotid
link
ara
h
two
differ
ratio
pic
iss
per
protein
hpic
iss
per
protein
immunogen
pic
hpic
evalu
femal
mice
immun
twice
ug
pic
hpic
ara
h
sera
analyz
antiara
h
respons
spleen
harvest
ara
h
ifng
respons
measur
vitro
mice
immun
ara
h
elicit
predominantli
respons
indic
respons
anim
immun
pic
show
significantli
enhanc
respons
strong
ifng
respons
indic
respons
hpic
immun
mice
elicit
littl
antibodi
respons
presum
due
iss
block
b
cell
epitop
induc
ifng
respons
assess
allergen
pic
hpic
histamin
releas
measur
blood
peanut
allerg
donor
treat
vitro
pic
hpic
ara
h
histamin
releas
detect
low
concentr
ara
h
ngml
higher
concentr
pic
ngml
undetect
concentr
higher
hpic
ngml
ige
bind
competit
assay
also
confirm
reduct
allergen
follow
trend
isslink
allergen
link
iss
ara
h
increas
respons
allergen
block
ige
recognit
epitop
ara
h
thu
isslink
ara
h
appear
promis
candid
safe
immunotherapi
product
treat
peanut
allerg
subject
introduct
immunotherapi
studi
advers
effect
sensit
patient
worsen
therapeut
respons
amount
withdraw
later
method
allergi
center
therapeut
trial
immunotherapi
hous
dust
mixmit
undertaken
sinc
therapeut
dose
housedust
mixmit
patient
age
year
sex
diagnost
scratchprick
test
appropri
antigen
prepar
report
localsystem
advers
effect
detail
result
pleas
see
attach
tabl
detail
case
worsen
exist
allerg
statu
note
analysi
reveal
initi
slow
rise
allergen
specif
ige
later
follow
rise
gradual
fall
igeonli
patient
could
complet
immunotherapi
fear
advers
effect
conclus
utmost
carefollowup
incid
mortal
outcom
report
late
incid
advers
effect
significantli
lower
premed
antihistamin
significantli
elderli
younger
age
even
document
hazard
benefici
effect
far
exceed
harm
effect
background
preval
allerg
diseas
human
popul
steadili
increas
seafood
allergi
seriou
food
allergi
although
hypersensit
reaction
caus
seafood
long
know
biochem
immunolog
studi
seafood
allergi
begun
late
shrimp
abalon
frequent
report
caus
earli
asthmat
respons
object
investig
crossreact
shrimp
abalon
method
shrimp
abalon
extract
prepar
raw
seafood
sera
patient
hongkong
studi
asthma
consumpt
seafood
ige
elisa
analys
comfirm
combin
sensit
shrimp
abalon
specificig
elisa
assay
accomplish
shrimp
abalon
extract
inhibit
elisa
immunoblot
assay
inhibit
shrimp
abalon
extract
result
elisa
inhibit
show
ige
antibodi
shrimp
abalon
crossreact
time
elisa
inhibit
shrimp
abalon
extract
elisa
inhibit
percent
shrimp
extract
abalon
extract
significantli
higher
shrimp
extract
abalon
extract
p
furthermor
signific
correl
elisa
inhibit
percent
shrimp
extract
abalon
extract
inhibit
sdspage
immunoblot
shrimp
abalon
allergen
respect
conclus
indic
sensit
agent
shrimp
abalon
demonstr
signific
crossreact
find
confirm
primari
crossreact
allergen
shrimp
abalon
allergen
respect
b
sun
wu
n
zhong
guangzhou
china
hong
kong
background
hous
dust
mite
dermatophagoid
farina
derf
major
sourc
aeroallergen
implic
express
atop
disord
includ
asthma
allerg
rhiniti
atop
dermat
particular
strong
circumstanti
evid
suggest
hous
dust
mite
antigen
import
precipit
factor
asthma
mani
hous
duse
mite
allergen
proteas
elicit
airway
inflamm
stimul
releas
cytokin
bronchial
epitheli
cell
object
investig
whether
der
f
allergen
proteas
induc
cytokin
product
epitheli
cell
line
method
cell
expos
four
differ
concentr
serial
addit
der
f
incub
compar
without
incub
allergen
cytokin
supernat
assay
elisa
revers
transcript
pcr
also
perform
result
cell
treat
der
f
allergen
show
serial
chang
cohes
monolay
signific
increas
level
cytokin
product
compar
untrea
sampl
statist
significantli
increas
addit
der
f
caus
releas
time
concentrationdepend
manner
p
respect
level
elev
h
h
allergen
exposur
increas
time
continu
increas
level
present
supernat
h
h
time
show
concentr
depend
induct
express
well
increas
express
conclus
hdminduc
airway
inflamm
may
includ
der
fmediat
releas
inflammatori
mediat
proteolyt
activ
allergen
may
stimul
releas
proinflammatori
cytokin
human
bronchial
epithelium
suggest
product
bronchial
epitheli
cell
may
play
role
pathogenesi
allerg
asthma
purpos
studi
delin
immun
injuri
mechan
involv
autoimmun
inner
ear
diseas
introduc
plasmid
dna
encod
cytokin
infg
inner
ear
btubulin
microtubular
protein
found
import
autoantigen
menier
diseas
well
autoimmun
hear
loss
hear
loss
induc
mice
guinea
pig
immun
tubulin
molecul
autoimmun
hear
loss
could
result
cytokin
respons
autoimmun
injuri
test
hypothesi
guinea
pig
immun
tubulin
cfa
boost
two
week
later
introduc
nake
dna
encod
infg
inject
left
side
inner
ear
round
window
volum
pb
inject
right
side
control
abr
record
inject
week
inject
anim
sacrif
tempor
bone
examin
infg
immunocytochem
stain
ear
inject
plasmid
dnainfg
enhanc
hear
loss
db
degener
spiral
ganglion
found
ear
howev
inject
nake
dna
encod
infg
chang
express
infg
inner
ear
result
suggest
autoimmun
hear
loss
could
result
respons
inner
ear
autoantigen
tubulin
import
molecul
hair
cell
support
cell
within
sensori
epithelium
organ
corti
found
auto
autoantigen
autoimmun
hear
loss
includ
diseas
object
studi
induc
hear
loss
mice
vari
dose
antigen
evalu
pathogenesi
autoimmun
hear
loss
induc
tubulin
mice
mice
immun
tubulin
hear
evalu
auditori
brainstem
respons
abr
distort
product
otoaccoust
emiss
dpoae
mice
hear
loss
abr
dpoae
test
morpholog
studi
tempor
bone
show
spiral
ganglion
degener
tunel
stain
posit
cell
note
immun
mice
thu
studi
show
tubulin
autoantigen
hear
loss
anim
model
human
autoimmun
hear
loss
patient
includ
diseas
support
nih
introduct
oral
polio
vaccin
opv
unit
state
current
replac
inactiv
polio
vaccin
ipv
given
parentr
past
studi
look
relationship
vaccin
asthma
preval
none
investig
relationship
regard
vaccin
rout
name
oral
versu
parentr
studi
investig
relationship
vaccin
rate
live
attenu
oral
administ
polio
vaccin
parentr
administ
vaccin
dtp
mmr
two
potenti
depend
factor
asthma
preval
rate
asthmacaus
death
rate
method
look
data
nation
center
health
statist
yearli
public
health
unit
state
morbid
mortal
weekli
report
surveil
summari
two
databas
compil
cover
age
popul
unit
state
sinc
primari
period
childhood
vaccin
one
databas
contain
inform
asthma
relat
death
vaccin
rate
dtp
mmr
opv
cover
year
databas
compil
inform
self
report
asthma
preval
vaccin
rate
dtp
measl
rubella
opv
cover
period
ttest
use
statist
analysi
result
statist
signific
correl
found
vaccin
rate
asthma
preval
rate
data
dtp
p
measl
p
rubella
p
indic
statist
signific
posit
correl
asthma
preval
oral
polio
vaccin
one
vaccin
fail
display
signific
relationship
asthma
preval
rate
p
statist
analysi
prove
correl
vaccin
rate
unit
state
children
age
asthmacaus
death
insignific
p
conclus
opv
administ
oral
rather
parentr
display
relationship
asthma
preval
could
due
fact
live
attenu
oral
administr
polio
vaccin
may
induc
mucos
immun
simul
normal
pathogen
rout
entri
bodi
childhood
vaccin
relationship
asthmacaus
death
rate
alfrayh
riyadh
saudi
arabia
introduct
hered
play
major
role
asthma
allerg
diseas
mechan
underli
inherit
disord
poorli
understood
studi
therefor
analyz
risk
confer
famili
histori
asthma
atopi
childhood
asthma
method
total
children
yr
select
randomli
three
citi
saudi
arabia
hail
taif
gizan
questionnair
similar
one
use
intern
studi
allergi
asthma
childhood
isaac
self
administerd
medic
supervisionapart
demogrph
detail
questionnair
includ
question
symptom
physician
diagnosi
asthma
rhiniti
eczema
famili
histori
condit
famili
member
group
immedi
famili
rel
asthma
atopi
defin
ever
physician
diagnosi
condit
inform
also
avail
exposur
cigarett
somk
least
one
member
smoker
household
pet
rel
risk
develop
asthma
estim
term
odd
ratio
bivari
analys
use
chi
squar
test
p
valu
consid
signific
less
result
histori
asthma
immedi
famili
rel
confer
fold
fold
risk
develop
childhood
asthma
odd
ratio
confid
interv
ci
respect
rhiniti
immedi
famili
rel
associ
fold
increas
risk
childhood
asthma
ci
respect
wherea
histori
eczema
confer
fold
risk
ci
childhood
asthma
present
immedi
famili
histori
eczema
rel
associ
risk
environment
factor
exposur
cigarett
smoke
confer
fold
risk
develop
childhood
asthma
ci
p
wherea
exposur
pet
signific
risk
foctor
conclus
presenc
asthma
atopi
either
biolog
parent
rel
constitut
signific
risk
childhood
asthmaparicularli
presenc
evironment
risk
factor
murin
local
lymph
node
assay
llna
develop
altern
guinea
pig
model
assess
contact
sensit
potenti
howev
need
develop
nonradioisotop
endpoint
llna
radioisotop
method
requir
use
special
facil
studi
investig
evalu
lymphocyt
subpopul
lymph
node
cell
follow
allergen
irrit
treatment
femal
balbc
mice
treat
topic
applic
dorsum
ear
sensit
dncb
toluen
diisocyan
tdi
ahexylcinnamaldehyd
hca
irrit
sodium
lauryl
sulfat
sl
daili
three
consecut
day
lymph
node
ln
cell
harvest
final
treatment
phenotyp
analysi
lymphocyt
subset
perform
flow
cytometri
allergen
dncb
tdi
hca
irrit
sl
increas
cell
number
compar
vehicl
increas
percentag
cell
mice
treat
dncb
tdi
compar
vehicl
control
treat
sl
mice
treat
dncb
hca
tdi
show
preferenti
increas
percentag
cell
compar
vehicl
irritanttr
mice
increas
cell
mice
treat
dncb
tdi
hca
signific
increas
observ
mice
treat
sl
mice
treat
dncb
tdi
show
increas
percentag
cell
compar
vehicl
irritanttr
mice
result
suggest
analysi
b
cell
activ
marker
b
cell
may
use
differenti
allergen
irrit
respons
drain
lymph
node
chemic
treat
mice
frieri
yc
huang
east
meadow
ny
introduct
nitric
oxid
import
biomark
inflamm
airway
epitheli
cell
exhal
breath
asthmat
subject
previous
demonstr
product
antigenstimul
human
bronchial
epitheli
cell
effect
omalizumab
monoclon
antiig
antibodi
product
cell
leyko
bt
et
al
j
allergi
clin
immunol
suppl
studi
investig
potenti
role
ige
receptor
cell
character
effect
omalizumab
antigen
egf
stimul
cell
medium
contain
atop
serum
method
human
alveolar
epitheli
cell
stimul
iuml
ragwe
ra
au
dust
mite
dm
ngml
egf
expos
either
budesonid
omalizumab
hour
product
measur
duplic
highli
sensit
elisa
result
omalizumab
budesonid
inhibit
product
hour
cell
stimul
p
dm
ra
alon
howev
hour
omalizumab
budesonid
significantli
inhibit
product
stimul
dm
egf
p
conclus
product
marker
inflamm
omalizumab
demonstr
signific
antiinflammatori
effect
distal
alveolar
cell
inhibit
product
stimul
antigen
egf
medium
contain
atop
serum
persist
inflamm
asthma
may
play
role
airway
remodel
treatment
omalizumab
may
benefici
effect
chronic
airway
inflamm
patient
asthma
oral
toler
trigger
regulatori
mechan
abl
downmodul
antigenspecif
b
cell
respons
address
last
effect
sever
regimen
oral
toler
ovalbumin
naiv
antigen
prime
mice
bcell
function
focus
furthermor
analyz
specif
antibodi
respons
eight
month
postimmun
prolif
respons
express
b
cell
cell
involv
oral
toler
asn
mice
immun
intraperiton
rout
mgalum
boost
day
prime
dap
ova
feed
done
differ
day
antigen
prime
other
protocol
mice
fed
twice
prime
total
ova
group
boost
dap
result
show
mice
fed
naiv
statu
fed
twice
immun
demonstr
long
last
ige
ab
respons
inhibit
month
immun
mice
show
mark
inhibit
antigenspecif
prolif
respons
restor
mab
vitro
stimul
evalu
flow
cytometri
spleen
cell
cultur
hour
upon
ova
stimul
show
import
decreas
b
express
b
cell
naiv
fed
mice
remain
inhibit
month
immun
addit
mab
enhanc
express
detect
b
cell
naiv
fed
mice
molecul
express
cell
naiv
fed
mice
remain
unchang
follow
ova
stimul
peak
express
detect
ova
stimul
control
group
find
reinforc
cell
anerg
statu
naiv
fed
mice
due
less
cell
divis
consequ
low
rate
activ
cell
result
show
antigen
feed
immun
induc
long
last
anergi
mediat
impair
tb
cell
cooper
ab
product
due
decreas
costimulatori
molecul
express
b
cell
neg
signal
effect
express
introduct
vascular
endotheli
growth
factor
vegf
basic
fibroblast
growth
factor
bfgf
fibronectin
fn
promot
angiogenesi
put
compon
airway
remodel
albuterol
exacerb
airway
hyperrespons
bronchospasm
releas
proinflammatori
cytokin
small
airway
smooth
muscl
cell
studi
evalu
effect
albuterol
r
albuterol
r
secret
factor
normal
human
lung
fibroblast
nhlf
myofibroblast
myonhlf
presenc
absenc
tgf
allergen
method
nhlf
stimul
differenti
myonhlf
pgml
tgf
dosedepend
effect
r
evalu
secret
vegf
bfgf
fn
nhlf
myonhlf
without
auml
pteronyssinu
dp
pnuml
ragwe
ra
uml
pgml
tgf
serumfre
media
c
co
collect
hr
assay
elisa
result
nhlf
follow
observ
vegf
secret
higher
r
rel
p
bfgf
secret
increas
rel
r
p
lower
concentr
presenc
either
dp
caus
increas
secret
bfgf
rel
r
presenc
myonhlf
follow
observ
caus
increas
secret
fn
rel
r
effect
increas
addit
conclus
dosedepend
manner
albuterol
stimul
releas
bfgf
fn
nhlf
myonhlf
respect
enhanc
dust
mite
andor
potenti
contribut
matrix
remodel
observ
chronic
asthma
vegf
overexpress
protect
effect
chronic
hypoxia
recruit
immun
cell
alveoli
increas
vegf
r
albuterol
could
contribut
effect
vivo
asthmat
bfgf
bal
sputum
asthmat
fn
contribut
subepitheli
fibrosi
promot
angiogenesi
increas
bfgf
fn
albuterol
could
detriment
time
enhanc
matrix
deposit
remodel
subset
asthmat
ozdemir
c
moor
ravindranath
savasan
detroit
mi
new
orlean
la
background
mast
cell
mc
shown
demonstr
natur
cytotox
mous
fibrosarcoma
cell
line
cultur
incub
effect
postul
mediat
solubl
andor
membran
tnf
recent
fasl
mc
chymas
serin
proteas
granzym
h
chymas
activ
propos
mediat
mast
cellmedi
cytotox
thu
granuleexocytosi
chymas
granzym
h
solubl
tnfand
death
receptor
membranebound
tnfand
fasl
pathway
appear
oper
process
aim
follow
earlier
observ
longterm
liquid
culturegrown
human
bone
marrow
mast
cell
cytotox
human
leukemia
cell
coincub
experi
investig
mast
cellmedi
cytotox
natur
killerlymphokineactiv
killer
cellsensit
cell
short
term
cultur
without
stimul
first
time
method
human
bone
marrow
mononuclear
cell
cultur
methyl
cellulos
support
scf
mast
cell
coloni
develop
six
week
transfer
liquid
medium
maintain
week
experi
cytotox
investig
raji
daudi
cell
hour
coincub
establish
flow
cytometr
cellmedi
cytotox
assay
result
coincub
earli
apoptot
late
apoptot
necrot
death
earli
apoptot
late
apoptot
necrot
death
target
cell
kill
demonstr
daudi
raji
cell
respect
daudi
cell
kill
stay
stabl
earli
apoptot
late
apoptot
despit
small
number
experi
daudi
cell
kill
statist
signific
compar
control
howev
cell
elimin
occur
mast
celldaudi
cell
conjug
seen
wrightgiemsa
slide
figur
conclus
result
demonstr
human
mc
caus
cellmedi
cytotox
certain
cell
rel
shortterm
suggest
possibl
contribut
granuleexocytosi
pathway
mc
natur
cytotox
indic
faster
mc
respons
immun
surveil
ozdemir
buyukavci
ravindranath
savasan
detroit
mi
erzurum
turkey
background
effect
melatonin
mlt
cellular
immun
controversi
recent
mlt
demonstr
activ
nk
cell
membran
nuclear
high
affin
receptor
also
shown
pharmacolog
concentr
mlt
nm
could
cytotox
differ
human
cancer
aim
aim
investig
effect
mlt
alon
combin
peripher
blood
lymphocyt
pbl
lymphokin
activ
killer
lak
cell
gener
cytotox
method
pbl
cultur
day
presenc
mlt
differ
concentr
without
uml
cell
viabil
determin
trypan
blue
exclus
test
cellmedi
cytotox
lymphocyteslak
cell
daudi
cell
studi
use
establish
flow
cytometr
cellmedi
cytotox
assay
result
although
concentr
mlt
affect
cell
prolifer
much
day
significantli
inhibit
prolifer
day
p
consist
known
antiprolif
effect
mlt
concentr
mlt
also
mildli
inhibit
prolifer
day
howev
minim
rebound
concentr
day
consist
report
mlttreat
pbl
reduc
respons
mitogen
mlt
combin
suppress
prolifer
day
howev
mlt
concentr
pbl
count
increas
gradual
day
although
mlt
treatment
alon
enhanc
cellmedi
cytotox
mlt
combin
treatment
concentr
increas
significantli
compar
baselin
activ
figur
conclus
mlt
combin
concentr
result
superior
lymphocyt
prolifer
lak
cellmedi
leukemia
cell
kill
mltinduc
increas
pbl
shown
earlier
might
mechan
observ
mlt
consid
immunotherapi
adjunct
treatment
ae
fusaro
jr
victor
cr
oliveira
ca
brito
ea
futata
maciel
aj
duart
mn
sato
paulo
brazil
matern
exposur
allergen
pregnanc
even
postnat
period
may
influenc
allergi
onset
newborn
antigen
antibodi
transmiss
sought
verifi
effect
matern
antigen
exposur
concept
gestat
breastfeed
period
offspr
type
hypersensit
respons
femal
balbc
mice
immun
ova
extractalum
boost
twice
th
mate
normal
balbc
male
day
sensit
da
other
group
immun
mother
also
receiv
oral
administr
ova
along
pregnanc
nonimmun
mother
receiv
ova
breastfeed
offspr
immun
normal
mice
immun
intraperiton
ova
boost
da
result
show
import
decreas
tgflevel
amniot
fluid
milk
immun
mother
mate
comparison
obtain
normal
mother
ova
exposur
pregnanc
immun
mother
decreas
significantli
transfer
tgfbi
breastfeed
tgfisoform
found
high
level
amniot
fluid
similar
level
tgftransfer
placenta
newborn
detect
immun
mother
group
pup
mother
expos
ag
pregnanc
show
increas
spleen
cell
number
wherea
produc
e
ifnsecret
induc
antigen
neither
alter
respons
mitogen
matern
ovaimmun
induc
mark
inhibit
specif
ige
antibodi
respons
immun
pup
contrast
enhanc
ige
respons
detect
immun
pup
mother
expos
ova
postnat
period
result
show
preconcept
immun
exert
protect
effect
offspr
ige
develop
exacerb
ige
respons
due
mother
antigen
exposur
breastfeed
find
suggest
rather
utero
antigen
prime
occurr
postnat
period
may
contribut
offspr
earli
life
sensit
financi
support
fapesp
introduct
reason
increas
incid
allerg
diseas
western
countri
still
unknown
mercuri
import
pollut
factor
human
increasingli
expos
prior
studi
effect
mercuri
mitogen
stimul
human
lymphocyt
indic
immun
respons
result
inconsist
difficult
reproduc
phorbol
myrist
acet
pma
direct
activ
protein
kinas
c
shown
play
role
mercuri
induc
product
anim
therefor
investig
effect
mercuri
pmaactiv
human
peripher
blood
mononuclear
cell
pbmc
method
pbmc
individu
cultur
day
cultur
medium
contain
pma
ionomycin
presenc
absenc
mercur
chlorid
gammaifn
concentr
measur
elisa
cultur
supernat
cell
death
apoptosi
determin
annexin
stain
fluoresc
activ
cell
sort
fac
cellprolifer
assess
result
day
cultur
pmaionomycinstimul
small
amount
compar
untreat
pbmc
pgml
versu
pgml
howev
mercuri
induc
fold
increas
product
ad
pmaactiv
cell
pgml
p
gamma
ifn
product
strongli
increas
pbmc
treat
pmaionomycin
pgml
versu
pgml
unstimul
cell
drop
markedli
cell
treat
mercuri
plu
pmaionomycin
addit
mercuri
induc
increas
cell
death
apoptosi
reduc
cell
prolifer
conclus
strongli
stimul
product
pmaionomycin
treat
pbmc
cell
viabil
gammaifn
product
drop
significantli
preliminari
result
suggest
human
exposur
mercuri
may
play
role
observ
increas
incid
allerg
diseas
industri
world
background
mast
cell
mc
shown
induc
natur
cellmedi
cytotox
longterm
hr
vitro
assay
system
cytotox
mediat
least
two
pathway
secretori
via
exocytosi
mc
granul
contain
serin
proteas
granzym
chymas
solubl
tnfand
nonsecretori
celltocel
contact
via
membran
tnfand
fasl
chymas
induc
apoptosi
neonat
rat
cardiomyocyt
human
vascular
smooth
muscl
cell
object
studi
investig
mc
mediat
cytotox
nklaksensit
cell
short
term
hr
unstimul
cultur
method
human
bone
marrow
mononuclear
cell
cultur
methylcellulos
support
stem
cell
factor
mast
cell
coloni
develop
week
transfer
liquid
imdm
maintain
week
flow
cytometr
cytotox
assay
use
determin
cytotox
daudi
raji
cell
line
hr
hr
hour
control
consist
cell
line
without
mast
cell
hr
hr
hour
result
rational
establish
antibodi
respons
rate
children
recurr
infect
fulli
immun
pneumococc
conjug
vaccin
method
analyz
patient
refer
clinic
recurr
infect
despit
complet
immun
pneumococc
conjug
vaccin
age
accord
acip
guidelin
assess
patient
check
immun
statu
antibodi
titer
streptococcu
pneumonia
serotyp
includ
vaccin
assess
standard
elisa
patient
assembl
group
nonimmun
group
laboratori
data
prior
vaccin
immun
group
consist
respond
nonrespond
accord
antibodi
titer
iuml
respect
data
analyz
use
epi
info
spss
result
mean
age
year
nonrespond
year
respond
signific
statist
differ
group
regard
age
race
sex
ten
patient
identifi
fail
respond
serotyp
includ
pneumococc
conjug
vaccin
signific
statist
differ
nonimmun
immun
nonrespond
serotyp
conclus
identifi
special
immunolog
phenotyp
specif
antibodi
defici
sad
patient
normal
total
immunoglobulin
normal
respons
protein
antigen
fail
respond
conjug
pneumococc
polysaccharid
yate
r
deshazo
j
butler
g
howel
j
farley
h
liu
n
nanayakkura
gbyi
r
rockhold
jackson
ms
oxford
ms
introduct
venom
invicta
consist
disubstitut
piperidin
alkaloid
toxic
insect
bird
farm
anim
recent
report
morbid
mortal
elderli
patient
massiv
fire
ant
sting
suggest
potenti
system
mammalian
toxic
evalu
toxic
respons
system
administr
two
structur
verifi
synthet
invicta
venom
alkaloid
solenopsin
cisisom
isosolenopsin
rat
method
spragu
dawley
rat
anesthet
isofluran
paralyz
gallamin
artifici
ventil
instrument
record
arteri
blood
pressur
bp
mm
hg
heart
rate
hr
bpm
chang
left
ventricular
contractil
lvc
p
addit
group
rat
chronic
instrument
record
bp
hr
anim
consciou
freelymov
result
solenopsin
mgkg
iv
dosedepend
lower
bp
hr
lvc
mgkg
iv
hypotens
mmhg
bradycardia
bpm
decreas
lvc
p
mark
isosolenopsin
mgkg
iv
produc
respons
similar
solenopsin
mgkg
iv
solenopsin
mgkg
iv
elicit
tonicclon
convuls
respiratori
arrest
consciou
freelymov
rat
hematuria
seen
solenopsin
isosolenopsin
superfus
work
isol
perfus
rat
heart
um
solenopsin
elicit
mark
revers
decreas
lvc
cardiac
arrest
occur
um
solenopsin
conclus
result
demonstr
alkaloid
possess
signific
depress
activ
cardiac
respiratori
system
rat
neurolog
cardiorespiratori
effect
account
lethal
small
mammal
wild
may
contribut
advers
cardiovascular
effect
note
human
massiv
fire
ant
sting
introduct
asthma
attack
ph
exhal
breath
condens
ebc
decreas
two
log
order
return
normal
level
corticosteroid
therapi
ion
channel
thought
particip
transport
ion
suspect
mediat
airway
inflamm
asthma
well
determin
whether
allergen
directli
alter
airway
mucos
ph
ion
function
measur
nasal
ph
nasal
potenti
differ
pd
nasal
allergen
challeng
nac
method
ten
allerg
rhinit
subject
age
femal
underw
crossov
singleblind
placebocontrol
studi
challeng
allergen
dust
mite
grass
cat
control
diluent
two
differ
occas
random
order
via
nasal
spray
nasal
ph
measur
surfac
nasal
mucosa
ph
probe
nasal
mucosa
pd
measur
nasal
mucosa
forearm
skin
subject
also
fill
nasal
symptom
scale
measur
taken
baselin
hour
hour
hour
nac
result
nasal
symptom
score
increas
significantli
immedi
allergen
compar
control
challeng
vs
respect
statist
signific
differ
nasal
ph
signific
decreas
compar
baselin
vs
chang
ph
correl
significantli
invers
chang
symptom
number
sneez
challeng
nasal
pd
chang
significantli
challeng
conclus
allergen
decreas
nasal
mucos
ph
late
phase
challeng
allerg
rhinit
subject
decreas
airway
mucos
ph
asthma
exacerb
may
caus
aggrav
allerg
inflamm
nasal
potenti
differ
chang
allergen
challeng
fund
niaid
acaai
foundat
introduct
uv
induc
differenti
tand
blymphocyt
suppress
natur
killer
cell
render
tolerogen
effect
induc
apoptosi
result
local
system
immunosuppress
method
lymphocyt
studi
use
indirect
immunofluoresc
method
employ
monoclon
antibodi
cdmarker
hlai
hlaii
blood
volunt
age
year
uv
exposur
control
exposur
blood
vitro
dose
kj
hour
exposur
medial
surfac
elbow
joint
vivo
dose
kj
result
direct
exposur
blood
result
signific
reduct
number
lymphocyt
probabl
due
direct
phototox
effect
signific
modif
aggreg
number
lymphocyt
amount
thelper
uv
exposur
skin
seen
uv
number
cell
express
marker
significantli
increas
exposur
uv
vitro
induc
reduc
number
cell
bear
howev
vivo
exposur
signific
increas
number
cell
express
observ
uv
exposur
blood
reduc
significantli
hlai
reduc
hlaii
dr
reduc
express
uv
exposur
skin
increas
significantli
hlai
hlaii
dr
insignificantli
decreas
express
increas
due
blood
uv
exposur
insignific
reduct
reduc
reduc
express
conclus
uv
start
cascadelik
respons
includ
apoptosi
lead
chang
nk
cell
helper
suppress
lymphocyt
number
consist
immunomodul
effect
uv
radiat
background
previou
investig
shown
involv
histamin
histamin
receptor
h
h
h
h
ige
synthesi
atop
lymphoprolif
diseas
ige
respons
may
depend
concentr
histamin
histamin
receptor
antagonist
agonist
goal
investig
evalu
role
concentr
histamin
h
h
antagonist
along
import
preexist
level
ige
determin
ige
respons
method
ige
synthesi
studi
mnc
cultur
patient
year
old
mild
atop
asthma
rhiniti
patient
high
level
total
ige
specif
ige
ragwe
pollen
hous
dust
mite
epiderm
mold
allergen
patient
divid
two
group
accord
serum
ige
level
spontan
ige
synthesi
group
low
level
iuml
group
b
high
level
iuml
serum
level
total
ige
group
iuml
group
b
iuml
fub
hydrogenmal
use
h
h
specif
antagonist
result
histamin
high
concentr
suppress
low
concentr
stimul
spontan
ige
synthesi
h
h
antagonist
fub
activ
depend
preexist
level
ige
high
concentr
antagonist
increas
ige
synthesi
group
group
b
high
spontan
level
ige
synthesi
synthesi
group
increas
fold
p
h
h
blockad
cancel
ige
suppress
effect
high
concentr
histamin
addit
histamin
mnc
cultur
stimul
ige
synthesi
fold
fub
effect
igestimulatori
effect
low
concentr
histamin
allergen
ragwe
stimul
mnc
cultur
fub
costimulatori
effect
ige
synthesi
induc
histamin
conclus
ige
stimul
respons
depend
concentr
histamin
h
h
antagonist
well
preexist
level
serum
ige
ige
spontan
synthesi
introduct
preliminari
data
shown
oral
contracept
precipit
worsen
attack
hereditari
angioedema
hae
thought
estrogen
affect
synthesi
degrad
bradykinin
result
edema
object
object
determin
differ
among
variou
oral
hormon
prepar
name
combin
monophas
combin
multiphas
progesteron
hormon
replac
therapi
regard
effect
frequenc
hae
exacerb
method
patient
studi
consist
women
age
diagnos
hae
receiv
care
institut
women
meet
criteria
activ
hae
foundat
access
associ
web
page
patient
answer
sixteen
item
questionnair
past
present
birth
control
pill
hormon
replac
therapi
usag
impact
frequenc
exacerb
result
patient
complet
questionnair
taken
current
take
oral
contracept
pill
hormon
replac
therapi
women
taken
monophas
birth
control
pill
worsen
increas
number
sever
exacerb
howev
women
use
combin
multiphas
birth
control
pill
worsen
women
tri
progesteron
birth
control
pill
worsen
isol
estrogen
hormon
replac
increas
number
exacerb
androgen
use
concurr
oral
contracept
pill
hormon
replac
therapi
exacerb
decreas
conclus
abl
demonstr
statist
benefit
one
oral
contracept
pill
prepar
anoth
sampl
size
howev
preliminari
data
support
oral
contracept
pill
produc
less
exacerb
less
symptom
combin
multiphas
pill
concurr
androgen
treatment
introduct
atop
dermat
ad
associ
multipl
immunolog
abnorm
includ
imbal
subset
blood
circul
lymphocyt
form
cellular
infiltr
inflam
skin
mani
studi
function
phenotyp
properti
lymphocyt
ad
limit
either
peripher
blood
skininfiltr
lymphocyt
purpos
studi
evalu
compar
content
phenotyp
properti
lymphocyt
blood
inflam
skin
ad
patient
materi
method
adult
age
year
patient
chronic
ad
select
criteria
hanifin
patient
gave
written
inform
consent
lymphocyt
peripher
blood
phenotyp
flow
cytometri
skin
biopsi
obtain
eczemat
area
cryosect
doubl
immunohistochemistri
perform
phenotyp
lymphocyt
blood
skin
panel
monoclon
antibodi
use
includ
hladr
cla
result
immunophenotyp
analys
peripher
blood
lymphocyt
show
predomin
cell
cell
phenotyp
doubl
immunohistochemistri
skin
biopsi
reveal
epidermi
rare
constant
presenc
cellsmm
cell
cellsmm
dermal
inflammatori
infiltr
predomin
cell
cellsmm
cellsmm
domin
inflammatori
infiltr
consist
phenotyp
cellsmm
cell
conclus
ad
skin
inflamm
associ
appear
circul
lymphocyt
activ
form
lymphocyt
regulatori
properti
lymphocyt
recruit
circul
skin
home
properti
form
main
constitu
dermal
inflammatori
infiltr
contact
dermat
cd
compris
spectrum
inflammatori
skin
reaction
usual
caus
exposur
nonimmunogen
low
molecular
weight
substanc
hapten
failur
diagnos
condit
may
result
chronic
disabl
condit
impair
qualiti
life
yrold
white
male
present
sever
symmetr
distribut
facial
maculopapular
rash
secondari
excori
lesion
prior
appear
rash
patient
appli
lubriderm
skin
moistur
dri
skin
standard
thin
layer
rapid
use
epicutan
true
test
contain
chemic
agent
suspend
vehicl
attach
adhes
back
appli
patient
back
hr
posit
reaction
observ
skin
site
paraben
mix
applic
lubriderm
prepar
use
patient
contain
paraben
contrast
newer
prepar
advanc
therapi
lubriderm
parabenfre
complet
resolut
facial
lesion
occur
follow
discontinu
lubriderm
use
oral
topic
corticosteroid
therapi
case
report
illustr
commonli
use
moistur
contain
sensit
agent
could
detect
standard
patch
test
part
diagnost
armamentarium
everi
allergistimmunologist
report
commonli
use
effect
moistur
lubriderm
caus
sever
allerg
cd
use
standard
thin
layer
rapid
use
epicutan
true
patch
test
panel
effect
diagnost
tool
detect
offend
agent
rational
studi
aim
establish
possibl
differ
cutan
sensit
common
aeroallergen
children
year
old
method
studi
conduct
includ
infant
silesiasouthern
part
polandthes
infant
refer
allergi
unit
due
respiratori
symptom
like
rhiniti
otiti
pharyng
cough
bronchiti
recur
eye
symptom
conjunct
oral
symptom
skin
prick
test
spt
major
aerollergen
environ
hdii
birch
alternaria
cladosporium
tree
done
children
spt
mm
larger
consid
posit
patient
classifi
three
group
posit
famili
atopi
ii
smoke
ciggarettemoth
father
iii
cat
dog
home
iv
coexist
food
allergi
examin
children
boy
preval
sensitis
found
follow
latex
birch
grass
pollen
posit
spt
latex
first
seen
group
prevel
doubl
finish
year
conclus
studi
cutaneuo
sensitis
start
appear
chlidren
background
propylen
glycol
pg
may
induc
allerg
contact
dermat
acd
skin
irrit
reaction
topic
formul
frequent
contain
pg
present
low
concentr
pimecrolimu
cream
nonsteroid
inflammatori
cytokin
inhibitor
object
studi
design
assess
incid
cutan
respons
pimecrolimu
cream
patient
allerg
pg
determin
natur
acd
irrit
sever
method
doubleblind
random
vehiclecontrol
withinpati
studi
subject
allerg
pg
underw
patchtest
pg
pimecrolimu
cream
vehicl
follow
repeat
open
applic
test
roat
applic
site
assess
investig
use
scale
rang
reaction
spread
bullou
reaction
hour
patch
remov
complet
roat
result
pg
allergi
confirm
patchtest
patient
two
patient
show
posit
patchtest
reaction
pimecrolimu
cream
vehicl
indic
acd
contrast
patient
demonstr
sign
acd
pimecrolimu
cream
appli
normal
condit
ie
without
occlus
roat
statist
analysi
show
significantli
less
reaction
pimecrolimu
patchtest
site
pg
patchtest
site
p
pg
concentr
onesid
exact
binomi
test
median
sever
lower
pimecrolimu
cream
vs
pg
p
pg
respect
wilcoxon
signedrank
test
conclus
pilot
studi
suggest
pimecrolimu
cream
appli
normal
condit
use
safe
patient
pg
allergi
introduct
chronic
idiopath
urticaria
alway
respons
antihistamin
therapi
multipl
altern
agent
tri
report
two
case
tacrolimu
success
treat
condit
method
case
report
two
patient
chronic
idiopath
urticaria
treat
tacrolimu
patient
yo
wm
present
urticaria
go
sever
month
durat
urticari
lesion
hour
urticaria
treat
sever
medic
includ
hydroxyzin
cyproheptadin
ceterizin
montelukast
colchicin
dapson
intoler
hydroxychloroquin
montelukast
seem
provid
modest
benefit
continu
daili
urticaria
lesionsday
two
month
therapi
tacrolimu
ad
montelukast
bid
patient
yo
wf
histori
biopsyproven
urticaria
suffer
episod
urticaria
sinc
age
six
respons
system
steroid
thirti
year
urticaria
develop
recurr
urticaria
age
time
treat
hydroxyzin
doxepin
montelukast
loratadin
ceterizin
fexofenadin
colchicin
dapson
even
prednison
littl
improv
symptom
start
tacrolimu
bid
monotherapi
daili
urticaria
result
one
month
treatment
tacrolimu
bid
patient
decreas
number
urticaria
dose
tacrolimu
increas
four
week
urticaria
resolv
remain
tacrolimu
total
six
month
taper
discontinu
continu
remiss
urticaria
patient
complet
resolut
hive
two
dose
tacrolimu
two
month
remain
free
urticaria
tacrolimu
bid
conclus
patient
sever
chronic
urticaria
unrespons
multipl
therapi
tacrolimu
like
cyclosporin
may
efficaci
tacrolimu
may
also
truli
immunomodulatori
capabl
induc
remiss
urticaria
sv
gerasimov
lviv
ukrain
introduct
recent
studi
suggest
probiot
use
prevent
treatment
atop
dermat
ad
children
clinic
effect
probiot
vari
greatli
depend
specif
strain
current
conduct
search
promis
probiot
use
complementari
therapi
infant
young
children
ad
method
studi
infant
age
week
ad
establish
use
hanifin
rafka
criteria
patient
evenli
alloc
among
probiot
nonprobiot
treatment
group
use
quota
alloc
system
sever
ad
defin
use
scorad
index
infant
qualiti
life
assess
use
idqol
index
patient
examin
week
treatment
withwithout
probiot
powder
formul
b
infanti
l
acidophilu
billion
cfuday
ddsjunior
ua
laboratori
compar
preposttreat
valu
indic
amount
mometason
furoat
use
employ
pair
unpair
ttest
result
baselin
infant
either
group
compar
age
gender
durat
diseas
scorad
idqol
indic
medic
taken
previou
week
enter
studi
patient
maintain
allergen
elimin
diet
due
milk
egg
white
allergi
treatment
withwithout
probiot
mean
scorad
index
decreas
respect
howev
mean
amount
mometason
furoat
use
nonprobiot
treatment
group
significantli
greater
g
vs
g
despit
recommend
use
drug
given
addit
parent
children
take
probiot
report
improv
infant
qualiti
life
seen
decreas
idqol
index
nonprobiot
group
decreas
idqol
signific
advers
event
treatment
group
conclus
preliminari
result
suggest
probiot
may
corticosteroidspar
effect
improv
qualiti
life
infant
ad
clear
trend
toward
reduct
scorad
index
chang
significantli
probabl
due
limit
number
patient
involv
introduct
aim
studi
analyz
risk
factor
sever
atop
dermat
ad
first
month
life
method
children
age
less
month
ad
divid
two
group
accord
six
area
six
sign
atop
dermat
sassad
score
children
score
less
classifi
mild
ad
score
sever
ad
patient
fed
breast
milk
cow
milk
formula
allergen
food
given
except
rice
veget
analyz
gender
feed
pattern
famili
histori
allergi
number
sibl
total
ige
specif
ige
common
food
allergen
egg
white
cow
milk
wheat
soy
capfeia
assay
total
eosinophil
count
ul
sever
ad
ul
mild
ad
p
result
total
ige
uml
sever
ad
uml
mild
ad
specif
ige
egg
white
wheat
soy
uml
uml
uml
sever
ad
uml
uml
uml
mild
ad
p
associ
sever
ad
cow
milk
uml
sever
ad
uml
mild
ad
show
differ
gender
feed
pattern
famili
histori
allergi
number
sibl
significantli
associ
sever
ad
conclus
sever
ad
associ
sensit
food
allergen
first
month
life
although
fed
food
background
atop
dermat
ad
inflammatori
skin
diseas
diagnos
primarili
children
shown
neg
impact
qualiti
life
qol
pimecrolimu
cream
nonsteroid
topic
calcineurin
inhibitor
demonstr
efficaci
acut
treatment
longterm
manag
pediatr
adult
ad
doubleblind
vehiclecontrol
studi
secondari
aim
evalu
impact
parent
qualiti
life
pimecrolimusbas
corticosteroid
cs
base
treatment
regimen
children
ad
method
children
age
month
year
mean
year
mild
sever
ad
random
receiv
treatment
pimecrolimu
vehicl
cream
emolli
dri
skin
pimecrolimu
vehicl
bid
appli
first
sign
ad
sever
flare
midpot
topic
cs
fluticason
mometason
indic
oncedaili
use
ad
replac
even
studi
drug
applic
maximum
week
ad
resolv
parent
complet
parent
index
qualiti
lifeatop
dermat
piqolad
valid
questionnair
measur
parent
needsbas
qol
baselin
week
studi
complet
chang
piqolad
score
baselin
week
compar
treatment
neg
chang
indic
improv
result
parent
patient
group
report
improv
piqolad
score
week
greater
improv
pimecrolimu
group
mean
chang
piqolad
score
baselin
week
pimecrolimu
group
vs
csbase
treatment
group
vs
improv
respect
ancova
analysi
use
treatment
center
main
effect
baselin
score
covari
compar
chang
piqolad
score
two
treatment
group
pimecrolimu
treatment
demonstr
favor
chang
approach
statist
signific
ci
conclus
treatment
regimen
util
pimecrolimu
cream
benefici
effect
parent
qualiti
life
compar
corticosteroidbas
regimen
benefit
consist
measur
efficaci
studi
introduct
atop
dermat
chronic
inflammatori
recurr
skin
disord
preval
increas
recent
decad
littl
known
mexico
citi
aim
studi
evalu
preval
sever
atop
eczema
pediatr
popul
method
crosssect
questionnair
survey
isaac
phase
questionnair
conduct
random
sampl
schoolchildren
age
year
year
educ
center
four
northern
counti
mexico
citi
children
posit
respons
question
presenc
itchi
relaps
skin
rash
last
month
consid
atop
dermat
children
whose
symptom
result
sleep
disturb
night
per
week
consid
sever
atop
eczema
statist
analys
done
spss
window
chi
squar
size
sampl
determin
folow
isaac
specif
calcul
statcal
program
result
complet
data
avail
children
age
year
school
children
age
year
high
school
male
femal
respons
rate
high
age
year
age
year
preval
symptom
atop
dermat
last
month
age
age
year
medic
diagnos
atop
eczema
children
age
year
year
respect
report
eczema
account
age
year
respect
children
symptom
sever
atop
dermat
account
symptom
atop
dermat
also
found
major
children
begun
skin
manifest
atop
dermat
age
year
old
conclus
preval
atop
eczema
similar
group
age
result
agre
found
two
studi
acomplish
mexican
citi
cuernavaca
chihuahua
countri
latin
america
like
brazil
chile
costa
rica
although
found
lowest
valu
sweden
japan
australia
studi
includ
object
skin
examin
requir
confirm
find
kaplan
meev
liao
st
varghes
g
georg
charleston
sc
bridgewat
nj
introduct
symptom
chronic
idiopath
urticaria
ciu
profound
impact
patient
health
qualiti
life
safeti
efficaci
fexofenadin
fex
bid
treatment
ciu
previous
establish
two
multicent
doubleblind
random
placebocontrol
trial
studi
evalu
efficaci
safeti
qd
dose
fex
hcl
mg
dose
schedul
could
offer
advantag
term
patient
complianc
conveni
method
multicent
random
doubleblind
parallelgroup
placebocontrol
studi
consist
singleblind
placebo
runin
period
day
follow
day
treatment
period
male
femal
age
year
diagnosi
ciu
activ
diseas
enrol
patient
random
receiv
either
fex
hcl
mg
qd
placebo
qd
primari
endpoint
chang
baselin
mean
daili
number
wheal
mnw
score
mean
daili
sever
pruritu
measur
scale
treatment
period
assess
reflect
patient
secondari
efficaci
measur
includ
modifi
total
symptom
score
motss
compris
sum
number
frequenc
size
durat
lesion
sever
pruritu
mnw
pruritu
sever
also
assess
instantan
trough
drug
level
immedi
prior
dose
result
treatment
period
patient
treat
fex
experienc
significantli
greater
improv
mnw
pruritu
score
compar
placebo
group
p
similarli
treatment
period
individu
weekli
timepoint
mean
reduct
reflect
pm
reflect
mean
daili
motss
significantli
greater
patient
fex
group
compar
placebo
group
p
comparison
mean
reduct
instantan
mnw
pruritu
score
greater
receiv
fex
receiv
placebo
mnw
pruritu
score
signific
differ
frequenc
treatment
emerg
advers
event
two
treatment
group
clinic
relev
chang
observ
respect
clinic
laboratori
data
vital
sign
ecg
conclus
studi
demonstr
qd
dose
fex
hcl
mg
offer
effect
welltoler
relief
symptom
ciu
introduct
wheal
pruritu
associ
chronic
idiopath
urticaria
ciu
often
debilit
profound
impact
patient
qualiti
life
specif
ciu
shown
neg
affect
patient
mobil
sleep
energi
level
social
interact
emot
wellb
purpos
studi
examin
impact
treatment
fexofenadin
hcl
fex
mg
healthrel
qualiti
life
hrql
among
patient
ciu
method
part
multicent
random
doubleblind
parallelgroup
placebocontrol
studi
design
evalu
efficaci
safeti
oncedaili
dose
fex
mg
ciu
impact
treatment
hrql
also
examin
patient
ask
complet
dermatolog
life
qualiti
index
dlqi
work
product
activ
impair
questionnair
wpai
baselin
week
final
visit
earli
termin
primari
endpoint
mean
chang
baselin
dlqi
total
score
use
mean
data
evalu
perform
week
postbaselin
measur
secondari
endpoint
includ
chang
baselin
individu
dlqi
domain
wpai
score
addit
analys
conduct
examin
reliabl
valid
respons
hrql
measur
result
total
patient
includ
hrql
popul
fex
placebo
patient
fex
group
experienc
significantli
greater
improv
mean
dlqi
total
score
placebo
group
pattern
repeat
respect
individu
domain
symptom
feel
daili
activ
leisur
person
relationship
treatment
group
report
improv
product
measur
chang
baselin
use
wpai
patient
random
fex
experienc
significantli
less
impair
work
perform
activ
receiv
placebo
dlqi
demonstr
reliabl
cronbach
dlqi
wpai
found
valid
respons
instrument
ciu
popul
conclus
studi
demonstr
oncedaili
dose
fex
mg
improv
hrql
patient
ciu
assess
chang
dlqi
total
score
algozzin
lee
wong
l
anzisi
manchest
nh
centerport
ny
syosset
ny
mamaroneck
ny
symptom
allerg
nonallerg
rhiniti
may
significantli
impact
patient
qualiti
life
caus
fatigu
headach
cognit
impair
system
symptom
appropri
manag
allerg
rhiniti
import
effect
manag
coexist
complic
respiratori
condit
eg
asthma
sinus
otiti
media
addit
mani
commonli
use
overthecount
otc
antihistamin
caus
perform
impair
may
impact
daili
activ
design
brief
tenquest
allergi
survey
attempt
determin
patient
treat
allergi
evalu
patient
selfassess
impact
allergi
daili
activ
identifi
differ
treatment
outcom
primari
care
allergist
practic
patient
invit
complet
survey
anonym
complet
survey
collect
enter
microsoft
access
databas
evalu
minitab
util
statist
calcul
four
hundr
thirti
seven
patient
complet
survey
fiftyeight
percent
survey
respond
women
adult
age
patient
survey
care
allergist
compar
primari
care
patient
treat
allergist
report
allergi
vs
p
receiv
medic
averag
vs
p
pollen
common
allergi
type
report
among
patient
major
patient
receiv
prescript
medic
primari
care
patient
receiv
therapi
otc
treatment
compar
allergist
patient
vs
p
seventyfour
percent
primari
care
patient
report
allergi
symptom
control
compar
allergist
patient
p
patient
receiv
treatment
allergist
report
less
impact
allergi
daili
activ
lower
score
signifi
less
impact
compar
patient
seen
primari
care
vs
p
result
survey
suggest
allergist
treat
complex
patient
patient
multipl
allergi
uncontrol
symptom
util
prescript
medic
despit
find
patient
treat
allergist
report
less
impact
allergi
daili
activ
introduct
patogen
mechan
nasal
polyp
unknowthey
frecuent
associ
aspirin
intoler
intrins
asthma
chronic
sinus
young
sindrom
cystic
fibrosi
kartagen
syndrom
churgstrauss
syndromechem
mediat
found
nasal
polyp
follow
histamin
serotonin
leukotrien
norepinefrin
possibl
leukotrien
implic
mediat
bronchoconstrict
inflammatori
leukotrien
level
also
shown
elev
patient
sinonas
polyposi
figur
hypothesi
antileukotrien
might
play
signific
role
control
polyposi
symptom
secundari
sinonas
diseas
might
viabl
altern
longterm
oral
steroid
therapi
repeat
surgic
debrid
purpos
studi
undertaken
evalu
potenti
role
leukotrien
receptor
antagonist
recurr
polyposi
associ
asthma
improv
factor
implic
design
studi
clinic
assay
prospect
tripl
blind
materialsand
method
studi
involv
patient
male
women
mean
age
year
rang
year
select
criteria
inclus
criteria
nasal
polyp
associ
astha
allerg
non
allergicexclus
criteria
patient
concurr
ill
use
sistem
local
corticosteroidsor
kind
antileukotrien
within
month
prior
beggin
studyw
made
alleatori
select
patient
reciv
montelukast
mgsday
nasal
steroid
beclometason
mgsday
patient
reciv
loratadin
plu
mgsday
nasal
steroid
beclometason
patint
oper
fee
transnas
endoscip
polypectomi
plu
montelukast
nasal
steroid
beclometason
ige
serum
level
prick
test
vitro
scan
celullar
nasal
lavag
eosinophil
neutrophil
cytokin
nasal
laveg
elisa
test
result
ther
tendenc
improv
group
surgerymontelukastloc
steroid
symptom
object
measur
second
place
improv
group
montelukastloc
steroid
wors
improv
subject
objet
group
local
steroid
loratadinepseudoefedrin
use
placebo
introduct
sensori
percept
intranas
corticosteroid
in
vari
among
product
unpleas
affect
adher
therapi
method
conduct
crosssect
studi
patient
across
allergi
immunolog
clinic
unit
state
respond
ask
choos
pair
hypothet
in
differ
sensori
attribut
composit
base
prior
research
measur
salient
sensori
attribut
smell
tast
aftertast
throat
rundown
nose
runout
feel
spray
nosethroat
attribut
describ
intens
level
tast
low
weak
tast
moder
strong
tast
high
tabl
outcom
includ
import
score
sensori
attribut
patient
willing
adher
in
lowest
level
sensori
attribut
compar
one
moder
level
result
prefer
decreas
increas
intens
level
sensori
attribut
import
attribut
aftertast
patient
tast
throat
rundown
nose
runout
smell
feel
spray
one
attribut
tie
import
instruct
take
in
daili
month
patient
state
would
definit
abl
follow
doctor
advic
will
adher
given
in
contain
lowest
level
sensori
attribut
compar
one
moder
level
p
conclus
patient
prefer
decreas
increas
intens
level
sensori
attribut
affect
patient
willing
adher
tailor
in
patient
prefer
may
lead
improv
treatment
satisfact
adher
introduct
high
preval
rhiniti
asthma
comorbid
persist
notic
epidemiolog
studi
last
year
object
evalu
preval
rhiniti
asthma
comorbid
portugues
popul
includ
atop
nonatop
patient
method
retrospect
studi
perform
clinic
record
patient
attend
immunoallergolog
outpatientsclin
month
januari
june
review
data
collect
concern
clinic
histori
rhiniti
andor
asthma
aeroallergensskin
prick
test
respiratori
function
evalu
result
among
patient
attend
appoint
studi
period
rhiniti
andor
asthma
f
mean
age
year
patient
respiratori
diseas
includ
atop
nonatop
diagnosi
asthma
rhiniti
diseas
made
respect
atop
patient
respect
nonatop
patient
rhiniti
diagnos
atop
asthmat
nonatop
patient
asthma
patient
rhiniti
asthma
also
diagnos
atop
patient
nonatop
patient
conclus
studi
popul
rhiniti
frequent
diagnos
patient
asthma
viceversa
therebi
lead
high
preval
comorbod
associ
frequent
atop
patient
data
compar
found
recent
literatur
result
suggest
clinic
investig
asthma
mandatori
manag
patient
rhiniti
well
asthmat
patient
routin
submit
clinic
evalu
rhiniti
introduct
cetirizin
hcl
c
shown
effect
fexofenadin
hcl
f
control
season
allerg
rhiniti
sar
symptom
hr
postdos
howev
efficaci
c
f
compar
hr
postdos
respons
treatment
middl
dose
interv
need
address
method
random
doubl
blind
placebo
p
control
studi
design
compar
efficaci
toler
singl
dose
c
mg
f
mg
p
hr
postdos
ragweedsensit
sar
subject
subject
meet
entri
criteria
expos
predetermin
control
level
ragwe
pollen
eeu
prime
doubl
blind
treatment
subject
assess
rhiniti
symptom
half
hr
interv
pollen
exposur
prime
qualifi
period
baselin
hr
postdos
primari
efficaci
endpoint
chang
baselin
total
symptom
sever
complex
tssc
score
hr
postdos
tssc
score
sum
sever
rate
symptom
runni
nose
sneez
itchi
nosepalatethroat
itchywateri
eye
result
total
subject
mean
age
femal
random
c
f
p
baselin
characterist
compar
among
group
tssc
c
produc
greater
reduct
tssc
score
hr
greater
reduct
overal
ie
averag
hr
postdos
period
compar
f
respect
c
f
reduc
tssc
score
p
hr
overal
p
includ
individu
symptom
p
c
howev
effect
f
runni
nose
sneez
hr
overal
itchywateri
eye
hr
itchi
nosethroatpal
overal
p
rate
discontinu
due
advers
event
ae
low
c
f
p
incid
treatmentemerg
ae
similar
c
f
p
somnol
occur
subject
c
f
p
conclus
c
produc
greater
improv
rhiniti
symptom
compar
f
p
hr
post
dose
hr
postdos
period
treatment
safe
well
toler
background
medic
util
pattern
patient
suffer
season
allerg
rhiniti
sar
well
document
although
mani
antiallerg
medic
prescrib
daili
use
actual
usag
unknown
recogn
quit
variabl
method
subject
posit
ragwe
skin
test
mail
survey
third
week
ragwe
season
solicit
natur
sever
sar
symptom
usag
pattern
reason
choic
antiallerg
medic
result
subject
complet
survey
preval
symptom
decreas
order
sneez
runni
nose
itchygritti
eye
stuffi
itchi
nose
wateri
eye
itchi
palatethroat
postnas
drip
redburn
eye
headach
itchi
ear
cough
short
breath
wheez
sar
patient
use
antihistamin
frequent
follow
decongest
combin
antihistaminedecongest
product
intranas
corticosteroid
medic
mostli
taken
intermitt
rather
daili
antihistamin
nasal
corticosteroid
conclus
constel
nasal
symptom
common
season
allerg
manifest
follow
ocular
palat
ear
irrit
antihistamin
frequent
use
medic
treat
symptom
succeed
decongest
alon
combin
signific
proport
subject
took
allergi
medic
includ
nasal
corticosteroid
intermitt
rather
regularli
underscor
relev
singledos
evalu
drug
efficaci
ak
elli
e
rafeiro
jd
ratz
jh
day
kingston
canada
background
tradit
assess
season
allerg
rhiniti
sar
medic
efficaci
util
random
control
trial
week
season
addit
studi
method
employ
singledos
respons
use
control
allergen
challeng
environment
exposur
unit
eeu
comparison
allerg
symptom
gener
control
allergen
challeng
occur
ragwe
season
symptom
done
method
subject
known
sar
ragwe
mail
survey
third
week
ragwe
season
solicit
natur
sever
sar
symptom
subject
particip
subsequ
control
allergen
challeng
studi
use
eeu
ask
complet
similar
survey
document
symptom
gener
model
complet
survey
compris
primari
analysi
group
result
subject
complet
ragwe
season
survey
subject
complet
eeu
survey
complet
symptom
gener
eeu
exposur
similar
elicit
ragwe
season
except
cough
vs
respect
p
subject
report
symptom
sever
eeu
experienc
typic
ragwe
season
day
less
sever
peak
ragwe
season
day
conclus
allerg
upper
respiratori
tract
symptom
produc
control
ragwe
pollen
exposur
eeu
similar
natur
degre
experienc
ragwe
season
support
evid
eeu
valid
model
studi
sar
r
nave
wingertzahn
brookman
kaida
shah
konstanz
germani
florham
park
nj
princeton
nj
tokyo
japan
rational
ciclesonid
cic
new
corticosteroid
develop
treatment
allerg
rhiniti
ar
cic
prodrug
hydrolyz
activ
metabolit
desisobutyrylciclesonid
descic
target
tissu
cic
low
oral
bioavail
highli
bound
plasma
protein
therefor
cic
administ
nasal
spray
expect
minim
local
system
effect
object
primari
object
evalu
safeti
toler
repeat
escal
dose
cic
mcgday
given
nasal
spray
day
healthi
asymptomat
subject
sar
secondari
object
determin
pk
cic
descic
evalu
effect
cic
endogen
cortisol
method
singlecent
random
placebocontrol
doubl
blind
modifi
sequenti
dose
studi
six
cohort
random
cohort
iv
consist
healthi
subject
given
dose
cic
mcg
bid
cohort
vi
asymptomat
sar
subject
receiv
mcg
bid
cohort
compris
subject
receiv
cic
subject
receiv
placebo
safeti
assess
conduct
record
advers
event
ae
clinic
laboratori
eye
nasal
examin
find
serum
urin
sampl
taken
evalu
cortisol
level
cic
descic
serum
concentr
determin
lcmsm
result
trend
observ
ae
compar
cic
placebo
treatment
addit
subject
experienc
seriou
ae
withdrew
studi
due
ae
trial
cortisol
level
show
differ
dose
group
activetr
subject
placebotr
subject
addit
serum
concentr
cic
descic
major
serum
sampl
shown
lower
limit
quantif
lloq
pgml
cic
pgml
descic
therefor
descript
statist
could
calcul
conclus
ciclesonid
nasal
spray
dose
evalu
safe
well
toler
healthi
asymptomat
sar
subject
detect
effect
cic
serum
urinari
free
cortisol
concentr
addit
pk
paramet
could
calcul
cic
nasal
spray
virtual
undetect
serum
despit
use
sensit
assay
prefer
treatment
allergi
avoid
air
filtrat
logic
room
air
purifi
limit
efficaci
new
devic
creat
envelop
air
free
allergen
particl
around
head
sleep
person
allerg
rhiniti
frequent
caus
daytim
somnol
pilot
studi
effect
zephyr
symptom
season
allerg
rhiniti
ragwe
hay
fever
daytim
sleepi
method
subject
age
ragwe
hay
fever
studi
ragwe
season
use
subject
hisher
control
usual
allergi
medicin
allow
except
loratadin
rescu
outcom
measur
symptom
score
junip
rhiniti
qualiti
life
questionnair
toler
rate
epworth
sleepi
scale
first
week
subject
qualifi
symptom
score
enter
oneweek
treatment
period
zephyr
third
week
posttreat
observ
period
result
particip
show
symptom
improv
whole
group
averag
reduct
morn
symptom
reduct
even
symptom
sleepi
score
improv
rhiniti
qol
improv
zephyr
system
well
toler
evidenc
respons
sever
statement
regard
zephyr
use
toler
score
strongli
disagre
strongli
agre
system
bother
sleep
mean
score
nois
level
affect
abil
sleep
mean
score
temperatur
fine
mean
score
system
get
way
sleep
mean
score
conclus
zephyr
significantli
reduc
season
hay
fever
symptom
daytim
sleepi
improv
qualiti
life
welltoler
subject
zephyr
may
provid
maxim
environment
control
bedroom
allergen
exposur
irrespect
ambient
airborn
allergen
level
room
nasal
congest
import
symptom
associ
signific
morbid
rhiniti
suffer
disrupt
sleep
lead
daytim
fatigu
loss
concentr
decreas
product
potenti
result
symptom
studi
employ
onlin
interview
rhiniti
suffer
harri
interact
onlin
databas
conduct
order
understand
symptom
identifi
determin
impact
nasal
congest
daili
activ
respond
least
year
age
experienc
nasal
congest
season
allerg
perenni
allerg
andor
perenni
nonallerg
rhiniti
result
show
respond
agre
nasal
congest
bothersom
symptom
rhiniti
experienc
nasal
congest
daili
experienc
sever
time
per
week
surprisingli
sleep
import
factor
affect
nasal
congest
twothird
respond
felt
sleep
moder
significantli
impact
nasal
congest
half
felt
difficult
get
good
night
rest
congest
sleep
interrupt
disturb
nasal
congest
approxim
night
per
week
averag
furthermor
sleep
disrupt
nasal
congest
contribut
daytim
fatigu
respond
indic
typic
tire
fatigu
day
experi
nasal
congest
addit
felt
activ
requir
concentr
read
moder
significantli
impact
nasal
congest
studi
confirm
nasal
congest
caus
rhiniti
suffer
signific
problem
beyond
stuffi
nose
consequ
healthcar
provid
need
ensur
rhiniti
patient
nasal
congest
primari
complaint
manag
effect
desloratadin
dl
clarinex
nonsed
oral
antihistamin
metabol
dl
howev
phenotyp
polymorph
observ
patient
result
reduc
format
dl
preval
safeti
profil
poor
metabol
dl
examin
pharmacokinet
clinic
trial
poor
metabol
defin
subject
dl
dl
auc
ratio
dl
halflif
hour
pediatr
studi
spars
sampl
approach
util
screen
poor
metabol
plasma
concentr
ratio
dl
dl
hour
classifi
subject
poor
metabol
total
adult
pediatr
subject
year
old
phenotyp
singl
dose
dl
loratadin
overal
preval
poor
metabol
phenotyp
preval
compar
adult
pediatr
subject
greater
popul
among
black
pediatr
adult
caucasian
pediatr
adult
pharmacokinet
analysi
found
exposur
dl
approxim
higher
poor
metabol
normal
metabol
appar
differ
dl
exposur
among
poor
metabol
differ
age
group
treat
ageappropri
dose
multipledos
day
safeti
profil
dl
examin
pediatr
poor
metabol
year
placebocontrol
trial
adult
poor
metabol
year
pharmacokinet
trial
pool
ae
rate
low
compar
poor
metabol
placebo
subject
shown
tabl
ae
appear
subject
treatment
group
adult
poor
metabol
differ
cardiovascular
safeti
profil
ecg
result
includ
qtc
interv
among
group
conclus
express
dl
poor
metabol
phenotyp
independ
age
higher
black
caucasian
exposur
dl
poor
metabol
independ
age
administ
ageappropri
dose
safeti
profil
dl
poor
metabol
differ
placebo
age
least
old
result
consist
high
therapeut
index
dl
desloratadin
dl
extens
metabol
dl
subsequ
glucuronid
enzym
respons
format
activ
metabolit
unknown
poor
metabol
dl
repres
subset
popul
reduc
abil
form
dl
poor
metabol
defin
subject
dl
dl
exposur
ratio
dl
halflif
hr
pk
paramet
adult
pediatr
poor
metabol
follow
repetit
administr
dl
character
clinic
pharmacolog
trial
summar
tabl
exposur
dl
auc
poor
metabol
approxim
greater
correspond
valu
normal
metabol
cmax
greater
magnitud
reduct
format
dl
concurr
increas
exposur
dl
associ
poor
metabol
phenotyp
similar
pediatr
adult
subject
ageappropri
dose
despit
increas
exposur
dl
poor
metabol
increas
advers
event
frequenc
chang
electrocardiograph
paramet
dose
normal
mg
b
least
squar
mean
ratio
anova
logtransform
data
extract
sourc
variat
due
age
group
metabol
statu
ratio
contrast
metabol
statu
c
lower
upper
confid
interv
base
logtransform
data
introduct
mani
patient
season
allerg
conjunct
sac
complain
symptom
dri
eye
previous
report
patient
sac
experi
discomfort
dri
eye
anywher
day
per
week
overal
sever
dri
eye
symptom
tend
rang
mild
sever
preliminari
cross
studi
evalu
benefit
nedocromil
sodium
ophthalm
solut
use
twice
daili
compar
nedocromil
sodium
ophthalm
solut
use
refresh
ocular
lubric
treatment
dri
eye
symptom
associ
sac
week
method
patient
minimum
twoyear
histori
sac
dri
eye
posit
skin
prick
test
toward
grass
pollen
age
enrol
patient
evalu
four
visit
complet
daili
diari
includ
scale
grade
allerg
conjunct
dri
eye
symptom
clinic
visit
complet
osdi
rqlq
rhiniti
qualiti
life
questionnair
osdi
ocular
surfac
diseas
index
develop
assess
dri
eye
symptom
impact
vision
relat
function
rqlq
evalu
qualiti
life
patient
allerg
conjunct
last
visit
patient
physician
assess
treatment
effect
addit
refresh
nedocromil
sodium
ophthalm
solut
daili
grass
pollen
count
preform
use
burkhard
sampler
result
patient
male
femal
enrol
drop
patient
experienc
minim
symptom
start
season
due
low
concentr
grass
pollen
preliminari
analysi
carri
use
pair
ttest
preform
ocular
averag
score
two
treatment
period
signific
differ
treatment
group
red
light
sensit
tear
eye
reduct
dri
eye
symptom
report
patient
use
refresh
eye
drop
number
drop
requir
vari
patient
treatment
period
improv
patient
rqlq
conclus
patient
prefer
addit
refresh
eyedrop
allevi
sac
dri
eye
symptom
studi
need
carri
use
refresh
eye
drop
larger
number
patient
sac
dri
eye
symptom
c
laforc
raleigh
nc
introduct
object
studi
determin
abil
azelastin
nasal
spray
improv
rhiniti
symptom
qualiti
life
paramet
season
allerg
rhiniti
patient
remain
symptomat
treatment
fexofenadin
method
placebocontrol
doubleblind
studi
began
openlabel
leadin
period
patient
receiv
fexofenadin
mg
bid
day
patient
improv
less
fexofenadin
random
treatment
week
azelastin
nasal
spray
azelastin
nasal
spray
plu
fexofenadin
placebo
primari
efficaci
variabl
chang
baselin
day
thetot
nasal
symptom
score
tnss
consist
runni
nose
sneez
itchi
nose
nasal
congest
score
record
twice
daili
patient
diari
card
addit
qualiti
life
assess
use
rhiniti
qualiti
life
questionnair
rqlq
result
week
treatment
azelastin
nasal
spray
p
azelastin
nasal
spray
plu
fexofenadin
p
significantli
improv
thetnss
compar
placebo
base
patient
complet
tnss
rqlq
data
overal
rqlq
score
also
significantli
p
improv
compar
placebo
conclus
azelastin
nasal
spray
effect
treatment
patient
season
allerg
rhiniti
respond
well
fexofenadin
significantli
improv
qualiti
life
paramet
compar
placebo
result
studi
indic
azelastin
nasal
spray
import
altern
oral
antihistamin
consid
initi
manag
season
allerg
rhiniti
w
berger
mission
viejo
ca
object
evalu
improv
time
azelastin
nasal
spray
treatment
patient
moderatetosever
season
allerg
rhiniti
sar
remain
symptomat
treatment
loratadin
fexofenadin
method
studi
multicent
doubleblind
placebocontrol
trial
began
openlabel
leadin
period
patient
receiv
either
loratadin
mg
qd
studi
fexofenadin
mg
bid
studi
patient
improv
loratadin
random
treatment
azelastin
nasal
spray
spraysnostril
bid
azelastin
nasal
spray
spraysnostril
bid
plu
loratadin
mg
qd
desloratadin
mg
qd
placebo
patient
improv
fexofenadin
random
treatment
azelastin
nasal
spray
spraysnostril
bid
azelastin
nasal
spray
spraysnostril
bid
plu
fexofenadin
mg
bid
placebo
primari
efficaci
variabl
chang
baselin
day
total
nasal
symptom
score
tnss
consist
runni
nose
sneez
itchi
nose
nasal
congest
symptom
sever
recordedam
pm
diari
card
scale
result
studi
patient
treat
azelastin
nasal
spray
experienc
increas
improv
intnss
day
treatmentth
improv
approxim
greater
placebo
day
studi
differ
placebo
statist
signific
p
day
overal
studi
patient
treat
azelastin
improv
tnss
compar
placebo
group
studi
patient
treat
azelastin
improv
tnss
compar
placebo
group
conclus
azelastin
nasal
spray
effect
treat
patient
moderatetosever
sar
remain
symptomat
treatment
either
loratadin
fexofenadin
azelastin
demonstr
firstday
effect
patient
treat
azelastin
experienc
increas
improv
rhiniti
symptom
studi
periodsazelastin
nasal
spray
effect
treatment
altern
oral
loratadin
fexofenadin
appropri
firstlin
therapi
manag
sar
introduct
larg
openlabel
azelastin
astelin
nasal
spray
patient
experi
trial
conduct
patient
sar
vmr
mix
rhiniti
allerg
rhiniti
nonallerg
trigger
analysi
evalu
effect
azelastin
nasal
spray
treat
rhiniti
symptom
subset
patient
histori
asthma
sinus
method
patient
enter
openlabel
protocol
treat
week
azelastin
nasal
spray
dosag
spray
per
nostril
bid
week
patient
complet
questionnair
assess
onset
action
symptom
improv
satisfact
therapi
qualiti
life
result
total
rhiniti
patient
receiv
azelastin
monotherapi
studi
period
data
analyz
patient
asthma
sinus
greater
percentag
patient
sever
rhiniti
compar
overal
popul
nasal
congest
postnas
drip
report
bothersom
rhiniti
symptom
week
treatment
azelastin
nasal
spray
patient
asthma
patient
sinus
report
complet
control
congest
postnas
drip
addit
patient
asthma
report
chest
tight
short
breath
wheez
somewhat
complet
control
patient
sinus
report
headach
facial
pain
somewhat
complet
control
treatment
azelastin
nasal
spray
conclus
azelastin
nasal
spray
provid
effect
control
rhiniti
symptom
includ
nasal
congest
postnas
drip
patient
histori
asthma
sinus
introduct
epinastin
antihistamin
mast
cell
stabil
antiinflammatori
properti
epinastin
ophthalm
solut
evalu
treatment
allerg
sign
symptom
elicit
felin
dander
cat
exposur
room
method
particip
age
year
histori
ocular
allergi
cat
posit
skin
prick
reaction
cat
dander
ocular
itch
score
scale
within
minut
enter
cat
room
subject
wore
tb
mask
cat
room
reduc
effect
inhal
allergen
minut
exposur
drop
epinastin
hcl
instil
one
eye
olopatadin
instil
fellow
eye
environment
exposur
cat
dander
continu
anoth
minut
prior
instil
minut
instil
conjunctiv
hyperemia
chemosi
scale
ocular
itch
tear
ocular
burn
nasal
itch
rhinorrhea
scale
assess
result
instil
singl
drop
ophthalm
epinastin
significantli
reduc
ocular
itch
mean
preinstil
score
mean
score
minut
instil
p
despit
continu
exposur
cat
dander
entir
period
similarli
ocular
burn
tear
hyperemia
significantli
reduc
epinastin
treatment
p
chemosi
weakli
induc
cat
room
exposur
mean
preinstil
score
howev
epinastin
treatment
decreas
instil
epinastin
also
significantli
reduc
nasal
itch
rhinorrhea
score
p
result
olopatadin
statist
differ
howev
chang
baselin
itch
score
epinastinetr
eye
greater
seen
olopatadinetr
eye
major
timepoint
conclus
ophthalm
epinastin
indic
prevent
itch
associ
allerg
conjunctivitisthi
studi
show
treatment
catsensit
subject
ophthalm
epinastin
follow
environment
exposur
cat
dander
significantli
reduc
ocular
itch
sign
symptom
allerg
conjunct
object
object
studi
evalu
azelastin
nasal
spray
cetirizin
fluticason
placebo
treatment
patient
symptomat
season
allerg
rhiniti
method
doubleblind
placebocontrol
pilot
trial
patient
season
allerg
rhiniti
studi
began
placebo
leadin
period
follow
blind
treatment
period
day
day
efficaci
variabl
chang
baselin
day
total
nasal
symptom
score
tnss
consist
rhinorrhea
sneez
itchi
nose
nasal
congest
onset
action
base
tnss
hour
follow
initi
administr
studi
drug
chang
baselin
day
chang
tnss
tnss
score
twice
daili
pm
rate
scale
patient
record
minimum
tnss
least
day
leadin
period
congest
score
least
day
qualifi
entri
qualifi
patient
random
treatment
azelastin
nasal
spray
spray
per
nostril
bid
plu
placebo
capsul
qd
cetirizin
tablet
qd
plu
placebo
nasal
spray
fluticason
spray
per
nostril
qd
plu
placebo
capsul
qd
placebo
nasal
spray
plu
placebo
capsul
result
azelastin
significantli
p
improv
tnss
compar
cetirizin
fluticason
placebo
begin
minut
initi
administr
cetirizin
significantli
improv
tnss
versu
placebo
minut
fluticason
show
signific
differ
placebo
evalu
period
azelastin
significantli
p
improv
tnss
day
chang
baselin
compar
cetirizin
fluticason
placebo
conclus
azelastin
nasal
spray
improv
tnss
patient
moderatetosever
season
allerg
rhiniti
addit
azelastin
nasal
spray
demonstr
onset
action
significantli
improv
tnss
versu
cetirizin
fluticason
placebo
hour
initi
administr
introduct
epinastin
antihistamin
mast
cell
stabil
antiinflammatori
properti
develop
treatment
allerg
conjunct
efficaci
toler
epinastin
assess
compar
levocabastin
method
elig
patient
random
doublemask
parallelgroup
activecontrol
environment
clinic
trial
year
old
recent
diagnosi
season
allerg
conjunct
patient
instil
drop
epinastin
hcl
levocabastin
ophthalm
solut
eye
bid
week
patient
investig
assess
efficaci
toler
studi
visit
day
baselin
assess
overal
efficaci
toler
studi
exit
advers
event
monitor
result
epinastin
provid
superior
itch
relief
compar
levocabastin
see
figur
mean
ocular
itch
score
treatment
visit
epinastin
levocabastin
scale
baselin
score
epinastin
levocabastin
mean
sum
score
ocular
itch
tear
foreign
bodi
sensat
treatment
visit
significantli
better
epinastin
levocabastin
studi
exit
epinastinetr
patient
rate
overal
efficaci
good
highest
possibl
rate
versu
levocabastinetr
patient
minut
postinstil
epinastinetr
levocabastinetr
patient
rate
toler
good
studi
exit
epinastinetr
levocabastinetr
patient
rate
overal
toler
good
investig
rate
similar
treatmentrel
advers
event
occur
epinastinetr
patient
frequent
eye
pain
skin
itch
levocabastinetr
patient
frequent
doubl
vision
influenzalik
symptom
ae
mild
moder
conclus
result
confirm
therapeut
potenti
epinastin
efficaci
treatment
suitabl
longterm
use
throughout
allergi
season
ophthalm
epinastin
superior
levocabastin
relief
ocular
symptom
patient
allerg
conjunct
welltoler
sinc
chronic
inflamm
histopatholog
landmark
otiti
media
effus
clinic
observ
led
us
believ
combin
cysteinyl
leukotrien
receptor
antagonist
montelukast
oral
antibiot
may
efficaci
monotherapi
oral
antibiot
treatment
serou
otiti
media
studi
twenti
pediatr
patient
age
year
year
random
open
label
trial
compar
efficaci
combin
montelukast
mg
mg
chewabl
tablet
qd
dose
accord
patient
age
oral
antibiot
amoxicillinclavulan
potassium
mgkgday
divid
dose
everi
hour
monotherapi
oral
antibiot
amoxicillinclavulan
potassium
treatment
otiti
media
effus
efficaci
treatment
option
assess
use
pneumat
otoscopi
imped
tympanometri
audiometri
monitor
clinic
cours
middl
ear
effus
treatment
group
combin
group
montelukast
antibiot
resolut
otiti
media
effus
occur
day
contrast
group
treat
monotherapi
oral
antibiot
resolut
otiti
media
effus
occur
day
conclus
combin
montelukast
plu
oral
antibiot
effect
monotherapi
oral
antibioticth
combin
montelukast
plu
antibiot
may
safer
shorter
therapi
given
safeti
issu
long
term
use
system
antibiot
introduct
random
doubleblind
placebocontrol
studi
conduct
environment
exposur
chamber
eec
compar
efficaci
three
dose
olopatadin
nasal
spray
topic
antiallergi
treatment
season
allerg
rhiniti
sar
versu
placebo
spray
method
patient
age
year
old
histori
sar
screen
consent
evalu
posit
skin
test
ragwe
allergen
enrol
irbapprov
studi
total
prime
patient
expos
ragwe
allergen
eec
random
olopatadin
olopatadin
olopatadin
placebo
vehicl
spray
spraysnostril
morn
symptom
selfassess
use
scale
total
nasal
symptom
score
tnss
compris
sneez
runni
itchi
stuffi
nose
via
diari
period
interv
studi
period
safeti
also
assess
result
obviou
trend
indic
dosedepend
respons
olopatadin
though
concentr
statist
differ
three
concentr
olopatadin
clearli
efficaci
placebo
spray
first
time
point
minut
continu
end
session
olopatadin
exhibit
safeti
profil
compar
placebo
conclus
olopatadin
nasal
spray
exhibit
dosedepend
respons
onset
action
three
concentr
olopatadin
appar
first
postdos
timepoint
minut
efficaci
maintain
throughout
next
hour
olopatadin
nasal
spray
safe
welltoler
effect
treatment
sar
eec
chamber
c
slonim
tampa
fl
object
assess
patient
subject
respons
treatment
allerg
conjunct
use
azelastin
hydrochlorid
ophthalm
solut
method
particip
physician
select
patient
practic
receiv
azelastin
hydrochlorid
ophthalm
solut
drop
per
affect
eye
twice
daili
day
patient
prior
ocular
allergi
medic
allow
particip
day
treatment
azelastin
hydrochlorid
patient
rate
experi
azelastin
hydrochlorid
via
selfadminist
survey
question
answer
patient
result
baselin
patient
report
ocular
itch
affect
work
school
andor
leisur
activ
least
somewhat
use
azelastin
hydrochlorid
patient
achiev
either
moder
complet
relief
ocular
itch
includ
report
complet
relief
itch
seventyon
percent
patient
treat
previous
topic
prescript
antiallergi
medic
ocular
itch
seventi
percent
patient
previous
treat
topic
prescript
antiallergi
medic
treatment
previou
medic
user
experienc
least
moder
relief
itch
treat
azelastin
hydrochlorid
sixtyf
percent
previouslytr
patient
rate
azelastin
hydrochlorid
somewhat
better
much
better
previou
medic
conclus
result
suggest
azelastin
hydrochlorid
ophthalm
solut
effect
treatment
ocular
itch
associ
allerg
conjunct
rate
patient
regardless
whether
treat
previous
topic
prescript
antiallergi
medic
object
determin
associ
food
allergi
acid
reflux
adult
method
conduct
retrospect
chart
review
atop
adult
patient
academ
otolaryng
allergi
practic
adult
test
posit
adult
test
neg
food
allergi
includ
studi
chart
review
diagnosi
gastroesophag
reflux
disord
gerd
includ
histori
laryngopharyng
reflux
lpr
peptic
ulcer
diseas
pud
popul
preval
ci
acid
reflux
estim
histor
studi
lock
gr
et
al
preval
clinic
spectrum
gastroesophag
reflux
populationbas
studi
olmstead
counti
minnesota
gastroenterolog
similar
subject
popul
preval
gerd
studi
arm
well
total
studi
group
atop
adult
compar
histor
control
result
subject
test
posit
food
allergi
diagnosi
gerd
ci
case
subject
demonstr
food
allergi
posit
gerd
ci
case
total
studi
group
preval
gerd
ci
chi
squar
analysi
preval
gerd
significantli
higher
total
studi
group
compar
histor
control
subject
test
neg
food
allergi
statist
signific
higher
preval
gerd
control
popul
preval
gerd
group
test
posit
histor
control
show
signific
differ
compar
studi
arm
signific
differ
preval
gerd
conclus
preval
acid
reflux
disord
higher
subject
food
allergi
compar
histor
control
although
statist
signific
note
adult
test
neg
food
allergi
control
popul
regard
preval
gerd
may
reflect
fact
individu
examin
otolaryngologist
offic
like
acid
reflux
disord
gener
popul
overal
atop
subject
higher
incid
acid
reflux
disord
statist
signific
subject
without
food
allergi
suryadevara
dl
hamilo
boston
introduct
recent
studi
suggest
cr
without
nasal
polyposi
crssnp
cr
nasal
polyposi
crscnp
repres
distinct
patholog
entiti
wish
determin
whether
condit
differ
clinic
present
method
twoyear
period
new
patient
come
univers
base
specialti
clinic
meet
criteria
cr
enrol
outcom
studi
patient
indic
four
major
facial
painpressureheadach
nasal
obstruct
nasal
purulencedischarg
hyposmiaanosmia
four
minor
fever
halitosi
dental
pain
cough
criteria
cr
experienc
rhinoscopi
perform
look
nasal
polyp
polypoid
tissu
sinu
area
preval
symptom
compar
group
chi
squar
analysi
result
popul
mean
age
femal
caucasian
africanamerican
asian
hispan
patient
nonsmok
least
major
criteria
major
minor
criteria
cr
enrol
fortyon
patient
crscnp
mean
number
major
criteria
greater
crscnp
crssnp
vs
nasal
obstruct
hyposmiaanosmia
preval
crscnp
p
respect
facial
painpressureheadach
preval
crssnp
p
preval
symptom
crscnp
nasal
purulencedischarg
hyposmiaanosmia
facial
painpressureheadach
nasal
obstruct
contrast
preval
symptom
crssnp
facial
painpressureheadach
nasal
purulencedischarg
hyposmiaanosmia
nasal
obstruct
none
symptom
absolut
distinguish
condit
differ
found
two
group
fever
halitosi
dental
pain
cough
conclus
conclud
patient
crscnp
greater
burden
symptom
cr
much
higher
preval
hyposmiaanomsia
find
consist
studi
show
comparison
crssnp
crscnp
tend
difficult
treat
higher
rate
relaps
intens
medic
therapi
subramanian
et
al
j
rhinolog
le
mansfield
ee
philpot
c
posey
el
paso
tx
research
triangl
park
nc
daytim
sleepi
common
complaint
sar
patient
often
complain
mental
slow
difficulti
concentr
think
present
studi
evalu
whether
effect
therapi
sar
would
decreas
dss
improv
object
measur
cp
dss
measur
use
epworth
sleep
scale
ess
object
cp
measur
use
test
variabl
attent
tova
valid
test
thirti
two
adult
male
femal
year
histori
sar
compat
physic
exam
correspond
posit
allergi
test
volunt
week
random
doubl
blind
placebo
control
studi
one
week
inf
placebo
pl
baselin
subject
receiv
either
activ
inf
continu
pl
maintain
daili
nasal
symptom
dairi
ess
subject
took
tova
test
end
weekli
nasal
symptom
score
significantli
improv
inf
pl
vs
nasal
congest
inf
pl
pn
runni
nose
inf
pn
pl
pn
sneez
inf
pl
pn
total
weekli
ess
abnorm
decreas
significantli
inf
group
pl
group
vs
inf
pl
pn
respons
time
tova
test
initi
somewhat
slow
significantli
decreas
inf
pl
treatment
vs
inf
msec
msec
pl
msec
msec
pn
result
demonstr
sar
associ
dss
cp
problem
mechan
like
sleep
disord
breath
associ
nasal
congest
obstruct
effect
treatment
nasal
congest
inf
led
decreas
dss
improv
cognit
perform
le
mansfield
c
graham
el
paso
tx
new
york
ny
increas
recognit
sleep
disturb
daytim
tired
occur
activ
ar
mechan
appear
nasal
congest
obstruct
lead
sleep
disord
breath
result
poor
qualiti
sleep
practic
part
initi
histori
question
regard
fatigu
snore
sleep
problem
tired
address
sleep
problem
tired
grade
accord
follow
scale
effect
daili
activ
troubl
littl
troubl
troubl
troubl
lot
total
disrupt
review
consecut
chart
patient
allerg
rhiniti
document
histori
physic
examin
allergi
test
femal
male
age
rang
patient
parent
recogn
commonli
snore
state
chronic
fatigu
grade
answer
concern
sleep
problem
tired
even
reveal
ar
patient
percept
problem
see
tabl
gener
higher
sleep
problem
respons
associ
higher
tired
score
nation
survey
unselect
popul
suggest
percent
adult
consid
sleep
problem
high
frequenc
sleep
relat
problem
tired
sampl
prompt
us
add
detail
question
regard
sleep
relat
event
intak
histori
opinion
question
specif
relat
sleep
daytim
tired
includ
evalu
allerg
rhiniti
conclud
sleep
relat
problem
tired
may
common
patient
allerg
rhiniti
previou
report
rw
weber
j
garcia
r
faruqi
banerji
g
georg
studi
investig
group
denver
co
bridgewat
nj
nj
introduct
intranas
glucocorticosteroid
triamcinolon
acetonid
taa
safe
effect
treatment
persist
allerg
rhiniti
par
new
hfa
propel
deliveri
system
taahfa
recent
develop
studi
primarili
assess
longterm
safeti
taa
deliv
via
new
devic
well
longterm
efficaci
method
patient
age
yr
par
enrol
openlabel
studi
center
us
patient
receiv
taahfa
daili
runin
period
adjust
dose
daili
base
symptom
sever
dose
standard
daili
across
patient
month
ensur
suffici
longterm
safeti
data
maximum
dose
physic
exam
includ
measur
vital
sign
laboratori
measur
taken
baselin
month
studi
end
independ
patient
physician
global
symptom
evalu
perform
baselin
week
month
thereaft
patient
record
advers
event
ae
daili
diari
card
result
patient
includ
studi
report
ae
incid
ae
similar
compar
allerg
rhiniti
longterm
studi
frequent
report
ae
pharyng
rhiniti
local
reaction
headach
epistaxi
sinus
tabl
ae
mildtomoder
intens
patient
withdrew
studi
due
ae
clinic
relev
chang
physic
exam
vital
sign
laboratori
measur
total
seriou
ae
sae
report
breast
carcinoma
depress
postop
spinal
fluid
leak
staphylococc
infect
sae
thought
relat
studi
drug
final
visit
patient
either
moder
markedcomplet
relief
symptom
use
global
symptom
score
similarli
physician
rate
patient
either
moder
markedcomplet
relief
conclus
longterm
administr
taahfa
exhibit
good
safeti
toler
profil
provid
moderatetocomplet
symptom
relief
patient
treat
par
introduct
secondgener
nonsed
antihistamin
ah
lower
tendenc
cross
bloodbrain
barrier
caus
central
nervou
system
side
effect
firstgener
agent
howev
studi
suggest
differ
secondgener
ah
regard
cognit
function
impair
method
medlin
literatur
search
perform
use
search
term
antihistamin
impair
antihistamin
psychomotor
antihistamin
central
effect
well
individu
ah
name
acrivastin
cetirizin
desloratadin
ebastin
fexofenadin
levocetirizin
loratadin
mequitazin
mizolastin
find
secondgener
ah
review
welldesign
placeboand
positivecontrol
studi
human
use
object
measur
cognit
impair
includ
result
public
identifi
inclus
criteria
includ
object
assess
drive
perform
critic
flicker
fusion
divid
attent
task
larg
variat
number
avail
welldesign
studi
rigor
assess
agent
fexofenadin
cetirizin
number
ah
ebastin
acrivastin
loratadin
mequitazin
mizolastin
impair
recommend
dose
higher
dose
small
number
avail
studi
newer
ah
desloratadin
levocetirizin
produc
impair
recommend
dose
mg
howev
higher
dose
investig
cetirizin
studi
variabl
impair
recommend
mg
dose
higher
seen
number
studi
contrast
fexofenadin
hcl
dose
mg
nonimpair
larg
number
studi
one
studi
indic
impair
one
task
critic
track
observ
first
dose
fexofenadin
hcl
mg
subsequ
dose
howev
author
conclud
dose
mgday
safe
patient
drive
conclus
secondgener
ah
less
impair
firstgener
newer
ah
produc
impair
recommend
dose
differ
becom
import
patient
agent
caus
sedat
patient
use
beyond
recommend
dose
conclus
fexofenadin
ah
found
nonimpair
studi
even
doubl
recommend
us
dose
shaver
rb
berkowitz
c
lutz
p
jone
c
qiu
meev
st
varghes
g
georg
woodstock
ga
bridgewat
nj
introduct
fexofenadin
fex
antagonist
proven
efficaci
treatment
allerg
rhiniti
ar
date
live
catroom
challeng
studi
assess
efficaci
fex
catallergen
induc
ar
studi
assess
efficaci
singl
dose
fex
hci
mg
prevent
control
catallergen
induc
ar
use
catroom
challeng
model
method
singlecent
prospect
random
doubleblind
placebocontrol
twoway
crossov
studi
consist
screen
visit
one
two
prime
visit
two
treatment
period
separ
day
washout
qualifi
subject
random
treatment
sequenc
placebo
follow
fex
fex
follow
placebo
baselin
endpoint
obtain
prior
studi
drug
administr
minut
enter
cat
challeng
room
allergen
challeng
allergen
challeng
initi
hour
postdos
treatment
period
primari
endpoint
chang
baselin
total
symptom
score
tss
sum
rhinorrhea
itchi
nosepalatethroat
sneez
itchywateryr
eye
minut
allergen
exposur
hour
postdos
compar
placebo
endpoint
includ
chang
individu
symptom
score
includ
nasal
congest
level
airborn
feli
domesticu
allergen
fel
determin
result
subject
screen
random
complet
studi
sequenc
respect
mean
chang
tss
baselin
significantli
less
fex
compar
placebo
minut
initi
cat
allergen
challeng
significantli
greater
percentag
reduct
individu
symptom
score
sneez
nasal
congest
observ
fex
compar
placebo
minut
challeng
although
level
fel
vari
wide
balanc
treatment
group
overal
incid
treatmentemerg
advers
event
ae
low
compar
group
seriou
ae
occur
conclus
studi
demonstr
singl
dose
fex
hci
mg
effect
well
toler
prophylact
agent
allevi
ar
symptom
induc
exposur
cat
allergen
largescal
clinic
trial
warrant
confirm
find
rational
allerg
rhiniti
children
thought
associ
sever
comorbid
disord
conduct
follow
studi
assess
whether
children
diagnos
hypertrophi
tonsil
andor
adenoid
evalu
allergist
like
demonstr
object
evid
allergen
sensit
children
similarli
evalu
without
evid
upper
airway
obstruct
method
record
past
ten
year
identifi
hospit
databas
presenc
allergi
clinic
visit
code
hypertrophi
adenoid
andor
tonsil
review
record
confirm
diagnosi
accur
includ
subject
reliabl
skin
prick
vitro
test
specif
ige
aeroallergen
perform
comparison
randomli
obtain
age
testingtyp
similar
sampl
first
group
subject
exclud
second
group
skin
test
perform
commerci
allergen
extract
appli
vitro
test
feia
posit
skin
test
least
wheal
mm
flare
mm
greater
neg
control
posit
vitro
valu
kul
greater
posit
pollen
mix
addit
perform
search
insur
databas
determin
mani
local
children
code
allerg
rhiniti
result
pediatr
allergi
patient
adenoidtonsillar
hypertrophi
test
ci
least
one
posit
test
without
adenoidtonsillar
hypertrophi
ci
least
one
posit
test
observ
differ
ci
standard
error
differ
percentag
z
score
correspond
p
valu
percentag
children
allerg
rhiniti
ci
conclus
number
allergistref
children
adenoid
andor
tonsillar
hypertrophi
test
posit
aeroallergen
slightli
less
number
similar
children
without
diagnos
test
posit
clear
adenoidtonsillar
hypertrophi
associ
higher
risk
allerg
rhiniti
prospect
studi
allergi
test
children
adenoid
andor
tonsillar
hypertrophi
might
provid
inform
could
alter
referr
pattern
berger
w
storm
kimura
beck
galant
westbrook
mission
viejo
ca
colorado
spring
co
pensacola
fl
miami
fl
orang
ca
background
patient
allerg
rhinoconjunct
often
treat
nasal
spray
system
allergi
therapi
forgo
therapi
specif
target
ocular
symptom
rhiniti
qualiti
life
questionnair
rqlq
allerg
conjunct
qualiti
life
questionnair
acqlq
instrument
use
quantifi
rel
benefit
vari
medic
regimen
object
determin
extent
benefit
gain
qualiti
life
eye
drop
treatment
ocular
allergi
olopatadin
ad
rhiniti
patient
preexist
regimen
nasal
system
allerg
treatment
method
four
week
prospect
multicent
openlabel
crossov
qualiti
life
studi
occur
allergi
season
visit
patient
complet
rqlq
acqlq
questionnair
assess
baselin
qualiti
life
patient
random
receiv
ocular
allergi
therapi
olopatadin
patanol
bid
concomit
system
nasal
rhiniti
treatment
week
either
visit
visit
group
visit
visit
group
b
visit
visit
patient
complet
rqlq
acqlq
result
total
patient
complet
studi
group
group
b
experienc
eye
allergi
symptom
least
day
previou
week
report
baselin
acqlq
baselin
score
rqlq
acqlq
group
compar
clinic
signific
improv
baselin
global
rqlq
acqlq
seen
follow
addit
ocular
therapi
group
rqlq
acqlq
similar
improv
seen
across
domain
questionnair
acqlq
correl
rqlq
applic
domain
conclus
mani
allerg
rhiniti
patient
use
nasal
system
medic
also
suffer
ocular
allerg
symptom
patient
qualiti
life
improv
maxim
addit
topic
antiallergi
eye
drop
result
benefici
effect
qualiti
life
studi
addit
olopatadin
eye
drop
patient
medic
regimen
result
signific
improv
eye
symptom
relat
qualiti
life
domain
overal
qualiti
life
h
milgrom
r
lanier
fc
hampel
b
kittner
denver
co
fort
worth
tx
new
braunfel
tx
bridgewat
nj
introduct
fexofenadin
nonsed
select
antagonist
current
indic
use
children
age
year
season
allerg
rhiniti
number
countri
includ
us
excel
safeti
profil
age
group
studi
design
assess
safeti
toler
fexofenadin
children
age
year
allerg
rhiniti
ar
method
studi
multicent
doubleblind
random
placebocontrol
parallelgroup
design
children
age
year
ar
random
either
placebo
twice
daili
bid
fexofenadin
hcl
mg
bid
week
treatment
given
oral
granul
powder
capsul
content
mix
two
teaspoon
appl
sauc
treatmentemerg
advers
event
teae
record
subject
parentscaregiv
assess
investig
clinic
laboratori
variabl
physic
examin
vital
sign
ecg
evalu
also
assess
subgroup
children
placebo
fexofenadin
result
baselin
demograph
similar
treatment
group
approxim
children
group
experienc
least
one
teae
unusu
unexpect
teae
observ
fexofenadin
group
total
group
analyz
teae
bodi
system
assess
separ
age
group
clinic
meaning
differ
observ
two
treatment
group
treatment
group
major
subject
overal
age
group
experienc
teae
rate
mild
moder
intens
subject
experienc
teae
consid
possibl
relat
studi
medic
placebo
fexofenadin
percentag
discontinu
due
teae
also
compar
treatment
group
placebo
fexofenadin
subgroup
assess
clinic
relev
chang
seen
baselin
laboratori
variabl
vital
sign
ecg
physic
examin
either
treatment
group
introduct
efficaci
safeti
fexofenadin
hcl
mg
bid
proven
two
larg
phase
iii
studi
pediatr
subject
age
year
season
allerg
rhiniti
addit
safeti
fexofenadin
demonstr
pediatr
subject
year
age
allerg
rhiniti
ar
subsequ
two
studi
assess
pharmacokinet
safeti
toler
fexofenadin
mg
bid
pediatr
subject
month
year
age
method
studi
multicent
random
doubleblind
placebocontrol
parallelgroup
design
enrol
pediatr
subject
age
month
year
weigh
kg
age
year
year
weigh
kg
subject
diagnosi
ar
assess
previou
medic
histori
pattern
suggest
physic
find
subject
random
receiv
fexofenadin
hcl
mg
mg
granul
powder
twicedaili
placebo
minimum
day
safeti
evalu
base
advers
event
ae
vital
sign
electrocardiogram
ecg
physic
examin
result
total
subject
random
studi
fexofenadin
hcl
mg
bid
placebo
fexofenadin
hcl
mg
bid
placebo
respect
children
receiv
fexofenadin
receiv
placebo
experienc
least
one
treatmentemerg
ae
teae
incid
teae
respect
studi
teae
experienc
mild
moder
intens
incid
possiblyrel
teae
also
similar
treatment
studi
clinic
relev
chang
baselin
studi
end
observ
vital
sign
ecg
physic
examin
conclus
find
studi
show
fexofenadin
mg
mg
bid
well
toler
safeti
profil
compar
placebo
pediatr
subject
age
month
year
season
allerg
rhiniti
sar
patient
remain
symptomat
antagonist
cetirizin
nasal
glucocorticosteroid
mometason
furoat
addit
omalizumab
recombin
human
chimer
antiig
monoclon
antibodi
may
provid
addit
efficaci
suboptim
control
season
allerg
rhiniti
patient
open
label
trial
patient
symptomat
sar
current
use
cetirizin
mg
qd
mometason
furoat
mcgnostril
qd
random
continu
exist
therapi
cetirizin
mometason
addon
omalizumab
subcutan
everi
week
week
dose
accord
patient
weight
baselin
ige
level
exist
therapi
cetirizin
mometason
furoat
endpoint
trial
includ
rhinomanometri
nasal
symptom
score
composit
score
nasal
congest
rhinorrhea
sneez
post
nasal
drip
itch
flexibl
rhinopharyngolaryngoscopi
examin
mean
efficaci
measur
end
trial
reveal
signific
improv
paramet
examin
treatment
group
receiv
omalizumab
addon
exist
therapi
compar
group
conclus
addit
omalizumab
combin
cetirizin
plu
mometason
furoat
effect
combin
cetirizin
plu
mometason
furoat
treament
season
allerg
rhiniti
patient
appear
omalizumab
ad
combin
antagonist
cetirizin
nasal
corticosteroid
mometason
furoat
primari
end
point
rhinomanometri
symptom
score
significantli
improv
background
base
offici
statist
data
preval
allerg
diseas
russia
increas
time
past
year
still
lowest
european
countri
studi
done
region
russia
base
isaac
program
shown
preval
allergi
significantli
higher
indic
offici
statist
health
depart
goal
investig
studi
preval
allerg
diseas
children
south
russian
region
method
studi
done
two
step
accord
isaac
program
guidelin
first
step
questionnair
given
total
school
children
age
group
year
old
group
b
two
citi
krasnodar
novorossiysk
southern
russia
second
step
physic
exam
skin
prick
test
differ
allergen
pollen
mold
cat
dust
mite
food
etc
pulmonari
function
test
perform
result
wheez
report
group
group
b
children
within
past
month
sever
asthma
report
mild
group
group
b
moder
group
group
b
sever
group
group
b
studi
children
major
case
asthma
note
allerg
asthma
group
children
high
incid
allergi
perenni
allergen
dust
mite
cat
mold
indoor
allergen
group
group
b
percentag
allergi
pollen
accordingli
allerg
rhiniti
symptom
note
group
group
b
atop
dermat
symptom
skin
itch
observ
year
old
year
old
famili
histori
atopi
notic
group
group
b
children
conclus
preval
allerg
diseas
south
russia
similar
one
european
countri
preval
asthma
associ
increas
incid
allergi
due
indoor
pollen
allergen
preval
rhiniti
atop
dermat
south
russia
parallel
asthma
acknowledg
would
like
thank
hollistersti
lab
greer
antigen
lab
allergen
sampl
object
examin
cost
effect
telithromcyin
vs
azithromycin
treatment
mild
acut
sinus
current
level
antimicrobi
resist
method
consid
adult
mild
acut
sinus
symptom
durat
day
decis
analyt
model
creat
compar
strategi
therapi
azithromycinamoxicillinclavulanatelevofloxacin
aziamclev
telithromycinamoxicillinclavulanatelevofloxacin
telamclev
consid
outcom
respons
initi
therapi
cost
time
complet
antibiot
therapi
clinic
resolut
due
respons
antibiot
spontan
resolut
assum
bacteria
resist
vitro
would
resist
vivo
time
resist
level
base
us
protekt
surveil
studi
model
paramet
preval
bacteri
infect
frequenc
caus
pathogen
rate
spontan
resolut
base
publish
literatur
fail
improv
day
switch
next
line
therapi
analyz
claim
data
manag
care
organ
estim
nondrug
charg
initi
followup
care
appli
costtocharg
ratio
drug
cost
estim
use
wholesal
acquisit
cost
plu
overhead
dispens
cost
adjust
year
us
result
model
predict
telamclev
strategi
would
result
improv
day
compar
aziamclev
telithromycin
strategi
lower
mean
cost
vs
although
telithromycin
cost
azithromycin
telamclev
strategi
slightli
lower
total
drug
cost
vs
due
less
need
addit
antibiot
cours
mean
time
complet
therapi
day
telamclev
day
aziamclev
sensit
analys
show
telamclev
superior
health
outcom
even
vitro
resist
organ
also
resist
vivo
telamclev
also
lower
cost
least
case
bacteri
vitro
resist
organ
least
resist
vivo
conclus
base
result
obtain
use
decis
analyt
model
initi
treatment
mild
acut
rhinosinus
telithromycin
may
result
improv
outcom
lower
cost
initi
treatment
azithromycin
rational
delta
crud
term
use
describ
rhinosinus
syndrom
mississippi
delta
region
local
percept
associ
chemic
crop
dust
region
produc
especi
cotton
high
rate
mold
allergi
climat
extrem
mild
winter
hot
humid
summer
larg
volum
rain
thirtyf
percent
inhabit
live
poverti
level
african
american
patient
agricultur
intens
delta
suffer
asthma
almost
twice
rate
neighbor
hill
rate
pesticid
use
among
highest
nation
preval
estim
rhinosinus
region
delta
crud
chronic
mani
patient
exacerb
occur
summer
fall
especi
chemic
spray
defoli
conduct
crosssect
questionnair
base
pilot
studi
begin
character
rhinosinus
popul
method
sinus
treatment
outcom
questionnair
two
modif
given
consecut
patient
present
north
sunflow
region
hospit
er
sunflow
outpati
clinic
one
month
prior
begin
summer
crop
dust
question
delta
crud
ad
survey
anonym
allow
irb
exempt
result
consecut
patient
return
complet
questionnair
admit
delta
crud
patient
claim
delta
crud
significantli
sinu
headach
nasal
pruritu
conjunct
chest
symptom
see
tabl
signific
differ
antibiot
prescript
er
visit
miss
work
six
patient
delta
crud
hospit
allergi
reason
compar
three
patient
without
delta
crud
despit
sever
symptom
patient
receiv
sinu
ct
scan
patient
prescrib
intranas
corticosteroid
conclus
pilot
studi
preval
chronic
rhinosinus
symptom
delta
crud
sever
sinu
pulmonari
ocular
symptom
evalu
treatment
may
suboptim
econom
disadvantag
rural
region
character
delta
crud
pollen
count
ige
mediat
diseas
environment
contribut
compar
studi
relat
region
need
introduct
patient
rhiniti
commonli
experi
sinu
pain
pressur
spp
mani
patient
recurr
acut
bacteri
sinus
rab
base
presenc
recurr
sever
spp
nasal
symptom
abil
patient
differenti
rhiniti
rab
evalu
review
subject
screen
log
previous
report
clinic
trial
flonas
fluticason
propion
nasal
spray
mcg
fp
method
efficaci
fp
studi
two
trial
subject
spp
due
allerg
rhiniti
two
trial
subject
receiv
cefuroxim
axetil
treat
acut
episod
rab
spp
screen
log
examin
determin
mani
subject
thought
spp
exclud
studi
upper
respiratori
sinu
infect
rab
screen
log
examin
determin
mani
subject
symptom
acut
episod
rab
exclud
studi
neg
sinu
xray
ct
scan
rab
symptom
experienc
screen
visit
subject
qualifi
studi
also
evalu
result
subject
screen
spp
studi
exclud
evid
sinu
upper
respiratori
tract
infect
clinic
diagnos
investig
subject
screen
log
data
rab
studi
exclud
neg
sinu
xray
ct
scan
subject
qualifi
rab
studi
preval
symptom
includ
nasal
congest
mucopurul
discharg
facial
pain
tender
sinu
area
sinu
headach
malais
subject
fever
one
symptom
nasal
congest
rate
clinician
sever
greater
subject
either
studi
conclus
subject
determin
spp
due
allerg
rhiniti
mani
determin
symptom
progress
sinu
infect
symptom
experienc
subject
rab
consist
inflamm
includ
fever
may
expect
untreat
bacteri
sinu
infect
appreci
patient
role
inflamm
sinu
diseas
may
result
selfdiagnosi
sinu
infect
demand
antibiot
liposom
small
particl
consist
lipid
bilay
membran
use
deliv
drug
includ
amphotericin
b
effici
less
toxic
case
allergi
liposom
amphotericin
b
lab
report
date
although
report
convent
amphotericin
b
cab
desensit
knowledg
case
lab
desensit
describ
yet
yo
patient
lymphoma
treat
lab
pulmonari
aspergillosi
within
minut
infus
develop
urticaria
hypotens
tachycardia
treat
appropri
drug
anaphylaxi
second
attempt
administ
lab
result
similar
anaphylact
reaction
desensit
lab
success
complet
use
modifi
protocol
base
desensit
cab
jaci
mg
infus
minut
mg
infus
minut
mg
infus
minut
mg
infus
minut
mg
infus
minut
mg
infus
minut
mg
infus
minut
mg
infus
minut
conclus
desensit
lab
lifesav
drug
invas
fungal
diseas
perform
success
